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Abstract 
Sesquiterpene cyclases convert linear isoprenyl diphosphates into complex hydrocarbon structures 
that include multiple ring systems, chiral centres and various stereochemistry. The wild tomato plant 
(Solanum habrochaites) has shown resistance against herbivore attack that is not observed in the 
domesticated moneymaker tomato species. Wild tomatoes release sesquiterpenes; 7-epizingiberene 
and its dehydrogenated form (R)-curcumene to repel adult whiteflies prior to landing, whilst 
moneymaker tomatoes do not exhibit this ability. 7-Epizingiberene has been reported as toxic to 
whitefly and a phytoalexin that causes birth defects in offspring. As a result, the use of 
7-epizingiberene to combat whitefly infestation gives a new possibility for crop protection, 
circumventing the use of potentially dangerous and environmentally damaging pesticides.  
This thesis focuses on 7-epizingiberene synthase (EZS), a sesquiterpene cyclase that defies 
convention by using (2Z,6Z) farnesyl diphosphate as its substrate and not the universal substrate 
(2E,6E) farnesyl diphosphate. The project is divided into three sections. The first section involved the 
synthesis of (2Z,6Z) farnesyl diphosphate followed by the expression and purification of 
7-epizingiberene synthase. Due to cost implications of purchasing (2Z,6Z) farnesol, multiple synthetic 
routes were investigated for the synthesis (2Z,6Z) farnesyl diphosphate. A 
Horner-Wadsworth-Emmons olefination using a Still-Gennari modified reagent gave the greatest 
yield of the Z isomer which was used for further reactions. Various cell lines and expression tags 
were used to optimise EZS expression and purification, whilst incubations of synthesised (2Z,6Z) 
farnesyl diphosphate with EZS gave catalytic products consistent with literature. 
The second portion of the project was the synthesis of (2Z,6Z)-[1-3H]-farnesyl diphosphate for the 
measurement of steady state parameters of EZS and EZS mutants. Multiple oxidations were 
attempted during the synthesis of radiolabelled substrate, with an oxoammonium-catalysed 
oxidation shown to retain the stereochemistry of the C2,C3 double bond. EZS mutants were used to 
investigate the metal binding motifs responsible for class I activity whilst numerous aromatic 
residues were subjected to single point mutation to investigate their role within the active site 
pocket. 
The third section involved the synthesis of substrate analogues to investigate the catalytic 
mechanism and substrate specificity of EZS. The synthesis of deuterated and fluorinated analogues 
were used to investigate prospective hydride shifts and carbocation intermediates respectively. The 
stereochemistry required for substrate turnover was probed by the synthesis of all isomers of 
farnesyl diphosphate whilst oxygenated and methylated substrates were synthesised for the 
potential production of novel sesquiterpene products.  
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Chapter 1 – Introduction 
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1.1 Terpenes 
 
The terpenome is comprised of over 50,000 structurally and stereochemically diverse natural 
compounds derived from the catalysis of linear isoprenyl diphosphates by terpene cyclases.1 
Terpenoids are ubiquitous throughout all kingdoms of life, possessing many different bioactivities in 
plants, animals, insects, bacteria, archea and fungi. Over half of known terpenoids are 
biosynthesised by plants with primary metabolites involved in photosynthesis, respiration and 
membrane structure. Secondary metabolites in plants are utilised for a range of purposes including 
pigmentation, protection from over exposure to light and provide crucial roles in defence. Some 
secondary metabolites are responsible for repelling herbivorous insects e.g. 7-epizingiberene (1) 
from Solanum habrochaites (wild tomato)2,3 and (-)-germacrene D (2) from Hemizizygia petiolata 
essential oil.4 Contrastingly, some secondary metabolites e.g. β-phellandrene (3) are synthesised by 
Epipactis (terrestrial orchids) for the attraction of Episyrphus balteatus (marmalade hoverfly) for 
pollination.5  
In addition to uses in nature, terpene hydrocarbon skeletons can be further functionalised for uses 
as rubber, flavourings ((R)-(-)-carvone (4))6, antibiotics (pentalenolactone (5))7, natural 
contraceptives (gossypol (6))8, anti-malarial (artemisinin (7))9 and anti-cancer (taxol®(8))10 
pharmaceuticals11 (Figure 1). 
 
 
Figure 1. 7-Epizingiberene (1), (-)-germacrene D (2), β-phellandrene (3), (R)-(-)-carvone (4), pentalenolactone (5), 
gossypol (6), artemisinin (7) and taxol (8). 
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The variety and complexity of natural products within the terpenome contrasts with the fact that 
they are derived from two simple isoprenoid building blocks; isopentenyl diphosphate (IDP, 16) and 
dimethylallyl diphosphate (DMADP, 17).12 Two pathways for the biosynthesis of IDP (16) and DMADP 
(17) are known. The mevalonate pathway (Figure 2) functions in eukaryotes, the cytosol of plants 
and some bacteria; and was considered the universal source of IDP and DMADP after its elucidation 
in the late 1950s.13,14 The second biosynthetic pathway is known as the non-mevalonate or 
deoxyxylulose phosphate (DOX) or methylerythritol phosphate (MEP) pathway (Figure 3)  and was 
recently discovered by Rohmer et al.,15 and Arigoni et al.16 This pathway is active inter alia in bacteria 
and the chloroplasts of green algae and higher plants.13 
1.1.1 Mevalonate Pathway 
The mevalonate pathway begins with the Claisen condensation of two acetyl-coenzyme A (9) 
molecules to give thio ester 10.14 The subsequent aldol reaction between 10 and 11 is catalysed by 
HMG-CoA synthase to yield 3-hydroxy-3-methylglutaryl-CoA (12). The reduction of 12 with HMG-CoA 
reductase and two equivalents of NADPH gives mevalonic acid (13).17 The reduction is followed by 
sequential phosphorylations by mevalonate kinase and adenine triphosphate to give 
5-phosphomevalonic acid (14) and 5-diphosphomevalonic acid (15) respectively.18 The ATP-mediated 
decarboxylation and water elimination of 15 is catalysed by diphosphomevalonate decarboxylase to 
give isopentenyl diphosphate (16).13,19 Isomerisation of IDP (16) to DMADP (17) by isopentenyl 
diphosphate isomerase (IPI) proceeds via the reversible proton tautomerisation to the Re face of the 
IDP (16) double bond. This is proceeded by the stereospecific removal of the 2-pro-R-proton to give 
17 in an approximate equilibrium ratio of 3:1 (DMADP(17):IDP(16)) (Figure 2).20,21 
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Figure 2. Mevalonate pathway (top) and IPI catalysed isomerisation of IDP (16) to DMADP (17) (bottom). 
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1.1.2 Non-mevalonate Pathway 
The non-mevalonate pathway begins with catalytic condensation of pyruvate (18) and 
glyceraldehyde-3-phosphate (19) by 1-deoxy-ᴅ-xylulose-5-phosphate synthase (DXPS) and cofactor 
thiamine diphosphate (TPP) to give 1-deoxy-ᴅ-xylulose-5-phosphate (20) and carbon dioxide.13,22 
Isomerisation to the aldehyde 2-C-methyl-ᴅ-erythose-4-phosphate (21) by DXPS reductoisomerase 
(IspC) is followed by a NADPH reduction within the same enzyme giving 
2-C-methyl-ᴅ-erythritol-4-phosphate (22).23 A cytidyl phosphate moiety (CTP) is transferred to 22 via 
IspD catalysis to give 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol (23) followed by phosphorylation 
by IspF to the respective 2-phosphate (24).24,25 IspF catalyses the only known natural cyclic 
diphosphate via the elimination of cytidyl monophosphate (CMP) to yield 
2-C-methyl-ᴅ-erythritol-2,4-cyclodiphosphate (25). The mechanisms responsible for the final two 
steps of the non-mevalonate pathway are disputed. However; they are known to be catalysed by 
two highly oxygen sensitive iron-sulphur cluster proteins; IspG and IspH respectively.26,27 A reductive 
ring opening of 25 catalysed by IspG forms 1-hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate (26). 
IspH catalyses the two step single-electron transfer from an iron-sulfur cluster and consequent 
cleavage of the hydroxyl moiety to give the allylic carbanion (27). Protonation of the carbanion can 
yield either IDP (16) or DMADP (17) (Figure 3).23,24,28 
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Figure 3. The non-mevalonate pathway. 
 
1.1.3 Prenyltransferase 
Activated isoprene moieties; isopentenyl diphosphate (IDP, 16) and dimethylallyl diphosphate 
(DMADP, 17) biosynthesised via the mevalonate or non-mevalonate pathways are substrates for 
prenyl transferase (not prenylating enzymes which share the same name). This class of enzymes 
catalyse the successive head to tail condensation reactions of IDP (16) and DMADP (17) giving larger 
isoprenyl diphosphates such as the monoterpene (C10) parent geranyl diphosphate (GDP, 30), the 
sesquiterpene (C15) parent farnesyl diphosphate (FDP, 31) and the diterpene (C20) parent 
geranylgeranyl diphosphate (GGDP, 32).29,30 The biosynthesis begins with the dissociation of 
diphosphate from 17 resulting in the allylic cation 28.31 The cation then undergoes nucleophilic 
attack from a molecule of IDP (16) forming a stabilised tertiary carbocation 29. Deprotonation occurs 
at a secondary α-carbon to give geranyl diphosphate (GDP, 30).32 Elongated isoprenyl diphosphates 
are consequently used as substrates for their respective terpene cyclase to begin the production of a 
multitude of natural products (Figure 4).31 
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Figure 4. Biosynthesis of terpenoids (top) and nomenclature of isoprenoid substrates (bottom). 
Due to the numerous chain lengths possible, Koyama and Ogura classified prenyltransferases into 
four groups depending on chain length and stereochemistry generated.13 Class I prenyltransferases 
catalyse short chain products from GDP (C10, 30) to GGDP (C20, 32) with E selectivity. Class II 
prenyltransferases elongate FDP (C15, 31) to hexaprenyl (C30) and heptaprenyl diphosphate (C35) 
whilst class III catalyses the formation of octaprenyl (C40) and decaprenyl diphosphate (C50) from FDP 
(31) with E selectivity. Contrastingly, class IV prenyl transferases catalyse the elongation of FDP (31) 
to nonaprenyl (C45) and decaprenyl diphosphate (C50) but with Z selectivity. 
Original stereochemical investigations into the mechanism of Z-selective enzymes were carried out 
on rubber biosynthesis. It was observed that chain elongation and Z double bond formation 
progressed via the removal of the 2-pro-S-hydrogen from IDP (16) in contrast to the abstraction of 
the 2-pro-R-hydrogen by E specific prenyl transferases.33 It was postulated that the stereoselectivity 
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of E or Z selective prenyl transferases arose from the specific removal of the C2 proR or proS proton 
of IDP (16) (Figure 5).34 
 
 
Figure 5. Proposed mechanisms of E (top) and Z (bottom) selective prenyltransferases. 
In contrast, multiple investigations of Z-selective prenyltransferases have reported the removal of 
the 2-pro-R-hydrogen.35–37 In recent literature, two Z-selective class I prenyltransferases have been 
discovered in Solanum habrochaites30 and S. lycopersicum38 for the biosynthesis of (2Z,6Z) farnesyl 
diphosphate (38) and neryl diphosphate (39) (Figure 6).  
 
 
Figure 6. Biosynthesis of (2Z,6Z) FDP (38) and neryl DP (39) by catalysis of DMADP (17) and IDP (16) with Z selective 
prenyltransferase. 
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1.2 Terpene cyclases 
Terpene cyclases catalyse the stereospecific conversion of linear isoprenyl diphosphate precursors 
(Figure 4) to a multitude of cyclic compounds.39 As detailed in section 1.1, terpenoid products have a 
wide range of applications spanning the pharmaceutical industry to semiochemicals9 for plant 
defence.40,41 Terpene cyclases vary in terms of substrate and product promiscuity. Table 1 
exemplifies selected terpene cyclases and the terpenoid products arising from their catalytic action: 
Table 1 - Terpene cyclases with respective substrates and products (modified from publication by Pazouki et  al.
42
 
Terpene 
Cyclase 
Species TPS 
family 
Substrate Terpenoid products Reference 
Germacrene A 
synthase (GAS) 
Achillea 
milefolium 
Sesqui- FDP (31) 
 
 
GDP (30) 
 
 
 
NDP (39) 
germacrene A (40), β-elemene (41), 
β-selinene (42), α-selinene (43) 
 
mycrene (44), (E)-β-ocimene (45), 
limonene (46), terpinolene (47), 
camphene (48), α-pinene (49) 
 
(+)-2-carene (50), γ-terpinene (51), 
α-terpinene (52), α-fenchene (53), 
α-thujene (54) 
Pazouki 
et al.43 
Santalene 
synthase (SaS) 
Santalum 
album 
Sesqui- FDP (31) 
 
 
 
 
Z-FDP (38) 
 
 
 
 
 
GDP (30) 
α-santalene (55), β-santalene (56), 
epi-β-santalene (57), 
α-exo-bergamotene (58), 
α-farnesene (59), β-farnesene (60) 
 
α-endo-bergamotene (61), 
α-santalene (55), 
(Z)-β-farnesene (62), 
epi-β-santalene (57),  
β-santalene (56) 
 
Linalool (63), geraniol (64), 
terpineol (65), α-pinene (49), 
camphene (49) 
Jones 
et al.44 
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α-Bisabolene 
synthase (ABS) 
Abies grandis Sesqui- FDP (31) 
 
GDP (30) 
(E)-α-bisabolene (66) 
 
(+)-Limonene (46) 
Bohlmann 
et al.45 
Lanosterol 
synthase (LS) 
- Tri- 2,3-
monoepoxy
squalene 
(MOS) 
Lanosterol (67) Huff 
et al.46 
β-ocimene 
synthase 
Arabidopsis 
thaliana 
Mono- FDP (31) 
 
GDP (30) 
α-farnesene (59) 
 
(E)-β-ocimene (45) 
Huang 
et al.47 
 
Figure 7. Structures of terpene cyclase products listed in Table 1. 
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Though substrates and enzymatic products may differ, the mechanisms of all terpene cyclases are 
initiated via the formation of an initial carbocation.48 The enzyme guides the substrate through a 
cascade of carbocation rearrangements, cyclisations, hydride or alkyl shifts and deprotonation. The 
hydrophobic pocket of the active site is equipped to stabilise the formation of numerous 
carbocations, simulating an inert organic solvent whilst π-electrons of aromatic residues and the 
diphosphate co-product stabilise carbocation intermediates.11,49 The initial cation is established via 
two different mechanisms and has led to the classification of terpene cyclases into class I and class II 
cyclases. 
 
1.2.1 Class I terpene cyclases 
Class I terpene cyclases catalyse the conversion of isoprenyl diphosphate substrates via the metal-
dependent cleavage of the diphosphate moiety of the substrate to yield an initial carbocation as the 
first step. The structure of class I terpenoid cyclases consists of an α-helical bundle with a tertiary 
fold that was first observed in the crystal structure of avian FDP synthase.50 Class I catalysis is 
confined to the α-helical bundle with bacterial cyclases comprised solely of this domain. In plants, 
multi-domain class I cyclases are also known.51 Non-catalytic domains can be dormant whilst the β 
domains of some plant sesquiterpene cyclases have been shown to assist catalysis by capping the 
active site when the substrate in bound.52,53 Epi-aristolochene54 synthase and α-bisabolene 
synthase55 are examples of terpene cyclases that are comprised of an αβ and αβγ architecture, 
respectively, with no activity observed in the β and γ domains (Figure 8).  
 
                       
Figure 8. Cartoon representation of the X-ray crystal structures of three class I terpene cyclases. Left: avian FDP synthase 
(representative of the α-helical bundle in which class I activity is confined).
50
 Middle: epi-aristolochene synthase 
showing the class I active α domain (blue) and the inactive β domain (green).
56
 Right: α-bisabolene synthase, a three-
domain plant terpene cyclase with inactive β (central) and γ (dark blue) domains.
57
  
A conserved DDxxD(E) metal ion binding motif located on helix D is present across the entire class 
and is responsible for the coordination of two metal ions .58 A variant second motif positioned on 
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helix H is referred to as the NSE/DTE motif corresponding to a (N,D)Dxx(S,T)xxxE sequence for 
binding  a third metal ion is also conserved.51 The NSE motif is generally found within fungi and 
bacteria whilst the DTE motif in commonly found in plant terpene synthases (Figure 9). The 
diphosphate group of the isoprenoid substrate coordinates with the metal ions enabling formation 
of the substrate-enzyme complex.59 
 
                 
Figure 9. Cartoon representation of the class 1 catalytic alpha domain from the X-ray crystal structure of avian FDP 
synthase outlining the position of the DDxxD and NSE conserved motifs.
50
  
In contrast, δ-cadinene synthase (DCS) from Gossypium arboreum has a second DDxxD region in 
place of the NSE/DTE motif; 60 and (R)-germacrene D synthase from Solidago canadensis where the 
DDxxD motif is replaced by an NDxxD sequence. Although slightly different, these motifs also chelate 
a trio of divalent magnesium (or manganese) ions that are required for the binding and subsequent 
cleavage of the diphosphate moiety.61 
 
1.2.2 Class II terpene cyclases  
Class II terpene cyclases are defined by protonation-initiated catalysis of isoprenyl diphosphate 
substrates. The structure of class II cyclases consists of two α-helical structures referred to as the β 
and γ domains.62 The general catalytic acid responsible for class II catalysis arises from a central 
aspartate rich motif (DXDD) positioned at the interface of the β and γ domains.63 Examples of three 
domain (αβγ) class II terpenoid cyclases are also known.64,65 Ent-copalyl synthase contains a 
functional class II active site at the interface of the β and γ domains with a residual, non-functioning 
α domain.66 
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Figure 10. Left: Carton representation of the X-ray crystal structure of abietadiene synthase and Right: Class II active site 
highlighting the DxDD motif positioned at the interface of the β and γ domains of abietadiene synthase.
67
  
The initial carbocation is formed via the protonation of the distal double bond or the protonation of 
an epoxide derivative of this bond, resulting in ring opening. The intramolecular cascade of 
carbocations ensuing from various cyclisations generally leads to the formation of multicyclic 
structures.62 In the majority of cases, class II terpene cyclases catalyse reactions involving diterpene 
(geranylgeranyl diphosphate, 32),68 triterpenes69 and derived-oxidosqualene precursors.70 However, 
class II catalysed reactions have been observed in the formation of the sesquiterpene drimane (79) 
and the biosynthesis of tetra / sesterterpenoids.71 More commonly these enzymes catalyse the 
formation of stereochemically and structurally complex products incorporating between one and 
five cyclisations and rearrangements within a single reaction.72 
 
1.2.3 Bifunctional terpene cyclases 
Class I and class II activities are situated in the α-domain and at the interface of the β and γ domains 
respectfully. Contrastingly, plant terpene cyclases containing α, β and γ domains could be 
monofunctional (class I or class II) or bifunctional (class I and II).62 
An example of a bifunctional terpene cyclase is abietadiene synthase from Abies grandis.64 
Abietadiene synthase is responsible for the biosynthesis of (–)-abieta-8,14-diene (abietadiene) from 
GGDP (32) and is a precursor to (-)-abietic acid (75), utilised by grand fir trees (Abies grandis) in 
response to bark beetle attack.73 The mechanism proceeds via two consecutive reactions catalysed 
by the class II and class I active sites.74 Protonation of the distal double bond of 32 results in three 
consecutive ring closures and deprotonation to give (+)-copalyl diphosphate (69). Dissociation from 
the class II active site into the bulk solvent and is followed by substrate binding to the class I active 
site.74 Once bound, metal dependent cleavage of the diphosphate ester via a concerted ring closure 
gives cation (70).75 The ring closure is proceeded by an intramolecular proton transfer and a [1,2] 
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methyl migration to give cations 71 and 72 respectively.76 Deprotonation of 72 gives abietadiene 
(34) or elimination can yield levopimaradiene (73) and neoabietadiene (74) (Figure 11).77 
 
Figure 11. Catalytic mechanism of abietadiene synthase. 
Singular and multidomain class I and II terpene cyclases are present throughout nature with 
conserved characteristics observed across multiple organisms. In addition to the classification of 
terpene cyclases via class I or II mechanisms, further categorisation of cyclases is derived according 
to their favoured isoprenyl substrate.  
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1.3 Sesquiterpene cyclases 
 
The terpene synthase family consists of multiple sub groups each of which are designated by the 
isoprenyl diphosphate substrate they employ. Sesquiterpene synthases catalyse the metal 
dependent turnover of FDP (31).78 The production of over 300 mono-, bi-, and tricyclic products are 
known from a multitude of plant, bacterial and fungal enzymes (Figure 12).79 Sesquiterpene 
synthases generally act via a class I mechanism with an α-helical structure and the conserved 
DDxxD/E and NSE/DTE motifs incorporated at the tertiary structural fold.62 
 
 
Figure 12. Examples of sesquiterpene products from terpene cyclase catalysed conversion of FDP (31); aristolochene 
(76), zingiberene (33), drimane (77), (-)-α-copaene (78), germacrene D (2), humulene (79), δ-cadinene (80) and 
curcumene (81). 
 
1.3.1 The mechanism of initial cyclisations catalysed sesquiterpene cyclases 
Sesquiterpene cyclases catalyse a number of cyclisations i.e. [1,6] and [1,10] ring closures. A class I 
mechanism used by sesquiterpene cyclases can adopt two mechanisms of diphosphate cleavage to 
catalyse a ring closure; a stepwise or concerted mechanism. However, the stereochemistry of (2E,6E) 
FDP (31) prohibits a [1,6] cyclisation even though sesquiterpene products containing a 6-membered 
ring are found in nature (Figure 13). 
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Figure 13. Prevention [1,6] cyclisation (2E,6E) FDP (31) due to a transoid configured cation (82). 
 
1.3.2 Amorphadiene Synthase  
Due to the stereochemistry of (2E,6E) FDP (31), enzymes such as amorphadiene synthase (ADS) 
catalyse a stepwise mechanism to form nerolidyl diphosphate (84).80 The formation of nerolidyl 
diphosphate (84) allows for the rotation of the C2, C3 double bond to a cisoid conformation. The 
mechanism of ADS begins with the removal of the diphosphate group forming the transoid farnesyl 
carbocation (83). The diphosphate group attacks the C3 carbon giving nerolidyl diphosphate (83) 
allowing the free rotation of the C2, C3 bond. Ionisation of the diphosphate group is followed by a 
[1,6] cyclisation to afford the bisabolyl cation (86) with a subsequent [1,3] hydride shift yielding 
cation (87). A [1,10] ring closure and deprotonation at the prenyl tail gives amorpha-4,11-diene (89) 
(Figure 14).80–83  
 
 
Figure 14. Catalytic mechanism of amorphadiene synthase. 
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1.3.3 Aristolochene Synthase 
Although the formation of the nerolidyl diphosphate (84) intermediate is proposed in the 
mechanisms of numerous sesquiterpene cyclases, it is not the only mode of cyclisation.80,84,85 
Aristolochene synthase (AS) adopts a different approach to diphosphate cleavage. Figure 15 outlines 
the dissociation of OPP and the proposed catalytic mechanism of aristolochene synthase. 
Diphosphate cleavage is a result of SN2-like attack of the C10,C11 -bond at C1 of (2E,6E) FDP (31) 
resulting in concerted generation of the germacryl cation (90).86 It is proposed that the OPP anion is 
positioned in an ideal proximity to C13 to act as a base and deprotonates 61 to yield germacrene A 
(40).87 Due to the weak basic nature of the OPP anion, its conjugate acid is able to serve as a 
BrØnsted acid when coordinated to three Mg2+ ions. Protonation of the C6,C7 double bond affords 
the eudesmane cation (91) which undergoes a [1,2] hydride shift and a [1,2] methyl shift to give 92 
and 93 respectively. Finally, deprotonation of cation 93 gives aristolochene (76).88 
 
 
Figure 15. Catalytic mechanism of aristolochene synthase. 
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1.4 Methods of examining the catalytic mechanisms of sesquiterpene 
cyclases 
 
Catalysis by sesquiterpene cyclases involves the intricate guidance of carbocations to a complex and 
stereochemically pure product. From the initial formation of the farnesyl cation (83), numerous 
cascades of carbocations, hydride and alkyl shifts, cyclisations, protonations and deprotonations are 
involved, influenced by the enzyme.89 Table 1 (section 1.1) outlines examples of promiscuous 
terpene cyclases able to accept multiple substrates and catalyse the formation numerous products.90 
γ-Humulene synthase found in grand fir trees (Abies grandis) is a further example of a sesquiterpene 
cyclase that catalyses the turnover of FDP (31) to 52 products.91 In general, sesquiterpene cyclases 
exhibit remarkably high fidelity by catalysing the formation of a single product. Metal binding motifs 
for substrate-enzyme binding (section 1.2.1) and hydrophobic/aromatic active site residues 
orientate the isoprenoid-tail into a favoured configuration.92,93 This templating effect enables the 
distinction of similar energy pathways, stabilising carbocations and substrate configuration 
throughout the mechanism.60  
Numerous experimental methods are available to study the mechanisms of terpene cyclases. 
Mechanistic investigations are commonly focused on potential carbocation intermediates, probing 
their formation via two approaches. Aza-analogues are used to mimic putative carbocation 
intermediates with an ammonium species94 and fluorinated analogues95 interrupt the mechanism by 
destabilising carbocation formation. The stereospecific incorporation of deuterium in place of 
hydrogen96 enables elucidation of specific hydride shifts within the mechanism and site directed 
mutagenesis for the single point mutation of critical residues to probe their effect on catalytic 
efficiency and product formation.97 
1.4.1 Aza-analogues 
The investigation of cyclase mechanisms is made difficult by the intrinsic instability and transient 
nature of the carbocation intermediates that are formed. It is not possible to isolate these unstable 
intermediates, however, the use of quaternary nitrogen containing analogues imitates the positive 
species (Figure 16).98 The sp2 hybridised carbocation is replaced with a sp3 hybridised nitrogen or sp2 
hybridised iminium ion. These aza-analogues are intended to mimic the stereochemical and 
electrostatic properties of generated intermediates as closely as is possible.61 Due to the positive 
charge residing on an aza-analogue being stable, the enzyme is unable to catalyse further reactions 
that would occur with the corresponding carbocation. As a result, the analogues are often tightly 
bound to the active site acting as competitive inhibitors of the enzyme.77 Inhibition of a terpene 
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cyclase by an aza-analogue therefore suggests that the corresponding carbocation is generated 
within the mechanism.99  
 
 
Figure 16. Examples of carbocations and their corresponding aza-analogues: bisabolyl cation (86), aza-bisabolyl cation 
(94), eudesmane cation (91) and aza-eudesmane cation (95). 
 
1.4.2 Fluorinated analogues 
A second method for probing carbocation formation is the incubation of fluorinated analogues with 
a sesquiterpene cyclase and analysis of incubation products.100 Fluorinated substrates have been 
used in the mechanistic investigation of terpene cyclases as the size of fluorine relative to the 
substituted hydrogen does not greatly affect binding affinities.11 Though substrate-enzyme binding is 
not hindered, the electronegative nature of fluorine exhibits a strong electronic influence on 
carbocations at the α, β and γ-positions. Inductive effects of fluorine increase the energy of the 
carbocation at the β and γ-positions making carbocation formation unfavourable, whilst a 
carbocation at the α-position is stabilised by π-donation of the fluorine lone pair or 'alpha effect' 
(Figure 17).101  
 
 
Figure 17. Electron withdrawing and donating effects of a fluorine substituent potential carbocations at the α, β and γ 
positions: Stabilisation of α-cation (96) via alpha effect (left), destabilisation of β-cation (97, middle) and γ-cation (98, 
right) via the inductive effect. 
Fluorinated analogues have been utilised to investigate the mechanism of aristolochene synthase 
(AS) (Figure 15).102 The [1,10] ring closure could proceed via two methods. The first is a stepwise ring 
closure by dissociation of the diphosphate group forming the farnesyl cation (83) and nucleophilic 
attack by the C10,C11 double bond to give the germacryl cation (90). The second method is a 
concerted mechanism by an intramolecular SN2-like reaction. To investigate the whether a stepwise 
or concerted mechanism occurs, (2Z,6E)-2-fluorofarnesyl diphosphate (99) was incubated with 
aristolochene synthase (AS). Incubation of 99 with AS would inhibit the formation of fluoro-cation 
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(100), in contrast a concerted mechanism would give cation (101) and yield a fluorinated product. 
The incubation gave a single enzymatic product that was found to be 2-fluorogermacrene A (102). 
The formation of 102 gives evidence for a concerted mechanism and insight into the formation of 
the fluoro-eudesmane cation (103). In the catalytic mechanism of AS (Figure 15), the [1,6] cyclisation 
following the formation of the germacryl cation (90) generates the eudesmyl cation (91). The 
presence of fluorine at the C2 position reduces the nucleophilicity of the C2,C3 double bond 
prohibiting formation of the fluoro-eudesmyl cation (103) and its protonation thereby inhibiting the 
enzyme (Figure 18).103,104 
 
 
Figure 18. Possible outcomes from the incubation of (2Z, 6E)-2 fluorofarnesyl diphosphate (99) with aristolochene 
synthase (AS). 
A second fluorinated analogue 12,13-difluorofarnesyl diphosphate (104) was incubated with AS to 
determine the nature of the initial ring closure. Incubation of 104 would inhibit the formation of the 
fluoro-germacryl cation (105) and inhibit substrate turnover whilst a stepwise mechanism may yield 
12,13-difluorinated farnesenes 108 and 109 (Figure 19).105 
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Figure 19. Possible outcomes from the incubation of (2E,6E)-12,13-difluorofarnesyl diphosphate (105) with aristolochene 
synthase (AS). 
The incubation of 104 and AS resulted in no detectable enzymatic products. Evidence from 
incubations of fluorinated substrate 99 and 104 with aristolochene synthase determined that the 
substrate goes through a concerted [1,10]-cyclisation via an intramolecular SN2 like reaction to form 
the germacryl cation (90) (Figure 15). 
In contrast, the incubation of (2E,6E)-10-fluorofarnesyl diphosphate (110) with germacrene A 
synthase (GAS) resulted in 10-fluorohumulene (114). The presence of fluorine at the C10 position 
would be expected to destabilise the formation of the fluoro-germacryl cation (115) leading to 
inhibition of GAS. The formation of 10-fluorohumulene demonstrates that GAS is able to catalyse an 
anti-Markovnikov [1,11]-macrocyclisation from the C10, C11 double bond due to the fluorine atom 
invoking α-stabilisation of the cation at the C10 position (113) (Figure 20).106  
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Figure 20. Catalytic mechanism of germacrene A (GAS) synthase (top) and proposed mechanism for the incubation of 
110 with GAS (bottom). 
1.4.3 Isotopologues 
Isotopologues of (2E,6E) farnesyl diphosphate (31) have been critical in the elucidation of some 
chemical steps catalysed by terpene cyclases and for following reaction kinetics. Radiolabelled 
substrates have been utilised by numerous research groups for the measurement of steady state 
kinetics.97,107–112 The identification of hydride shifts catalysed by terpene cyclases are investigated by 
the incorporation of deuterium (2H) at specific positions.113,114 Analysis of the deuterated enzymatic 
product when compared to the natural product would show an increase (+1 m/z) on the respective 
mass spectrum fragment and the loss of the corresponding proton signal on the 1H NMR 
spectrum.115,116 
Picaud et al. published an investigation of the hydride shifts that occur in the reaction catalysed by 
ADS (Figure 14).117 Three deuterated analogues were synthesised for the investigation of the [1,3] 
hydride shift taking place immediately after the [1,6] ring closure; (2E,6E)-[1,1-2H2]-FDP (116), 
(2E,6E)-(R)-[1-2H] -FDP (122) and (2E,6E)-(S)-[1-2H]-FDP (127). Deuterated analogues 116, 122 and 
127 were incubated with ADS and were shown via gas chromatography-mass spectrometry (GC-MS) 
to produce deuterated amorpha-4,11-diene products. The EI+ mass spectrum of amorpha-4,11-diene 
(89) has four fragment cations of interest 112, 113, 114 and 115 (Figure 21), which can used to 
analyse deuterated products by comparison of mass spectra and respective fragmentations. 
Incubation of substrates 116, 122 and 127 and respective products would result in a m/z ratio 
increase of +1 or +2 depending on which deuteride was shifting during the mechanism (Figure 22).  
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Figure 21. Ions observed in the mass spectrum of amorpha-4,11-diene (89). 
The incubation of double deuterated substrate 116 showed a mass increase of +2 of fragment peaks 
indicative of cations 118, 119 and 120 with a +1 increase of 121 (Figure 22). These fragmentations 
show deuterium movement from the C2 to C6 position giving cation 121 with an m/z = 94 (Figure 
22). The incubation of (2E,6E)-(R)-[1-2H]-FDP (122) and ADS was proposed to give deuterated 
amorpha-4,11-diene (119) at the C6 position. The respective fragmentations for cations 126 and 125 
provided strong evidence for [1,3] hydride shift of the proR proton with no m/z increase of 125 
whilst a +1 increase was observed with all fragmentations; 124, 125 and 126. To confirm the hydride 
shift of the proR proton, (2E,6E)-(S)-[1-2H]-FDP (127) was incubated with ADS. The resulting mass 
spectrum showed fragmentations consistent with cations 129, 130, 131 and (Figure 22); a +1 m/z 
increase of proposed cations 122, 123, 124 and 125 (Figure 21). These m/z increases of deuterated 
fragments give evidence the proS proton does not move during the ADS mechanism, generating 
deuterated product 128.117  
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Figure 22. Pentane extractable products from the incubations of deuterated analogues 116, 122 and 127 with 
amorphadiene synthase and the resultant fragmentation and cation intermediates generated during GC-MS analysis. 
The incubation of deuterated substrates 116, 122 and 127 with ADS and analysis of their respective 
enzymatic products 117, 123 and 129 via mass spectrometry shows how isotopologues are a 
powerful tool for the elucidation of hydride shifts. 
1.4.4 Plasticity residues 
Plasticity residues are specific amino acid residues within the active site of terpene cyclases that are 
responsible for catalytic promiscuity54,97 It has been proposed that secondary metabolic enzymes can 
evolve to develop substrate promiscuity and an expanded product range118 within the host 
organism. Plasticity residues can have significant functions within enzyme specificity with key 
mutations shown to effect product profile and reaction rates.75,119 Terpene cyclases have been 
shown to have a lower catalytic efficiency than the majority of central metabolic enzymes with an 
average kcat  value approximately 30 times lower.
120 In terms of efficiency, terpene cyclases are not 
optimised by nature however enzymatic products have direct applications of great importance. 
Metabolic engineering of plasticity residues could enable proteins with improved substrate turnover 
relative to the natural enzyme, accessing terpenoid products that are synthetically challenging to 
acquire in significant quantities. 
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A publication by Li et al.,121 reported the mutation of specific residues of Artemisia annua α-bisabolol 
synthase (AaBOS) that are responsible for product specificity. A tetra-substituted mutant AaBOS-M1 
(V373N, I395V, N398I and L399T) and penta-substituted mutant AaBOS-M2 (V373N, L381A, I395V, 
N398I and L399T) were produced to investigate residue plasticity. Incubation of AaBOS-M1 and 
AaBOS-M2 with (2E,6E) FDP (31) yielded 29.3% and 68.8% of γ-humulene (134) respectively 
alongside α-bisabolol (133), (Figure 23).121 
 
 
Figure 23. Product distribution of AaBOS, AaBOS-M1 and AaBOS-M2. 
The L399T mutation of AaBOS-M2 resulted in a 39.5% increase of γ-humulene (134) formation with 
respect to AaBOS-M1, however single point residue mutations of AaBOS did not vary product 
formation giving evidence of a synergistic effect of residues. 
A single point mutation T399S A. annua amorpha-4,11-diene synthase (AaADS), AaADST399S showed a 
drastic increase in catalytic efficiency with respect to the wild type enzyme with kcat and kcat/KM 
increasing by 83% and 71.7% respectively. 
Table 2. Kinetic parameters of AaADS and AaADST399S (modified from publication by Li et al.
121
). 
Kinetic parameter AaADS AaADST399S 
KM (µM) 3.56 3.79 
kcat (s
-1) 1.37 2.51 
Vmax (µMs
-1mg-1) 4.12 x 10-3 7.53 x 10-3 
kcat / KM (µMs
-1) 0.385 0.662 
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Plasticity residues can have a dramatic effect on the rate and product distribution of terpene 
cyclases; however the full contribution of these specific amino acids has not been studied in detail. 
 
1.5 Non canonical sesquiterpene cyclases 
 
Although sesquiterpene cyclases can vary in terms of product promiscuity and the presence of 
archaic non-functional domains, several features are conserved throughout the class of terpenoid 
cyclases.122 The conserved DDxxD/E and NTE/DSE motifs, a single catalytic α domain consisting alpha 
helical bundle and the use of (2E,6E) farnesyl diphosphate (31) are universal traits adopted by the 
sesquiterpene cyclase family. However, individual cases of non-canonical sesquiterpene cyclases 
exist that contrast with these generalities.123 
1.5.1 Geosmin Synthase 
Geosmin synthase is a non-canonical sesquiterpene cyclase that uses (2E,6E) FDP (31) as a substrate 
but forms a product containing 12 carbons. Geosmin synthase from S. coelicolor is a class I 
sesquiterpene cyclase that contains two catalytically active α domains.124,125 As previously discussed, 
class I terpene cyclases generally consist of a single α domain in which the class I active site resides 
however, multiple non-active domains may still be present as part of the protein structure. This 
bifunctional cyclase adopts an αα domain structure126 with the first catalytic mechanism occurring in 
the α domain at the N terminus.127  
A magnesium-dependent [1,10] cyclisation yields two products; germacradienol (136, 85%) and 
germacrene D (2, 15%)(red). After dissociation from the N-terminal active site, germacradienol 
(136)128, rebinds to the C-terminal active site, undergoing protonation-dependent cyclisation and 
fragmentation to give 137 and acetone. A [1,2] hydride shift, protonation and subsequent quenching 
of the carbocation by water gives geosmin (139, blue), (Figure 24).129,130 Geosmin synthase is an 
uncommon example of a terpene cyclase catalysing the formation of product with less carbons than 
in the isoprenyl substrate.130 
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Figure 24. Catalytic mechanism of geosmin synthase. 
 
1.5.2 Santalene and Bergamotene Synthase 
Santalene and bergamotene synthase (SBS) is a three domain class I sesquiterpene cyclase isolated 
from the chloroplasts of the wild tomato plant, S. habrochaites.131 In contrast to the majority of 
sesquiterpene synthases, santalene and bergamotene synthase does not utilise the 'universal' 
substrate (2E,6E) FDP (31) as a substrate instead it utilises the cisoid isomer (2Z,6Z) FDP (38) as a 
substrate, exhibiting product promiscuity with the formation of five different sesquiterpenes 
products.3 
The proposed mechanism begins with the formation of the cisoid farnesyl cation (140) resulting from 
the removal of the diphosphate moiety. A [1,6] ring closure then gives bisabolyl cation isomers 141 
and 145 with either a [2,7] or [3,7] cyclisation yielding the cation precursors for the bergamotene or 
santalene products respectively. The formation of (-)-exo-α-bergamotene (58) requires the rotation 
of the C6,C7 bond of cation 141 (red arrow). The rotation is followed by a [2,7] cyclisation and 
deprotonation to give 58 (Figure 25). A [2,7] cyclisation of 141 without rotation gives cation 143. 
Deprotonation of the methylene (blue) or methyl (green) group of cation 143 gives (-)-endo-α-
bergamotene (61) or (+)-endo-β-bergamotene (144) respectively (Figure 25). After the formation of 
cation 145, a [3,7] cyclisation gives cationic intermediate 146 after which the mechanism can 
proceed in two ways. A[3,4] methyl shift and deprotonation of the resultant cation 147 gives (-)-epi-
β-santalene (57). Alternatively, a [2,4] cyclisation of 146 yields (+)-α-santalene (55) (Figure 25).132 
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Figure 25. Catalytic mechanism of santalene and bergamotene synthase and products; (-)-exo-α-bergamotene (58), 
(-)-endo-α-bergamotene (61), (+)-endo-β-bergamotene (144), (-)-epi-β-santalene (57) and (+)-α-santalene (55). 
Santalene and bergamotene synthase (SBS) was the first published example of a sesquiterpene 
synthase that does not utilise (2E,6E) FDP (31) as a substrate introducing a new class of terpene 
cyclases with cisoid isoprenoid substrate specificity. 
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1.6 Applications of sesquiterpene cyclases 
 
With a multitude of sesquiterpene cyclases and their products characterised, an abundance of 
applications concerning sesquiterpene products have been developed. Terpenoid natural products 
have applications within the pharmaceutical,133 fuel134 and food industries135 whilst others can be 
utilised by humans for the same purpose they are synthesised.106 Understanding the structure, 
mechanism and substrate/product promiscuity of sesquiterpene cyclases could provide opportunity 
to quickly access structures of high complexity without the need for extensive synthetic procedures.  
1.6.1 Pharmaceuticals 
An example of a sesquiterpene utilised within medicine is amorpha-4,11-diene (89).83 Produced from 
(2E,6E) FDP (31) through the magnesium dependent catalysis of amorphadiene synthase (ADS), 89 is 
a precursor of the potent anti-malarial drug artemisinin (7)(Figure 26).80 Originally isolated from 
sweet wormwood (Artemisia annua), the compound’s unusual highly oxygenated core is responsible 
for the drug’s activity.136 82 
Gossypol (6) isolated from the seed stem and root of the cotton plant (Gossypium) is a derivative of 
the sesquiterpene δ-cadinene (80) (Figure 26). In addition to cytotoxic properties, gossypol has been 
proposed as a form of male contraceptive.137 Studies funded by the Chinese government revealed 
that the drug was effective, well tolerated and did not result in changes in blood pressure, weight or 
main biochemical parameters.138 Two undesirable side effects of gossypol were noted; hypokalemia 
(a reduction in blood potassium) in 10% of users and the irreversibility of the contraceptive effect in 
approximately 10% of users. However, research investigating the application of gossypol as a 
contraceptive is on-going.8 
α-Bisabalol (133) is produced by α-bisabalol synthase (AaBOS) from (2E,6E) FDP (31) (Figure 26) and 
is found in chamomile (Matricia recutita).139 The sesquiterpene alcohol is responsible for many 
beneficial effects associated with chamomile and reported to exhibit anti-inflammatory, 
antibacterial, anti-allergic, drug permeation and vermifugal (an agent that destroys or expels 
parasitic worms) properties.140 The Food and Drug Administration (FDA) gave α-bisabolol (133) a 
Generally Regarded as Safe (GRAS) status allowing its use within commercial products.141 
These examples are only a small number of the biologically interesting sesquiterpene products 
utilised within the pharmaceutical industry. Terpene cyclases give access to many structures of 
interest that are difficult to synthesise with high yield and correct chirality and stereochemistry 
through traditional synthetic organic routes. Unfortunately, though terpene cyclases can yield 
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complex structures, they are also a bottle neck within industrial processes as substrate turnover and 
product extraction can be problematic.  
 
 
Figure 26. Sesquiterpene cyclases that yield pharmaceutically interesting products; amorphadiene synthase (ADS, top), 
δ-cadinene synthase (DCS, middle) and α-bisabalol synthase (AaBOS, bottom). 
1.6.2 Biofuels 
Dwindling fossil fuel reserves and energy security have highlighted an interest in the production of 
sustainable fuel sources. The use of sesquiterpene derived biofuels is an attractive alternative to 
currently used petroleum based fuels.142 Low hygroscopy, high energy density and good fluidity at 
low temperatures advocates their use as a plausible replacement that could be assimilated into the 
current infrastructure.143 Two sesquiterpene derived products; farnesane (149) and bisabolane (152) 
have been proposed as potential alternatives.144 
Farnesene is the collective name for 3 stereoisomers; (2Z,6E)-α-farnesene (148), (2E,6E)-α-farnesene 
(59) and E-β-farnesene (60) all of which are utilised as semiochemicals by various plants, (Figure 
27).145–147 Farnesene is produced by a wide range of organisms with the hydrogenated derivative 
farnesane (149) a potential renewable fuel source. Farnesane has a cetane number of 58 (cetane 
number of diesel fuels must be within a 40-60 range)148 and a -78 ᵒC cloud temperature when 
compared to D2 diesels (-3 ᵒC) gives a potential replacement for diesel and jet fuel.149  
Bisabolene synthases are the sesquiterpene cyclases responsible for the biosynthesis of bisabolene 
products and are generated in various conifer species to repel attacking species.45,150,151 Bisabolane 
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(152) is the hydrogenated derivative of three bisabolenes; α-bisobolene (66), β-bisabolene (150) and 
γ-bisabolene (151) (Figure 27). Monocyclic derived, hydrogenated sesquiterpene products such as 
bisabolane (152) are comparable with farnesane. An equivalent low cloud temperature (-78 ᵒC) and 
a favourable density (bisabolane = 0.88 gmL-1, farnesane = 0.77 gmL-1) give premise as a diesel 
alternative.152  
The application of sesquiterpene products as biofuels is not confined to the use of bisabolane (152) 
or farnesane (149), as many other monocyclic products are available. However, as with 
pharmaceutically applicable products using sesquiterpene cyclases, substrate turnover and product 
extraction could be slower than the required demand. 
 
 
Figure 27. Sesquiterpene cyclases whose products have applications as biofuels; farnesene synthase (FS, top) and 
bisabolene synthase (BS, bottom). 
1.6.3 Food and flavourings 
Plant sesquiterpene products are often responsible for plant defence; however, some examples 
exhibit a second function as flavouring in food. Zingiberene (33) is a monocyclic sesquiterpene 
isolated from ginger (Zingiber officinale) (Figure 28). Zingiberene synthase (ZS) catalyses the 
cyclisation of (2E,6E) FDP (31) to give 33 which constitutes up to 30% of essential oils within ginger 
rhizomes and is responsible for the distinct flavour.153,154 
(-)-β-Caryophyllene (153) is a constituent of various essential oils and can be isolated from the stems 
and flowers of cloves (Syzygium aromaticum)155 and rosemary (Cannabis sativa).156 
(-)-β-caryophyllene (153) also contributes to the spice of black pepper.157 The presence of four and 
nine membered rings is scarce in nature making (-)-β-caryophyllene (153) a rare structure (Figure 
28). 
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Hernandulcin (154) is a derivative of α-bisabolol (133), the product of α-bisabolol synthase (AaBOS) 
(Figure 28). The compound was known to the Aztec civilisation as the 'sweet plant', later identified as 
Lippia dulcis.158 The principle sweet component was concentrated in the leaves and flowers and 
judged by a human taste panel as more than 1000 times sweeter than sucrose.159 Due to a mint 
aftertaste, intense sweetness and no link to tooth decay; hernandulcin (154) is a proposed additive 
for oral hygiene products.160 
Sesquiterpenes are often the main constituents in natural flavours. Essential oils are often blends of 
terpenoid products with 33, 153 and 154 being examples of sesquiterpene products responsible for 
intense flavours.  
 
 
Figure 28. Sesquiterpene cyclases with products applicable as flavourings; zingiberene synthase (ZS, top), caryophyllene 
synthase (CS, middle) and α-bisabolol synthase (AaBOS, bottom). 
1.6.4 Semiochemicals and agriculture 
Semiochemicals are compounds produced by organisms which signal the change in development or 
behaviour of another organism without physiological activity. Within this class of chemicals are plant 
stress signals that are responsible for plant defence including phytopheromones that also play a role 
in plant development.161 Semiochemicals are not restricted to plant-herbivore interactions with 
chemically mediated communication also occurring between certain ant species (Formica 
subsericea) and the majority of aphid (aphidinae) species.162 It was observed by Nault et al. that 
when Formica subsericea were exposed to aphid alarm pheromones, they extended their antennae 
and opened their mandibles in preparation for attack from aphids.163 Many plant derived 
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semiochemicals are sesquiterpene products with the variety of stereochemistry and chirality 
allowing for these compounds to act as both herbivore repellents and pollinator attractants.164,165  
Semiochemicals have been investigated as replacements for commercial insecticides with the mode 
of action and subsequent impact on human and environmental health being inherently different to 
current chemical insecticides.166,167 With health concerns of insecticides and potential chemical run 
off into water systems, the use of semiochemicals increases safety for humans and non-targeted 
species, with the reduction of pesticide use, increase of pest predator activity166 and therefore 
increased biodiversity in agriculture ecosystems.168  
Two sesquiterpenes of interest are (E)-β-farnesene (60) and (-)-β-caryophyllene (153) (Figure 29). 
Both sesquiterpenes have been discussed previously for their roles in biofuels and food respectively. 
However, the functions of 60 and 153 in nature may be applicable to agriculture. (E)-β-Farnesene 
(60) is an alarm pheromone for the majority of aphid species169,170 and an attractant to the aphid 
predator, Asian lady beetle (Harmonia axyridis).165 (-)-β-Caryophyllene (153) also acts as an 
attractant to the male Asian lady beetle171 whilst the female showed no behavioural changes. 
Combination of sesquiterpenes 60 and 153 have potential in push-pull strategies utilising Asian lady 
beetles as a control for aphid infestation.165 The push-pull strategy requires a combination of 
(E)-β-farnesene (60) and (-)-β-caryophyllene (153); the presence of 60 acts as a deterrent for target 
pests from a protected host, with a combination of 60 and 150 attracting the respective predators as 
a secondary defence.172 
A second strategy in plant defence is the use of pest attractants i.e. the Bark beetle (Scolytus 
multistriatus) sex pheromone, (-)-α-cubebene (155) (Figure 29). An investigation in 1969 observed 
an increased attraction of male Bark beetles in response to (-)-α-cubebene (155) produced by virgin 
females tunnelling in elm logs.173 The Bark beetle is responsible for the spread of Dutch elm disease 
which decimated the non-resistant population of elm trees across America and Europe.174 The 
isolation of (-)-α-cubebene (155) gave rise to a trap and kill methodology of pest control. In contrast 
to using pest alarm pheromones that could result in infestations at other locations, the use of an 
attractant allowed for the trapping of the pests to slow the spread of disease.175 
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Figure 29. Sesquiterpenes with semiochemical products; (E)-β-farnesene (60), (-)-β-caryophyllene (153), (-)-α-cubebene 
(155) and (S)-germacrene D (2). 
Germacrene D synthase (GDS) catalyses the turnover of (2E,6E) FDP (31) to (S)-germacrene D (2) 
(Figure 29), a potent arthropod repellent effective towards aphids,176 ixodid ticks and red poultry 
mites.177 Touchet et al. reported the synthesis and incubation of novel isoprenyl diphosphate 
substrates with GDS and GDS mutants, generating novel germacrene products to use in aphid 
behavioural assays. The incubation of (2E, 6E)-14-methylfarnesyl diphosphate (156) with GDS(Y406F) 
yielded 14 methyl germacrene D (157) which like the natural product, was found to be a repellent to 
aphids. In contrast, the incubation of (2E,6E)-14,15-dimethylfarnesyl diphosphate (158) with 
GDS(Y406F) yielded a 14,15-dimethyl germacrene D (159) which was found to be a potent aphid 
attractant (Figure 30).178 
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Figure 30. Novel isoprenoid substrates 141 and 143 incubated with GDS(Y406A). 
This is an example of using modified isoprenoid substrates and sesquiterpene mutants to generate 
novel sesquiterpene products with similar and contrasting properties. Applications of sesquiterpenes 
cover a wide range of industries. The understanding and characterisation of sesquiterpene cyclases 
allows for the production of natural and novel sesquiterpene products with a plethora of 
applications.  
 
1.7 Whitefly, 7-epizingiberene and 7-epizingiberene synthase 
 
Herbivorous insects are a serious threat to agriculture through feeding on crops and their ability to 
transmit viruses capable of devastating the crop population in the area.3 With food production being 
an essential commodity contributing substantially to the global economy, measures must be taken 
to minimise crop destruction.179 Since the late 1980s, large areas spanning from Florida to South 
America have been plagued by geminiviruses as a result of whitefly infestation.180 As a result, the 
whitefly is now thought of as a major world pest concerning various agronomic and horticultural 
crops including tomatoes.181 However, various plants are capable of emitting varying amounts of 
volatile terpenoids (monoterpenes and sesquiterpenes) as a defence mechanism when infested with 
herbivores.41 An example of this comes in the form of wild tomatoes (Solanum habrochiates) that 
unlike their cultivated counterparts (e.g. moneymaker) exhibit significant herbivore resistance.2,182  
Santalene, bergamotene and 7-epizingiberene (1) are phytoalexins (a substance that is produced by 
plant tissues in response to contact with a parasite and specifically inhibits the growth of that 
parasite) the latter a repellent that is toxic to whitefly. Derivatives of 7-epizingiberene (1) may be 
more potent and stable repellents of whitefly and find use for increased protection of crop 
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populations from this devastating pest. The use of terpenes within agriculture should decrease the 
use of chemical pesticides which can have a devastating effect on the environment.183 
SBS and EZS are found within the wild tomato plant (Solanum habrochiates) and are members of a 
recently discovered class of sesquiterpene synthases have been that selectively use (2Z,6Z) farnesyl 
diphosphate ((2Z,6Z) FDP, 38).3 The substrate selectivity of these enzymes is intriguing as it is 
unconventional for the majority of characterised sesquiterpene synthases to act in this manner.2 
SBS and EZS are responsible for catalysing the Mg2+-dependent conversion of (2Z,6Z)-FDP (38) to 
three bergamotene  products 58, 61, 144 and two santalene products 56 and 5730 whilst EZS 
selectively and specifically yields 7-epizingiberene (1) (Figure 31).2  
 
 
Figure 31. Products arising from EZS and SBS catalysed turnover of (2Z,6Z) FDP (38). 
Generally, sesquiterpene precursors are synthesised via the MEV pathway however, EZS and SBS are 
found within the plastids suggesting that the formation of the isoprenyl precursor is produced using 
the DXP pathway.184 Z-Prenyltransferase is responsible for the synthesis of (2Z,6Z) FDP (38) following 
the DXP pathway and is found within the plastids of the wild tomato plant alongside SBS and EZS.184 
(2E,6E) FDP (31) is synthesised within the cytosol (MEV pathway, Figure 2) and is therefore not 
available to act as a substrate for SBS and EZS. 
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7-Epizingiberene synthase (EZS) contains three domains and could potentially exhibit both class I and 
II catalytic activity. Due to structural similarities to diterpene synthases, it could be postulated that it 
displays class II activity.14 However, since 7-epizingiberene synthase appears to catalyse diphosphate 
cleavage exclusively, activity associated with the class I active site, the β and γ domains appear 
catalytically silent.3 
 
 
Figure 32. Cartoon representation of EZS (left) and cartoon representation of the EZS catalytic alpha domain with (2Z,6Z) 
FDP (38) (right).
185
 
The catalytic mechanism of EZS is currently unknown. However, mechanistic predictions can be 
made based on knowledge of previously studied sesquiterpene synthases. Figure 33 outlines the 
plausible mechanistic routes that could be catalysed by EZS. 
As EZS exhibits class I activity, the initial carbocation is formed via diphosphate cleavage. EZS could 
favour a concerted [1,6] ring closure to form the bisabolyl cation (86). Alternatively, a stepwise ring 
closure with diphosphate cleavage forming a farnesyl cation (141) followed by a [1,6] ring closure to 
form 86. Numerous hydride shifts are then possible to attain the final product. A [1,3] hydride shift 
from C1 or C5 (shown in red and blue respectively) are possible, giving carbocations 161 and 162 
followed by a deprotonation to give 7-epizingiberene (1). Alternatively, a [1,2] hydride shift from C6 
(green) to give 160 followed by a second [1,2] hydride shift either from C1 or C5 (shown in red and 
blue respectively) to give 161 and 162 proceeded by deprotonation is conceivable to give 
7-epizingiberene (1). 
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Figure 33. Plausible reaction pathways that could be catalysed by EZS. 
Current publications concerning 7-epizingiberene synthase (EZS) by Bleeker et al.2,3 and Sallaud et 
al.30 have investigated gene isolation, plant cross breeding and bioassays to elicit an 
electroantennogram response in whitefly. Characterisation and a crystal structure have yet to be 
attained for EZS with KM and kcat values calculated using a GC-MS assay. All publications concerning 
EZS and SBS outline how both enzymes have high substrate specificity toward (2Z,6Z) farnesyl 
diphosphate (38) and not (2E,6E) farnesyl diphosphate (31). There have been no investigations into 
EZS substrate promiscuity towards stereoisomers of 31, (2E,6Z) farnesyl diphosphate and (2Z,6E) 
farnesyl diphosphate (341).  
Investigation of the mechanism, characterisation and substrate specificity of EZS may elucidate 
which novel substrates could yield analogues of 7-epizingiberene (1). A greater insight into EZS 
substrate specificity could yield a library of sesquiterpene products with semiochemical properties. 
As with germacrene D synthase site directed mutagenesis and incubation of novel substrates 
produced repellent and attractant semiochemicals that have applications for crop protection (Figure 
30). A greater understanding of EZS may yield similar results, with metabolic engineering to 
incorporate EZS into cultivated tomato species previously proposed by Bleeker et al.3  
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1.8 Project Aims 
 
7-Epizingiberene synthase represents a new class of sesquiterpene cyclases that defy convention by 
exclusively utilising the cisoid isomer of the previously thought ʿuniversalʾ substrate FDP (31) and 
therefore warrants investigation. The initial aim of the project was the synthesis of the natural EZS 
substrate, (2Z,6Z)-farnesyl diphosphate (38) followed by expression and purification of 
7-epizingiberene synthase. Following the purification of EZS; the synthesis of radiolabelled (2Z,6Z) 
farnesyl diphosphate, (2Z,6Z)-[1-3H]-FDP (229), was required for the kinetic characterisation of EZS. 
The purpose was to discover a low cost and reproducible synthesis of 38 as the precursor (2Z,6Z) 
farnesol (167) costs £1011.00 per mg (at the time of writing), whilst the transoid isomer (2E,6E) 
farnesol (353) costs £99.00 for 100 g. It is not viable to purchase (2Z,6Z) farnesol (167) in sufficient 
quantity to conduct research. Site directed mutagenesis was used to investigate class I and potential 
class II activity of EZS as well as probing the significance of specific aromatic residues within the class 
I active site pocket 
The second segment of the project focused on the synthesis of fluorinated substrates and 
isotopologues for mechanistic investigation. As discussed in sections 1.4.2 and 1.4.3, the use of these 
substrates can give evidence towards carbocation formation and hydride shifts that occur 
throughout the mechanism. Synthesis of stereoisomers of (2Z,6Z) farnesyl diphosphate (38) and 
their respective monoterpene substrates (2E,6Z) farnesyl diphosphate (342), (2Z,6E) farnesyl 
diphosphate (341), (2E,6E) farnesyl diphosphate (31), neryl diphosphate (39) and geranyl 
diphosphate (30) were used to give understanding to the substrate selectivity of EZS. The insight of 
substrate specificity allows for the synthesis of novel isoprenoid substrates for incubation with EZS. 
Analogues of EZS could exhibit repellent or attractant properties enabling greater herbivore 
resistance for cultivated tomato species.  
  
40 
 
 
 
Chapter 2 – Synthesis of (2Z,6Z) farnesyl diphosphate and the 
Expression and Purification of EZS and Mutants 
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2.1 Preface 
 
As the common substrate of sesquiterpene cyclases, preparation procedures for (2E,6E) farnesyl 
diphosphate (31) are well documented in literature.11,106,117,146,186,187 The precursor (2E,6E) farnesol 
(353) can be purchased directly and converted to 31 in two steps; halogenation and 
diphosphorylation.188 This low cost procedure is not time consuming or labour intensive in 
comparison to the preparation of (2Z,6Z) farnesyl diphosphate (38). The equivalent precursor, 
(2Z,6Z) farnesol (167) is too expensive to purchase in the required quantities.  
This chapter outlines the investigation of a high throughput, low cost synthesis of 38. This substrate 
was used to test the activity of EZS and mutants which had been heterologously expressed in E. coli. 
The methods used to optimise expression and purification of EZS of sufficient purity and quantity to 
perform characterisation assays are also described within this chapter.  
Site directed mutagenesis was used to investigate the conserved DDxxE and NSE metal binding 
motifs and specific active site aromatic residues. Mutants were generated by Dr Veronica González 
González and Mindaugas Kalvaitis with DNA sequencing of the plasmids used to confirm desired 
mutations. However, the expression, purification and characterisation of soluble protein had not 
been investigated with regards to the EZS or any respective mutants. Residues were selected using a 
homology model of EZS based on α-bisabolene synthase containing bound (2Z,6Z) farnesyl 
diphosphate (38) and three magnesium ions. The homology model was generated by Professor 
Andrea Brancale from the Cardiff University School of Pharmacy and Pharmaceutical Sciences with 
cartoon representations of the model used throughout this chapter. 
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2.2 Synthesis of (2Z,6Z) farnesyl diphosphate (38) 
2.2.1 Modified Wittig approach 
The preliminary steps of the proposed synthesis of EZS substrate (2Z,6Z) farnesyl diphosphate (38)2 
(Figure 34) were based on protocols outlined by Garneau et al.,189 and Kato et al.190 leading to an 
alkene-forming reaction used by José et al.,191 to synthesise a 10:1 ratio of 2-Z:2-E isomers (167 and 
168). (2Z,6Z) Farnesol (167) would then be used in the synthesis of 38.  
 
 
Figure 34. Proposed synthesis of (2Z,6Z) farnesyl diphosphate (38) using a modified Wittig reaction to give the Z C2,C3 
double bond as the stereoisomer. 
Nerol (163) was brominated using phosphorus tribromide to yield neryl bromide (164) in 
approximately quantitative yield. The carbon chain was extended by alkylating 164 with ethyl 
acetoacetate using potassium carbonate in dry acetone. Neryl keto ester (165) was decarboxylated 
by refluxing with potassium hydroxide in methanol to provide neryl acetone (166) for the key step. 
In the procedure outlined by José et al.,191 the betaine intermediate of the Wittig reaction was 
deprotonated with a stronger base (sec-BuLi) and reacted with formaldehyde to form the 
hydroxymethylene unit predominantly in the Z configuration (10:1 Z:E) (Figure 35). 
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Figure 35. Proposed mechanism of the José procedure.
191
 
Addition of n-butyl lithium to (methyl)triphenylphosphonium bromide (170) in dry tetrahydrofuran 
at 0 ᵒC formed the ylide reagent. The reaction was stirred for 30 min, cooled to -78 ᵒC and 171 added 
prior to stirring for a further 45 min at this temperature. Deprotonation of betaine intermediate 172 
by addition of sec-butyl lithium was followed by stirring for a further 60 min. The reaction was 
warmed to 0 ᵒC over 30 min and to room temperature over a further 2.5 h. Reaction products 
isolated via flash chromatography did not give 1H NMR signals for alkene or methylene 
environments characteristic of the required product. 
Numerous aspects of the reaction could lead to this failure. It was initially suspected that the betaine 
intermediate (172) was collapsing prior to the addition of sec-butyl lithium giving triphenyl 
phosphine oxide and a terminal alkene. However, analysis of 1H NMR spectra of the isolated 
products showed no trace of a terminal alkene which would give two doublets at approximately 4.6 
ppm with distinctive germinal coupling (1-3 Hz). The majority of recovered material was 166 and 
triphenyl phosphine. This suggests that the formation of intermediate 172 did not occur, possibly 
due to wet solvent or degraded n-butyl lithium. The reaction was repeated in turn with freshly 
distilled tetrahydrofuran and fresh n-butyl lithium but still yielded only a small quantity of an 
unidentified product. 
The formaldehyde used for the modified Wittig procedure was prepared from cracking 
paraformaldehyde by distillation immediately prior to use. The 1H NMR spectrum of the 
formaldehyde was inspected prior to use to ensure sufficient purity. Ethanal was used in place of 
formaldehyde to investigate whether addition of intact paraformaldehyde hindered product 
formation (Figure 36). Formation of the secondary alcohol would suggest that the formaldehyde was 
causing the reaction to fail. However, the reaction yielded the same results indicating formation of 
the betaine intermediate or its subsequent deprotonation were at fault. 
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Figure 36. Modified Wittig reaction substituting formaldehyde with ethanal. 
 
2.2.2 Wittig approach 
An alternative approach to the modified Wittig reaction191 using reagent 179 was explored (Figure 
37). The use of a hydroxylated reagent would remove the requirement of formaldehyde from the 
reaction. Kitahara et al.,192 and Syeda et al.,193published protocols outlining the a single step 
synthesis of allylic alcohols from aldehyde precursors using similar Wittig reagents. 
 
 
Figure 37. Proposed synthesis of (2Z,6Z) farnesol (167) using a Wittig salt to give the Z C2,C3 double bond. 
Direct reaction of (2-hydroxyethyl)triphenylphosphonium bromide (179) and neryl acetone (166) 
with two equivalents of n-butyl lithium as a base yielded only 166. The Wittig reaction requires ylide 
formation prior to the betaine intermediate. Deprotonation of the hydroxyl group on 179 could be 
followed by intramolecular attack of phosphorus giving triphenyl phosphine oxide and ethane as 
reaction products. Alternatively, intermolecular reactions between multiple deprotonated species 
may give dimer, trimer or polymer products. Subsequent variations shown in Table 3 gave 166 as the 
only isolated compound. A THP protection of 179 was attempted to stop unwanted interactions of 
intermediates but was unsuccessful due to the insolubility of 179 in DCM and hexane. 
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Table 3 - Reaction conditions attempted for the synthesis of the C2,C3 double bond using a Wittig salt. 
Solvent Volume / mL Base equivalents Reaction time prior to 166 / min Product 
3 1 60 X 
3 2 60 X 
3 2.5 60 X 
6 2 60 X 
6 2.5 60 X 
9 2 60 X 
9 2.5 60 X 
3 2.5 30 X 
3 2.5 90 X 
6 2.5 30 X 
6 2.5 90 X 
9 2.5 30 X 
9 2.5 90 X 
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2.2.3 Directed Wittig approach 
Multiple publications outline the use of (carbethoxymethylene)triphenylphosphorane (188) in E 
selective olefination reactions.194–196 Chen et al.,197 published the use of 188 in a directed Wittig 
reaction to  achieve 100% Z selectivity by using a hydroxylated starting material. A synthesis (Figure 
38) was proposed using a procedure outlined by Scheid et al.,198 to synthesise α-hydroxylated neryl 
acetone (187) for use in a Z selective directed Wittig reaction. N-Bromo succinimide (NBS) 
bromination of tert-butyl acetoacetate (182) gave varying yields (18-100%) with the yields of 
repetitions being consistently low (18-25%). Reaction yields from acetylation of 183 to give 184 were 
consistent with literature.197  Crude neryl bromide (164) was freshly prepared as outlined in Figure 
34 and alkylated with 184 using potassium carbonate in dry acetone. Analysis of isolated compounds 
by 1H NMR spectroscopy showed no peaks corresponding to the product. Due to high yields of 183 
not being reproducible the pathway was not pursued further.  
 
 
Figure 38. Proposed synthesis of (2Z,6Z) farnesol (167) using a directed Wittig reaction to give the Z C2,C3 double bond. 
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2.2.4 Anastasia approach 
Installation of the C2,C3 double bond giving a 1:1 mixture of E:Z ethyl farnesoate esters was 
attempted via a procedure published by Anastasia et al.199 The synthesis of 167 would follow a 
similar synthetic route outlined in Figure 34:  
 
Figure 39. Synthesis of (2Z,6Z) farnesyl diphosphate (38) using an Anastasia reaction to give the Z C2,C3 double bond. 
An experimental procedure published by Faraldos et al.,200 was followed for the olefination of 166 
(Figure 39). n-Butyl lithium was added to ethoxy acetylene (191) in dry THF at -78 ᵒC. The reaction 
mixture was stirred for 1 h prior to the addition of 166 at -40 ᵒC and then stirred for a further 1 h. 
The reaction was quenched with 1M H2SO4 and stirred at room temperature for 16 h. The crude 
product was purified via flash chromatography to give a 1:1 mixture of E and Z ethyl farnesoates 192 
and 193. 
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Figure 40. Proposed reaction mechanism outlined by Anastasia et al.
199 
The reaction mechanism proposed by Anastasia et al.,199 involves the nucleophilic attack of water on 
intermediate 198. The reaction is restricted to a 1:1 ratio of E:Z isomers as this interaction can occur 
freely from both sides (Figure 40). The reaction is difficult to monitor as product formation is not 
detectable until after quenching by H2SO4 and water.  
Partial separation of the E and Z farnesoate esters was achieved via flash chromatography over silica 
(5% ethyl acetate in hexane). Improved isomer separation by flash chromatography was possible 
after esters 192 and 193 were reduced to alcohols 168 and 167 using diisobutyl aluminium hydride 
(DIBALH). Alcohol 167 was brominated using phosphorus tribromide and the crude product (169) 
diphosphorylated via stirring with tris-tetrabutylammonium diphosphate in anhydrous acetonitrile. 
The crude diphosphate was passed through a cation exchange column [Amberlyst 131 (wet H+ form) 
mesh cation exchange resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% 
isopropanol)] to give the ammonium salt as a white powder after lyophilisation. Cation exchange of 
the diphosphate moiety aids the removal of excess diphosphate and purification via high 
performance liquid chromatography (HPLC). Fractions containing product as viewed from the UV-vis 
trace from HPLC purification were lyophilized to give 38 as a white powder.  
The olefination reaction was found to be the bottle-neck of the synthetic pathway. Variable yields 
and expensive reagents limited the through put and scale up substrate synthesis. Therefore, a 
different approach to 38 was investigated to circumvent the use of costly reagents allowing for the 
scale up of reactions.  
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2.2.5 Horner-Wadsworth-Emmons approach 
A Horner-Wadsworth-Emmons (HWE) reaction was investigated to replace the Anastasia reaction.199 
Three HWE reagents, were used; triethyl phosphonoacetate (202) first published by Horner et al.,201 
and later defined by W. Wadsworth and W. Emmons,202 ethyl (diphenoxyphosphoryl)acetate (203) 
proposed by Ando et al.,203 and the Still-Gennari modification204 of 202; ethyl P, P-bis(2,2,2-
trifluoroethyl)phosphonoacetate (204) (Figure 41). 
Reagent 202 is an alternative reagent to a Wittig salt to yield E double bonds from the olefination of 
aldehydes.201 The use of ketone 166 causes’ greater steric interactions decreasing the stereo-
selectivity achieved. Reagents 203 and 204 have increased Z stereoselectivity203,204 though unlike 202 
are not commercially available. Reagent 202 was therefore used to optimise reaction conditions 
prior to the use of 203 and 204 to increase the Z stereoselectivity.  
 
 
Figure 41. Horner-Wadsworth-Emmons reagents investigated for the optimisation of Z bond formation. 
Ethyl (diphenoxyphosphoryl)acetate (203) was prepared via the procedure published by Ando et al., by 
the condensation of diphenyl phosphite (205) and ethyl bromoacetate (206) (Figure 42).203 The single 
modification to the experimental was the addition of diphenyl phosphite (205) and ethyl 
bromoacetate (206) via syringe pump to ensure the addition of reagents at a constant rate over 30 
minutes in place of using a dropping funnel. 
 
 
Figure 42. Synthesis of ethyl (diphenoxyphosphoryl)acetate (203). 
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Figure 43. Synthesis of P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate (204). 
The Still–Gennari reagent (204) (Figure 43) was prepared using the protocol published by Messik et 
al.205 Triethyl phosphonoacetate 202 and trimethylsilyl chloride (TMSCl) were sealed in a pressure 
tube and stirred for 7 days at 100 ᵒC. The quantity of 205 that could be synthesised was limited by 
the pressure tube volume and reaction timescale. A 5 h reflux of 202 with trimethylsilyl bromide 
(TMSBr) eliminated the use of pressure tubes due to the higher boiling point of TMSBr compared to 
TMSCl (79 ᵒC and 57 ᵒC respectively). Procedures for the synthesis of 206 and 204 were followed 
directly from the publication.205 However, purification of 204 was changed from a distillation to flash 
chromatography (50% ethyl acetate in hexane) with the removal of residual 2,2,2-trifluoro ethanol 
(207) under reduced pressure. 
Solvent, cation and temperature effects of HWE reactions with aldehydes to achieve E selectivity 
were investigated by Thompson et al.,206 and a similar investigation was carried out to increase 
reaction yield and Z:E ratio. Sodium hydride (NaH), lithium diisopropyl amide (LDA), potassium 
hexamethyldisilazide (KHMDS) and n-butyl lithium (n-BuLi) were used in attempt to increase the Z 
isomer formation when a softer counter cation was present (Li < Na < K). Thompson suggested that 
harder counter cations and higher reaction temperatures enable easier dissociation of the betaine 
intermediates. This allows the thermodynamically favourable threo intermediate (210) formation to 
give the E isomer over the kinetically favoured erythro configuration (214) resulting in the Z isomer 
(Figure 44). 
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Figure 44. The formation of threo (210) and erythro (214) intermediates during a Horner-Wadsworth-Emmons reaction. 
Thompson concluded that the solvation of betaine intermediate and cation chelation have greater 
effect on lithium-containing bases. The use of dimethoxyethane (DME) in place of THF doubled the 
ratio of E:Z when lithium containing bases were used. However, this effect was not replicated when 
potassium and sodium containing bases were employed.  
Comparison of THF and toluene may indicate if the effect of lower polarity and dipole moment are 
applicable. It was found that the use of NaH in toluene at 0 ᵒC consistently gave the highest yield and 
the highest proportion of Z isomer in the isolated product. Table 4 outlines the various conditions for 
reaction optimisation. 
Table 4. Reaction conditions investigated for the optimal conditions for Z double bond formation via a 
Horner-Wadsworth-Emmons reaction. 
Reagent Solvent Base Temperature / ᵒC Ratio 
192 (E):193 (Z) 
Yield of  
193 (Z)/ % 
202 THF n-BuLi 0 4:1 14 
202 THF KHMDS 0 4:1 11 
202 THF LDA 0 4:1 8 
202 THF NaH 0 4:1 17 
202 Toluene n-BuLi 0 4:1 14 
202 Toluene n-BuLi -78 4:1 12 
202 Toluene NaH 0 4:1 19 
202 Toluene NaH -78 4:1 18 
203 THF n-BuLi 0 2:1 21 
203 THF NaH -78 2:1 23 
203 Toluene n-BuLi -78 2:1 21 
203 Toluene NaH 0 2:1 29 
204 THF n-BuLi 0 1:1 33 
204 THF NaH 0 1:1 38 
204 Toluene n-BuLi -78 1:1 31 
204 Toluene NaH -78 1:1 38 
204 Toluene NaH 0 1:1 43 
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Figure 45. Synthesis of (2Z,6Z) farnesyl diphosphate (38) using a Horner-Wadsworth-Emmons reaction. 
Neryl acetone (166) was prepared as previously described. The optimised conditions highlighted 
yellow in Table 4 were used for the olefination of 166 giving a 1:1 ratio of E:Z ethyl farnesoate esters 
192 and 193. The yields of this reaction were consistently high (reaction yield: 74-86%, yield of Z 
isomer: 37-43%) with the starting material readily recovered by flash chromatography. The 
preparation of 204 using TMSBr also allowed for a larger scale synthesis than was possible using the 
Anastasia olefination. The Still-Gennari modified Horner-Wadsworth-Emmons reaction was used as 
the primary method for installing Z double bonds (Figure 45). 
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2.3 Heterologous expression and Purification of EZS  
 
EZS gene without 36 amino acid N-terminus signalling peptide63 inserted with a pET21a vector in 
conjunction with a TEV cleavage site and C-terminal His6-tag was hetereogeneously expressed in 
Escherichia coli (E. coli) BL21 (DE3) cells. Transformation of this plasmid into the E. coli BL21 (DE3) 
cells was followed by overnight growth on an ampicillin containing agar plate. Bacterial colonies that 
had grown overnight were resistant to ampicillin and a single colony was used to innoculate 
lysogeny broth growth medium (LB medium) containing ampicillin and incubated in a shaker at 37 ᵒC 
overnight. A sample of the overnight expression was placed into fresh LB media containing 
ampicillin. The culture was incubated in a shaker at 37 ᵒC until the optical density (OD at 600 nm) of 
the cells reached and protein expression induced by the addition of isopropyl 
β-D-1-thiogalactopyranoside (IPTG). Induced cells were incubated in a shaker overnight at 20 ᵒC and 
were harvested by centrifugation. The resulting pellets were used immediately or stored at -20 ᵒC. 
Conditions for the optimal heterologous expression and purification of EZS were investigated and 
enzyme activity was tested by incubation with (2Z,6Z) FDP (38), with pentane extractable products 
analysed by GC-MS. 
 
2.3.1 Optimising expression temperatures 
The plasmid containing EZS DNA was transformed into E. coli BL21 (DE3) cells and protein expression 
tested with induction temperatures of 16 ᵒC, 20 ᵒC, 25 ᵒC overnight and 37 ᵒC for 4 h after the 
addition of IPTG. SDS PAGE analysis of whole cell extracts could not identify clear expression bands 
at the appropriate molecular weight (Appendix figure). A band above the 66.2 kDa was visible at 37 
oC, corresponding to the expected molecular mass of EZS (88.5 kDa) but low expression levels meant 
this was inconclusive.  
2.3.2 Purification of the insoluble fraction 
Heterologous expression could not be conclusively identified from analysis of the SDS PAGE. 
Although a protein band of correct molecular mass was not observed, purification of EZS was 
attempted to see if protein had been expressed; using Ni-NTA methods to confirm production by 
SDS PAGE and to determine the most suitable conditions for expression. Cells from the incubations 
were re-suspended in cell lysis buffer (100 mM NaCl, 5mM βME, 20 mM TRIS base, 1% TWEEN 20, 
pH 7.0) and the cells lysed by sonication. The cell debris and supernatant solution were separated 
using a centrifuge before two methods were used in attempts to purify EZS: basic extraction of 
insoluble protein and Ni-NTA column. A basic extraction involves the unfolding of the proteins within 
inclusion bodies through raising the pH to a high level in order to solubilise them and then lowering 
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the pH again to refold the desired protein, ideally other proteins will precipitate and can be removed 
by centrifugation. The pH of the re-suspended pellet is increased to ~pH 11 to unfold the tertiary 
structure and stirred for half an hour prior to re-folding by decreasing the pH to pH 7-8. Harvested 
cells from each expression temperature were re-suspended in cell lysis buffer (100 mM NaCl, 5mM 
βME, 20 mM TRIS base, 1% TWEEN 20, pH 7.0) and cells lysed via sonication. The crude extracts 
obtained by centrifugation and the resultant pellets re-suspended in cell lysis buffer (CLB). A Basic 
extraction was performed on the insoluble fractions from the expressions (0.5 L culture) at each 
temperature, followed by purification by Ni-NTA column. SDS PAGE analysis showed purified protein 
with the mass of EZS in fractions corresponding to 5, 20 and 50 mM imidazole (Figure 46). 
 
 
Figure 46. SDS-polyacrylamide gel showing samples from the basic extraction and Ni-NTA purification of EZS(WT) in E. 
coli BL21(DE3) expressed at 37 ᵒC for 4 h. Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) insoluble fraction after 
basic extraction, 3) soluble fraction after basic extraction, 4) sample loaded onto Ni-NTA column, 5) flow through, 6) 
empty, 7) cell lysis buffer (CLB) with 5 mM imidazole, 8) CLB with 20 mM imidazole, 9) CLB with 50 mM imidazole, 10) 
CLB with 70 mM imidazole, 11) CLB with 100 mM imidazole, 12) CLB with 150 mM imidazole,. 13) CLB with 200 mM 
imidazole, 14) CLB with 300 mM imidazole and 15) CLB with 500 mM imidazole. 
The activity of the purified protein from the insoluble fraction and partially purified by a Ni2+ affinity 
column was tested but no products could be identified via GC-MS analysis of the pentane 
extractable products for any of the tested expression temperatures. Within cell lysis buffer (CLB), 
additives are used to increase the stability of a protein in solution. Surfactant (TWEEN 20) aids the 
solubility of proteins by the formation of micelles whilst NaCl neutralises the net charge of the 
protein, both limiting protein-protein interaction and aggregation. Varying amounts of TWEEN 20 (1-
5%) and NaCl (20-500 mM) were included within the cell lysis buffer (CLB) but these did not improve 
purification methods. The protein band with the same molecular mass was eluted at low imidazole 
concentrations indicating that the His tag may have hidden from effectively chelating to the Ni2+ 
resin or it was not the correct protein. Due to more or one of these issues the protein was not 
catalytically active. 
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2.3.3 Purification of the soluble fraction 
Due to extraction of protein from the insoluble fraction being unsuccessful, (2Z,6Z) FDP(38) was 
incubated with a sample of the soluble fraction immediately after sonication which  showed an 
enzymatic product peak in the pentane extracts via GC-MS. Purification from the soluble proportion 
by Ni2+ affinity column enabled visualisation of a band with the approximate molecular mass of EZS. 
Bound protein was eluted with a gradient wash of imidazole solution of increasing concentrations; 5, 
20; 50, 70, 100, 150, 200, 300 and 500 mM. The EZS band was observed in fractions eluting at 
concentrations of 70, 100 and 150 mM imidazole when analysed by SDS PAGE (Figure 47). In all 
fractions containing EZS, a number of impurities were also visible on the SDS PGE. Despite 
impurities, the fractions containing the protein of the expected mass of EZS were combined, dialysed 
in cell lysis buffer to remove imidazole and a sample from the dialysed solution incubated with 
(2Z,6Z) FDP (38). GC-MS analysis of the pentane extractable extracts from the incubation of (2Z,6Z) 
FDP (38) with the dialysed protein sample showed the same peak observed from the incubation of 
38 with the crude lysate. Samples from the sonicated cells of each expression temperature were 
visualised by SDS polyacrylamide gel. Analysis of the gel showed that the expression of EZS at 20 ᵒC 
overnight was the only condition to give a visible band at the correct molecular weight in the soluble 
fraction (Figure 47). Therefore, a 20 ᵒC overnight expression of EZS after induction with IPTG was 
used as the expression temperature. 
 
                            
Figure 47. SDS polyacrylamide gels showing samples from sonication (left) and Ni-NTA purification of EZS from 
expression in E. coli BL21(DE3) cells expressed at 20 ᵒC overnight. Left: Lane 1) protein molecular weight ladder (x10
3
 
Mr), 2) E. coli BL21(DE3) cells pre-induction 3) E. coli BL21(DE3) cells post expression, 4) insoluble fraction after 
sonication, 5) soluble fraction after sonication. Right: Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) sample 
loaded onto Ni-NTA column, 3) flow through, 4) CLB with 5 mM imidazole, 5-7) CLB with 20 mM imidazole, 8) CLB with 
50 mM imidazole, 9) CLB with 70 mM imidazole, 10) CLB with 100 mM imidazole, 11) CLB with 150 mM imidazole, 12) 
CLB with 200 mM imidazole, 13) CLB with 300 mM imidazole, 14) CLB with 500 mM imidazole, 15) Ni-NTA column wash 
with 0.1 M NaOH. 
Further purification steps were needed for full characterisation of EZS, as multiple impurities could 
be observed in the same fractions of the protein of the expected mass of EZS by SDS PAGE. Anion 
exchange fast protein liquid chromatography (FPLC) with a quaternary ammonium functionalised 
sepharose column (Q-seph column) was chosen as the subsequent purification step. In this 
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technique, protein is placed onto the column and will bind ionically to the quaternary ammonium 
groups of the resin. The strength of ionic bonding is determined by the negative surface charge of 
the protein which is eluted using an increasing gradient of NaCl in the elution buffer. Increasing the 
concentration of Cl- ions in the eluent results in anion exchange and protein elution from the 
column. The theoretical isoelectric point (pI) (the pH at which the net charge on a protein is zero) for 
EZS was calculated to be approximately 6.0 using ExPasy Bioinformatics Resource Portal translate 
tool. Though this pH is used as the pI value, it is an approximation. The calculation considers the 
charges of all residues and does not take into account which residues are at the protein surface or 
within the bulk of the protein to which the pH of the buffer will not have an effect. 
Elution fractions with 70, 100 and 150 mM imidazole (Figure 47) from the Ni2+ column were dialysed 
into a second buffer (20 mM NaCl, 5 mM βME, 20 mM TRIS base) at pH 8 rather than pH 7. This 
increase in pH would increase the overall negative charge of the protein resulting in stronger 
bonding to the Q-sepharose column and hopefully enable elution without impurities. Analysis of 
fractions corresponding to the peaks on the UV trace (280 nm) of the FPLC chromatogram (Figure 
48) via SDS PAGE showed the removal of unwanted proteins from the sample; however, slight 
impurities were still present within the same fraction as EZS (Figure 49). 
 
Figure 48. FPLC chromatogram of anion exchange chromatography using a Q-sepharose anion exchange column, for the 
purification of protein the same mass as EZS, showing the UV trace at 280 nm. 
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Figure 49. SDS polyacrylamide gel showing samples anion exchange FPLC (Q-sepharose column) purification. Lane 1) 
protein molecular weight ladder (x10
3
 Mr), 2-3) waste fractions, 4-12) impurities removed during purification, 13) 
fraction containing EZS and large impurity with molecular mass ~25 kDa, 14-15) fraction containing EZS eluted at 140-
160 mM [NaCl]. 
Incubation of the FPLC purified fraction with (2Z,6Z) FDP (38) and analysis of the pentane extractable 
products yielded the same product observed in the previous incubations of using crude extract and 
initial Ni2+column purification. In an attempt to isolate pure EZS, a second Ni2+-NTA affinity column 
was performed with the same imidazole elution gradient as previously described. The purification 
removed some impurities at lower imidazole (5-50 mM) concentration leaving the EZS eluted with 
slight impurities at higher imidazole concentrations (70-200 mM) (Figure 50). 
 
 
Figure 50. SDS polyacrylamide gel showing samples of Ni-NTA purification of FPLC products. Lane 1) protein molecular 
weight ladder (x10
3
 Mr), 2) sample loaded onto Ni-NTA column, 3) flow through, 4-5) CLB with 5 mM imidazole, 6-7) CLB 
with 20 mM imidazole, 8-9) CLB with 50 mM imidazole, 10) CLB with 70 mM imidazole, 11) CLB with 100 mM imidazole, 
12) CLB with 150 mM imidazole, 13) CLB with 200 mM imidazole, 14) CLB with 300 mM imidazole, 15) CLB with 500 mM 
imidazole. 
Though the majority of impurities were removed and incubations of the fraction yielded the same 
enzymatic product upon incubation with 38 as observed in previous incubations, slight impurities 
were still observed (Figure 50). For characterisation of the protein, a pure sample in measurable 
quantities needed to be attained with a reproducible method. 
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2.3.4 TEV Cleavage 
The impurities present with EZS displayed a similar affinity to the Ni2+ resin as exhibited by the 
His-tag of EZS (Figure 50). It was proposed that the removal of the His-tag using tobacco etch virus 
(TEV) protease following the purification steps outlined in section 2.3.3 could help isolate EZS. A final 
Ni-NTA affinity column would result in pure EZS being eluted in the flow-through whilst the cleaved 
His-tag and impurities remained bound to the column. TEV protease is a 25 kDa chymotrypsin-like 
protease with a highly sequence-specific recognition site and is often used for the removal of affinity 
tags from purified recombinant proteins.207 Its high sequence specificity allows for precise cleavage 
of the His-tag from EZS due to the incorporation of the ENLYFQ\S cut site situated between the 
affinity tag and the protein.208,209 The TEV protease used also contains a His-tag and will therefore 
bind to the Ni2+-NTA affinity column with the cleaved His-tag and impurity upon purification. 
TEV protease was placed in the dialysis tubing (14 kDa membrane) with the combined fractions of 
the second Ni2+ affinity column (Figure 50) to remove imidazole and undergo cleavage in a single 
step. The SDS polyacrylamide gel of the fraction from the subsequent Ni2+-NTA affinity column 
showed pure a single band corresponding to EZS in the flow-through (Figure 51). However, fractions 
from the Ni2+ affinity column also showed EZS and the impurity within the same fraction implying 
that not all protein had undergone cleavage. Fractions containing pure and impure EZS were 
incubated with 38 to establish whether removal of the His-tag from the protein affected activity. GC-
MS analysis of the pentane extractable products showed both samples were active. The TEV 
cleavage step was repeated at 5 ᵒC and 25 ᵒC overnight with separate batches of protein. Complete 
cleavage of the His-tag was never achieved; however a reproducible and effective purification 
technique for EZS was achieved. 
 
 
Figure 51. SDS polyacrylamide gel showing samples of Ni-NTA purification of EZS His-tag cleavage experiment using TEV 
protease. Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) sample loaded onto Ni-NTA column, 3) flow through, 4) 
CLB with 5 mM imidazole, 5) CLB with 20 mM imidazole, 6) CLB with 50 mM imidazole, 7) CLB with 70 mM imidazole, 8) 
CLB with 100 mM imidazole, 8) CLB with 150 mM imidazole, 9) CLB with 200 mM imidazole, 10) CLB with 300 mM 
imidazole, 11) CLB with 500 mM imidazole. 
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Although EZS was purified successfully, the quantities generated were insufficient for use in 
incubations and characterisation assays, with a concentration 3 µM (3 mL of buffer) determined by 
Bradford assay.210 Due to this, further avenues were explored to increase the expression levels of 
EZS. 
 
2.4 Improving expression yields with expression tags 
 
Purification of EZS showed low expression of soluble protein which gave insufficient purity for 
downstream analysis (Figure 51). To increase the production of soluble protein, the use of 
expression tags were investigated. Expression tags are used to improve the production of 
recombinant proteins by improving the folding and solubility. Though the mechanism of action is not 
well understood, two explanations are available: the fusion of a stable structure to an insoluble 
protein will increase stability and improve folding, or the ‘‘molten globule hypothesis’’ which states 
the presence of a fusion tag may act as a nucleus for folding.211,212 
2.4.1 Maltose Binding Protein 
Maltose-binding protein (MBP) has an approximate molecular mass of 42 kDa and is commonly used 
as an expression tag. MBP is used with recombinant proteins with a dual purpose of increasing 
solubility and aiding purification by use as an affinity tag.213214 Previous expression and purification of 
EZS yielded poor expression of soluble protein and difficulty during purification. A MBP-EZS fusion 
protein would ideally increase EZS solubility whilst giving a different method of purification that 
would circumvent the issue of non-specific binding observed with purification via Ni2+-NTA affinity 
column (Figure 47). 
The MBP-EZS fusion protein was designed and constructed by Dr Robert Mart using a golden gate 
assembly method. A plasmid harbouring the MBP-EZS gene was incorporated into E. coli BL21(DE3) 
competent cells and expressed using the protocol previously outlined (section 2.3.3). Harvested cells 
were re-suspended in cell lysis buffer (CLB), lysed by sonication and the resultant insoluble and 
soluble fractions analysed by SDS PAGE to inspect the expression of the construct. A combined 
approximate mass of EZS (88 kDa) and MBP (42 kDa)215 would give a band at 130 kDa; above the 
116.2 kDa marker of the protein ladder. The SDS PAGE of soluble and insoluble fractions after 
sonication showed a band with the same molecular mass as the EZS-MBP construct in the soluble 
fraction which is not present within the insoluble fraction.  
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A Ni2+-NTA affinity column was used as a primary method of purification of the soluble fraction and 
bound protein washed with cell lysis buffer before being washed with a gradient of imidazole 
solutions of increasing concentration: 5, 20, 100, 200 and 500 mM. The SDS PAGE showed that the 
band with the same molecular mass as MBP-EZS did not bind to the Ni2+affinity column (Figure 52).  
 
Figure 52. SDS polyacrylamide gel showing samples of Ni-NTA purification of soluble fraction after sonication of cells 
containing the MBP-EZS construct protein. Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) sample loaded onto Ni-
NTA column, 3) flow through, 4) CLB with 5 mM imidazole, 5) CLB with 20 mM imidazole, 6) CLB with 100 mM imidazole, 
7) CLB with 200 mM imidazole an 5) CLB with 500 mM imidazole. 
An incubation of a sample from the soluble fraction with (2Z,6Z) FDP (38) was conducted to 
determine the activity of the protein of correct molecular mass before attempting purification. 
Although a band of correct molecular mass for EZS could not be observed in the soluble fractions of 
previous purifications by SDS PAGE (Figure 47), substrate turnover was still observed via GC-MS 
analysis of the pentane extractable products from the incubation of 38 and the crude lysate. 
Unfortunately, no enzymatic products were visible from the analysis of the pentane extract from the 
incubation compound 38 with a sample of the soluble fraction (crude lysate) from the purification of 
MBP-EZS and the construct was not investigated further. 
 
2.4.2 Guanidine Binding Protein 
Guanidine binding protein expression tag (GB1) is used to aid the solubilisation of insoluble 
recombinant protein by co-expression.216 The GB1 domain is derived from guanine nucleotide-
binding protein and consists of 56 residues with an approximate weight of 8 kDa. Due to its small 
size, GB1 is often used as a fusion tag for the expression of proteins for protein NMR samples and 
has been reported to significantly improve the over expression of recombinant proteins in E. coli.217 
The GB1-EZS construct was designed and prepared by Dr Robert Mart via golden gate assembly. The 
fusion protein was transformed into E. coli BL21(DE3) competent cells and protein expression 
induced by the addition of IPTG. Two different expression conditions were performed; 37 ᵒC for 4 h 
and 20 ᵒC overnight and cells harvested by centrifugation post expression. Samples of harvested 
cells were run on an SDS PAGE and did not show a band with the same molecular mass as GB1-EZS. 
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However, overexpression bands were also not observed with previously investigated expressions. 
The harvested cells from both expressions were re-suspended in cell lysis buffer and the cells lysed 
by sonication. Cell debris in the sonicated suspensions was separated from the lysate by 
centrifugation and the resultant insoluble and soluble fractions of both expressions were analysed 
by SDS PAGE. Analysis showed large quantities of a protein with the same molecular mass GB1-EZS 
in the insoluble fractions of both expressions. However, slight bands for a protein of correct 
molecular mass were observed in the soluble fractions from the expression at 20 ᵒC overnight. A 
basic extraction of the insoluble fractions were attempted to extract protein, resulting in a band with 
the same molecular mass of the GB1-EZS construct in the supernatant when analysed by SDS PAGE 
(Figure 53). 
 
 
Figure 53. SDS polyacrylamide gels showing samples from sonication and basic extraction of the GB1-EZS construct. Lane 
1) protein molecular weight ladder (x10
3
 Mr), 2) E. coli BL21(DE3) cells post expression, 3) soluble fraction after 
sonication, 4) insoluble fraction after sonication, 5) insoluble fraction after basic extraction, 6) soluble fraction after 
basic extraction. 
Incubations of the samples from the soluble fraction (20 ᵒC overnight expression) and the lysate 
after the basic extractions of the insoluble fraction (37 ᵒC for 4 hours and 20 ᵒC overnight) showed 
no enzymatic products in the pentane extractable products via GC-MS. The purpose of the construct 
was to enhance the expression of soluble protein that in turn would aid purification. The GB1-EZS 
construct did significantly increase expression however, the minimal protein that could be extracted 
from the cells was not active and therefore new avenues for protein expression were investigated. 
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2.5 Investigating Different Cell Lines to Increase Expression of EZS 
 
2.5.1 E. coli ArcticExpress RP 
At conventional expression temperatures (20 – 40 ᵒC) high expression can decrease the cells’ ability 
to correctly fold recombinant protein giving insoluble protein and inclusion bodies. However, colder 
expression temperatures can increase the yield of soluble protein.218 E. coli chaperonins GroEL and 
GroES are co-expressed by the cell to assist with the stabilisation and refolding of un- or partially 
folded proteins. However, these chaperonins have been shown to lose 70% of their activity at colder 
expression temperatures (12 ᵒC) when compared to the optimal 30 ᵒC incubation temperature.219 
The ArcticExpress RP expression strain was designed to co-express the cold adapted chaperonins 
Cpn10 and Cpn60 from the psychrophilic bacterium sourced from Antarctic sea water, Oleispira 
antarctica.218 Cpn10 and Cpn60 chaperonins have 74% and 54% amino acid similarity to GroEL and 
GroES respectively. Both chaperonins exhibit high protein refolding activities in vitro at lower 
temperatures (4-12 ᵒC), 16 fold greater than at 30 ᵒC. Co-expression of these chaperonins within 
ArcticExpress cells has been shown to improve protein folding at lower temperatures to potentially 
give greater yields of soluble, active recombinant protein.220 
The plasmid containing EZS gene was incorporated into ArcticExpress RP cells, protein expression 
induced by the addition of IPTG and EZS expressed overnight at 10 ᵒC for 24 h. Cells from the 
expression were harvested by centrifugation and re-suspended in cell lysis buffer (CLB). 
Re-suspended cells were lysed by sonication, cell debris separated from the lysate by centrifugation 
and samples from soluble and insoluble fractions analysed by SDS PAGE. Analysis showed a large 
expression band with the same molecular mass as EZS present within the insoluble fraction (Figure 
54). A slight band of the same molecular mass was also visible within the soluble fraction however, 
the yield of the soluble protein looked comparable to that observed with protein expression in E. coli 
BL21(DE3) (Figure 47). A sample from the soluble fraction was incubated with 38 and the pentane 
extractable products analysed by GC-MS showing the same product observed in previous 
incubations (section 2.3.3). 
A basic extraction was attempted on the insoluble fraction to investigate whether insoluble protein 
could be purified. Samples of the insoluble and soluble fractions before basic extraction were 
analysed by SDS PAGE and showed a band with the same molecular mass as EZS remained within the 
insoluble fraction (Figure 54). To ensure no active protein had been extracted and not been 
observed, a sample from the soluble fraction was incubated with 38 however no enzymatic products 
were observed in the pentane extracts when analysed by GC-MS. 
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Figure 54. SDS polyacrylamide gels showing samples from sonication and basic extraction of the EZS(WT) expressed in E. 
coli ArcticExpress RP  for 24 h at 10 ᵒC. Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) insoluble fraction after 
sonication, 3) soluble fraction after sonication, 4) insoluble fraction after basic extraction, 5) soluble fraction after basic 
extraction. 
 
2.5.2 E. coli C41 (DE3) pLysS 
C41(DE3) pLysS competent cells are derived from BL21(DE3) strain containing a mutation that 
decreases the activity of the T7 RNA polymerase (RNAP). This reduced level of T7 RNAP activity 
prevents cell death that can be associated with the over expression of recombinant toxic proteins. 
C41(DE3) pLysS also contain a chloramphenicol resistant plasmid which expresses small quantities of 
T7 lysozyme that is an inhibitor of T7 RNA polymerase and also suppresses the basal expression of T7 
RNA polymerase prior to induction.221–223 
A greater density of cells is required for higher yields of protein due to the limitation of the T7 RNA 
polymerase within each cell. When using Luria-Bertani (LB) medium,224 the cells were incubated at 
37 ᵒC prior to induction at an OD600 of 0.8-1.0 in contrast to previous cell lines in which protein 
expression was induced at an OD600 of 0.6. Terrific-Broth (TB) medium is an enriched medium 
developed to improve yields of E. coli and growth was used as the primary growth medium; with 
protein expression induced at an OD600 of 0.6. The high cell density required for the overproduction 
of proteins can lead to acidic conditions to which phosphate buffer present within TB media 
regulates physiological pH for cell growth.225 
A plasmid containing EZS gene was incorporated into E. coli C41 (DE3) pLysS competent cells and 
cultures grown in TB media. An investigation of how expression is affected by cell stress was 
conducted by temperature shock. Three incubations were conducted; the first incubation was 
cooled to 10 ᵒC directly before induction of protein expression by the addition of IPTG (cold shock), 
the second was placed in a 42 ᵒC water bath for 40 seconds before induction (heat shock) and the 
third induced directly (no shock). Induced cells were then incubated overnight at 20 ᵒC. The cells 
from each expression were harvested by centrifugation and the cells re-suspended in cell lysis 
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buffer. The suspended cells were lysed by sonication, cell debris removed via centrifuge and a 
sample of the soluble fraction incubated with (2Z,6Z) FDP (38). GC-MS analysis of the pentane 
extractable products showed no products from heat shocked incubation and two different products 
from the cold shock and no shock incubations respectively.  
A Ni2+-NTA affinity column was used for the purification of the soluble fraction from the cold shock 
incubation. Bound protein was eluted as previously stated (section 2.3.3) and analysis of the SDS 
PAGE showed pure protein with a band at the same molecular mass as EZS in the 70 and 100 mM 
fractions and the same band with impurities eluted at 20 and 50 mM imidazole concentrations. 
Samples from each elution were incubated with 38 to assess whether active protein was present. 
The pentane extractable products of the incubations were analysed via GC-MS and showed no 
enzymatic products for the pure protein eluted at 70 and 100 mM imidazole concentrations. 
Incubation of the impure fractions (eluents at 20 and 50 mM imidazole) showed an enzymatic 
product with a molecular ion peak m/z = 204. However, the mass spectrum of the product peak was 
not the same as the enzymatic product previously observed. 
Harvested cells from the no shock incubation were re-suspended in cell lysis buffer, lysed by 
sonication, cell debris separated from the lysate using a centrifuge and samples from the insoluble 
and soluble fractions analysed via SDS PAGE. As previously observed with the cold shock incubation, 
a band with the same molecular mass as EZS was not present in the insoluble fraction and could not 
be seen in the soluble fraction due to the presence of multiple impurities. Incubation of a sample 
from the soluble fraction with (2Z,6Z) FDP (38) and analysis of the pentane extractable product via 
GC-MS. The mass spectrum of the enzymatic product observed on the total ion chromatogram 
showed a molecular ion peak m/z = 204 that was not the same product from the incubation of 
purified protein and 38 from the cold shock expression.  
Purification of the soluble fraction using a Ni2+-NTA affinity column gave a band with the same 
molecular mass as EZS in fractions 70 – 300 mM imidazole when samples from the eluent fraction 
were analysed by SDS page. The fractions in which the band was observed were combined, dialysed 
into cell lysis buffer to remove imidazole, concentrated and a sample incubated with 38. Pentane 
extractable products were analysed via GC-MS and showed a single enzymatic product. A sample of 
the purified protein was analysed by SDS PAGE. In comparison to previous expressions, analysis of 
the SDS PAGE showed minor impurities with a greater ratio of a protein with the same molecular 
mass as EZS to other proteins in the same fraction. 
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A second Ni2+-NTA affinity column with the same gradient of imidazole elution was used to remove 
impurities observed by SDS PAGE after the previous purification step. Analysis of the fractions from 
the second Ni2+-NTA affinity column showed a protein with the same molecular mass as EZS was 
eluted at by 70 mM imidazole solution. The fraction was dialysed to remove imidazole and a sample 
of the fraction incubated with 38. GC-MS analysis of the pentane extractable products from the 
incubation showed the same enzymatic product previously observed from the incubation of the 
sample from the first Ni2+-NTA affinity column with 38. This showed that the expression of EZS using 
E. coli C41 (DE3) pLysS competent cells with no shock treatment gave improved quantities of active 
enzyme, compared to previous methods. However; after two Ni-NTA columns, one impurity 
remained in the soluble fraction and therefore a new method protocol was investigated to ensure 
the protein with the same molecular mass as EZS was responsible for the generation of enzymatic 
product. 
Purification of protein with the correct molecular mass for EZS from the soluble fraction for 
characterisation was achieved via a three step process. The first purification step was a Ni2+-NTA 
affinity column of the soluble fraction after sonication, with a step wise elution of 5, 20, 300 and 500 
mM imidazole solution, with protein elution observed by SDS PAGE analysis in the 300 and 500 mM 
fractions (Figure 55). The appropriate fractions from the Ni2+-NTA affinity column were combined 
and purified by anion exchange (Q-sepharose column) FPLC. SDS PAGE analysis of the eluted 
proteins showed a band with the same molecular mass as EZS and a single impurity at an 
approximate molecular mass of 18.4 kDa (Figure 56). The protein partially purified by FPLC was 
isolated and buffer exchanged (100 mM NaCl, 5 mM βME, 20 mM TRIS base and pH 8.0) using a spin 
column with a 50 kDa membrane yielding a single band of the correct mass on the SDS PAGE (Figure 
56). Incubation of the purified protein with (2Z,6Z) FDP (38) and analysis of the pentane extractable 
products by GC-MS gave the same enzymatic product observed from the incubation of the protein 
partially purified from the no shock expression. This protocol was adopted as the primary method 
for the purification as it yielded pure active protein and removed the need for time consuming 
dialysis steps. 
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Figure 55.SDS polyacrylamide gels showing samples from sonication and Ni-NTA purification of EZS from expression in E. 
coli C41(DE3) pLysS cells expressed at 20 ᵒC overnight. Left: Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) E. coli 
C41(DE3) pLysS cells post expression, 3) insoluble fraction after sonication, 4) soluble fraction after sonication, 5) empty, 
6) protein molecular weight ladder (x10
3
 Mr), 7) sample loaded onto Ni-NTA column, 8-9) CLB with 5 mM imidazole, 10-
12) CLB with 20 mM imidazole, 13-14) CLB with 300 mM imidazole, 15) CLB with 500 mM imidazole. 
 
 
                
Figure 56. SDS polyacrylamide gels showing samples anion exchange FPLC (Q-sepharose column) purification (left) and 
sample after spin column with 50 kDa membrane cut off (right). Left: Lane 1) protein molecular weight ladder (x10
3
 Mr), 
2-7) impurities removed during purification, 8) fraction containing EZS and impurity with molecular mass ~18.4 kDa 
eluted at 140-160 mM [NaCl]. Right: Lane 1) protein molecular weight ladder (x10
3
 Mr), 2) EZS sample after purification / 
buffer exchange using spin column with 50 kDa membrane cut off. 
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Circular dichromism (CD) spectroscopy was used to analyse the secondary structure of EZS. The 
structures of sesquiterpene cyclases comprise α-helical bundles with which a distinct CD spectrum 
containing two minima at 208 nm and 222 nm. Previous protocols for EZS purification by the 
Allemann group involved basic extraction yielding inactive or unstable protein. It was proposed that 
the harsh refolding conditions employed to extract protein from the insoluble fractions was 
responsible for the loss of activity by misfolding (section 2.3.2). Purification of EZS in the soluble 
fraction had not been attempted and therefore it was not known whether the structure of the 
soluble protein was purely α-helical or misfolded.  
The CD spectrum of EZS (Figure 57) showed the characteristic minima for an α-helical secondary 
structure. This spectrum was then used as a reference for future work concerning single point 
mutations EZS gene to ensure that single amino acid substitutions had not caused structural 
changes. 
 
 
Figure 57. Circular dichromism spectrum of EZS. The sample was prepared by taking concentrated EZS sample (Figure 
56), in 20 mM Tris base buffer pH 8.0 and diluting in 10 mM potassium phosphate buffer pH 8.0 to achieve the final EZS 
concentration of 10 μM. Prior to each individual CD scan, a blank containing potassium phosphate buffer was 
performed. Molar residue ellipticity was calculated using equation 1.1 (8.1.12), and data plotted. The path length of 
quartz cuvette was 1 mm and total volume was 300 μL.  
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2.6 Incubation of (2Z,6Z) farnesyl diphosphate (38) and EZS 
 
Analysis of the pentane extractable products from (2Z,6Z) farnesyl diphosphate (38) incubation with 
pure EZS via GC-MS yielded two enzymatic products (Figure 58). A major peak at 15.3 min and a 
minor peak at 14.9 min corresponding to 7-epizingiberene (1) and curcumene (81) respectively are in 
agreement with literature. The mass spectra of the compound eluted at 15.3 min (Figure 60), 
showed a molecular ion peak with m/z = 204 indicative of a sesquiterpene product and the mass 
spectrum of 14.8 min (Figure 61), showed a molecular ion peak with m/z = 202 corresponding to an 
oxidised product.  
Farnesenes were synthesised from (2Z,6Z) farnesol (167) to confirm enzymatic products were not 
resulting from the cleavage of the diphosphate group and subsequent deprotonation which would 
also give a m/z = 204. The farnesene standard was run using the same method on GC-MS and was 
observed to give a retention time of 23.4 min and a mass spectrum that was distinctive from 
enzymatic products (Figure 62). However, this mass spectrum matched the product from the cold 
shock incubation showing that the cold shock protocol resulted in the production of a farnesene 
product by EZS incubation with (2Z,6Z) FDP (38). 
 
Figure 58. Total ion chromatogram of the pentane extractable products arising from incubation of 38 with EZS. 
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Figure 59 outlines the possible molecular ion fragments that may be responsible for the major 
species observed in the EI+ mass spectrum (Figure 60). 
                 
                 
         
Figure 59. Possible fragments of 217 and m/z values. 
 
Figure 60. Mass spectrum of the compound eluting at 15.3 min on the total ion chromatogram in Figure 58. 
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Extending the reaction time resulted in a negligible increase in curcumene (81) and atmospheric 
exposure did not result in further oxidation (Figure 58). It was noted that when air was removed 
from the incubation with additional pentane filling the incubation vial, the curcumene product was 
significantly reduced without the need to degas buffers or undertake incubations under inert 
conditions.  
The mass spectrum of 81 (Figure 61), shows a fragmentation pattern containing all fragment peaks 
observed in the respective mass spectrum of 7-epizingiberene (1) excluding the m/z = 204 peak. 
 
 
Figure 61. Mass spectrum of the compound eluting at 14.8 min on the total ion chromatogram in Figure 58. 
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Figure 62. Mass spectrum of farnesene product generated from (2Z,6Z) farnesol (167). 
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2.7 Site Directed mutagenesis 
 
2.7.1 Metal binding motifs 
Alterations to the conserved residues in these active site motifs should also reveal their importance 
in catalysis, possibly modifying KM and kcat values. Several active site residues were changed using 
site directed mutagenesis to alanine (A) to remove the negative charge of residues thought to be 
responsible for the chelation of magnesium ions in the active site. The removal of the charge should 
affect the binding of respective magnesium ions and cease or severely limit enzymatic activity. 
Four metal binding motif mutants were generated. The aspartate (D) and glutamate (E) residues of 
the DDXXE motif were altered to generate EZS(D495A) and EZS(E499A) whilst the asparagine (N) and 
glutamate (E) residues of the NSE motif were altered to generate EZS(N640A) and EZS(E648A). 
Cartoon representations of targeted residues prior to mutation with orientation to (2Z,6Z) FDP (38) 
and magnesium ions are shown in Figure 63 (D495 and E499) and Figure 64 (N640 and E648). 
 
           
Figure 63. Cartoon representations of EZS homology model based on α-bisabolene synthase. Residues D495 (left) and 
E499 (right) of the conserved DDxxE motif are highlighted showing their orientation to bound magnesium ions and 
(2Z,6Z) FDP (38).
185
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Figure 64. Cartoon representations of EZS homology model based on α-bisabolene synthase. Residues D495 (left) and 
E499 (right) of the conserved DDxxE motif are highlighted showing their orientation to bound magnesium ions and 
(2Z,6Z) FDP (38).
185
 
The method of mutant expression and purification was duplicated from the protocol used to 
produce active EZS (section 2.5.2). Incubation of (2Z,6Z) FDP (38) with each mutant and analysis of 
the pentane extractable products via GC-MS showed no enzymatic products were produced by 
EZS(D495A), EZS(E499A) and EZS(N640A). The incubation EZS(E648A) with 38 did gave an enzymatic 
product which was found to be 7-epizingiberene (1) via GC-MS analysis of the pentane extractable 
products.  
 
2.7.2 Aromatic active site residues 
Active site aromatic residues are crucial for the stabilisation of unstable carbocation intermediates 
by electron donation from the delocalised π-system.226 In addition to the stabilising effect, aromatic 
residues are large; therefore steric interactions may influence substrate binding and folding into 
reaction ready conformations. Mutation of these residues to alanine (A) could have two effects on 
enzyme activity; destabilisation of carbocation intermediates and increased substrate promiscuity 
resulting from less steric bulk allowing for greater mobility of substrate within the active site.227 
As the crystal structure of EZS is not known, a homology model based on α-bisabolene synthase was 
generated to identify potential active site aromatic residues that are in close proximity to the bound 
substrate. These residues were targeted for alteration to alanine to generate four EZS mutants; 
EZS(F598A), EZS(F705A), EZS(Y483A) and EZS(Y716A). 
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Figure 65. Cartoon representations of EZS homology model based on α-bisabolene. Putative aromatic active site 
residues F598, F705, Y483 and Y716 are highlighted showing their orientation to bound magnesium ions and (2Z,6Z) FDP 
(38).
185
 
 
            
Figure 66. Cartoon representations of EZS homology model based on α-bisabolene synthase. Putative aromatic residues 
F598 (left) and F705 (right) are highlighted showing their orientation to bound magnesium ions and (2Z,6Z) FDP (38).
185
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Figure 67. Cartoon representations of EZS homology model based on α-bisabolene synthase. Putative aromatic residues 
Y483 (left) and Y716 (right) are highlighted showing their orientation to bound magnesium ions and (2Z,6Z) FDP (38).
185
 
EZS aromatic active site mutants EZS(F598A), EZS(F705A), EZS(Y483A) and EZS(Y716A) were 
incubated with (2Z,6Z) FDP (38) and the pentane extractable products analysed via GC-MS. Mutants 
EZS(F598A), EZS(F705A) and EZS(Y716A) showed no enzymatic products giving evidence that the 
residue is important during catalysis as CD spectroscopy (section 2.7.3) showed mutants were folded 
correctly. Alternatively the mutation from a large to a small residue caused steric changes to the 
active site inhibiting activity. Contrastingly, EZS(Y483A) yielded 7-epizingiberene (1) as an enzymatic 
product giving evidence that the residue may not contribute directly to the mechanism. 
 
2.7.3 CD spectroscopy of EZS mutants 
CD spectra of all EZS mutants generated were measured to assess whether each single amino acid 
substitution had altered the global secondary structure of the protein significantly. Of the 8 mutants 
generated, two were active; EZS(E648A) and EZS(Y483A) the CD spectra of which can be are shown 
in Figure 69 and Figure 70 respectively. Both spectra show minima at 208 and 222 nm that are 
characteristic of an α-helical secondary structure. This distinctive trace confirms that the alterations 
to the protein did not alter the secondary structure. The CD spectra of other mutants were also 
measured; EZS(D495A) and EZS(E499A) (Figure 68), EZS(N640A) (Figure 69), EZS(F598A) (Figure 70) 
and EZS(F705A) (Figure 71) showing the same characteristic minima for an α-helical structure 
indicating that none of the alterations performed significantly altered the overall protein fold. 
The CD spectra of EZS(Y716A) (Figure 71) showed a slight decrease in molar ellipticity between 
240-320 nm. Though the difference in amplitudes may imply a partial misfolding, the CD spectra 
contained the distinctive two minima at 208 nm and 222 nm for an -helical secondary structure. As 
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no other minima representative of β-sheets (218 nM) or random coils (195 nm) were observed, the 
discrepancies were not thought to arise from structural change but experimental variability. 
Samples were prepared by taking a sample (Figure 56, section 2.5.2) in 20 mM Tris base buffer pH 
8.0 and diluting in 10 mM potassium phosphate buffer pH 8.0 to achieve the final EZS concentration 
of 10 μM. Prior to each individual CD scan, a blank containing potassium phosphate buffer was 
performed. Molar residue ellipticity was calculated using equation 1.1 (8.1.12) and data plotted. The 
path length of quartz cuvette was 1 mm and total volume was 300 μL 
 
   
Figure 68. Circular dichromism spectra of EZS(D495A) (left) and EZS(E499A) (right). 
   
Figure 69. Circular dichromism spectra of EZS(N640A) (left) and EZS(E642A) (right). 
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Figure 70. Circular dichromism spectra of EZS(Y483A) (left) and EZS(F598A) (right). 
   
Figure 71. Circular dichromism spectra of EZS(F705A) (left) and EZS(Y716A) (right). 
 
 
Figure 72. Overlaid circular dichromism spectra of EZS(WT) and EZS mutants. 
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The CD spectra of the individual EZS mutants and wild type enzyme were overlaid to confirm that 
the single point mutations did not affect protein structure (Figure 72). Two mutant proteins 
exhibited activity upon incubation with 38 however, the remaining six did not. As the overall protein 
structure remained constant across all mutants, the loss of activity was directly related to the 
alteration of key active site residues. 
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2.8 Summary 
Outlined in this chapter were the numerous synthetic routes investigated for the preparation of 
(2Z,6Z) farnesyl diphosphate (38). Though published literature had shown a procedure for the 
synthesis of (2Z,6Z) farnesol (167) directly from neryl acetone (166) using a modified Wittig reaction, 
this synthesis could not be replicated and therefore, different procedures were investigated. Two 
synthetic routes yielded 38; the Anastasia approach and the Horner-Wadsworth-Emmons synthesis 
utilising a Still-Gennari modification. Both protocols gave a 1:1 ratio of (2Z,6Z) farnesol (167) and 
(2E,6Z) farnesol (168) with modification of reaction conditions not increasing the ratio of the Z 
isomer in relation to the E isomer. The Horner-Wadsworth-Emmons synthesis achieved a 41% yield 
of 167 over the olefination and reduction steps whilst the Anastasia synthesis gave a 24% yield of 
167. The Horner-Wadsworth-Emmons synthesis was chosen as the method for synthesising 38 over 
the Anastasia protocol due to higher yield, lower cost of reagents and easier reaction scale up. 
EZS was overexpressed in E. coli BL21 (DE3) and ArcticExpress RP cells. Investigation of the soluble 
fraction showed that active EZS was present though attempts at purification were unsuccessful due 
to low expression of soluble protein. Although the use of expression tags MBP and GB1 did not 
increase the expression of soluble protein, large expression bands were observed via SDS PAGE for 
the GB1-EZS fusion protein though purification of protein proved problematic. 
The use of E. coli C41 (DE3) pLysS cells for the expression of EZS yielded larger expression of soluble 
protein than observed comparative EZS expressions using E. coli BL21 (DE3) and ArcticExpress RP 
cells. The greater expression of EZS allowed for a 3 step purification yielding protein of sufficient 
purity and quantity to confirm the isolated protein was solely responsible for substrate turnover and 
characterisation assays.  
Out of the eight mutants incubated with (2Z,6Z) farnesyl diphosphate (38), two EZS mutants; 
EZS(E648A) and EZS(Y483A) gave enzymatic product. Mutation of selected metal binding residues 
showed that the aspartate (A) and glutamate (E) residues of DDxxE and the asparagine (N) residue of 
NSE were crucial for enzyme activity. In contrast the glutamate residue of NSE was not crucial for 
catalysis with enzymatic product observed in the pentane extracts of EZS(E648A) incubation with 38. 
The mutation of aromatic active site residues in mutants; EZS(F598A), EZS(F705A) and EZS(Y716A) 
resulted in the loss of enzyme activity, giving evidence that they contribute to the catalytic 
mechanism. Analysis of the mutants overall fold using circular dichromism spectroscopy showed that 
all mutants had the same secondary structure as the wild type and therefore loss of activity did not 
result from misfolding (Figure 72). 
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Chapter 3 – Characterisation of EZS and Investigation of active site 
residues 
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3.1 Preface 
 
This chapter will outline the synthesis of radiolabelled (2Z,6Z) farnesyl diphosphate; 
(2Z,6Z)-[1-3H]-farnesyl diphosphate (229) for the kinetic characterisation of 7-epizingiberene 
synthase (EZS) and mutants. Characterisation of sesquiterpene cyclases by the Allemann group has 
required (2E,6E)-[1-3H]-farnesyl diphosphate for steady state kinetic assays. (2E,6E)-[1-3H]-farnesyl 
diphosphate is commercially available but the radiolabelled substrate for EZS is not commercially 
available and required synthesis. 
Prior to steady state kinetic characterisation of EZS, incubation conditions concerning time, pH and 
buffer concentrations required optimisation. Steady state kinetic parameters KM, kcat and Vmax were 
calculated for EZS, EZS(E648A) and EZS(Y483A) to determine the effect of the single point mutations 
on catalytic efficiency. 
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3.2 Radioactive isotopologue 
 
3.2.1 Synthesis of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) 
Numerous publications have outlined pathways for the incorporation of tritium at the C1 position of 
farnesyl diphosphate and analogous substrates. The chosen alcohol is typically oxidised to the 
corresponding aldehyde and subsequently reduced with sodium borotritide (NaBT4) to yield the 
desired radiolabelled product.  
Numerous oxidations published in the literature for (2E,6E) farnesyl diphosphate (31) were 
attempted to yield (2Z,6Z) farnesal (217).228, 229, 113 Manganese (IV) oxide has been previously used 
within the Allemann group for this purpose. However, oxidation of (2Z,6Z) farnesol (167) resulted in 
a 1:1 mixture of (2Z,6Z) farnesal (217) and (2E,6Z) farnesal (220). The reaction was repeated 
numerous times and variations to determine the cause of isomeric scrambling. Table 5 shows 
variation in MnO2 equivalents, time, temperature and solvent attempted for the oxidation. 
 
Table 5. Variations of time, temperature, solvent, reagent molar equivalence isomeric scrambling of the C2,C3 bond 
during the oxidation of (2Z,6Z) farnesol (167) to (2Z,6Z) farnesal (217). 
Time / h MnO2 equiv. Solvent Temp / ᵒC Scrambling (Y/N) 
16 5 Hexane 25 Y 
16 10 Hexane 25 Y 
16 20 Hexane 25 Y 
16 30 Hexane 25 Y 
48 30 Hexane 25 Y 
16 30 Hexane 68 Y 
16 30 Hexane 0 Y 
48 30 Hexane 0 Y 
4 30 DCM 25 Y 
16 30 DCM 25 Y 
48 30 DCM 25 Y 
 
The oxidation was initially performed for 16 hours with 5 equivalents of MnO2. The reaction had not 
gone to completion after this time period and it was initially proposed that the poor condition of old 
reagent was the cause. Fresh manganese (IV) oxide was used under the same conditions; however 
the reaction still did not go to completion. The reaction was repeated with 30 equivalents of MnO2 
and a longer reaction time of 48 hours however, the reaction did not proceed to completion. DCM 
was used in place of hexane and the reaction went to completion after 48 hours with 30 equivalents 
of MnO2. Though starting material was now fully consumed, each variation attempted exhibited 
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scrambling of the stereochemistry C2,C3 double bond when analysed via 1H NMR spectroscopy. Two 
doublets characteristic of an aldehyde environment were observed at 9.90 and 9.85 ppm integrating 
to one proton. Two doublets integrating to one proton were also observed at 5.82 and 5.78 ppm 
corresponding to the alkene proton at the C2 position (Figure 73). The presence of two aldehyde and 
alkene (C2 position) proton environments on the 1H NMR spectrum gives evidence that the oxidation 
procedures were causing isomeric scrambling of the C2,C3 double bond. 
 
 
Figure 73. A 
1
H NMR spectrum of a mixture of aldehydes (2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienal (217) and 
(2E,6Z)-3,7,11-trimethyldodeca-2,6,10-trienal (220). 
Yamamoto et al.228 published that E/Z isomerisation of the C2, C3 double bond occurred in the 
presence of MnO2 at room temperature however, isomerisation did not occur when reacted with 
MnO2 at 0 ᵒC in hexane. Reaction conditions were duplicated with (2Z,6Z) farnesol (167) and 
isomerisation still occurred. Consequently, an alternative method of oxidation was sought. A Swern 
oxidation230 and a Dess-Martin oxidation231 were investigated as possible oxidation methods.  
Both methods resulted in the E/Z isomerisation of the C2/C3 double bond. It was proposed that 
residual base or acid in the reaction mixtures; NEt3 in the Swern oxidation or acetic acid in the 
Dess-Martin reaction were responsible. The presence of base or acid could aid tautomerisation of 
the aldehyde to an enolate (221) or enol (219) allowing the free rotation of the C2/C3 sigma bond. 
Subsequent tautomerisation to the aldehyde would yield a mixture of E and Z isomers (Figure 74). 
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Figure 74. Plausible mechanisms for the acid catalysed isomerisation (top) and base catalysed isomerisation (bottom) of 
(2Z,6Z) farnesal (217) to (2E,6Z) farnesal (220). 
An alternative oxidation procedure was found in a publication by Bobbitt et, al.232 The use of an 
oxoammonium oxidation reagent, 4-acetamido-2,2,6,6-tetramethyl-1-oxopiperidin-1-ium tetra 
fluoroborate salt (TEMPO salt) (226) in DCM was shown to achieve fast and high yielding oxidation 
reactions with an allylic alcohol substrate. 226 was prepared from the corresponding free radical by 
oxidation with sodium hypochlorite and subsequent reaction with fluoroboric acid (Figure 75). 
 
 
Figure 75. Synthesis of 4-acetamido-2,2,6,6-tetramethyl-1-oxopiperidin-1-ium tetra fluoroborate salt (226). 
Oxidation of (2Z,6Z) farnesol (167) with TEMPO salt (226) resulted in a single aldehyde product and 
was passed through a silica plug to remove excess oxidation reagent. Dess Martin and Swern 
oxidation products both required purification via column chromatography as multiple reaction 
products were observed. Nuclear Overhauser Effect Spectroscopy (NOESY) was used to confirm the Z 
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isomer showing close spatial arrangement of the aldehyde proton and methylene environment. The 
use of the TEMPO salt gave a quick method of oxidation with aldehyde 217 of sufficient purity to be 
used without further purification isolated after passing the crude reaction mixture through a short 
silica plug.  
 
 
Figure 76. Synthesis of (2Z,6Z)-[1-
3
H]-farnesyl diphosphate (229). 
The next step of the synthesis was the incorporation of tritium by reducing aldehyde 217 with 
sodium borotritide, the radiolabelled equivalent of sodium borohydride. Sodium borohydride 
reactions typically use protic solvents such as methanol or ethanol which result in the evolution of 
H2(g). To restrict the emission of gaseous radioactive waste, anhydrous tetrahydrofuran was used as 
the reaction solvent. Micromolar quantities of sodium borotritide (NaBT4) were required for 
radiolabelling and unreacted farnesal (217) was subsequently reduced with excess unlabelled 
sodium borohydride to drive the reaction to completion. Bromination, diphosphorylation and ion 
exchange proceeded via established protocol outlined in chapter 2. Radioactive diphosphate was not 
purified via HPLC with excess pyrophosphate removed using a SNAP Ultra C18 Biotage column. Use 
of the enclosed column for purification reduced the risk of radioactive contamination (Figure 76). 
Lyophilisation of the fractions gave purified (2Z,6Z)-[1-3H]-farnesyl diphosphate (229). A sample of 
229 was dissolved in water and dispersed in Ecoscint A scintillation cocktail and the radioactivity of 
229 analysed using a liquid scintillation counter and found to have a specific activity of 2.8 mCi 
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mmol-1 (equation 1.4, 8.1.13). The liquid scintillation counter quantified radioactivity in counts per 
minute (CPM) which was converted to activity using equation 1.2 (8.1.13). 
All reactions and radioactivity were monitored via TLC analysis. The silica, to which the product was 
bound, was removed from the plate emulsified in Ecoscint A scintillation cocktail and radioactivity 
analysed using a liquid scintillation counter. This method was particularly useful in the reduction of 
217 as a secondary spot was visible via TLC. However, when the compound bound silica was 
suspended in Ecoscint A scintillation cocktail and measured using a liquid scintillation counter, 
analysis showed no radioactivity was present.  
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3.3 Kinetic characterisation of EZS 
 
3.3.1 Incubation optimisation 
The steady state kinetic parameters for the reaction of EZS catalysing the turnover of (2Z,6Z) FDP 
(38) to 7-epizingiberene synthase were determined using a radiolabelled-substrate assay. A 
concentration range of (2Z,6Z)-[1-3H]-FDP (229) was incubated with a known concentration of EZS 
for a defined time period. Organic incubation products were extracted with hexane and eluted 
through a short silica column with hexane. Any aqueous soluble residual material would not be 
extracted into organic layer with only enzymatically derived hydrocarbon products passing through 
the silica. Organic extracts were emulsified with Ecoscint O scintillation cocktail and analysed using a 
liquid scintillation counter. The results (CPM) were converted to a rate using equation 1.2 (8.1.13) 
and fitted to a Michaelis-Menten curve to determine Vmax, KM and kcat. 
Incubation conditions were optimised prior to the measurement of steady state parameters. The 
catalysis buffer for the incubation of (2Z,6Z)-[1-3H]-FDP (229) with [EZS] was taken from the protocol 
published by Bleeker et al.3 The buffer comprised of 25 mM HEPES ((2[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid), 10 mM MgCl2 and 5 mM DTT (dithiothreitol) at pH 7.2 was used as a 
starting reference for the optimisation of [EZS], [MgCl2], pH and incubation length.  
For the optimisation of EZS concentration, an [EZS] range 2–200 nM was incubated with 229 in 
catalysis buffer (25 mM HEPES, 10 mM MgCl2, 5 mM DTT, pH 7.2) for 10 minutes at 30 ᵒC. The 
hexane extracted products were emulsified in Ecoscint O scintillation cocktail and analysed using a 
liquid scintillation counter. The reaction rate increased linearly with [EZS] and plateaued to a 
maximum between [EZS] of 50–200 nM. The plateau at higher concentrations suggests enzyme 
aggregation thereby altering the concentration of active enzyme, which is required for the 
calculation of steady state parameters. However, the reaction rate at concentrations in the linear 
range (2–50 nM) is directly proportional to [EZS] therefore the concentration remains constant. A 
[EZS] of 30 nM was chosen as it resides central within the linear range with adequate activity for 
steady state kinetic experiments (Figure 77).  
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Figure 77. Plot of reaction rate for EZS catalysed production of radiolabelled products from (2Z,6Z)-[1-
3
H]-FDP (229) 
against various [EZS]. Reaction conditions: buffer (25 mM HEPES, 10 mM MgCl2, 5 mM DTT, pH 7.2), 10 minutes, 30 ᵒC. 
 
The concentration of Mg2+ was optimised using the same reaction conditions previously stated 
(section 3.3.1). A [Mg2+] range of 2–20 mM was used in the incubation of 229 with EZS (30 nM) for 
10 minutes at 30 ᵒC. The plot of rate vs. [Mg2+] showed an increase in reaction rate to a maximum at 
15 mM with an increase in [Mg2+] concentration to 20 and 25 mM resulted in a diminished reaction 
rate. A [Mg2+] of 15 mM was therefore chosen as the optimal [Mg2+] concentration as it yielded the 
fastest rate (Figure 78). 
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Figure 78. Plot of reaction rate for EZS catalysed production of radiolabelled products from (2Z,6Z)-[1-
3
H]-FDP (229) 
against various [Mg
2+
]. Reaction conditions: 30 nM [EZS], buffer (25 mM HEPES, 10 mM MgCl2, 5 mM DTT, pH 7.2), 10 
minutes, 30 ᵒC. 
In order to determine the optimal reaction time, incubations of EZS (30 nM) and 
(2Z,6Z)-[1-3H]-farnesyl diphosphate (229) in catalysis buffer (25 mM HEPES, 15 mM MgCl2, 5 mM 
DTT, pH 7.2) at 30 ᵒC for variable time lengths. A time range from 5–20 minutes was examined with 
the results showing a linear positive correlation between rate and time. A reaction time of 10 
minutes was chosen as the ideal reaction length as sufficient counts were detected for analysis after 
this time (Figure 79). 
 
Figure 79. Plot of reaction rate for EZS catalysed production of radiolabelled products from (2Z,6Z)-[1-
3
H]-FDP (229) 
against various end-point times for the stopped assay. Reaction conditions: 30 nM [EZS], buffer (25 mM HEPES, 15 mM 
MgCl2, 5 mM DTT, pH 7.2), 30 ᵒC. 
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For the determination of the optimal reaction pH, EZS (30 nM) was incubated of with 
(2Z,6Z)-[1-3H]-farnesyl diphosphate (229) in catalysis buffer (25 mM HEPES, 15 mM MgCl2, 5 mM 
DTT) for 10 minutes at 30 ᵒC, over a pH range of 5-10.5. 
Optimisation of pH was approached using different buffers to span a pH range. The range pH 6–10 
was investigated using three buffers; MES (2–(N-morpholino)ethanesulfonic acid) for pH 6–6.5, 
HEPES for pH 7–8.5 and CHES (N-cyclohexyl-2-aminoethanesulfonic acid) for pH 9–10 (Figure 80). 
To assess whether these different buffers affected the reaction outcome, a second experiment using 
MTEN buffer (50 mM MES, 25 mM TRIS Base, 25 mM ethanolamine, 100 mM NaCl) was performed. 
This allowed incubation across a pH range of 5 – 9 to be analysed with no change in buffer (Figure 
80).  
The third investigation was over a larger pH range 5– 10.5 using MES (pH 5-6.5), HEPES (pH 7-8.5) 
and AMP (2-amino-2-methyl-1-propanol, pH 10.5) (Figure 81) 
Figures 8 and 9 show that changes in buffer did not alter the overall outcome. pH 8.0 was chosen as 
optimal for carrying out future incubations as the curve reaches a maximum at pH 8.5 either side of 
which the rate of EZS decreases. 
 
 
Figure 80. Plot of reaction rate for EZS catalysed production of radiolabelled products from (2Z,6Z)-[1-
3
H]-FDP (229) 
against various pH; pH 6-10 (left) and pH 5-9 (right). Reaction conditions: 30 nM [EZS], buffer (25 mM HEPES, 15 mM 
MgCl2, 5 mM DTT) for 10 minutes at 30 ᵒC. 
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Figure 81. Plot of reaction rate for EZS catalysed production of radiolabelled products from (2Z,6Z)-[1-
3
H]-FDP (229) 
against  various pH. Reaction conditions: 30 nM [EZS], buffer (25 mM HEPES, 15 mM MgCl2, 5 mM DTT) for 10 minutes at 
30 ᵒC. 
 
3.3.2 Steady state kinetic parameters of EZS catalysed reaction 
Measurement of the steady state kinetic parameters proceeded using the optimised conditions; 
[EZS] = 30 nM in catalysis buffer (25 mM HEPES, 15 mM MgCl2, 5 mM DTT, pH 8) for 10 minutes at 30 
ᵒC. A KM value of 7.12 ± 2.86 µM and a kcat of 0.29 ± 0.10 s
-1
 were reported by Bleeker et al. 
Measurements were therefore carried out varying the concentration of (2Z, 6Z)-[1-3H]-FDP (229) 
from 0.2 to 70 µM. Values of 6.23 ± 0.6 µM and 0.047 ± 0.001 s-1 were found for KM and kcat 
respectively (Figure 82). A change in methodology from GC-MS (used by Bleeker et. al.3) to 
radiolabelled assays (utilised in this investigation), have been reported to give different values for 
steady state kinetic parameters. Though comparable values using both methods have been reported 
for bacterial terpene cyclases,233,234 kinetic assays utilising radiolabelled FDP are preferable. This is 
because radiolabelled assays are able to detect product at much lower substrate concentrations and 
a larger range of data can be obtained, GC-MS can be insensitive to the levels of product formed at 
sub-KM concentrations for terpene cyclase catalysed reactions. 
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Figure 82. A representative graph for the calculation of steady state kinetic parameters of EZS. 
Comparisons of the steady state kinetic parameters of EZS with other sesquiterpene cyclases shows 
that the KM and kcat values determined in this work are fairly typical of this group of enzyme 
catalysed reactions. The KM of (2Z,6Z) FDP (38) with EZS when compared to (2E,6E) FDP (31) with 
other sesquiterpene cyclases is the same order of magnitude (with the exception of aristolochene 
synthase). It can also be noted that EZS appears to have a lower affinity towards (2Z,6Z) FDP (38) 
than other sesquiterpene cyclases to (2E,6E) FDP (31). The KM of (2Z,6Z) FDP (38) with EZS is double 
that of the other cyclases with the exception of γ-humulene synthase (Table 5). The kcat value 
however, is very similar to that of aristolochene synthase and germacrene A synthase, showing a 
comparably high substrate turnover. With the exception of aristolochene synthase, the catalytic 
efficiency of EZS appears to be similar to that of other terpene cyclases. 
Table 6. Comparison of steady state kinetic measurements for the turnover of [1-
3
H]-substrates with terpene cyclases. 
Terpene cyclase Substrate kcat / s
-1 KM / µM kcat/KM / s
-1 µM 
(x10-3) 
EZS(WT) 38 0.047 ± 0.001 6.2 ± 0.6 7.6 ± 0.8 
δ-Cadinene Synthase 31 0.01 ± 0.001 3.2 ± 0.5 3.1 ± 0.6 
PR-Aristolochene 
Synthase 
31 0.043 ± 0.002 0.6 ± 0.1 71.6 ± 12.4 
Amorphadiene 
Synthase 
31 0.01603 ± 0.0006 2.25 ± 0.3 7.1 ± 1.0  
Germacrene A 
synthase 
31 0.043 ± 0.02 3.4 ± 0.3 12.6 ± 6.0 
R-Germacrene D 
synthase 
31 0.02 3.0 ± 0.3 6.7 ± 0.3 
S-Germacrene D 
synthase 
31 0.03 2.9 ± 0.3 10.3 ± 0.3 
γ-humulene synthase 31 0.024 4.7 5.1 
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The synthesis of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) allowed for the characterisation and 
comparison of EZS(WT) with other sesquiterpene cyclases. The steady state kinetics parameters 
were found to be comparable to the values published by Bleeker et al.3 However, the use of a 
radiolabelled substrate in place of a GC-MS methodology gave a significant decrease in kcat.  
 
3.3.3 Steady state kinetic parameters of EZS(E648A) catalysed reaction 
Incubation of (2Z, 6Z) FDP (38) with the four metal binding motif mutants; EZS(D495A), EZS(E499A), 
EZS(N640A) and EZS(E648A) and analysis of the pentane extractable products via GC-MS showed 
only mutant EZS(E648A) was active (section 2.7.1). Steady state kinetics of EZS(E648A) catalysed 
turnover of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) were performed using under the same 
reaction conditions as for the wild type enzyme (section 3.3.2) and fitted to a Michaelis-Menten 
curve (Figure 83). 
 
 
Figure 83. A representative graph for the calculation of steady state kinetic parameters of EZS(E648A). 
The KM and kcat were found to be 5.32 ± 0.5 µM and 0.023 ± 0.001 s
-1 respectively with a kcat/KM = 4.3 
x10-3 ± 0.0004 s-1 µM. These values indicated a higher binding affinity and slower substrate turnover 
resulting in a lower catalytic efficiency when compared to the wild type parameters determined 
earlier (KM = 6.2 ± 0.6 µM, kcat = 0.047 ± 0.001 s
-1, kcat/KM = 7.6 x10
-3 ± 0.0008 s-1 µM). In contrast to 
the asparagine residue, the glutamate residue of the NSE motif appeared to not be crucial for 
catalysis. The mutation glutamate to alanine (EZS(E648A)) was directly responsible for the decrease 
in enzymatic efficiency when compared to the wild type. However, the mutant was still capable of 
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catalysis. This result gives evidence that the single point mutation of glutamate residue E648 to 
alanine increased the substrate binding of EZS despite the NSE motif being responsible for the 
coordination of a magnesium ion for diphosphate binding. 
3.3.4 Steady state kinetic parameters of EZS(Y483A) catalysed reaction 
EZS aromatic active site mutants EZS(F598A), EZS(F705A), EZS(Y483A) and EZS(Y716A) were 
incubated with (2Z, 6Z) FDP (38) and the pentane extractable products analysed via GC-MS showing 
only mutant EZS(Y483A) was active (section 2.7.2). Steady state kinetics of EZS(Y483A) catalysed 
turnover of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) were performed using under the same 
reaction conditions as for the wild type enzyme (section 3.3.2) and fitted to a Michaelis-Menten 
curve (Figure 84). 
 
 
Figure 84. A representative graph for the calculation of steady state kinetic parameters of EZS(Y483A). 
The KM and kcat were found to be 2.87 ± 0.4 µM and 0.037 ± 0.001 s
-1 respectively with a kcat/KM = 
12.9 x10-3 ± 0.0018 µM. As observed with EZS(E648A), the mutation resulted in a higher binding 
affinity and slower substrate turnover to that of EZS(WT). The Y483A single point mutation resulted 
in the highest binding affinity whilst not decreasing substrate turnover to the extent of the E648A 
mutation. The EZS(Y483A) mutant therefore exhibited largest catalytic efficiency of the three 
enzymes tested (Table 7). 
  
95 
 
Table 7. Comparison of steady state kinetic measurements for the turnover of (2Z,6Z)-[1-
3
H]-FDP (229) EZS(WT), 
EZS(E648A) and EZS(Y483A). 
EZS(XX) kcat / s
-1 KM / µM kcat/KM / s
-1 µM 
(x10-3) 
WT 0.047 ± 0.001 6.2 ± 0.6 7.6 ± 0.8 
E648A 0.023 ± 0.001 5.3 ± 0.5 4.3 ± 0.4 
Y483A 0.037 ± 0.001 2.9 ± 0.4 12.9 ± 1.8 
 
Interestingly, the Y483A mutation appeared to have a greater effect on binding affinity than the 
E648A single amino acid substitution. These values indicated that the tyrosine (Y) residue within the 
active site has a greater influence on substrate binding than the glutamate (E) of the NSE metal 
binding motif. In concurrence with an increased affinity for the substrate, the mutation of the 
tyrosine (Y) residue to alanine (A) resulted in an increase in substrate turnover compared to the 
EZS(E648A) mutant. The increase in kcat indicates that the glutamate residue may aid product release 
from the active site. The product release is the rate limiting step due to an organic hydrocarbon 
product being released into an aqueous buffer.  
The E648A mutation lowered the catalytic efficiency of the enzyme in comparison to the wild type. 
However, other single point mutations of the metal binding motifs; D495A, E499A and N640A gave 
no enzymatic product when the respective mutant was incubated with (2Z,6Z) FDP (38). These 
results show that although the E648 residue influences catalytic efficiency, it is not crucial for 
activity. 
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3.5 Summary 
During the synthesis of 229 the stereochemical integrity of the C2,C3 double bond of (2Z, 6Z) 
farnesal (217) proved problematic due to acid or base catalysed isomerisation of the product , 
unsaturated aldehyde. Numerous attempts at replicating oxidations published for (2E,6E) farnesol 
(353) did not yield a single product and were often time consuming with low yield. A TEMPO 
catalysed reaction was found to be an ideal alternative to previous protocols. The short reaction 
time and simple isolation from the reaction mixture allowed the reaction product to be used without 
more extensive purification.  
Optimisation of incubation conditions revealed ideal conditions for EZS productivity to be: [EZS] = 30 
nM, [Mg2+] = 15 mM, and pH 8.0. The relationship of time and reaction rate was found to be linear 
within a range of 5-20 min; therefore an incubation time of 10 min was chosen to ensure sufficient 
product formation within a reasonable productive timeframe. Kinetic parameters determined from 
steady state kinetic assays show comparable catalytic efficiency to that of previously characterised 
sesquiterpene cyclases. 
Two EZS mutants; EZS(E648A) and EZS(Y483A) were active and characterised. The values determined 
from steady state kinetics showed a greater binding affinity and slower substrate turnover when 
compared to the wild type. Mutation of selected metal binding residue motif showed that the 
glutamate residue of NSE was not critical for enzyme activity. However, its mutation resulted in a 
loss of catalytic efficiency. Analysis of the data from the steady state kinetic experiments showed 
decreased substrate turnover and an increased binding affinity when compared with the wild type. 
EZS(Y483A) was found to have an effect on substrate binding affinity with the KM of 38 with 
EZS(Y483A) lower and the catalytic efficiency increased when compared to the wild type. 
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Chapter 4 –Examination of the catalytic mechanism of 
7-Epizingiberine Synthase  
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4.1 Preface 
 
This chapter outlines the synthesis of numerous analogues used as probes to investigate the 
catalytic mechanism of 7-epizingiberene synthase (Figure 85). Analogues synthesised include 
fluorinated analogues 230 and 231 to examine cation stability and deuterated analogues 232, 233 
and 234 to examine the stereo- and regiospecificity of hydride shift rearrangements of intermediate 
carbocations. 
 
 
Figure 85. (2Z,6Z) FDP analogues discussed within this chapter. 
Kinetic assays were performed in triplicate and non-linear regression was used to generate KM and 
kcat parameters to fit Michaelis-Menten curves to experimental data. Analogues that did not yield 
enzymatic products were tested as inhibitors and non-linear regression was similarly used to 
generate parameters to fit Michaelis-Menten curves to experimental data to establish KM, KM(app) and 
Ki values. Lineweaver-Burk plots were used to infer the mode of inhibition.  
All incubations were performed in tandem with an incubation containing substrate and incubation 
buffer, but no enzyme. This was used to identify which products arose via enzymatic involvement 
and not as a result of Mg2+ induced cleavage or other side products of substrate degradation. The 
GC-MS method remained constant; an injection temperature of 100 ᵒC was followed by a 
temperature gradient of 80 ᵒC (1 min hold) to 180 ᵒC (4 ᵒC increase min-1, 2 min hold).  
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4.2 Fluorinated Substrate analogues 
4.2.1 Synthesis of (2E,6Z)-2-fluorofarnesyl diphosphate (230) 
Fluorine-containing substrates are valuable tools for investigating the catalytic mechanisms of 
sesquiterpene synthases.106,109 The atomic radii of fluorine (41 pm) and hydrogen (53 pm)235 are 
approximate to one another, minimising unfavourable steric interactions in the active site. However, 
fluorine causes significant perturbations in the electronic structure of the substrate-enzyme complex 
and particularly affects the stability of carbocation intermediates. Fluorine can stabilise geminal 
carbocation formation (236) via the alpha effect, but its electronegative nature will raise the energy 
of the carbocation in the alpha position (237) and inhibit its formation (Figure 86). If positioned on 
an alkene, the presence of the fluorine significantly reduces the π-bond electron density and 
therefore the nucleophilicity and basicity of the bond in turn. 
 
 
Figure 86. Effect of fluorine on carbocation stability. 
The catalytic mechanism of EZS is currently not known. It is possible that the mechanism could 
proceed either via a concerted or by stepwise ring closure. Incorporation of fluorine at the C2 
position of 38 would inhibit a stepwise mechanism by increasing the energy of the farnesyl cation 
(141) via electron withdrawal. Contrastingly; a concerted mechanism would cyclise 38 to give 
carbocation (239) and possibly result in a fluorinated product (240) (Figure 87). 
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Figure 87. Possible stepwise and concerted mechanisms that may be catalysed by EZS and the expected effect of 
2-fluoro substitution on formation of 7-epizingiberine. 
The synthesis of 230 was achieved by chain extension of nerol (163) to yield neryl acetone (166). The 
commercially available Horner-Wadsworth-Emmons reagent triethyl-2-fluoro-2-phosphonoacetate 
(241) was employed to incorporate fluorine at the C2 position (Figure 88).  
 
Figure 88. Synthesis of (2E,6Z)-2-fluorofarnesyl diphosphate (230). 
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Olefination of 166 using 241 resulted in a tetra-substituted double bond with no stereocontrol. A 1:1 
ratio of E:Z isomers was obtained with the various conditions previously investigated (Table 4, 2.2.5). 
Reduction to alcohols 244 and 245 was followed by silica gel chromatography to isolate 245 for 
bromination and conversion to a diphosphate as previously described. The presence of fluorine 
necessitated increasing the bromination reaction time from 15 to 50 minutes. Even this extended 
reaction time was insufficient to consume all the starting material, but the appearance of multiple 
side products via thin layer chromatography (TLC) coincided with a decrease in overall yield when 
further increasing the reaction time. After work up, bromide 246 was the sole product observed by 
1H and Heteronuclear Single Quantum Coherence (HSQC) NMR spectroscopy. 
 
4.2.2 Incubation of (2E,6Z)-2-fluorofarnesyl diphosphate (230) and EZS 
Formation of an enzymatic product from an incubation of 230 and EZS would suggest a concerted 
ring closure to form the bisabolyl cation (86) (Figure 87). However, GC-MS analysis of the pentane 
extractable products of 230 and EZS incubation showed no enzymatic products were formed from 
the incubation, even after extended time, suggesting a stepwise mechanism inhibited by the 
presence of fluorine inhibiting the formation of the farnesyl cation (141). Competitive assays with 
(2Z,6Z)-[1-3H]-farnesyl diphosphate (229) and varying concentrations of 230 were performed to 
establish substrate binding and mode of inhibition. 
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Figure 89. Michaelis-Menten plots for incubations of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and  inhibitor 
(2E,6Z)-2-fluorofarnesyl diphosphate (230); 0 µM, 5 µM, 15 µM and 30 µM. 
Michaelis-Menten (Figure 89) and Lineweaver-Burk (Figure 90) plots show data trends characteristic 
of a competitive inhibitor. The data plots of the Lineweaver-Burk plot (Figure 90) for a competitive 
inhibitor intercept the same point of the y-axis. In this example, the linear plots intercept each other 
at a value < x = 0 and might not be considered as a competitive inhibitor. However, data points on a 
Lineweaver Burk plot visualising uncompetitive inhibitors do not intercept each other whilst the data 
points concerning non-competitive inhibition intercept at the x-axis. Consequently, 
(2E,6Z)-2-fluorofarnesyl diphosphate (230) is characterised as a competitive inhibitor with the 
discrepancy of the intercept attributed to experimental error. The Ki calculated from the KM(app) vs. 
[230] plot (Figure 90) was 5.37 ± 1.19 µM. This concentration is comparable to the KM of (2Z,6Z) FDP 
(38) at 6.2 ± 0.6 µM (Figure 82, chapter 3), showing fluorine had minimal effects on binding and 
caused an increase in the energy of the fluorofarnesyl cation (238) resulting in EZS inhibition.  
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Figure 90. Lineweaver-Burk Plot (left) and KM(app) vs. concentration plot (right) for 230. 
A stepwise [1,6] ring closure to produce the bisabolyl cation (86) (Figure 91) then requires 
carbocation rearrangements via various plausible hydride shifts, or combinations thereof, before 
deprotonation to yield 7-epizingiberene. 
 
 
Figure 91. 230 inhibition of EZS implies formation of bisabolyl cation (86) via a stepwise, rather than concerted reaction. 
 
4.2.3 Synthesis of (2Z,6E)-6-fluorofarnesyl diphosphate (231) 
Incubation of (2E,6E)-10-fluorofarnesyl diphosphate (110) with germacrene A synthase resulted in an 
unusual 1,11-macrocylisation and the formation of a fluorinated hydrocarbon (Figure 20, section 
1.4.2). Similarly, incubation of 231 with EZS should prohibit the formation of cation 248 and inhibit 
the enzyme (Figure 92). However, an anti-Markovnikov 1,7-macrocyclisation to yield a fluorinated 
hydrocarbon (250) might be possible (Figure 93). 
 
 
Figure 92. 231 inhibition of EZS by destabilisation of an on-path carbocation. 
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Figure 93. Potential outcome of a 1,7-cyclisation. 
(2Z,6E)–6-fluorofarnesyl diphosphate (231) was prepared through an extended version of the 
synthesis of previous analogues (Figure 94). Fluorine was installed at the C6 position via a 
Horner-Wadsworth-Emmons reaction using commercially available 6-methylheptan-2-one (251) and 
241.  
105 
 
 
Figure 94. Synthesis of (2Z,6E)–6-fluorofarnesyl diphosphate (231). 
The initial Horner-Wadsworth-Emmons reaction and subsequent bromination of fluorinated nerol 
(255) gave comparable yields of product to the analogous synthesis of 230 (Figure 88). Carefully 
maintaining the temperature of the bromination reaction at -10 ᵒC limited the formation of side 
products. The presence of fluorine did not affect the reactivity of the substrate throughout the 
remainder of the synthesis, with the Z-C2,C3 double bond installed by previously optimised 
conditions (Table 4, 2.2.5)  
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4.2.4 Incubation of (2Z,6E)-6-fluorofarnesyl diphosphate (231) and EZS 
Analysis of pentane extractable products from the incubation of (2Z,6E)-6-fluorofarnesyl 
diphosphate (231) and EZS by GC-MS analysis showed no enzymatic products suggesting that the 
presence of fluorine inhibits the formation of the bisabolyl cation. Competitive kinetics experiments 
were again used to establish if FDP analogue 231 was binding within the active site and the mode of 
inhibition. 
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Figure 95. Michaelis-Menten plots for incubations of (2Z,6Z)-[1-
3
H]-FDP with EZS and inhibitor (2Z,6E)-6-fluorofarnesyl 
diphosphate (231); 0 µM, 5 µM, 15 µM and 30 µM. 
Analysis of the data using Michaelis-Menten (Figure 95) and Lineweaver-Burk (Figure 96) plots show 
(2Z,6E)-2-fluorofarnesyl diphosphate (230) acts as a competitive inhibitor for EZS with linear plots of 
inhibition data intercepting the y-axis at the same point. The Ki of 231 was found by plotting KM(app) 
against [231] to be 3.04 ± 0.39 µM (Figure 96) showing an affinity of similar magnitude to EZS as 
(2Z,6Z)-FDP (38)(Figure 82). 
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Figure 96. Lineweaver-Burk Plot (left) and KM(app) vs. concentration plot (right) for inhibition of EZS by 231. 
 
4.3 Deuterated Analogues 
 
4.3.1 Synthesis of (2Z,6Z)-[6-2H]-farnesyl diphosphate (232) 
Numerous hydride shifts are possible en route from the bisabolyl cation (86) to 7-epizingiberene. 
Heavy isotopes have been used on many occasions to track hydride movements via mass 
spectrometry and 1H NMR analysis.115,116,236 The incubation of (2Z,6Z)-[6-2H]-farnesyl diphosphate 
(232) with EZS and analysis of enzymatic products would give insight into which hydride shifts occur. 
Hydride shifts in the catalytic mechanism of EZS could occur from the C1, C5 and C6 positions to 
stabilise the bisabolyl cation. Two [1,3] hydride shifts from C1 or C5 to C7 would quench the charge 
at the tertiary centre. Contrastingly, two consecutive [1,2] hydride shifts initially from the C6 to C7 
position followed by a second [1,2] hydride shift from either the C1 or C5 positions to the 
carbocation at the C6 position. The residing charges are then quenched via deprotonation. The 
incubation of (2Z,6Z)-[6-2H]-farnesyl diphosphate (232) with EZS would yield one of two deuterated 
products; 266 or 270 (Figure 97) depending on which combination of hydride shifts occur during the 
catalytic mechanism. Determination of the correct hydride shifts could then be elucidated via 
analysis using GC-MS or 1H NMR spectroscopy. 
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Figure 97. Two enzymatic products 235 and 239 that could occur from the incubation of 233 with EZS involving hydride 
shifts from the C1, C5 or C6 positions. 
Incorporation of deuterium at the C6 position was pursued in two ways (Figure 99). The first 
technique employed an Anastasia reaction199 which was quenched with deuterated sulfuric acid and 
deuterium oxide according to a procedure published by Faraldos et al.200 The reaction gave 100% 
deuterium incorporation. However, the reagents were costly, limiting the scales of subsequent 
reactions resulting in inadequate quantities of material later in the synthesis (Figure 39, 2.2.4). 
Therefore a second, scalable approach with cheaper reagents was sought to allow for a higher 
throughput of material. 
A second approach involved using a deuterated Still-Gennari/Horner-Wadsworth-Emmons reagent 
to incorporate the isotopic label. Deuteration of the reagent was attempted via a protocol outlined 
by Christianson et al.237 Reagent 204 and potassium carbonate were stirred for 48 hours in 
deuterium oxide and deuterated product extracted with ethyl acetate. However, even after 
repeating this procedure three times on the same material, only 80% isotopic labelling was achieved. 
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However, refluxing a mixture of 204 and potassium carbonate in deuterium oxide then extracting 
the reaction mixture with dichloromethane yielded 100% isotopically labelled reagent 204 (Figure 
98). 1H and 2H NMR spectroscopy was used to confirm labelling. The methylene of the starting 
material (P(CH2)C=O) was no longer visible of the 
1H NMR spectrum whilst a doublet at. δ 2.90 was 
visible of the 2H NMR spectrum showing incorporation. 
 
 
Figure 98. Isotopic labelling of 204. 
Ketone 251 which was used in both Anastasia and Horner-Wadsworth-Emmons olefination 
reactions, with the synthesis proceeding via steps described previously for other (2Z,6Z) FDP (38) 
analogues with modifications at the C6 position 231 (Figure 94). 
 
110 
 
 
Figure 99. Synthesis of (2Z,6Z)- [6-
2
H]-farnesyl diphosphate (232). 
Deuterated precursor 274 was synthesised under optimised Z-selective olefination conditions (Table 
4, 2.5.2). A 1:1 E:Z ratio was observed however, the reaction products showed only a 30% 
incorporation of deuterium as judged by 1H NMR and 2H NMR spectroscopy. Incorporation of 
deuterium was observed via 2H NMR spectroscopy with a singlet visible at δ = 5.53 ppm and a singlet 
integrating to 0.7 H representative a proton environment at δ = 5.53 ppm on the 1H NMR spectrum. 
The reaction was repeated with fresh reagent to ensure experimental error was not to blame for the 
low deuterium incorporation. It was speculated that proton deuterium exchange may have occurred 
during quenching and work up of the reaction. The reaction was therefore repeated and quenched 
with deuterium oxide in place of water, however no improvement in deuterium incorporation was 
observed.  
Proton-deuteron exchange via deprotonation of the alkene proton with n-butyl lithium and 
subsequent quenching with deuterium oxide did not achieved a greater incorporation than observed 
after the Horner-Wadsworth-Emmons olefination. The synthetic pathway was continued using the 
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30% labelled product (Figure 99). Incorporated deuterium was readily observed via 2H NMR 
spectroscopy and respective proton peaks were seen at the same ppm shift in 1H NMR spectra of 
284. Unfortunately, after bromination, diphosphorylation and purification steps diphosphate 232 
could not be recovered after lyophilisation.  
 
4.3.2 Synthesis of (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) 
Following cyclisation, the catalytic mechanism of 7-epizingiberine synthesis by EZS requires hydride 
shifts from either the C1 or the C5 positions. Hydride shifts from an allylic position have been shown 
by Tantillo et al. to be energetically favourable via computational methods.238 Therefore 
investigations of hydride shifts using isotopic labelling focussed on the C1 position. Two pathways 
are feasible: a [1, 3] hydride shift from the C1 to C7 position, or two consecutive [1, 2] hydride shifts 
firstly from the C6 to C7 position and then the C1 to C6 position. It is currently unknown which 
hydride; the proR or proS at the C1 position migrates. Stereoselective deuterium labelling and 
incubation with EZS was used to generate deuterated 7-epizingiberene products. GC-MS and analysis 
of the fragmentation pattern arising from the enzymatic products were used to investigate these 
rearrangements by comparing fragment masses with possible rearrangement pathways starting with 
233 (Figure 100). 
 
 
Figure 100. Possible hydride shifts from EZS catalysed reaction of 233. 
Attempts to synthesise 289 by direct reduction of ethyl farnesoates 193 with lithium aluminium 
deuteride (LiAlD4) yielded the desired product. However, due to the poor condition of the reducing 
agent the reaction could not be driven to completion and fresh reagent could no longer be 
purchased. A reduction outlined by Yamakawa et, al.239 showed reduction of esters using an in situ 
transmetalation reduction using lithium chloride and sodium borohydride. Various attempts at this 
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reduction using lithium chloride and sodium borohydride showed no reduction of 192 to 168 and 
was not investigated further. Instead, a sequential oxidation-reduction strategy was followed. 
Oxidation of (2Z,6Z) farnesol (167) with TEMPO furnished aldehyde 217 which was reduced with 
sodium borodeuteride (NaBD4) to incorporate a first isotopic label (Figure 101).  
 
 
Figure 101. Synthesis of (2Z,6Z)-(S)-[1-
2
H]-farnesyl diphosphate (233). 
An oxidation reaction using TEMPO salt reagent 226 resulted in a single aldehyde product which was 
found to be of sufficient purity and correct stereochemistry when analysed via 1H and NOESY NMR 
spectroscopy. Contrary to the synthesis of 229 (Figure 76), NaBD4 reductions were carried out in 
ethanol rather than THF with reaction times of protic solvent reductions being considerably shorter 
than those in THF. Unlike some other methods detailed in the literature,112 the TEMPO salt oxidation 
did not completely prefer H+ over D+ when oxidising of 287, with aldehyde 288 showing only 80% 
deuterium incorporation (Figure 102).  
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Figure 102. 
1
H NMR spectrum of aldehyde (257) with 80% deuterium incorporation. 
However, reduction of 288 with sodium borodeuteride followed by re-oxidation afforded aldehyde 
290 with which the characteristic aldehyde environment was not observed in the 1H NMR spectrum. 
Deuterium incorporation into aldehydes was confirmed using 2H NMR spectroscopy and mass 
spectrometry for the purified alcohols 287 and 289. 
Deuterated (2Z,6Z) farnesal (290) was then reacted with an alpine borane chiral reducing agent to 
yield the desired enantiomer. Reduction of aldehyde 290 with (R)-Alpine borane (294) delivers the 
hydride to the Re face of the aldehyde yielding the (S) enantiomer as the product. Stereochemical 
control arises from the coordination of the borane to the carbonyl oxygen atom. This coordination 
aligns the reacting partners for a hydride shift from the tertiary centre opposite to give -pinene 
(49) and a boro-ester product 292. Excess Alpine borane reagent was quenched with acetaldehyde 
and the boron-oxygen coordination complex was cleaved via the addition of ethanolamine to give 
the desired enantiomer 291 (Figure 103). 
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Figure 103. Reduction of 290 with (R)-alpine borane (293) at the Re face to give 291. 
Direct analysis of the enantiomeric excess via 1H NMR spectroscopy is not possible without the use 
of a chiral solvent, nor would chiral HPLC be able to distinguish between deuterium and hydrogen. 
Enantiomeric analysis was therefore investigated using Mosher’s ester derivatives followed by 1H 
NMR spectroscopic analysis. (2Z,6Z)-(S)-[1-2H]-farnesol (291) was reacted in turn with 
(S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (S-MTPA-Cl) and 
(R)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (R-MTPA-Cl) yielding a pair of 
diastereoisomers 297 and 288 respectively (Figure 104). 
 
 
Figure 104. Synthesis of Mosher’s esters 297 and 298. 
Mosher’s esters are commonly used for identifying enantiomers at secondary carbon centres. In 
solution the trifluoro group of MTPA adopts a rigid linear conformation between the carbonyl and 
enantiomeric proton (Figure 105). This conformation aligns the phenyl and methoxy groups of MTPA 
with the R1 and R
2 groups at the enantiomeric centre respectively. The close spatial arrangement of 
the methoxy group influences the 1H NMR resonance for R2 causing its chemical shift to move 
downfield. In contrast, the phenyl group causes shielding of R1 and its chemical shift will shift in the 
opposite direction. Synthesis of the Mosher’s ester with the contrasting MTPA enantiomer (Figure 
106) will result in the opposite effects on the 1H NMR spectroscopic resonances with the R1 peak 
shifting down field and the R2 peak shifting upfield.240,241 
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Figure 105. Lowest energy conformation of a Mosher’s Ester (S)-MTPA. 
 
 
 
Figure 106. Lowest energy conformation of a Mosher Ester (R)-MTPA. 
Analysis of R and S isotopically labelled primary alcohol was slightly more complicated due to the 
similarity of the deuterium and proton substituents at its chiral centre. As the deuterium and proton 
are very similar in size, there is no strong preference for either to adopt an eclipsed conformation 
with the trifluoromethyl group (Figure 105 and Figure 106); only the carbon chain is prohibited from 
adopting this conformation by its steric bulk. Figure 107 shows the two possible conformations of 
297 achievable through rotation around the carbon oxygen sigma bond. The proton rotates between 
alignment with the trifluoromethyl and phenyl groups whilst not being affected by the deshielding 
methoxy group on the opposing face. Figure 108 shows the lowest energy conformation of 298 and 
outlines the opposite effect with the proton environment able to rotate between alignment with the 
trifluoromethyl and methoxy groups. Interaction of the C1 proton with the methoxy group on 298 
results in de-shielding of the proton environment. This interaction causes downfield shift of the 
respective peak on the 1H NMR spectrum. When compared to the analogous peak of 297 a 
downfield shift of the 298 proton is observed on the 1H NMR spectrum. Contrary to secondary 
alcohols, the 1H NMR signals for R will not be affected by the synthesis of the Mosher’s ester. The 
rotation to align H or D with the trifluoromethyl group allows R group to interact with both phenyl 
and methoxy groups (Figure 107 and Figure 108), therefore shielding and de-shielding effects would 
be equilibrated and no net changes in chemical shift are be observed.242 
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Figure 107. Lowest energy conformations of 297. 
 
 
Figure 108. Lowest energy conformations of 298. 
 
1H NMR spectroscopic analysis of 297 and 298 showed the proton environment at the C1 position of 
298 was shifted downfield to 4.82 ppm compared to that of 297 at 4.77 ppm (Figure 109). It was also 
observed that the chemical shift of the alkene proton of R remained the same in both spectra as 
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predicted. Chemical shifts of 297 and 298 were concordant with literature values of 
(S)-[1-2H]-farnesyl-(S)--methoxy--(trifluoromethyl)phenyl-acetate (2E,6E isomer).243  
 
Figure 109. Overlaid 
1
H NMR spectra of (2Z,6Z)-(S)-[1-
2
H]farnesyl-(R)--methoxy--(trifluoromethyl)phenyl-acetate 
(298)(blue) and (2Z,6Z)-(S)-[1-
2
H]farnesyl-(S)--methoxy--(trifluoromethyl)phenyl-acetate (297)(red). 
Determination of enantiomeric excess (ee) was attempted via decoupling experiments using 1H NMR 
spectroscopy. Decoupling by irradiation of the C2 alkene peak (circled red in Figure 110) at δ = 5.4 
ppm of 297 and 297 gave two singlets for the proton environment at the C1 position (circled blue in 
Figure 110) at δ = 4.77 and 4.82 ppm respectively, with no other decoupled environments observed. 
The presence of one singlet environment on each spectrum indicates a single enantiomer is present 
(Figure 110). A racemic mixture would result in two doublets on a 1H NMR spectrum arising from 
two distinct proton environments. Upon irradiation, both environments would decouple to form two 
singlets. As only one peak in each spectrum experienced decoupling, a single enantiomer is present. 
However due to the small quantity of each ester synthesised, the product peaks of 297 and 298 are 
in close proximity to the baseline. For the calculation of ee, precise integration of each peak is 
required. Due to slight impurities in the same region as the peaks of interest disrupting the baseline, 
an exact enantiomeric excess could not be determined. However, due to the presence of one singlet 
environment on each spectrum after the irradiation at δ = 5.4 ppm, 291 was deemed to be of 
sufficient quality to use. 
298 297 
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Figure 110. 
1
H NMR Decoupling experiment for 297 (left) and 298 (right); irradiation at δ = 5.4 ppm resulting in the 
collapse of the respective doublets to singlets at δ = 4.77 (297, left) and 4.82 ppm (298, right). 
With the required enantiomer confirmed, diphosphorylation of 291 proceeded via chlorination as 
described previously rather than phosphorus tribromide bromination as chlorination by this method 
cleanly inverts the stereocentre,244,245 in this example yielding the R enantiomer. Diphosphorylation 
inverts the centre for a second time giving retention of stereochemistry over the two steps.  
 
4.3.3 Synthesis of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) 
A hydride shift from the (R) proton at the C1 position is a possibility in the catalytic mechanism of 
EZS. As with the (S) enantiomer 233, two deuterated products may be synthesised from the 
incubation of 234 and EZS with consecutive [1,2] hydride shifts giving 266 and a [1,3] hydride shift 
yielding 270 (Figure 111).  
 
Figure 111. Possible hydride shifts from EZS catalysed reaction of 234. 
The synthesis of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) was analogous to that of 233 (Figure 
101) but used (S)-alpine borane (302) as the reducing agent to yield the desired enantiomer (Figure 
112). 
 
298 297 
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Figure 112. Synthesis of (2Z,6Z)-(R)-[1-
2
H]-farnesyl diphosphate (234). 
 
 
Figure 113. Reduction of 290 with (S)-alpine borane (302) at the Si face to give 300. 
Mosher’s ester analysis of alcohol 300 as described above was used to confirm the required 
enantiomer had been synthesised. The 1H NMR spectrum showed a characteristic downfield shift of 
the C1 proton from the S-MTPA derived ester 303 (red, δ = 4.83 ppm) when compared to the 
R-MTPA derived ester 304 (blue, δ = 4.77 ppm) (Figure 114). 1H NMR decoupling experiments were 
utilised to confirm the presence of a single enantiomer. Upon irradiation of the alkene peak at δ = 
5.40 ppm the respective doublets of the C1 proton environments collapsed to singlets (Figure 115). 
Though slight impurities inhibited the calculation of ee, no surrounding proton environments were 
affected by irradiation and 300 was deemed of sufficient purity to use. 300 was chlorinated and 
diphosphorylated as previously described in order to prepare the diphosphate with retention of 
configuration. 
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Figure 114. Overlaid 
1
H NMR spectra of (2Z,6Z)-(R)-[1-
2
H]farnesyl-(S)--methoxy--(trifluoromethyl)phenyl-acetate 
(303)(red) and (2Z,6Z)-(R)-[1-
2
H]farnesyl-(R)--methoxy--(trifluoromethyl)phenyl-acetate (304)(blue). 
 
  
Figure 115. 
1
H NMR Decoupling experiment for 304 (left) and 303 (right); irradiation at δ = 5.4 ppm resulting in the 
collapse of the respective doublets to singlets at δ = 4.77 (304, left) and 4.83 ppm (303, right). 
 
4.3.4 Incubation of 233 and 234 with EZS 
The catalytic mechanism of EZS can proceed via two possible pathways from the C1 position; a [1,3] 
hydride shift or two consecutive [1,2] hydride shifts. Nor is it known which of the proR or proS 
hydrides migrate (Figure 116). 
 
303 
304 
303 304 
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Figure 116. Possible hydride shifts occurring from the C1 position during the catalytic mechanism of EZS 
 
4.3.5 Incubation of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) and EZS 
The incubation of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) with EZS could give rise to three 
different deuterated products depending on the catalytic mechanism followed (Figure 117). Analysis 
of the pentane extractable products via GC-MS yielded a single enzymatic product (Figure 118). 
 
 
Figure 117. Possible pentane extractable products arising from incubation of EZS and 234. 
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Figure 118. Total ion chromatogram of the pentane extractable products arising from incubation of 234 with EZS. 
The mass spectrum of this product was analysed and plausible fragments corresponding to the m/z 
values were assigned (Figure 119). Due to the various hydride shifts that are plausible during the 
catalytic mechanism of EZS (Figure 117), multiple deuterated products could be responsible for the 
peak on the gas chromatogram (Figure 118). The compound responsible for the peak at 15.29 
minutes (Figure 118) showed deuterium incorporation on the mass spectrum (Figure 119). An m/z 
increase of +1 is observed in numerous peaks of the mass spectrum when compared with the mass 
spectrum of 7-epizingiberene (1) (Figure 60, 2.6) indicating isotope labelling. 
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Figure 119. Mass spectrum of the compound eluting at 15.29 min on the total ion chromatogram. 
The mass spectrum (Figure 119) gives some insight into the destination of the C1 proR proton of 
(2Z,6Z) farnesyl diphosphate (38) in the EZS catalysed conversion of 134. Peaks at m/z = 205 and 203 
correspond to ionised deuterated 7-epizingiberene (306, 309 or 311) and curcumene respectively 
whilst a peak at m/z = 120 is also present indicating the deuteride undergoes a [1,3] shift (308) or 
remains in the same position (313) during the catalytic mechanism. Aromatisation of the ring would 
result in the loss of deuterium if a [1,2] shift had occurred from the C1 to the C6 position (223) 
within the catalytic mechanism giving a peak at m/z = 119, ruling out this scenario (Figure 120). 
  
124 
 
 
Figure 120. Fragmentations of product that give ions with m/z = 119 and 120. 
Two cations are plausible for the species with m/z = 106. A [1,3] shift giving deuterated product 270, 
ionisation and fragmentation would give cation 316 whilst no movement giving rise to 305 with 
ionisation and fragmentation to give cation 321. The m/z = 106 peak can only occur via no deuterium 
movement or a [1,3] hydride shift during the catalytic mechanism. Again this data disfavours 
consecutive [1,2] hydride shifts as ionisation, fragmentation and terminal alkene formation would 
remove the deuterium to give a major fragment 224 at m/z = 105 (Figure 121). 
 
Figure 121. Fragmentations of possible products that give m/z = 105 and 106. 
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A peak at m/z = 94 could correspond to possible two cations. Consecutive [1,2] hydride shifts or no 
movement of the R deuteron could give the m/z value observed for cations 322 and 323 respectively 
after product ionisation and fragmentation. A [1,3] shift and ionisation of the deuterated product 
270 would give 306 and consequent fragmentation would yield cation 225 with a m/z = 93 (Figure 
122). This data again disfavours consecutive [1,2] shifts, but additionally suggests the R deuteron 
does not migrate. 
 
 
Figure 122. Fragmentations of product that give m/z = 93 and 94. 
Lower m/z regions of the mass spectrum are more complicated and do not clearly implicate any of 
the possibilities. Fragmentation and aromatisation can affect the ratio m/z = 92:91 (Figure 123) and 
m/z = 78:77 (Figure 124). With no definitive way of knowing which fragments occur and at what 
ratios, relying on the interpretation of these peak ratios alone would not allow for the elucidation of 
the catalytic mechanism. However, the evidence gained from these fragmentation patterns and 
peaks discussed in Figure 120 and Figure 121 give insight into the role of proR proton at the C1 
position  
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Figure 123. Fragmentations of product that give m/z = 92 and 91. 
 
 
Figure 124. Fragmentations of product that give m/z = 78 and 77. 
Overall, the data strongly suggest that the R proton at the C1 position does not migrate during 
7-epizingiberene synthesis by EZS. The consequent fragmentation pattern is therefore as a result of 
the formation of deuterated 7-epizingiberene (305) (Figure 125).  
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Figure 125. Role of proR proton at C1 position. 
 
4.3.6 Incubation of (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) 
The pentane extractable products arising from the incubation of (2Z,6Z)-(S)-[1-2H]-farnesyl 
diphosphate (233) and EZS (Figure 126) were analysed via GC-MS. A single enzymatic product was 
observed at 15.27 min. However, several non-enzymatic products were also observed and identified 
as impurities from the substrate (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) (Figure 127). 
 
 
Figure 126. Possible incubation products of 134 and EZS. 
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Figure 127. Total ion chromatograms of the pentane extractable products from; the incubation 233 and EZS (top), the 
incubation 233 with no EZS (bottom. Enzymatic product eluted at 15.27 minutes (top). 
The mass spectrum of the compound eluted at 15.3 min shows a fragmentation pattern consistent 
with 7-epizingiberene (Figure 60, 2.6). Consistent with incubation products of 234 and EZS, peaks; 
205 and 203 imply deuterated 7-epizingiberene (306, 309 or 311) and curcumene respectively. Peaks 
at m/z = 160 and 120 are again plausible if the deuteride is undergoing a [1,3] shift or remaining in 
the same position. 
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Figure 128. Mass spectrum of the compound eluted at 15.27 minutes on the total ion chromatogram. 
A subtle difference in the peak intensity of m/z = 132 between the spectra shows that a non 
deuterated cation fragment is present. The relative intensity of the m/z = 133 to the 132 peak is 
significantly reduced in for the S-deuterium substrate (Figure 128) compared to the R-deuterium 
substrate (Figure 119). Two catalytic mechanisms could yield fragments 335 and 340; a [1,3] shift 
placing deuterium at the C7 position or consecutive [1,2] shifts to place deuterium at the C6 
position. Both positions would result in the loss of deuterium via alkene formation and 
aromatisation respectively after fragmentation of the parent molecular ions 306 ([1,3] hydride shift) 
and 305 (consecutive [1,2] hydride shifts). Contrastingly, no movement would yield a fragmentation 
peak at m/z = 133 (Figure 129) corresponding to cation 340.  
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Figure 129. Fragmentations of product to give m/z = 132 and 133. 
A peak at m/z = 106 corresponds to a deuterated fragments 316 and 321, that can only form if a 
[1,3] shift or no shift of the S C1 proton is occurring respectively. However, an m/z = 105 peak of 
equal intensity to the m/z = 106 peak is also observed on the mass spectrum 7-epizingiberene 
(Figure 60. 2.6). The m/z = 105 fragment cation 224 is only plausible via two consecutive [1,2] shifts, 
where fragmentation and deprotonation will remove the deuterium (Figure 121). The equal intensity 
of these two peaks (Figure 130) suggests multiple catalytic mechanisms may be at work. 
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Figure 130. Highlighted m/z = 105 and 106 fragmentation peaks. 
As outlined earlier (Figure 122), the m/z = 94 peak indicates the presence of deuterium on the ring 
which would occur from no deuterium movement (cation 323) or consecutive [1,2] hydride shifts 
(cation 322). The greater intensity of the m/z = 93 fragment peak (cation 225) in conjunction with 
the m/z = 94 fragment peak suggest that the catalytic mechanism may proceed via both and [1,3] 
and consecutive [1,2] shifts as a single mechanism would show only one fragment.  
Prevalent peaks corresponding to m/z = 91 (cation 226, Figure 123) and m/z = 77 (cation 228, Figure 
124) fragment cations suggest that deuterium is not positioned on the ring. The mass spectrum of 
the product from (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) incubation with EZS gave dominant 
peaks at m/z = 92 (cation 328, Figure 123) and 78 (cation 329, Figure 124), (Figure 119), strongly 
suggesting that the R deuteron at the C1 position was not involved within the catalytic mechanism. If 
the S deuteron was not utilised as part of the catalytic mechanism, it would remain on the ring as 
observed for the R deuteron of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234). In this scenario the 
same fragmentation peaks at m/z = 92 and 78 would be visible at the same intensity as in Figure 119. 
However, these fragmentation peaks are not observed in the mass spectrum taken from the 
incubation product of EZS and (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) (Figure 128). Although a 
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definitive pathway of the S deuteron cannot be elucidated, the absence of these peaks suggests that 
it may be utilised throughout the catalytic mechanism of EZS.  
This reasoning is not conclusive. In order to properly ascertain the role of the proS proton at the C1 
position 1H NMR experiments of the incubation products (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate 
(234) and (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) with EZS must be compared to a fully 
characterised 1H NMR spectrum of 7-epizingiberene (1). This would show the position of the 
deuterium on labelled product in relation to non-labelled 7-epinzingiberene (1) and allow the 
proposal of a suitable mechanism. From the evidence presented, it is plausible to suggest that the 
proS proton at the C1 position is utilised within the catalytic mechanism of EZS though not via which 
mechanism. 
 
 
Figure 131. Possible roles of the proS proton at the C1 position during the catalytic mechanism of EZS. 
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4.4 Summary 
This chapter outlined the synthesis of substrates designed to investigate the catalytic mechanism of 
7-epizingiberene synthase. GC-MS analysis of the pentane extractable products from the incubation 
of substrates and EZS gave insights into carbocation intermediates and hydride shifts occurring 
during the catalytic mechanism. 
The inhibition of EZS by (2E,6Z)-2-fluoro-FDP (230) gives evidence for a stepwise ring closure. The 
presence of fluorine at the C2 position resulted in the inhibition of EZS due to the electronegative 
nature of fluorine increasing the energy of the potential farnesyl cation (238, Figure 87). The 
increase in carbocation energy prevented the formation of the farnesyl cation (238), inhibition of the 
catalytic mechanism and evidence of a stepwise catalytic mechanism (Figure 91). 
(2Z,6E)-6-fluoro-FDP (231) was shown to be a competitive inhibitor of EZS via preventing the 
formation of the bisabolyl cation (248, Figure 92). The use of fluorinated analogues enabled 
clarification of two carbocation intermediates generated during the catalytic mechanism of EZS and 
elucidation of a stepwise mechanism (Figure 87) 
The exact nature of the hydride shifts could not be inferred from analysis of the pentane extractable 
products arising from incubations of 233 and 234 with EZS. The mass spectrum of 234 and EZS 
product gives strong evidence that the R proton at the C1 position does not undergo hydride shifts. 
Insight into the role of the C1(S) proton from analysis of the pentane extractable products of 233 
with EZS was not definitive, suggesting both [1,3] and consecutive [1,2] hydride shifts may be 
occurring.  
233 and 234 were synthesised for the investigation of a mechanism that utilises a single pathway. 
Therefore, a mechanism could not be determined by incubation of 233 and 234 with EZS alone. It 
was proposed that resonance of the C2,C3 double bond could stabilise the carbocation formation 
caused by hydride shifts from the C1 position. The respective hydride shifts from the C5 position 
were thought to be less favourable as stabilisation via resonance is not possible. However, as no 
definitive shifts were concluded via the incubation of C1 deuterated analogues 233 and 234 with 
EZS, hydride shifts from the C5 position are plausible. The elucidation of hydride shifts occurring 
during the catalytic mechanism of EZS requires the synthesis of deuterated analogues at the 
(2Z,6Z)-(S)-[5-2H]-farnesyl (426) diphosphate, (2Z,6Z)-(R)-[5-2H]-farnesyl (427) diphosphate and 
(2Z,6Z)-[6-2H]-farnesyl diphosphate (232). Analysis of the enzymatic products from the incubation of 
the deuterated analogues with EZS via GC-MS and 1H NMR spectroscopy would enable the 
determination of hydride shifts. 
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Chapter 5 – Synthesis and Incubation of Substrates to Probe 
EZS Substrate Specificity 
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5.1 Preface 
Literature regarding 7-epizingiberene synthase have stated that EZS will not except the 'universal 
substrate' (2E,6E) FDP (31) as a substrate showing high substrate specificity towards the cisoid 
isomer (2Z,6Z) FDP (38). This chapter outlines the synthesis of three stereoisomers of 38; (2E,6Z) FDP 
(342), (2E,6E) FDP (31) and (2Z,6E) FDP (341). The substrate specificity of EZS was investigated by 
incubation of the respective compounds with EZS and analysis of the pentane extractable products 
via GC-MS. 
The monoterpene substrate equivalents of 38 and 31 have also been synthesised. Sesquiterpene 
cyclases have been observed to utilise monoterpene substrates to generate terpenoid products.42 
Analysis of pentane extracts from the incubation of substrates 30 and 39 with EZS showed EZS 
accepted the monoterpene analogues as substrates; however, a large decrease in binding efficiency 
was observed when compared to the sesquiterpene substrates.  
Figure 132 shows the analogues that were synthesised and incubated with EZS that will be discussed 
within this chapter:  
 
 
Figure 132. Sesquiterpenoid and monoterpenoid substrates used for the investigation of the substrate stereoselectivity 
of EZS. 
As described in chapter 4, kinetic parameters for each compound were also measured to determine 
their potency and mode of action as inhibitors. Inhibition assays using neryl diphosphate (39) and 
geranyl diphosphate (30) were used to confirm substrate enzyme binding was occurring and 
approximate Ki values calculated from an IC50 plot. 
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5.2 (2E,6Z) farnesyl diphosphate (342) 
 
5.2.1 Synthesis of (2E,6Z) farnesyl diphosphate (342) 
The synthesis of (2E,6Z) farnesyl diphosphate (342) and subsequent incubation with EZS would show 
if the C2,C3 double bond stereochemistry is important for substrate turnover. Incubation of EZS with 
(2E,6Z) farnesyl diphosphate (342) could give further evidence of a stepwise or concerted ring 
closing mechanism as was inferred from analysis of (2E,6Z)-2-fluorofarnesyl diphosphate (230) as an 
inhibitor of EZS (Figure 87, 4.2.1). The bond orientation of the C2,C3 double bond is not aligned for 
an intramolecular SN2-like reaction adopted by a concerted mechanism. A stepwise mechanism 
could permit the rotation of the C2,C3 double bond via cis-nerolidyl diphosphate (344) (Figure 133). 
A [1,6] cyclisation affording the bisabolyl cation (86), hydride shifts and deprotonation would then 
give 7-epizingiberene (1).  
 
 
Figure 133. Potential outcome of the incubation of 342 with EZS via the cis nerolidyl diphosphate (344) intermediate. 
The rotation of the C2,C3 double bond is not uncommon in sesquiterpene cyclase catalysis with the  
allylic transposition essential for a 1,6 cyclase like amorphadiene synthase (ADS) (Figure 14, 
1.3.2).246,117 
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Figure 134. Synthesis of (2E,6Z) farnesyl diphosphate (342). 
The synthesis of (2E,6Z) farnesyl diphosphate (342) is shown in Figure 134. Neryl acetone (166) was 
synthesised as previously described (Figure 34, 2.2.5). The synthesis of 342 was slightly modified to 
that of 38 (Figure 45, 2.2.1) where the olefination reaction conditions were altered for greater E 
selectivity of the C2,C3 double bond (Table 4, 2.2.5).  
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5.2.2 Incubation of (2E,6Z) farnesyl diphosphate (342) and EZS 
GC-MS analysis of the pentane extractable products from the incubation of (2E,6Z) farnesyl 
diphosphate (342) with EZS showed no detectable enzymatic products even after extended reaction 
times. Kinetic parameters for 342 were measured to determine the potency and mode of action as 
an inhibitor. Increasing concentrations of 342; 5 µM, 15 µM and 30 µM were used to understand the 
mode enzyme inhibition. 
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Figure 135. Michaelis-Menten plots for incubations of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and inhibitor (2E,6Z) farnesyl 
diphosphate (342); 0 µM, 5 µM, 15 µM and 30 µM. 
The overlaid curves of the Michaelis-Menten kinetics (Figure 135) show that inhibition of EZS occurs 
with increasing concentrations of (2E,6Z) farnesyl diphosphate (342) with observable changes to the 
rate with the increasing addition of 342. The Lineweaver-Burk double-reciprocal plot shows the lines 
of different inhibitor concentration intercepting at one point on the y-axis (Figure 136). Interception 
at this point indicates 342 acts as a competitive inhibitor of EZS. Plotting KM(app) vs. inhibitor 
concentration allowed measurement of Ki = 2.86 ± 1.56 µM  for (2E,6Z) FDP (342) (Figure 136). 
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Figure 136. Lineweaver-Burke Plot (left) and KM(app) vs. concentration plot (right) for 342 inhibition assays. 
The comparable KM and Ki values of (2Z,6Z) FDP (38)(KM = 6.24 ± 0.641 µM) and (2E,6Z) FDP (342) (Ki 
= 2.86 µM) shows EZS has a high affinity for 342. The trans stereochemistry of the C2,C3 double 
bond does not appear to affect the binding efficiency of the enzyme-substrate complex however, Z 
conformation seems crucial for substrate activity. In contrast to studies previously conducted by the 
Allemann group on terpene cyclases such as ADS,80 EZS appears unable to generate a nerolidyl 
diphosphate intermediate (344) for rotation of the C2,C3 bond to permit a [1,6] cyclisation (Figure 
137).  
 
 
Figure 137. The unsuccessful turnover of (2E,6Z) farnesyl diphosphate (342) when incubated with EZS. 
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5.3 (2Z,6E) farnesyl diphosphate (341) 
 
5.3.1 Synthesis of (2Z,6E) farnesyl diphosphate (341) 
The C2, C3 double bond of (2Z,6E) farnesyl diphosphate (341) has Z stereochemistry and therefore 
ideally orientated for a [1,6] cyclisation. Figure 138 outlines potential mechanistic pathways if 341 
was accepted as a substrate. Alternatively (2Z,6E) farnesyl diphosphate (341) may inhibit the enzyme 
suggesting that stereochemistry of the C6,C7 double bond and orientation of the prenyl tail 
influences substrate turnover. 
 
 
Figure 138. Potential catalytic mechanism of EZS when incubated with (2Z,6E) farnesyl diphosphate (341). 
The synthesis of (2Z,6E) farnesyl diphosphate (341) was conducted following the procedure outlined 
in Figure 139. Substituting nerol (163) for geraniol (64) resulted in the C6,C7 E double bond of 341. 
The instillation of the C2,C3 Z double bond was achieved via a Horner-Wadsworth-Emmons reaction 
using the optimised conditions in (Table 4, 2.2.5) for the synthesis of 38 (Figure 45, 2.2.5). 
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Figure 139. Synthesis of (2Z,6E) farnesyl diphosphate (341). 
  
142 
 
5.3.2 Incubation of (2Z,6E) farnesyl diphosphate (341) and EZS 
GC-MS analysis of the pentane extractable products from the incubation of 341 with EZS showed no 
detectable enzymatic products were generated. Inhibition of EZS by 341 gives insight to the 
orientation of C6,C7 double required for the formation of product. Kinetic parameters for 341 were 
measured to determine the potency and mode of action as an inhibitor. Increasing concentrations of 
341; 5 µM, 15 µM and 30 µM were used to understand the mode enzyme inhibition. 
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Figure 140. Michaelis-Menten plots for incubations of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and inhibitor(2Z,6E) farnesyl 
diphosphate (341); 0 µM, 5 µM, 15 µM and 30 µM. 
The Michaelis-Menten plots show a clear indication of inhibition with both Vmax and KM(app) changing 
with addition of higher inhibitor concentrations (Figure 140). The mode of inhibition is not clear from 
this plot as the apparent variation of Vmax could indicate uncompetitive or non-competitive modes of 
inhibition. However, the values of Vmax are all of similar orders of magnitude and replotting the data 
as a Lineweaver-Burk double reciprocal plot (Figure 141) shows data trends characteristic of a 
competitive inhibitor with discrepancies of plotted data possibly caused by experimental error 
during the assay. A plot of KM(app) against (2Z,6E) FDP (341) concentration gave an inhibitor Ki of 7.64 
± 0.83 µM (Figure 141). This value is within the same magnitude as KM and Ki of (2Z,6Z) FDP (38)(KM = 
6.24 ± 0.641 µM) and (2E,6Z) FDP (342) (Ki = 2.86 ± 1.56 µM). The comparative Ki value of 341 to 342 
and the KM of 38 gives evidence that the stereochemistry of the C6,C7 double bond does not retract 
from the formation of the enzyme-substrate complex. 
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Figure 141. Lineweaver-Burke Plot (left) and KM(app) vs. concentration plot (right) for 341. 
The Z conformation of the C2,C3 double bond makes a 1,6 cyclisation plausible. However, inhibition 
of EZS when incubated with 341 gives evidence that the stereochemistry of the C6,C7 double bond is 
crucial for product formation (Figure 142). 
 
 
Figure 142. The unsuccessful turnover of (2Z,6E) farnesyl diphosphate (341) when incubated with EZS. 
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5.4 (2E,6E) farnesyl diphosphate (31) 
 
5.4.1 Synthesis of (2E,6E) farnesyl diphosphate (31) 
The investigation by Bleeker et al.,3 showed the incubation of EZS with (2E,6E) farnesyl diphosphate 
(31) resulted in no enzymatic products.3 31 is the natural substrate of sesquiterpene cyclases with 
EZS, santalene and bergamotene synthase (SBS) being the known exceptions.131, 3 The preparation of 
31 was required to corroborate results with published data.  
 
 
Figure 143. Synthesis of (2E,6E) farnesyl diphosphate (31) via halide intermediates 355 or 356. 
Synthesis of 31 proceeded via three different methods. Routes 1 and 2 investigated different 
halogenation protocols prior to the diphosphorylation reaction and purification previously discussed. 
Route 1 proceeded via a phosphorus tribromide bromination which achieved crude bromide 355 
with 100% yield and route 2 proceeded through a chlorination outlined by Collington et al.,247 and 
Davisson et al.188 Mesyl chloride and sec. collidine were added to a mixture of 353 in DMF at 0 ᵒC and 
stirred for 30 minutes. Lithium chloride was added to the reaction mixture and stirred for a further 
two hours and the reaction quenched with water giving the crude chloride 356 with 83% yield. The 
halogenations were both effective however, route 1 was favourable due to the shorter reaction time 
and higher percentage yield. 
145 
 
 
Figure 144. Synthesis of (2E,6E) farnesyl diphosphate (31). 
Route 3 was based on the synthesis of 38 (Figure 45, 2.2.5) and is outlined in Figure 144 and was 
investigated to utilise side product from the synthesis of (2Z,6E) farnesyl diphosphate (341) (Figure 
139). Modifications to the synthesis of 31 were the reaction conditions used for the olefination of 
38. As outlined in (Table 4, 2.2.5), the use of 204 and n-butyl lithium with tetrahydrofuran gave the 
greatest yield and ratio of E:Z isomers. Farnesoate esters 350 and 351 were partially separated for 
analysis prior to being pooled and reduced to the corresponding alcohols 352 and 353 which were 
separated via flash chromatography prior to bromination. 
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5.4.2 Incubation of (2E,6E) farnesyl diphosphate (31) and EZS 
The incubation of (2E,6E) farnesyl diphosphate (31) with EZS and subsequent GC-MS analysis of the 
pentane extractable products showed no enzymatic products. This result is in agreement with 
literature as 31 was proposed to not be a substrate of EZS.3 The substrate’s affinity to the enzyme or 
subsequent mode of inhibition was not investigated within the literature. Therefore, kinetic 
parameters for 31 were measured to determine the potency and mode of action as an inhibitor. 
Increasing concentrations of 31; 5 µM, 15 µM and 30 µM were used to understand the mode 
enzyme inhibition. 
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Figure 145. Michaelis-Menten plots for incubations of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and inhibitor (2E,6E) farnesyl 
diphosphate (31); 0 µM, 5 µM, 15 µM and 30 µM. 
Assays of previously discussed substrates 341 and 342 have shown that Z stereochemistry of the 
substrates double bonds are required for product formation. It has also been shown that other 
stereoisomers of (2Z,6Z) FDP (38); 341 and 342 act as competitive inhibitors. The Michaelis-Menten 
plots (Figure 145) of the increasing inhibitor concentrations used and the respective 
Lineweaver-Burke plot show that (2E,6E) FDP (31) acts as a competitive inhibitor. The plot of KM(app) 
against 31 concentration (Figure 146) gives a Ki of 4.17 ± 0.29 µM, consistent with values found for 
stereoisomers 341 and 342.  
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Figure 146. Lineweaver-Burke Plot (left) and KM(app) vs. concentration plot (right) for 31 inhibition assay. 
An enzymatic product was not observed from the pentane extractable products from the incubation 
of (2E,6E) farnesyl diphosphate (31) with EZS. This gives evidence that EZS is not able to invert the 
stereochemistry of the C2, C3 double bond and undergo a [1,6] cyclisation giving the bisabolyl cation 
(86) (Figure 147). Kinetic assays of 31 and the subsequent fitting of data to a Michaelis-Menten 
curve and Lineweaver Burke plot shows 31 inhibits the catalytic mechanism of EZS. The Lineweaver 
Burke plot shows the data points for each concentration of 31 intercepts at the same point at the 
y-axis, characteristic of a competitive inhibitor with a plot of [31] vs. KM(app) giving Ki values at similar 
concentrations observed for other stereoisomers. 
 
 
Figure 147. The unsuccessful turnover of (2E,6E) farnesyl diphosphate (31) when incubated with EZS. 
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5.5 Neryl diphosphate (39) and geranyl diphosphate (30) 
 
5.5.1 Synthesis of neryl diphosphate (39) and geranyl diphosphate (30) 
Sesquiterpene cyclases have been reported to accept monoterpene diphosphates neryl diphosphate 
(39) and geranyl diphosphate (31)48 as substrates. The C2,C3 double bond of 39 positions the 
diphosphate in the correct conformation for a [1,6] cyclisation to give the α-terpinyl cation (357). 
Various hydride shifts, cyclisations and deprotonations can give rise to numerous monoterpene 
products including terpenines such as α-terpenine (52),43 bicyclic products e.g. α-pinene (49) and 
phellandrenes such as α-phellandrene (358) (Figure 148).44 
 
 
Figure 148. Potential catalytic products of EZS incubation with neryl diphosphate (39). 
Neryl diphosphate (39) and geranyl diphosphate (30) were synthesised via the reaction pathways 
outlined in Figure 149 and Figure 150 respectively. PBr3 bromination of the alcohol precursors 166 
and 63 was preferred over other methods investigated (Figure 147). The crude bromides were used 
without purification, diphosphorylated and purified in the manner previously outlined for the 
synthesis of 38 (Figure 45, 2.2.5). 
 
 
Figure 149. Synthesis of neryl diphosphate (39). 
 
Figure 150. Synthesis of geranyl diphosphate (30). 
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5.5.2 Incubation of neryl diphosphate (39) and EZS 
The incubation of neryl diphosphate (39) with EZS and analysis of the pentane extractable products 
via GC-MS showed a single peak in the total ion chromatogram of 39 incubations with EZS and 
without EZS (Figure 151). The mass-spectrum of the compound responsible for each peak was cross 
referenced with the National Institute of Standards and Technology (NIST) library and found to be 
limonene. The Z stereochemistry of the C2,C3 double bond of 39 positions the analogue for a [1,6] 
cyclisation upon the loss of the diphosphate moiety. The presence of Mg2+ ions within the incubation 
buffer can assist the cleavage of diphosphate yielding the neryl cation. Cyclisation and 
deprotonation can give limonene without enzymatic catalysis. 
 
 
Figure 151. Total ion chromatograms of pentane extractable products from neryl diphosphate (39) incubations: neryl 
diphosphate (39) and EZS incubation (upper) and neryl diphosphate (39) with no EZS incubation (lower). 
Analysis of the pentane extracts from the incubation via GC-MS showed no enzymatic products were 
present. An inhibition assay increasing the concentration of neryl diphosphate (39) whilst keeping 
the concentration of (2Z,6Z)-[1-3H]-FDP (229) constant was performed. The assay was used to assess 
if neryl diphosphate (39) was binding to EZS or cyclising prior to the formation of the 
enzyme-substrate complex due to Mg2+ ions within the incubation buffer.  
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Figure 152. 39 IC50 plot for the incubation of (2Z,6Z)-[1-
3
H]-FDP (229)with EZS and  inhibitor neryl diphosphate (39); 0.01 
µM - 1000 µM range. 
The IC50 plot shows an approximate Ki of neryl diphosphate (39) as 474 ± 24 µM (Figure 152). In 
comparison to previous inhibitors incubated with EZS, the enzyme exhibited low affinity towards 39. 
As previously discussed, the ability of 39 to cyclise due to Mg2+ ions within the buffer may be a major 
reason for the low binding efficiency. The substrate may not be able to form the enzyme-substrate 
complex as cyclisation had already occurred. The shorter chain length of 39 in comparison to the 
natural substrate (2Z,6Z) farnesyl diphosphate (38) may also play a role in binding. It has been 
observed that the stereochemistry of the C2,C3 and C6,C7 double bonds are critical for product 
formation. However, the differing stereochemistry has not greatly affected the binding efficiency of 
the substrate to the enzyme. Binding of the diphosphate moiety to the DDxxE motif of EZS aids the 
removal of diphosphate. However, the large approximated Ki value from the incubation of 39 with 
EZS gives evidence that the prenyl tail contributes to substrate anchorage within the active site.  
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5.5.3 Incubation of geranyl diphosphate (30) and EZS 
GC-MS analysis of the pentane extractable products from the incubation of 30 with EZS showed no 
enzymatic products. In contrast to 39, geranyl diphosphate (30) has not been known to cyclise due 
to Mg2+ ions within catalysis buffer. The E stereochemistry of the C2,C3 double bond does not 
orientate the molecule into a favourable conformation for a [1,6] cyclisation. An inhibition assay 
increasing the concentration of geranyl diphosphate (30) and constant [229] was performed 
determine if 30 was binding with EZS and if applicable, an approximate Ki value. 
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Figure 153. 30 IC50 plot for the incubation of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and inhibitor geranyl diphosphate (30); 
0.01 µM - 1000 µM range. 
The IC50 plot shows that 30 does bind to EZS and inhibits the enzyme with an approximate Ki of 97.3 
± 24.6 µM (Figure 153). Though significantly tighter binding to EZS than observed with 39, this value 
is an order of magnitude greater than seen with farnesyl substrates. The large approximated Ki value 
in comparison to farnesyl substrates gives further evidence to the importance of the prenyl chain to 
binding as part of the enzyme-substrate complex. The farnesyl substrate equivalent, (2E,6E) FDP 
(31), exhibited a Ki of 4.17 µM giving evidence further that the prenyl tail contributes towards 
substrate binding. 
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5.6 Summary 
This chapter has focussed on the synthesis of FDP isomers and the analysis of enzymatic products 
from substrate incubations with EZS. Substrate specificity of EZS towards (2Z,6Z) FDP (38) and 
inhibition of enzymatic activity when incubated with analogues 342, 341 and 31 show the necessity 
for any novel substrate to contain all Z double bonds. 
Though the stereochemistry 342, 341 and 31 did not yield enzymatic product when incubated with 
EZS; the enzyme still exhibited a strong affinity to the FDP analogues which were shown to act as 
competitive inhibitors with Ki values similar to the KM of (2Z,6Z) FDP (38). The inhibition of the 
catalytic mechanism by the various analogues shows that the stereochemistry of the C2,C3 and 
C6,C7 double bonds are vital for product formation.  
EZS is unable to isomerise the stereochemistry of the C2,C3 double via the nerolidyl diphosphate 
intermediate (344) as observed in the catalytic mechanisms other sesquiterpene cyclases.104 The 
C6,C7 bond also has a role on product formation and appears to inhibit substrate turnover. This may 
result from orientation of the substrate in the active site preventing the [1,6] cyclisation occurring. 
Neryl diphosphate (39) and geranyl diphosphate (30) incubations with EZS did not yield enzymatic 
products. Approximate Ki values calculated from the IC50 curves for NDP (39) (Figure 152) and GDP 
(30) (Figure 153) showed a low affinity of EZS to both analogues. This low affinity gives some 
evidence that the prenyl tail has a role in binding within the enzyme-substrate complex with removal 
of the prenyl group decreasing the binding efficiency of EZS towards the substrate. A comparison of 
Ki values can be observed in Table 8. 
Table 8. Inhibition constants (Ki) of sesquiterpenoid and monoterpenoid substrates with EZS. 
Analogue Ki / µM 
(2E, 6Z) farnesyl diphosphate (342) 2.86 ± 1.56 
(2Z, 6E) farnesyl diphosphate (341) 7.64 ± 0.83 
(2E, 6E) farnesyl diphosphate (31) 4.17 ± 0.29 
Neryl diphosphate (38) *474 ± 24 
Geranyl diphosphate (30) *97.3 ± 24.6 
*approximate value from IC50 curve 
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Chapter 6 – Synthesis of Novel Substrates and Incubation 
with EZS 
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6.1 Preface 
 
This chapter outlines the synthesis of novel oxygen containing and methylated (2Z,6Z) FDP (38) 
analogues to be incubated with EZS with the aim of producing new sesquiterpenoids (Figure 154). 
 
 
Figure 154. Novel sesquiterpene analogues of (2Z,6Z) FDP (38) discussed in this chapter. 
The analogues were incubated with EZS as described in previous chapters. Products of successful 
incubations of analogues with EZS were analysed via GC-MS and compared to entries in the National 
Institute of Standards and Technology (NIST) library. The fragmentation patterns of novel products 
were compared with library data to give insight into plausible products based on existing 
sesquiterpene backbones. If no enzymatic product was observed, an inhibition assay and IC50 plot 
was used to establish that the analogue was binding to the enzyme and an approximate Ki.  
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6.2 Methylated substrates 
 
6.2.1 Synthesis of (2Z,6Z)-2-methylfarnesyl diphosphate (359) 
The incubation of (2E,6E)-14,15-dimethylfarnesyl diphosphate (158) with germacrene D synthase 
(GDS) resulted in an attractant semiochemical (Figure 30, 1.6.4) with properties in direct contrast to 
the repellent germacrene D (Figure 29, 1.6.9). (2Z,6Z)-2-Methylfarnesyl diphosphate (359) was 
synthesised with this result in mind, with the potential to form methylated zingiberene product 366 
upon incubation with EZS. Methyl groups would lower the energy of neighbouring carbocation 364 
(Figure 155) through electron donation. However, substrate binding may be hindered by adverse 
steric interactions resulting in inhibition of EZS rather than the formation of enzymatic product. 
 
 
Figure 155. Potential outcome of the incubation of EZS and 359 showing the electron donation of the methyl substituent 
towards neighbouring carbocations. 
A methylated Horner-Wadsworth-Emmons reagent (368) was synthesised to introduce a methyl 
substituent at the C2 position. An Arbuzov reaction248 yielded phosphonoacetate ester (368) which 
was trimethyl silylated, chlorinated then reacted with 2,2,2-trifluoroethanol (207) to yield a 
methylated Still-Gennari variant204,205 reagent 371 (Figure 156). 
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Figure 156. Synthesis of methylated Still-Gennari/Horner-Wadsworth-Emmons reagent 371. 
Reagent 371 was used for the olefination of neryl acetone (166), which was prepared as previously 
described (Figure 34, 2.2.1). The synthetic procedure progressed by the DIBALH reduction of the 
resultant methylated ethyl farnesoates esters 372 and 373 to their respective alcohols 374 and 375. 
PBr3 bromination and subsequent diphosphorylation yielded (2Z,6Z)-2-methylfarnesyl diphosphate 
(359) (Figure 157).  
 
 
Figure 157. Synthesis of (2Z,6Z)-2-methylfarnesyl diphosphate (359). 
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Reagent 371 and commercially available 368 were used in respective olefinations of 166. The 
Still-Gennari modification showed no improvement in stereocontrol, with both reagents yielding a 
1:1 ratio of E:Z methylated farnesoates esters 372 and 373. Unlike fluorinated analogues, 
bromination of 375 with phosphorus tribromide was not hindered by the presence of a methyl 
group.  
 
6.2.2 Incubation of (2Z,6Z)-2-methylfarnesyl diphosphate (359) with EZS 
Incubation of (2Z,6Z)-2-methylfarnesyl diphosphate (359) and EZS yielded six pentane extractable 
products (Figure 158). Three products (peaks at 18.14, 19.33 and 24.11 minutes) were shown not to 
be enzymatic products by comparison with a control experiment containing 359 in solution with no 
enzyme (Figure 159). Despite no impurities being visible in the 1H NMR spectrum or UV trace of HPLC 
of 359; the total ion chromatogram of pentane extractable products of the starting material showed 
the same impurities observed in the 359/EZS incubation (Figure 160). However, three peaks 
corresponding to enzymatic products from the incubation of 359 and EZS were eluted at 15.38, 
18.17 and 18.44 minutes. On the mass-spectra, all products had a molecular parent ion consistent 
with methylated products at m/z = 218. The generation of multiple sesquiterpenoid products 
resulting from (2Z,6Z)-2-methyl-FDP (359) incubation suggests EZS possesses a degree of promiscuity 
that has not previously been observed. 
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Figure 158. Total ion chromatogram of the pentane extractable products from incubation of 359 with EZS. 
 
Figure 159. Total ion chromatogram of the pentane extractable products from; incubation of 359 with EZS (positive, top) 
and 359 without EZS (negative, bottom). 
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Figure 160. Total ion chromatogram of the pentane extractable extracts of substrate 359. 
The peak at 15.38 minutes was determined to be 2-methylfarnesene comparison to the mass 
spectrum of farnesene products synthesised from (2Z,6Z)-2-methylfarnesol (375). The peak at 18.17 
minutes had a mass spectrum splitting pattern consistent with a zingiberene product (Figure 163). 
When compared to the mass spectrum of 7-epizingiberene, (Figure 60, 2.6), all major fragments 
were present with m/z values increased by 14, indicating a methylated product (Figure 162). As 
observed from the incubation and kinetics assays using (2E,6Z)-2-fluoro-FDP (230) (Figure 89, 4.2.2) 
the mechanism of EZS is likely to proceed via the farnesyl cation (364). The incorporation of a methyl 
group at the C2 position would stabilise cation formation through inductive effects. It is plausible 
that a [1,6] ring closure and required hydride shifts could proceed following the removal of the 
diphosphate group as the substrate has the same stereochemistry as (2Z,6Z) FDP (38) (Figure 161). 
 
 
Figure 161. Potential outcome of 359 incubation with EZS. 
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Figure 162. Possible fragmentations of 371 and the respective m/z values; m/z values of fragmentations in the upper 
and middle rows and increase by 14 due to methyl substituent. 
 
Figure 163. Mass spectrum and possible fragmentations of the enzymatic product eluted at 18.2 minutes. 
It is impossible to predict whether 2-methyl-7-epizingiberene (366) may act as either a repellent, 
attractant or have no semiochemical properties towards whitefly. However, a comparison of 
incubations results of (2Z,6Z)-2-methylfarnesyl diphosphate (359) with EZS and (2E,6Z) farnesyl 
diphosphate (342) with EZS (Figure 135, 5.2.2) suggests that the inhibition caused by 342 may not 
161 
 
due to steric hindrance. The methyl group at the C2 position of 359 gives further evidence that EZS 
inhibition by 342 is a result of the C1, C2 double bond stereochemistry preventing a [1,6] cyclisation 
from occurring (Figure 137, 5.2.2). 
The final enzymatic product at retention time 18.44 minutes did not have the characteristic splitting 
pattern observed for zingiberene products on the mass spectrum (Figure 164). 2-Methylfarnesene 
and (2Z,6Z)-2-methylfarnesol (375) were synthesised but analysis via GC-MS did not match the 
product. Comparison of the product fragmentation pattern was cross referenced with the NIST 
library however; due to the novel nature of the substrate, no insight to the product structure was 
gained. 
 
Figure 164. Mass spectrum of unknown enzymatic product that eluted at 18.4 minutes. 
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6.2.3 Synthesis of (2Z,6Z)-6-methylfarnesyl diphosphate (360) 
Incorporation of a methyl group at the C6 position could lower the energy of the bisabolyl-like cation 
intermediate (378) and may lead to methylated products 380 or 381 (Figure 165). 
 
 
Figure 165. Potential outcome and methylated enzymatic products from the incubation of 360 with EZS. 
Echoing the synthesis of (2Z,6E)-6-fluorofarnesyl diphosphate (231) (Figure 94, 4.2.3) the synthesis 
of (2Z,6Z)-6-methylfarnesyl diphosphate (360) was achieved from commercially available 368, no 
modification of reagent 368 was deemed necessary (Figure 166). 
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Figure 166. Synthesis of (2Z,6Z)-6-methylfarnesyl diphosphate (360). 
Chain extension of bromide 386 to give ketoester 387 appeared to result in the formation of 
rotamers. The two species were only observed via 1H NMR spectroscopy with two overlapping 
quartets at 2.64 and 2.61 ppm and overlapping triplets at 1.27 and 1.26 ppm signifying the two ethyl 
groups (Figure 167). The rotamers were not observed via 13C NMR and could not be separated. The 
synthetic route proceeded via decarboxylation of the rotamer mixture to give ketone 388 as a single 
product. Subsequent synthetic steps were continued using the established protocol for the synthesis 
of (2Z,6Z) FDP (38) (Figure 45, 2.2.5). 
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Figure 167. Cropped 
1
H NMR spectrum of rotamer intermediate 387 showing overlapping quartet and triplet peaks 
resulting from restricted rotation caused by the methyl substituent. 
 
6.2.4 Incubation of (2Z,6Z)-6 methylfarnesyl diphosphate (360) and EZS 
It was proposed that the incubation of (2Z,6Z)-6-methylfarnesyl diphosphate (360) and EZS may yield 
enzymatic products. Electron donation from methyl group at the C6 position could lower the energy 
of the bisabolyl-like cation (378) resulting in catalytic turnover of 360 by EZS. GC-MS analysis of the 
pentane extractable products showed no enzymatic products. An inhibition assay was therefore 
performed to assess binding and an approximate Ki of 360. 
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Figure 168. 360 IC50 plot for the incubation of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and  inhibitor (2Z,6Z)-6-methylfarnesyl 
diphosphate (360); 0.01 µM - 1000 µM range. 
The IC50 curve of the 360 inhibition assay gave an approximate Ki of 13.1 ± 1.7 µM (Figure 168), a 
value which is of the same magnitude observed for other farnesyl substrates (Table 8, 5.6). The 
presence of the methyl group at the C6 position therefore does not appear to greatly affect 
formation of an enzyme-substrate complex. Because the stereochemistry of 360 matches the natural 
substrate 38 the double bond must be correctly aligned, therefore the methyl group disrupts 
product formation. The methyl group may either effect the orientation of the substrate within the 
active site or directly inhibit the mechanism by impeding hydride shifts or cation formation. In 
contrast to the large Ki values observed of NDP (39) and GDP (30) 474 ± 24 µM and 97.3 ± 24.6 µM 
respectively, the presence of the additional prenyl unit appears to allow effective binding of the 
substrate to the active site. 
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6.3 Oxygenated analogues 
 
6.3.1 Synthesis of (2Z,6Z)–10,11-epoxyfarnesyl diphosphate (361) 
Oxygenated analogues have been reported as substrates for various sesquiterpene synthases 
including ADS, where incubation of oxygenated FDP analogues gave rise to oxygen-containing 
enzymatic products.9 Small changes to FDP substrates have been shown to have large effects on the 
properties of the natural product as discussed previously. Installation of an epoxide across the 
C10,C11 bond to form 361 may result in the oxygenated zingiberene product 394 after EZS 
incubation (Figure 169). 
 
 
Figure 169. Possible enzymatic product from the incubation of 361 with EZS. 
Synthesis of 361 began from (2Z,6Z) farnesol (167) which was synthesised via the procedure 
previously outlined (Figure 45, 2.2.5). Tetrahydropyran (THP) protection of alcohol 167 was followed 
by selective bromohydrin (396) formation at the distal double bond using N–bromosuccinimide in 
tetrahydrofuran/water. Intramolecular SN2-like epoxide ring closure with potassium carbonate in 
methanol yielded 397.249 Deprotection of the alcohol was followed by bromination with phosphorus 
tribromide and diphosphorylation gave 361 (Figure 170). 
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Figure 170. Synthesis of (2Z,6Z)-10,11-epoxyfarnesyl diphosphate (361). 
 
6.3.2 Incubation of (2Z,6Z)-10,11-epoxyfarnesyl diphosphate (361) and EZS 
Analysis of the pentane extractable products from the incubation of (2Z,6Z)-10,11-epoxyfarnesyl 
diphosphate (361) and EZS via GC-MS identified no enzymatic products. Unfortunately, a very 
limited quantity of 361 was available and it was not possible to run inhibition assays, limiting the 
conclusion that can be drawn from this experiment.  
 
6.3.3 Synthesis of (2Z,6Z,10Z)-12-methoxyfarnesyl diphosphate (362) 
Analogues containing modifications to the distal prenyl group have proven to be accepted as 
substrates by other sesquiterpene synthases.106 Introduction of a 12-methoxy group to 38 may yield 
enzymatic product 400 upon the incubation of 362 with EZS (Figure 171). In addition, the methoxy 
group introduces stereochemistry across the C10,C11 double bond which may influence substrate 
specificity. 
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Figure 171. Possible enzymatic product from the incubation of 362 with EZS. 
The synthesis of 362 began from epoxide 397. Formation of aldehyde 401 was achieved with sodium 
periodate and periodic acid as outlined by Corey et al,250 (Figure 172). 401 was subjected to a 
Horner-Wadsworth-Emmons reaction with a Still-Gennari modification,204 followed by reduction to 
alcohol 403 using DIBALH and methylation using sodium hydride and methyl iodide. Subsequent 
alcohol deprotection, bromination and diphosphorylation were carried out as previously outlined 
(Figure 39, 2.2.4). 
 
 
Figure 172. Synthesis of (2Z,6Z,10Z)-12 methoxyfarnesyl diphosphate (362). 
In contrast to olefination reactions using ketone substrates, reaction of aldehyde 401 under the Z 
selective modified conditions (Table 4, 2.2.5) proceeded to completion with negligible quantities of 
the E isomer observed via TLC or 1H NMR spectroscopic analysis. Methylation of alcohol 403 then 
followed. However, despite using excess methylation reagent, (up to 30 equivalents) the reaction did 
not go to completion even with extended reaction times. Deprotection of 404 to give alcohol 405 
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was carried out following a literature protocol.251 It was observed that if the reaction duration was 
extended, side products formed, decreasing the yield of desired product. The reaction was therefore 
monitored by TLC and upon consumption of starting material the reaction was quenched 
immediately, preventing side product formation. 
 
6.3.4 Incubation of (2Z,6Z,10Z)-12 methoxyfarnesyl diphosphate (362) and EZS 
GC-MS analysis of the pentane extractable incubation products of 362 with EZS showed one major 
enzymatic product at 21.6 minutes (Figure 173). The molecular ion peak m/z = 234 is consistent with 
a methoxy functionalised sesquiterpenoid product (Figure 175). Product formation from the 
incubation of 362 with EZS shows that analogues of (2Z,6Z) FDP (38) with modification at the C12 
position of the prenyl tail are potential targets for future substrates of EZS. 
 
 
Figure 173. Total ion chromatogram of the pentane extractable products from the incubation of 362 and EZS. 
The mass spectrum of another enzymatic product peak at 21.58 minutes suggested a cyclised 
methoxy sesquiterpenoid (Figure 175). Previous work within the Allemann Group (Dr Melodi 
Demiray) observed that the incubation of (2E,6E,10E)-12-methoxyfarnesyl diphosphate yielded two 
enzymatic products, 12-methoxy-β-sesquiphellandrene (407) and 12-methoxy-zingiberene (408), 
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upon incubation with amorphadiene synthase (ADS) (Figure 174). Both cyclised products showed 
fragmentations similar to that observed in the EZS generated product. 
 
    
Figure 174. Mass spectra of ADS generated products; 12-methoxy-β-sesquiphellandrene (407, left) and 
12-methoxy-zingiberene (408, right). 
Multiple fragments on the mass spectrum of the 21.6 peak support a methoxy-substituted cyclised 
product (Figure 175). Fragments at m/z = 203 and 202 give evidence to the removal of the methoxy 
group and deprotonation respectively. A dominant peak at m/z = 119 and fragmentations at m/z = 
105, 91 and 77 indicate a cyclised product as previously observed in the mass spectra of 
7-epizingiberene (1)(Figure 60, 2.6) and curcumene (81) (Figure 61, 2.6). The intensity of these 
fragments (Figure 174) offer further evidence of a [1,6] ring closure and a 
12-methoxy-7-epizingiberene (400) product. Figure 176 outlines the formation of a plausible 
methoxy zingiberene product resulting from the incubation of 362 and EZS. In order to rule out 
hydrolysis of 362, (2Z,6Z,10Z)-12-methoxyfarnesol (405) was analysed via GC-MS. The retention time 
of the gas chromatogram and the fragmentation patterns of the mass spectrum were different to 
that of the product. 
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Figure 175. Mass spectrum of EZS generated compound eluted at 21.6 minutes and proposed fragment assignments. 
 
 
Figure 176. Possible catalytic mechanism of EZS upon incubation with 362. 
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6.3.5 Synthesis of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363) 
With 362 shown to be a substrate for EZS, the corresponding (2Z,6Z,10E)-13-methoxyfarnesyl 
diphosphate (363) was a key analogue to probe the substrate scope and stereochemical preferences 
at the distal prenyl unit. The incubation of 363 with EZS may yield 411 (Figure 177) implying novel 
analogues of 7-epizingiberene (1) could be generated via the functionalisation of the both the C12 
and C13 positions of the substrate prenyl tail.  
 
 
Figure 177. Possible enzymatic product of 363 incubation with EZS. 
Preparation of 363 was proposed via a selenium dioxide (SeO2) oxidation of neryl acetone (166) to 
install a hydroxyl group at the C12 position. Methylation and a Horner-Wadsworth-Emmons reaction 
to install the C2, C3 double bond of 363 would be followed by a DIBALH reduction, bromination and 
diphosphorylation (Figure 178). 
 
 
Figure 178. Initial synthesis of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363) utilising a selenium oxide oxidation. 
Analysis of the 1H NMR spectrum of the selenium dioxide oxidation reactions showed three reaction 
products: the expected product 412, a product hydroxylated at the C8 position, and an aldehyde 
environment that was evident by a characteristic 1H NMR peak at 9.9 ppm. It was proposed that the 
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by-products arose from the oxidation of neryl acetone (166) at the C7 position and oxidation of 
hydroxylated neryl acetone (412) by excess selenium dioxide in the reaction mixture. Oxygenated 
products could not be separated via flash chromatography and olefination was not attempted. 
A modified route was therefore followed (Figure 179). Aldehyde 401 was synthesised in the same 
manner as previously discussed via the THP protection of (2Z,6Z) farnesol (167) (Figure 172), 
followed by with a Horner-Wadsworth-Emmons reaction to install the E C10,C11 double bond and 
then continued in the same manner outlined for the synthesis of 362 (Figure 172).  
 
 
Figure 179. Synthesis of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363). 
The key step within the synthesis of 363 was the Horner-Wadsworth-Emmons reaction to give E 
stereochemistry across the C10, C11 double bond for which conditions optimised in the synthesis of 
38 (Table 4, 2.2.5) were used. Negligible quantities of 402 were removed via flash chromatography. 
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6.3.6 Incubation of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363) and EZS 
GC-MS analysis of the pentane extractable products of 363 and EZS incubation yielded no enzymatic 
products. An inhibition assay was used to indicate whether 363 was bound to the active site and to 
approximate a value for Ki. 
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Figure 180. IC50 plot for the incubation of (2Z,6Z)-[1-
3
H]-FDP (229) with EZS and  inhibitor 
(2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363); 0.01 µM - 1000 µM range. 
The IC50 curve showed that 363 and EZS bind to form an enzyme-substrate complex with a Ki of 72.7 
± 6.8 µM (Figure 180), comparable to that of geranyl diphosphate (30), suggesting the methoxy 
group of 363 may cause unfavourable steric or electronic interactions with residues in the active 
site. 
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6.4 Summary 
Numerous methylated and oxygenated novel substrates were synthesised and incubated with EZS. 
Previous publications outlined the substrate specificity of EZS to only accept (2Z,6Z) FDP (38) 
reporting that (2E,6Z) FDP (342) and GDP (30) were not substrates, though further investigation of 
potential substrates was not performed. This work found evidence of EZS substrate promiscuity, 
with enzymatic products observed from the incubation of methylated and methoxygenated 
substrates 359 and 362.  
Three enzymatic products were detected via GC-MS of the pentane extracts of (2Z,6Z)-2-methyl FDP 
(359) incubation with EZS. One of the products was identified as methylfarnesene, produced through 
the removal of the diphosphate group and subsequent deprotonation and another product remains 
unidentified. The mass spectrum of the third product gave evidence for a cyclised zingiberene 
analogue, with preliminary analysis suggesting the product could be 2-methyl-7-epizingiberene. This 
result shows the potential of EZS to produce novel sesquiterpene products. Continuity of this 
investigation involves preparative scale incubations of 359 with EZS to determine enzymatic 
products via NMR spectroscopy. 
(2Z,6Z)-6-methyl FDP (360) proved to be an inhibitor of EZS with an approximate Ki similar to that 
calculated for (2E,6Z) FDP (342), (2Z,6E) FDP (341) and (2E,6E) FDP (31). Inhibition of EZS by 360 
could be due to substrate binding effects or hindering hydride shifts during the catalytic mechanism. 
A [1,2] hydride shift from the C6 position, Figure 131 (4.3.6), would not be possible for this substrate 
whilst a [1,3] hydride shift may also be disrupted resulting from the orientation of the methyl group 
within the active site obstructing hydride movement. 
Incubations of EZS and (2Z,6Z)-10,11-epoxyfarnesyl diphosphate (361) showed no enzymatic 
products, but (2Z,6Z,10Z)-12-methoxyfarnesyl diphosphate (362) incubation with EZS resulted in one 
major enzymatic product. The mass spectrum of the product analysed by GC-MS showed a 
fragmentation pattern consistent with a cyclised methoxygenated product. A sample of 
(2Z,6Z,10Z)-12-methoxyfarnesol (405) was analysed by the same method and was shown to have 
both different retention time and fragmentation pattern to that to that of the product. Whilst a 
preparative scale incubation of 405 and EZS is required to unambiguously assign its structure by 1H 
NMR spectroscopy, a comparison of fragmentation patterns to similar products previously isolated 
within the Allemann group supports the formation of a methoxyzingiberene product. However, 
12-methoxyfarnesene cannot be ruled out without synthesis and comparison of its fragmentation 
pattern with that of the enzymatic product. In contrast to 361, isomeric (2Z,6Z,10E)-13-methoxy FDP 
(363) was shown to be an inhibitor of EZS. An inhibition assay using 363 gave an approximate Ki an 
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order of magnitude larger than that observed for stereoisomer substrates 342, 341 and 31. 
However, the Ki of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate (363) appears to be lower than 
monoterpene substrates neryl diphosphate (39) and geranyl diphosphate (30) indicating that the 
prenyl tail plays a role in the substrate enzyme binding.  
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Chapter 7 – Conclusions and Future Work 
  
178 
 
7.1 Conclusion 
This project describes investigations of the Z-selective sesquiterpene cyclase; 7-epizingiberene 
synthase. These investigations were performed to elucidate the catalytic mechanism, 
stereochemical substrate specificity and promiscuity of EZS. This was achieved by the synthesis and 
incubation of (2Z,6Z) FDP(167) and numerous isotopologues, stereoisomers, fluorinated, oxygenated 
and methylated analogues with EZS.  
Substrates synthesised during this project are outlined in (Figure 181). Analogues highlighted green 
(38, 229, 233, 234, 259 and 362) yielded enzymatic products upon incubation with EZS. Analogues 
highlighted red (341, 342, 31, 230 and 231) were not accepted as substrates and their mode of 
inhibition investigated. Analogues highlighted purple (39, 30, 360 and 363) did not yield enzymatic 
product when incubated with EZS and were shown to bind to the enzyme though the mode of 
inhibition was not investigated. The analogue highlighted black (361) was not a substrate of EZS 
though determination of binding or mode of inhibition was not investigated. 
A synthesis of (2Z,6Z) farnesyl diphosphate (38) using a Still-Gennari204 modified 
Horner-Wadsworth-Emmons reaction202 as the key olefination reaction for the installation of the 
C2,C3 double bond gave an overall yield of 9% over seven steps. The olefination conditions 
investigated during this synthetic route were duplicated or modified in order to synthesise all other 
substrates excluding neryl diphosphate (39) and geranyl diphosphate (30). The reproducible method 
enabled the synthesis of multiple substrates to which analogues 359 and 362 yielded enzymatic 
products upon incubation with EZS.  
The synthesis of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229)(Figure 76, 3.2.1) allowed for the 
measurement of steady state parameters of EZS and EZS mutants that exhibited activity upon 
incubation with 38. Mutants of EZS were generated to investigate the metal binding motifs, DDxxE 
and NSE, responsible for class I activity whilst numerous aromatic residues were subjected to single 
point mutation to investigate their role within the active site pocket. Analysis of the data from the 
steady state kinetic experiments concerning EZS(E648A) showed decreased substrate turnover and 
an increased binding affinity when compared with the wild type. EZS(Y483A) was found to have an 
effect on substrate binding affinity with a lower KM of 38 with EZS(Y483A) and an increase in catalytic 
efficiency when compared to the wild type. 
Inhibition studies were also performed with EZS and substrates that did not yield enzymatic products 
upon incubation with EZS. Fluorinated substrates and stereo isomer analogues of (2Z,6Z) FDP (38) 
were investigated and found to be competitive inhibitors of EZS. Other analogues that were 
accepted as substrates were examined using radiolabelled assays and an IC50 plot each, with each 
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analogue exhibiting substrate binding and enzyme inhibition. (2Z,6Z)-10,11-Epoxyfarnesyl 
diphosphate (361) was not used within inhibition assays due to the quantity of substrate. The 
inhibitory nature of stereoisomers of 38 has shown that the Z stereochemistry of the C2,C3 and 
C6,C7 double bonds are crucial for substrate turnover. Analysis of data from inhibition assays 
performed with monoterpene analogues neryl diphosphate (39) and geranyl diphosphate (30) 
showed that the removal of the prenyl tail significantly reduces substrate binding to the active site. 
Analogues 39 and 30 exhibited KM values 1 and 2 orders of magnitude greater than their 
sesquiterpene equivalents 38 and 31. These results give insight that the prenyl tail is significant for 
substrate binding to the active site. 
Fluorinated analogues 230 and 231 were shown to be competitive inhibitors of EZS giving evidence 
of a stepwise ring closure during the catalytic mechanism. Inhibition of EZS when incubated with 230 
and 231 suggests the formation of the farnesyl (141) and bisabolyl (86) cations respectively. 
Deuterated analogues (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) and (2Z,6Z)-(R)-[1-2H]-farnesyl 
diphosphate (234) provided insight to the roles of the proR and proS protons at the C1 position. 
Analysis of the pentane extractable products from the incubations of substrates 233 and 234 with 
EZS suggests that the proR proton is not involved within the catalytic mechanism whilst the proS 
proton participates in a manner that was not fully elucidated. 
This project has furthered the understanding of the Z-selective sesquiterpene cyclase; 
7-epizingiberene. It was previously thought that EZS would only accept (2Z,6Z) farnesyl diphosphate 
(38) as a substrate, however this work has shown the protein has greater substrate promiscuity than 
previously acknowledged. Methylated analogue 359 and methoxygenated analogue 362 both 
yielded enzymatic products when incubated with EZS whilst analogues 360, 361 and 363 did not give 
enzymatic products, with 361 and 363 shown to inhibit EZS.  
This work gives precedence that EZS is able to accept substrates with modifications to the 
hydrocarbon skeleton. This provides a potential avenue for the synthesis of non-canonical substrates 
which upon incubation with EZS could generate analogues of 7-epizingiberene which may have 
agricultural importance. 
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Figure 181. Synthesised analogues: Analogues which EZS accepted as substrates (green). Analogues which acted as 
inhibitors of EZS and mode of inhibition investigated (red). Analogues that acted as EZS inhibitors (purple). Analogue 
which did not yield enzymatic product when incubated with EZS (black). 
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7.2 Future Work 
7.2.1 Inhibition studies 
Future work following the completion of this project could involve the synthesis of 361 and the 
investigation of substrates that do not yield enzymatic product upon incubation with EZS to 
determine their modes of inhibition. 
 
7.2.2 Preparative scale incubations 
(2Z,6Z) Farnesyl diphosphate (38), (2Z,6Z)-2-methylfarnesyl diphosphate (359), 
(2Z,6Z,10Z)-12-methoxy farnesyl diphosphate (362), (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) 
and (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) yielded enzymatic product upon incubation with 
EZS. Preparative scale incubations of each analogue with EZS and extraction of pentane extractable 
products should yield enough product for 1H NMR analysis. A 1H NMR spectrum of 38 and peak 
assignment would help elucidate the catalytic mechanism of EZS when compared to the 1H NMR 
spectra of the enzymatic products from the incubations of deuterated analogues 233 and 234 with 
EZS. (2Z,6Z)-2-methyl-FDP (359) and (2Z,6Z,10Z)-12-methoxy FDP (362) both yielded enzymatic 
products that were proposed to be analogous compounds of 7-epizingiberene. Preparative scale 
incubation of 362 and analysis of the extracted products by 1H NMR spectroscopy would aid 
characterisation of the methoxylated product. Equivalently, a preparative scale incubation of 359 
would enable the separation of the three enzymatic products by preparative scale thin layer 
chromatography. The analysis of each product by 1H NMR spectroscopy would assist the 
characterisation of the methylated enzymatic products. 
 
7.2.3 Proposed synthesis (2Z,6Z) farnesol (167) 
Various procedures were investigated to synthesise (2Z,6Z) farnesol (167). Two olefination 
procedures were successful; an Anastasia reaction199 and a Still-Gennari204 modified 
Horner-Wadsworth-Emmons reaction.202 Both reactions yielded (2Z,6Z) farnesol (167) and (2E,6Z) 
farnesol (168) in a 1:1 ratio. A synthesis using a directed Wittig reaction published by Chen et, al.,197 
giving 100% Z stereochemistry was also attempted using α-hydroxylated neryl acetone (187) in place 
of hydroxyl acetone (422). The synthesis of 187 to be the reactant in the directed Wittig reaction 
was not achieved and therefore the Z selective reaction was not performed. A synthesis of (2Z,6Z) 
farnesol (167) is outlined in Figure 182 using the published olefination reaction197 as the initial step.  
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Figure 182. Proposed synthesis of (2Z,6Z) farnesol (167). 
 
7.2.4 Synthesis of deuterated isotopologues  
Numerous hydride shifts are plausible within the EZS catalytic mechanism (Figure 183). This project 
focussed on the hydride shifts occurring from the C1 position; however isotopologues that would 
investigate hydride shifts from C5 and C6 positions could be synthesised in future. 
 
 
Figure 183. Plausible hydride shifts that require further investigation. 
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The synthesis of three deuterated isotopologues and analysis of the enzymatic products resulting 
from their incubation with EZS would give further insight into the catalytic mechanism. The synthesis 
of (2Z,6Z)-[6-2H]-farnesyl diphosphate (232) was outlined in Figure 99 (4.3.1) though isolation of the 
final diphosphate was not achieved and could not be repeated within the time constraints of the 
project. The synthesis of deuterated analogues (2Z,6Z)-(S)-[5-2H]-farnesyl diphosphate (426) and 
(2Z,6Z)-(R)-[5-2H]-farnesyl diphosphate (427) would also give information on the hydride shifts that 
may occur during the catalytic mechanism of EZS (Figure 184). 
 
 
Figure 184. Prospective future deuterated analogues 232, 426 and 427. 
The synthesis of 426 outlined in Figure 185 which echoes the synthesis of (2Z,6Z) FDP (167) (Figure 
45) and (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) (Figure 101). The preparation of deuterated 
neral (430) from nerol (163) is followed by a reduction using (R)-Alpine Borane (293) to yield the 
S-deuterated enantiomer 432 and chlorination to yield 433. The formation of the β-keto ester (434) 
is the step that requires investigation as the reaction may result in the inversion, retention or 
scrambling of chirality at the deuterated position. The synthetic pathway then proceeds via the same 
procedure as outlined in Figure 45 (2.2.5) to give (2Z,6Z)-(S)-[5-2H]-farnesyl diphosphate (426).  
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Figure 185. Proposed synthesis of (2Z,6Z)-(S)-[5-
2
H]-farnesyl diphosphate (426). 
The synthesis of (2Z,6Z)-(R)-[5-2H]-farnesyl diphosphate (427) would follow the same procedure 
outlined in Figure 185 however, deuterated aldehyde 430 would be reduced using (S)-Alpine Borane 
(302) instead of (R)-Alpine Borane (293) to give the desired enantiomer. 
 
7.2.5 Synthesis of novel FDP analogues 
Future work following the completion of this project could involve the synthesis of methylated 
analogues 439 and 440 (Figure 187). This project showed that EZS is able to accept 
(2Z,6Z)-2-methylfarnesyl diphosphate (359) and (2Z,6Z,10Z)-12-methoxyfarnesyl diphosphate (362) 
as substrates. These results give precedent that other analogous (2Z,6Z) FDP substrates incubated 
with EZS may yield 7-epizingiberene derivatives. 
 
185 
 
 
Figure 186. Prospective methylated analogues 439 and 440. 
The synthesis of (2Z,6Z,10Z)-12-methylfarnesyl diphosphate (439) is outlined in Figure 187. The 
synthesis starts from alcohol 403 (Figure 172, 6.3.3). The methyl group of 443 is incorporated after 
oxidation of 403 to aldehyde 441, a Wittig reaction to give 442 and hydrogenation of the terminal 
double bond.  
 
 
Figure 187. Proposed synthesis of (2Z,6Z,10Z)-12-methylfarnesyl diphosphate (439). 
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Chapter 8 – Materials and Methods 
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8.1 Biological Materials and Methods 
8.1.1 Bacterial strains and preparation 
Numerous chemically competent cell lines of E.coli were used during the course of this research; 
XL1-Blue cloning strain was used for the cloning of plasmid DNA and for the transformation and 
expression of protein; BL21(DE3), BL21 (DE3) – RP, ArcticExpress (DE3) and C41 (DE3) pLysS 
expression strains were used for the test and preparative expressions of 7-EZS (WT) prior to C41 
(DE3) pLysS being used for all expressions of  7-EZS (WT) and mutants. 
 
8.1.2 Competent Cells 
Calcium chloride Buffer I 
Calcium chloride (1.11 g, 100 mM) was dissolved in deionised water (100 mL). The solution was 
sterilised in an autoclave (121 ᵒC, 20 minutes) 
Calcium chloride Buffer II 
Calcium chloride (1.11 g, 100 mM) was dissolved in deionised water (50 mL) and glycerol (15 mL, 
15% v/v) was added. The solution was made up to final volume using deionised water prior to 
sterilisation in an autoclave (121 ᵒC, 20 minutes) 
Preparation of competent cells 
For the preparation of C41 (DE3) pLysS chemically competent cells an agar stab courtesy of Prof. 
Martin J. Warren from the School of Biosciences at the University of Kent. Agar stab was perforated 
with a sterile metal loop and sample spread onto an agar plate containing chloramphenicol (0.1 mM) 
and incubated at 37 ᵒC overnight. A single colony was placed into LB media (100 mL) with 50 µL 
chloramphenicol solution (25 mg/mL in ethanol) and grown overnight at 37 ᵒC. Overnight culture (1 
mL) was used to inoculate LB media (100 mL) containing 50 µL chloramphenicol solution (25 mg/mL 
in ethanol) and grown at 37 ᵒC to an optical density of 0.9 at 600 nm (OD600). The cells were 
harvested by centrifugation (4000 rpm / 10 minutes / 4ᵒC) and the supernatant discarded. The pellet 
was gently re-suspended in calcium chloride buffer I (40 mL) and centrifuged (4000 rpm / 10 minutes 
/ 4ᵒC). Supernatant was discarded and the pellet gently re-suspended in calcium chloride buffer II 
(10 mL) and divided into 50 µL aliquots, flash frozen in liquid N2 and stored at -80 ᵒC. 
For the preparation ofBL21 (DE3) chemically competent cells; a 50 µL aliquot was incubated in LB 
media (100 mL) and grown overnight at 37 ᵒC. Overnight culture (1 mL) was used to inoculate LB 
media (100 mL) and the same procedure was followed. 
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8.1.3 Super-competent cells 
Rubidium chloride buffer I 
Rubidium chloride (100 mM), potassium acetate (30 mM), calcium chloride (10 mM), manganese 
chloride (50 mM) were dissolved in deionised water and glycerol (15%) was added. The pH of the 
solution was adjusted to 5.8, the final volume made up using deionised water and sterilised by 
filtration through a sterile 0.2 µM syringe filter under aseptic conditions. 
Rubidium chloride buffer II 
Rubidium chloride (10 mM), 3-(N-morpholino)propanesulfonic acid (MOPS, 10 mM), calcium 
chloride (75 mM) were dissolved in deionised water and glycerol (15%) was added. The pH of the 
solution was adjusted to 6.5, the final volume made up using deionised water and sterilised by 
filtration through a sterile 0.2 µM syringe filter under aseptic conditions. 
Preparation of super-competent cells 
Agar stab was perforated with a sterile metal loop and sample spread onto an agar plate containing 
chloramphenicol (0.1 mM) and incubated at 37 ᵒC overnight. A single colony was placed into LB 
media (100 mL) with 50 µL chloramphenicol solution (25mg/mL in ethanol) and grown overnight at 
37 ᵒC. Overnight culture (1 mL) was used to inoculate LB media (100 mL) containing 50 µL 
chloramphenicol solution (25 mg/mL in ethanol) and grown at 37 ᵒC to an optical density of 0.9 at 
600 nm (OD600). The cells were harvested by centrifugation (4000 rpm / 10 minutes / 4ᵒC) and the 
supernatant discarded. The pellet was gently re-suspended in rubidium chloride buffer I (40 mL) and 
centrifuged (4000 rpm / 10 minutes / 4ᵒC). Supernatant was discarded and the pellet gently re-
suspended in rubidium chloride buffer II (10 mL) and divided into 50 µL aliquots, flash frozen in liquid 
N2 and stored at -80 ᵒC. 
 
8.1.4 Growth media and antibiotic solutions 
Luria-Bertani (LB) medium 
Sodium chloride (10 gL-1), yeast extract (5 gL-1) and tryptone (10 gL-1) were dissolved in deionised 
water and the resulting solution was sterilised in an autoclave (121 ᵒC, 20 minutes) and cooled to 
room temperature prior to use. Required antibiotics were added at time of use under sterile 
conditions. 
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Terrific-Broth (TB) medium  
Tryptone (12 g L-1), yeast extract (24 g L-1) and glycerol (4 mL L-1) were dissolved in deionised water 
(800 mL), the resulting solution adjusted to 900 mL with deionised water and sterilised in an 
autoclave (121 ᵒC, 20 minutes) and cooled to room temperature prior to use. Required antibiotics 
and phosphate buffer (0.17 M KH2PO4 and 0.72 M K2HPO4, 100 mL L
-1). 
Phosphate buffer 
Potassium phosphate monobasic (0.17 M, 23.14 g L-1) and potassium phosphate dibasic (0.72 M, 
125.4 g L-1) were dissolved in deionised water (1 L) and sterilised in an autoclave (121 ᵒC, 20 
minutes). 
LB agar plates 
Yeast extract (5 g L-1), sodium chloride (10 g L-1), tryptone (10 g L-1) and agar (15 g L-1) were dissolved 
in deionised water and sterilised in an autoclave (121 ᵒC, 20 minutes). The required antibiotic was 
added to the cooled agar (~40 ᵒC) and the resultant mixture poured into plates under aseptic 
condition. The plates were cooled prior to storage at 4 ᵒC. 
Ampicillin 
Ampicillin was dissolved in deionised water to give a 100 mgmL-1 solution which water filter 
sterilised through a 0.2 µM syringe filter under aseptic conditions and stored at 4 ᵒC. 
Chloramphenicol  
Chloramphenicol was dissolved in ethanol to give a 25 mgmL-1 and stored at 4 ᵒC. 
Kanamycin 
Kanamycin was dissolved in deionised water to give a 50 mgmL-1 solution which water filter sterilised 
through a 0.2 µM syringe filter under aseptic conditions and stored at 4 ᵒC. 
 
8.1.5 SDS-Page 
SDS resolving buffer 
A solution of Tris-Base (27.23 g, 1.5 M) in deionised water (100 mL) was adjusted to pH 8.8 and the 
final volume made to 150 mL. 
SDS stacking buffer 
A solution of Tris-Base (6.06 g, 0.5 M) in deionised water (80 mL) was adjusted to pH 6.8 and the 
final volume made to 100 mL. 
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Electrode running buffer (x10) 
SDS (10 g, 10% w/v), Glycine (150.14 g, 2 M) and Tris-base (30.3 g, 0.25 M) were dissolved in 
deionised water (1L). Electrode buffer was diluted 10 fold with deionised water prior to use. 
SDS sample Buffer 
Bromophenol blue (0.2 mL of 0.6% w/v solution), glycerol (2.5 mL), SDS (2 mL of 10% w/v solution), 
SDS stacking buffer (1.25 mL), deionised water (3.55 mL) and β-mercaptoethanol were mixed into 
solution and stirred at room temperature. 
Resolving gel (12%) 
Resolving buffer (2.5 mL), 10% (w/v) SDS (0.1 mL), deionised water (3.4 mL) and 30% acrylamide / 
bis-acrylamide (4.0 mL) were mixed together. Immediately prior to use; 10% ammonium persulfate 
solution (APS, 50 µL, 100 mgmL-1 in dH2O) and N,N,Nʾ,Nʾ-tetramethylenediamine (TEMED, 15 µL) 
were added to the solution a gently mixed to initiate polymerisation. 
Stacking gel (4%) 
Stacking buffer (2.5 mL), 10% (w/v) SDS (0.1 mL), deionised water (5.7 mL) and 30% acrylamide / bis-
acrylamide (1.7 mL) were mixed together. Immediately prior to use; 10% ammonium persulfate 
solution (APS, 50 µL, 100 mgmL-1 in dH2O) and N,N,Nʾ,Nʾ-tetramethylenediamine (TEMED, 20 µL) 
were added to the solution a gently mixed to initiate polymerisation. 
SDS gel stain 
Coomasie brilliant bluR-250 (60 mg) was dissolved in ethanol (10 mL). The resultant solution was 
made up to 1L with deionised water and acidified with concentrated hydrochloric acid (~2 mL). 
SDS-Page protocol 
Resolving and stacking gel solution were prepared as outlined above. The resolving gel was first 
poured, overlain with isopropanol and allowed to polymerise. Isopropanol was removed and 
stacking gel poured and allowed to polymerise after the addition of a comb to create loading wells. 
Fraction samples (10 µL) were incubated in SDS sample buffer (10 µL) for 5 minutes at 90 ᵒC and 
loaded onto the gel. Electrode running buffer was added and the gel run for 1 hour at 150 V. 
SDS-Page visualisation 
After gel had run, it was removed from the plates, submerged in water placed in a microwave for 2 
minutes. Water was replaced and the gel placed in the microwave for a further 2 minutes. Water 
was replaced with SDS gel stain, microwaved for 2 minutes and placed on a shaker to cool whilst 
stirring. SDS gel stain was decanted and the gel placed in water and microwaved for 2 minutes a 
further two times at which point all bands were visible and SDS gel stain was removed. 
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8.1.6 DNA purification 
Miniprep of DNA 
A single colony from an agar plate was used to inoculate LB medium (10 mL, containing appropriate 
antibiotic) and incubated overnight at 37 ᵒC whilst shaking. Cells were harvested via centrifugation 
(4000 rpm, 10 minutes, 4 ᵒC). Extraction and purification of DNA using a QIAprep spin miniprep kit 
(QIAGEN, Crawley, UK) via the manufacturers protocol was used in conjunction with EconoSpin All-
in-1 mini spin columns (Epoch Biolabs, Inc, TX, USA). 
Agarose gel DNA purification 
A DNA sample from the agarose gel was removed and 3 volumes of QG buffer to 1 volume gel (100 
mg gel ~ 100 µL) were added. The mixture was incubated at 50 ᵒC and vortexed periodically to aid 
solvation of the gel. Isopropanol (1 gel volume) was added to the sample, mixed by inversion and 
bound to a QIAquick column via centrifugation (1 minute). Buffer QG (500 µL) was added to the 
column and centrifuged for 1 minute. Buffer PE (750 µL) was added to the column and left to stand 
for 3 minutes prior to centrifugation for 1 minute. DNA was eluted into a clean eppendorf by the 
addition of autoclaved water (50 µL), left to stand for 1 minute and centrifuged for 1 minute. 
 
8.1.7 Transformation of Competent Cells 
The appropriate plasmid and competent cells were thawed at 0 ᵒC. DNA solution (1-1.5 µL) was 
added to competent cells and gently mixed. The DNA / cell mixture was incubated at 0 ᵒC for 30 
minutes and heat for 45 seconds at 42 ᵒC. The mixture was incubated at 0 ᵒC for 2 minutes prior to 
the addition of LB medium (1 ml, containing no antibiotic) and incubated for 1 hour under shaking at 
37 ᵒC. Cells were harvested by centrifugation (13000 rpm, 1 minute, Eppendorf centrifuge 5415R) 
and the majority of supernatant discarded. Cells were resuspended in remaining LB medium (~50 
µL), plated on agar plates containing appropriate antibiotic and incubated at 37 ᵒC overnight.  
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8.1.8 Expression of EZS 
General method of protein expression: A single transformed colony was used to inoculate 100 mL of 
growth medium (LB / TB) with appropriate antibiotic and the culture was shaken overnight at 37 ᵒC. 
Overnight growth (10 mL) was placed into 500 mL growth medium (LB / TB) and the appropriate 
antibiotics added. The inoculated broth was shaken at 37 ᵒC until the optical density of cells (OD at 
600 nm) reached 0.6 – 0.7 at which point isopropyl β-D-1-thiogalactopyranoside (IPTG, 60 mg) was 
added to induce protein expression. The medium was incubated at the required temperature an 
time as deduced by test expressions and cells harvested via centrifugation (4000 rpm, 15 minutes, 4 
ᵒC) and the respective cell pellet stored at -20 ᵒC. 
 
8.1.9 Purification methods 
Cell lysis buffer 1 
2-Mercaptoethanol (350 µL, 5 mM), TRIS Base (2.4 g / 20 mM), TWEEN 20 (91 µL, 1%) and sodium 
chloride (5.84 g, 100 mM) were dissolved in dH2O (900 mL) and the pH of solution adjusted to pH 7.5 
by the addition of hydrochloric acid (6 M). The mixture was then diluted to a volume of 1L with 
dH2O. 
Cell lysis buffer 2 
2-Mercaptoethanol (350 µL, 5 mM), sodium chloride (5.84 g, 100 mM) and TRIS Base (2.4 g / 20 mM) 
were dissolved in dH2O (900 mL) and the pH of solution adjusted to pH 7.5 by the addition of 
hydrochloric acid (6 M). The mixture was then diluted to a volume of 1L with dH2O. 
Cell lysis buffer 3 
Into dH2O (900 mL) was added sodium chloride (29.2 g, 500 mM), TRIS Base (2.4 g / 20 mM) and 
2-mercaptoethanol (350 µL, 5 mM). Hydrochloric acid (6 M) was added to the solution to adjust the 
pH to pH 8 and the mixture diluted with dH2O to a total volume of 1 L. 
Cell lysis buffer 4 
Sodium chloride (1.17 g, 100 mM), 2-mercaptoethanol (350 µL, 5 mM) and TRIS Base (2.4 g / 20 mM) 
were dissolved in dH2O (900 mL) and the pH of solution adjusted to pH 8 by the addition of 
hydrochloric acid (6 M). The mixture was then diluted to a volume of 1L with dH2O. 
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Sonication protocol 
Pellet was defrosted on ice and cell lysis buffer (~100 mL), lysozyme (~30 mg) and 
phenylmethanesulfonyl fluoride (PMSF, ~10 mg) were added with suspension achieved via stirring at 
5 ᵒC. Suspended cells were placed in and ice/salt bath and sonicated: time; 5 minutes pulse ON; 5 
seconds pulse OFF; 15 seconds. Lysed cell debris was harvested via centrifugation (18500 rpm, 40 
min, 4 ᵒC). 
Basic extraction protocol 
Insoluble fraction from sonication was suspended in cell lysis buffer (~60 mL) at 5 ᵒC. Sodium 
hydroxide (6 M) was added dropwise to the suspended cells to increase the pH to pH 11 and stirred 
at 5 ᵒC for 30 minutes. 2-mercaptoethanol (50 µL) was added to the suspension and the pH of the 
solution adjusted to pH 8 by the dropwise addition of hydrochloric acid (1 / 6 M) and stirred at 5 ᵒC 
for 30 minutes. Cell debris was harvested via centrifugation (18500 rpm, 40 min, 4 ᵒC). 
Ni2+-NTA affinity column protocol 
Ni2+affinity resin was equilibrated into appropriate buffer prior to the addition of supernatant 
containing extracted protein which was passed through the column 3 times. Numerous elution 
methods using increasing concentration of imidazole solutions were attempted to better elute 
impurities: 
1. Buffer (1 x CV), 5 mM (1 x CV), 20 mM (1 x CV), 50 mM (1 x CV), 70 mM (1 x CV), 100 mM (1 x 
CV), 150 mM (1 x CV), 200 mM (1 x CV), 300 mM (1 x CV) and 500 mM (1 x CV) 
2. Buffer (2 x CV), 5 mM (2 x CV), 20 mM (2 x CV), 50 mM (1 x CV), 70 mM (1 x CV), 100 mM (1 x 
CV), 150 mM (1 x CV), 200 mM (1 x CV), 300 mM (1 x CV) and 500 mM (1 x CV) 
3. Buffer (2 x CV), 5 mM (4 x CV), 20 mM (4 x CV), 50 mM (1 x CV), 70 mM (1 x CV), 100 mM (1 x 
CV), 150 mM (1 x CV), 200 mM (1 x CV), 300 mM (1 x CV) and 500 mM (1 x CV) 
4. Buffer (1 x CV), 5 mM (1 x CV), 20 mM (1 x CV), 300 mM (1 x CV) and 500 mM (1 x CV) 
5. Buffer (4 x CV), 5 mM (6 x CV), 20 mM (6 x CV), 300 mM (2 x CV) and 500 mM (1 x CV) 
 
CV = column volume  
Ni2+-NTA affinity column Imidazole buffer 1 
Imidazole (68.1 g, 1 M), 2-mercaptoethanol (350 µL, 5 mM), TRIS Base (2.4 g / 20 mM), TWEEN 20 
(91 µL, 1%) and sodium chloride (5.84 g, 100 mM) were dissolved in dH2O (900 mL) and the pH of 
solution adjusted to pH 7.5 by the addition of hydrochloric acid (6 M). The mixture was then diluted 
to a volume of 1L with dH2O. 
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Ni2+-NTA affinity column Imidazole buffer 2 
2-Mercaptoethanol (350 µL, 5 mM), imidazole (68.1 g, 1 M), sodium chloride (5.84 g, 100 mM) and 
TRIS Base (2.4 g / 20 mM) were dissolved in dH2O (900 mL) and the pH of solution adjusted to pH 7.5 
by the addition of hydrochloric acid (6 M). The mixture was then diluted to a volume of 1L with 
dH2O. 
Ni2+-NTA affinity column Imidazole buffer 3 
Into dH2O (900 mL) was added sodium chloride (29.2 g, 500 mM), TRIS Base (2.4 g / 20 mM), 
2-mercaptoethanol (350 µL, 5 mM) and imidazole (68.1 g, 1 M). Hydrochloric acid (6 M) was added 
to the solution to adjust the pH to pH 8 and the mixture diluted with dH2O to a total volume of 1 L. 
Ni2+-NTA affinity column Imidazole buffer 4 
Sodium chloride (1.17 g, 100 mM), 2-mercaptoethanol (350 µL, 5 mM), imidazole (68.1 g, 1 M) and 
TRIS Base (2.4 g / 20 mM) were dissolved in dH2O (900 mL) and the pH of solution adjusted to pH 8 
by the addition of hydrochloric acid (6 M). The mixture was then diluted to a volume of 1L with 
dH2O. 
Ni2+-NTA affinity column Imidazole buffer 5 
Imidazole (68.1 g, 1 M), 2-mercaptoethanol (350 µL, 5 mM), TRIS Base (2.4 g / 20 mM), TWEEN 20 
(91 µL, 1%) and sodium chloride (1.17 g, 20 mM) were dissolved in dH2O (900 mL) and the pH of 
solution adjusted to pH 7.5 by the addition of hydrochloric acid (6 M). The mixture was then diluted 
to a volume of 1L with dH2O. 
Dialysis protocol 
Solution requiring dialysis was placed in dialysis tubing with 14 kDa membrane. Dialysis tubing was 
then placed into desired buffer (3 L) and stirred slowly at 5 ᵒC. Dialysis was also achieved in four 
hours via the same protocol by replacing dialysis buffer (3 L) after 2 hours.  
Spin Column buffer exchange / purification 
Protein in solution was placed into a spin column with a molecular cut off of 50 kDa and 
concentrated to 1 mL. The concentrated mixture was diluted to 5 mL with pre-kinetics buffer and 
concentrated to 1 mL. The process was repeated a further 5 times. 
FPLC Q-sepharose low salt buffer 
Into dH2O (900 mL) was added Tris Base (2.4 g, 20 mM), 2-mercaptoethanol (350 µL, 5 mM) and 
sodium chloride (1.17 g, 20 mM). The pH of the solution was adjusted to pH 8.0 prior to the dilution 
of the mixture to 1L. Buffer was filtered under vaccuo and degassed immediately prior to use.  
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FPLC Q-sepharose high salt buffer 
Into dH2O (900 mL) was added Tris Base (2.4 g, 20 mM), 2-mercaptoethanol (350 µL, 5 mM) and 
sodium chloride (58.4 g, 1 M). The pH of the solution was adjusted to pH 8.0 prior to the dilution of 
the mixture to 1L. Buffer was filtered under vaccuo and degassed immediately prior to use.  
Anion exchange chromatography 
Protein samples from Ni-NTA affinity column were dialysed into to FPLC Q-sepharose low salt buffer. 
The resulting solution was injected and eluted through a resource Q-sepharose column with a 
gradient flow of FPLC Q-sepharose high salt buffer (70 mL, 0-50% gradient) at a flow rate of 3 
mLmin1 followed by an isocratic flow of FPLC Q-sepharose high salt buffer (18.1 mL, 100%) at 3 
mLmin-1. UV absorbance was monitored at 280 nm.252 
 
8.1.10 Bradford Assay 
The Bradford assay was used to determine the concentration of product in solution after 
purification.  
Bradford Reagent 
Brilliant Blue G250 (10 mg) was dissolved in ethanol (2 mL) and H3PO4 added (80%, 10 mL). dH2O was 
use to bring the final volume of solution to 100 mL where upon was stored in the dark at 4 ᵒC. 
Bradford Assay Protocol 
A solution of bovine serum albumin (BSA, 1 mgmL-1) in dH2O was used to prepare a range solutions 
of varying concentrations; 0 – 100 µgmL-1 in 200 µL of deionised water. Bradford reagent (800 µL) 
was added to a solution and left to stand for 2 minutes after which the absorbance was measured 
from 400 – 600 nm using a SHAMADZU BioSpec-mini UV spectrophotometer. The ratio of 
absorbance’s at 590 nm and 450 nm was calculated and plotted to give a standard curve. The 
procedure was repeated using samples of purified protein and the ratio of absorbance compared to 
the BSA standard curve to give the concentration of each sample.  
 
8.1.11 Incubation and GC-MS analysis of enzymatic products 
Incubation Buffer 
Magnesium chloride (71.5 mg, 15 mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 
298 mg, 25 mM) and dithiothreitol (88.6 mg, 5mM) was dissolved in dH2O (40 mL). The pH was 
adjusted to pH 8.0 by the addition sodium hydroxide (1 M) and diluted to 50 mL with distilled water. 
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Incubation Protocol 
Incubation buffer (200 µL), EZS (40 µL) and (2Z, 6Z) FDP (38, 10 µL, 20 mM)were placed in a GC-MS 
vial. Incubation mixture was overlain with pentane (1 mL) and incubated on a bench top shaker 
overnight. Incubation mixture and pentane were votexed for 5 seconds and the aqueous layer 
removed prior to the analysis of the pentane layer via GC-MS. 
GC-MS method 
Sample is injected at 80 ᵒC and oven temperature held constant for 1 minute. A temperature 
gradient of 4 ᵒC / min then follows for 15 minutes increasing the oven temperature from 80 to 180 
ᵒC. 
 
8.1.12 Circular dichromism spectroscopy 
Purified protein was buffer exchanged into KXPO4 (pH 8.0) buffer using a spin column (50 kDa 
molecular weight cut off). Protein stock was diluted with KXPO4 (pH 8.0) buffer to achieve a (10 µM) 
and circular dichromism experiments performed on an Applied PhotoPhysics Chirascan 
spectrometer. Spectra of protein (10 µM) KXPO4 (pH 8.0) buffer were measured between 190 nm 
and 600 nm in a 10 mm quartz cuvettes under N2. Each protein was scanned in triplicate and the 
average of the three scans used for data plotting and analysis. 
Calculation of mean residue molar ellipticity 
Data points obtained from the CD spectrum were converted to mean residue ellipticity (MRE) using 
equation 1.1: 
        
   
     
 
Ɵ = molar ellipticity in millidegrees 
n = number of peptide bonds in the protein 
c = molar concentration of protein in the sample 
l = path length in cm 
 
8.1.13 Steady State Kinetics 
EZS-pre kinetics buffer 
Sodium chloride (5.84 g, 100 mM), TRIS Base (2.4 g, 20 mM) and 2-mercaptoethanol (350 µL, 5 mM) 
were dissolved in dH2O (900 mL). Hydrochloric acid (1 M, 6 M and conc) was added to adjust the pH 
of the solution to pH 8.0 prior to dilution of the mixture to 1L with dH2O. 
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Kinetics catalysis buffer A 
Magnesium chloride (28.6 mg, 30 mM), TRIS base (30.1 mg, 25 mM) and dithiothreitol (15.4 mg, 10 
mM) were dissolved in dH2O (5 mL). The pH was altered to pH 8.0 and the solution diluted to 10 mL 
with deionised water. 
Kinetics catalysis Buffer B 
TRIS base (30.1 mg, 25 mM) was dissolved in dH2O (5 mL). The pH was altered to pH 8.0 and the 
solution diluted to 10 mL with deionised water. 
Steady State kinetics Protocol 
Buffer A (125 µL), buffer B (60-105 µL) and (2Z, 6Z)-[1-3H]-farnesyl diphosphate (0.1 - 70 µM) were 
placed in an eppendorf and cooled to 0 ᵒC. Volume buffer B varied for the concentration change of 
(2Z, 6Z)-[1-3H]-farnesyl diphosphate with a total volume of 235 µL. EZS (500 nM stock, 15 µL) was 
added to the solution at 0 ᵒC and overlain with hexane (1 mL). Eppendorf was placed in a bench top 
shaker and incubated (10 min, 350 rpm, 30 ᵒC). Incubations were immediately placed on ice and 
ethylenediaminetetraacetic acid (EDTA, 100 µL, 0.1 M) added. The reaction was vortexed for 5 
seconds, the hexane overlay removed and passed through silica into scintillation cocktail 
(PerkinElmer OPTI-FLUOR® O, 15 mL). Extraction of enzymatic product was repeated with Hexane 
(900 µL x 2) and the extracts passed through silica. Hexane (1 mL) was passed through the silica pad 
into scintillation cocktail and the hexane / cocktail mixture vortexed for 5 seconds. Radioactive 
mixture was analysed using a TRI-CARB 2900TR Liquid Scintillation Analyzer. 
Conversion of counts per minute (CPM) to rate 
Equation 1.2 
      
   
                 
 
CPM = Counts per minute 
Time = Incubation time (seconds) 
Equation 1.3 
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Calculation of specific activity 
Equation 1.4 
                   
     
             
 
 
Michaelis-Menten equation 
Equation 1.5 
   
    
  
 
        
      
 
v = rate of reaction 
[P] = product concentration 
Vmax = maximum rate of reaction system 
[S] = substrate concentration 
KM = Michaelis-Menten constant 
Calculation of kcat 
Equation 1.6 
                      
Vmax = maximum rate of reaction (the point at which all active sites are saturated) 
[ETotal] = total concentration of enzyme 
Kcat = substrate turnover number 
 
8.1.14 Inhibition Studies 
Inhibition assay – Steady state kinetics protocol 
Buffer A (125 µL), buffer B (60-105 µL), (2Z, 6Z)-[1-3H]-farnesyl diphosphate (0.2 – 70 µM) and 
inhibitor (5-30 µM)were placed in an eppendorf and cooled to 0 ᵒC. Volume of buffer B was varied 
for the concentration changes of (2Z,6Z)-[1-3H]-farnesyl diphosphate and inhibitor so the total 
volume of (2Z,6Z)-[1-3H]-farnesyl diphosphate, inhibitor and buffers was 235 µL. EZS (30 nM) was 
added to the solution at 0 ᵒC and overlain with hexane (1 mL). Eppendorf was placed in a bench top 
shaker and incubated (10 min, 350 rpm, 30 ᵒC). Incubations were immediately placed on ice and 
ethylenediaminetetraacetic acid (EDTA, 100 µL, 0.1 M) added. The reaction was vortexed for 5 
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seconds, the hexane overlay removed and passed through silica into scintillation cocktail 
(PerkinElmer OPTI-FLUOR® O, 15 mL). Extraction of enzymatic product was repeated with hexane 
(900 µL x 2) and the extracts passed through silica. Hexane (1 mL) was passed through the silica pad 
into scintillation cocktail and the hexane / cocktail mixture vortexed for 5 seconds. Radioactive 
mixture was analysed using a TRI-CARB 2900TR Liquid Scintillation Analyzer. 
Inhibition assay – inhibitor binding assay protocol 
Buffer A (125 µL), buffer B (60-105 µL), (2Z, 6Z)-[1-3H]-farnesyl diphosphate (8 µM) and inhibitor 
(0.01-1000 µM) were placed in an eppendorf and cooled to 0 ᵒC. Volume of buffer B was varied for 
the concentration changes of the inhibitor so the total volume of (2Z,6Z)-[1-3H]-farnesyl 
diphosphate, inhibitor and buffers was 235 µL. EZS (30 nM) was added to the solution at 0 ᵒC and 
overlain with hexane (1 mL). Eppendorf was placed in a bench top shaker and incubated (10 min, 
350 rpm, 30 ᵒC). Incubations were immediately placed on ice and ethylenediaminetetraacetic acid 
(EDTA, 100 µL, 0.1 M) added. The reaction was vortexed for 5 seconds, the hexane overlay removed 
and passed through silica into scintillation cocktail (PerkinElmer OPTI-FLUOR® O, 15 mL). Extraction 
of enzymatic product was repeated with hexane (900 µL x 2) and the extracts passed through silica. 
Hexane (1 mL) was passed through the silica pad into scintillation cocktail and the hexane / cocktail 
mixture vortexed for 5 seconds. Radioactive mixture was analysed using a TRI-CARB 2900TR Liquid 
Scintillation Analyzer. 
Lineweaver-Burk Plot 
A Lineweaver-Burk plot (double reciprocal plot) was used as method for visualising enzyme kinetics 
for the determination of the mode of inhibition. Plots were derived from fitting experimental data to 
the following equation 1.7: 
 
 
 
  
      
        
  
  
    
 
 
   
  
 
    
 
 
Graphical calculation of ki 
A plot of KM(app) vs. inhibitor concentration [I] was used to calculate the inhibition constant ki. 
Experimental data was used for data points and linear regression utilised to visualise the x-intercept 
representing ki. Equation 1.8: 
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Ki = inhibition constant 
[I] = inhibitor concentration 
KM(app) = apparent value of KM at different inhibitor concentrations 
Standard errors of the weighted mean 
A weighted average was calculates to estimate to true value of KM and kcat as each set of 
measurements for the same experiment was carried out separately and independently. The 
weighted average mean (Xwav) was calculated using the following equation 1.9: 
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XWAV = weighted average mean 
Wi= reciprocal square of each measurements uncertainty 
Xi = each value in the sample 
 
Calculation of Wi 
The reciprocal squares of each measurements of individual uncertainty were calculated using the 
following equation 1.10: 
    
 
  
  
Ơ = uncertainty of measurement 
Standard error of the weighted mean 
Equation 1.10 
      
 
√∑  
 
ƠWAV = standard error of the weighted mean 
Propagation of error 
The following equation was used to calculate the propagation of errors when appropriate (If Z = X/Y). 
Equation 1.11: 
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X and Y = experimentally measured values 
ΔX and ΔY = error of experimentally measured values 
Z = calculate value 
ΔZ = propagated error 
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8.2 Organic Synthesis Experimental 
 
All chemicals were purchased from Sigma-Aldrich, Alfa-Aesar, Fisher Scientific or Fluorochem and 
used without further purification unless otherwise stated.  
Anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), toluene, and acetonitrile were obtained from 
an MBraun SPS800 solvent purification system. 1H NMR, 2H NMR, 13C NMR, 31P NMR and 19F NMR 
spectra were measured on a Bruker Avance III 600, Bruker Avance 500, Bruker Avance III HD 400 and 
a Bruker Fourier 300 NMR spectrometer. The spectra are reported as chemical shifts in parts per 
million, downfield from tetramethylsilane (1H and 13C), trichlorofluoromethane (19F) and phosphoric 
acid (31P), multiplicity (s-singlet, d-doublet, t-triplet, q-quartet, quin-quintet, m-multiplet, dd-doublet 
of doublet and dq-doublet of quartet), integral, multiplicity, coupling and assignment, respectively. 
Assignments are made to the limitations of COSY, DEPT 90/135, NOESY and gradient HSQC spectra.  
Mass spectra were measured on a Waters GCT Premier time of flight mass spectrometer and a 
Waters LCT time of flight mass spectrometer. The methods used are the same as described in 
Section 8.1.11. Thin layer chromatography (TLC) was performed on pre-coated aluminium plates of 
silica G/UV254. TLC visualisations were performed with 4.2% ammonium molybdate and 0.2% ceric 
sulfate in 5% H2SO4 (Hanessian’s stain), 0.1% berberine hydrochloride in EtOH or UV light. 
Ion-exchange chromatography was performed using ion-exchange resin (Amberlyst 131 wet, H+ 
form) pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3 containing 2% isopropanol, 2 CV). 
Reverse phase HPLC was performed on a system comprising of a Dionex P680 pump and a Dionex 
UVD170U detector unit. The column used was a 150 x 21.2 mm Phenomenex Luna C-18 column. 
Crude diphosphates were eluted under isocratic conditions with 10% B for 20 min, a linear gradient 
to 60% B over 25 min, then a linear gradient to 100% B over 5 min and finally with 100% B for 10 
min; solvent B: acetonitrile; solvent A: 25 mM ammonium bicarbonate in water, flow rate 5.0 
cm3min-1, detection at 220 nm. 
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8.2.1 Synthesis of (2Z,6Z) farnesyl diphosphate (38) 
Preparation of (Z)-1-bromo-3,4-dimethylocata-2,6-diene (164): 
 
 
A stirred solution of nerol (10 g, 64.8 mmol, 1 eq.) in anhydrous tetrahydrofuran (25 mL) was cooled 
to -10 ᵒC and phosphorous tribromide (3.04 mL, 32.4 mmol, 0.5 eq.) was added dropwise. The 
resulting solution was stirred at -10 ᵒC for 15 minutes and then concentrated under reduced 
pressure. The resulting residue was dissolved in diethyl ether-hexane (1:1, 30 mL) and washed with 
saturated sodium hydrogen carbonate solution (3 x 15 mL), water (3 x 15 mL) and brine (15 mL). The 
organic fraction was dried over sodium sulfate, filtered and the solvent removed under reduced 
pressure. The product was further dried under vacuum for 1 hour to yield bromide 164 as a pale 
yellow oil (14 g, 99%) which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.55 (1H, t, J = 8.5 Hz, CHCH2Br), 5.18 – 5.09 (1H, m, CCHCH2), 4.02 (2H, 
d, J = 8.5 Hz, CH2Br), 2.16 (4H, m, CHCH2CH2C), 1.77 (3H, s, CH2C(CH3)CH), 1.70 (3H, s, CH3CCH), 1.63 
(3H, s, CH3CCH). 
Preparation of ethyl (Z)-2-acetyl-5,9-dimethyldeca-4,8-dienoate (165): 
 
 
Crude bromide 164 (14 g, 64.8 mmol, 1 eq.) was dissolved in anhydrous acetone (30 mL) and ethyl 
acetoacetate (16.9 g, 16.5 mL, 129.6 mmol, 2 eq.) and anhydrous potassium carbonate (18.0 g, 129.6 
mmol, 2 eq.) were added. The resulting suspension was refluxed at 60 ᵒC for 4 hours. The solution 
was then concentrated under reduced pressure and residue was dissolved in diethyl ether (20 mL) 
and washed with water (3 x 15 mL) and brine (15 mL) before being dried over sodium sulfate and the 
solvent removed under reduced pressure. The residue was purified by flash chromatography on 
silica gel (20% ethyl acetate in hexane) to yield 165 as a clear oil (13.46 g, 78%).  
1H NMR (300 MHz, CDCl3) δ 5.09 – 5.03 (2H, m, 2 x (CH3)CCH), 4.20 (2H, q, J = 7.1 Hz, CH3CH2O), 3.43 
(1H, t, J = 7.5 Hz, COCHCO), 2.55 (2H, t, J = 7.4 Hz, CCHCH2CH), 2.22 (3H, s, COCH3), 2.17-1.94 (4H, m, 
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2 x allylic CH2), 1.69(6H, s, 2 x CH3), 1.62 (3H, s, CH3), 1.28 (3H, t, J = 7.1 Hz,CH3CH2O). 
13C NMR (75 
MHz, CDCl3)
 δ 169.6 (CH3C(O)CH), 147.1 (CH3CH2OC(O)), 138.6 & 131.9 (2 x (CH3)CCH), 123.9 & 120.3 
(2 x CH3CCH), 61.3 (CH3CH2O), 60.0 (C(O)CHC(O)), 31.8 (allylic CH2), 29.00 (CH3C(O)), 26.5 
(CCHCH2CH), 26.3 (allylic CH2), 25.6 & 23.3 (2 x CH3), 17.5 (CH3), 14.0 (OCH2CH3). LRMS (EI
+): 248.18 
(5% [M – H2O]), 175.15 (7%), 159.12 (10%), 136.13 (50%), 121.10 (65%), 119.09 (75%), 109.10 (78%), 
93.07 (100%), 79.06 (45%), 67.05 (32%). HRMS (EI+): calculated for C16H24O2 [M-H2O]
+; 248.1776, 
found 248.1776. 
Preparation of (Z)-6,10-dimethylundeca-5,9-dien-2-one (166): 
 
 
Potassium hydroxide (8.5 g, 151.6 mmol, 1 eq.) was added to a solution of 165 (13.46 g, 50.5 mmol, 
1eq.) in methanol (20 mL) and refluxed at 65 ᵒC for 2 hours. The reaction mixture was then cooled, 
and then acidified with dilute hydrochloric acid (1 M, 10 mL). The mixture was extracted with diethyl 
ether (3 x 15 mL) and the organic layers combined and washed with saturated sodium hydrogen 
carbonate solution (3 x 10 mL), water (3 x 10 mL) and brine (10 mL). The organic portion was dried 
over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification via 
flash chromatography on silica gel (10% ethyl acetate in hexane) provided ketone 166 as a clear oil 
(9.8 g, 99%). 
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.03 (2H, m, 2 x (CH3)CCH), 2.45 (2H, t, J = 7.3 Hz, CH2C(O)), 2.26 
(2H, dd, J = 14.6, 7.2 Hz, CH2CH2C(O)), 2.14 (3H, s, CH2C(O)CH3), 210 – 1.95 (4H, m, 2 x allylic CH2), 
1.69 (6H, s, 2 x CH3), 1.61 (3H, s, (CH3)CCH). 
13C NMR (75 MHz, CDCl3)
 δ 209.00 (CH3C(O)), 142.7 & 
136.5 (2 x (CH3)CCH), 124.0 &123.3 (2 x (CH3)CCH), 43.9 (CH2CH2C(O)), 31.7 & 26.4 (2 x allylic CH2), 
29.8 (CH3C(O)), 25.6 & 23.2 (2 x (CH3)CCH), 22.1 (CH2CH2CO), 17.8 (CH3). LRMS (EI
+): 194.17 (7% [M]), 
176.15 (95%), 151.11 (35%), 133.10 (80%), 121.10 (85%), 105.06 (100%), 93.06 (95%), 79.05 (82%), 
69.06 (92%). HRMS (EI+): calculated for C13H22O [M]
+; 194.1671, found 194.1677. 
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Preparation of ethyl (2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienoate (193): 
 
 
A stirred suspension of sodium hydride (161 mg, 6.70 mmol, 1.3 eq.) in anhydrous toluene (40 mL) 
was cooled to 0 ᵒC and ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate  204 (2.05 g, 6.17 
mmol, 1.2 eq.) was added dropwise. The reaction mixture was stirred at room temperature for 1 
hour and cooled to 0 ᵒC. Neryl acetone 166 (1 g, 5.14 mmol, 1 eq.) was added dropwise and the 
reaction mixture stirred at room temperature for 16 hours. The reaction was quenched with water 
(20 mL) and products extracted with diethyl ether (3 x 20 mL). Organic extracts were washed with 
water (3 x 20 mL) and brine (3 x 20 mL), dried over sodium sulphate, filtered and concentrated under 
reduced pressure. Purification via flash chromatography (2% ethyl acetate in hexane) gave 193 as a 
clear oil (571 mg, 43%). 
1H NMR (300 MHz, CDCl3) δ 5.58 (1H, s, CCHC(O)OEt), 5.13 – 5.00 (2H, m, 2 x (CH3)CCH), 4.06 (2H, q, J 
= 7.1 Hz, OCH2CH3), 2.62 – 2.52 (2H, m, CH2(CH3)CCHC(O)), 2.15 – 2.04 (2H, m, CH2CH2(CH3)CCHC(O)), 
2.00 – 1.89 (4H, m, 2 x allylic CH2), 1.81 (3H, d, J = 1.3 Hz, CH2(CH3)CCHC(O)), 1.61 (6H, s, 2 x CH3), 
1.54 (3H, s, CH3), 1.20 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.3 (CHC(O)O), 160.1 
((CH3)CCHC(O)O), 135.8 & 131.5 (2 x (CH3)CCH), 124.4 & 124.3 (2 x (CH3)CCH), 116.2 (CCHC(O)O), 
59.4 (OCH2CH3), 33.7 (CH2(CH3)CCHC(O)), 31.9 & 26.63 (2 x CH2), 26.60 (CH2CH2(CH3)CCHC(O)) 25.7 & 
25.4 & 23.4 17.6 (4 x CH3), 14.1 (OCH2CH3). LRMS (EI
+): 264.21 (5% [M]), 218.17 (55%), 197.10 (55%), 
183.11 (45%), 159.08 (42%), 143.08 (40%), 128.07 (85%), 93.07 (100%), 82.04 (60%), 69.07 (25%). 
HRMS (EI+): calculated for C17H28O2 [M]
+; 264.2089, found 264.2089. 
 
 
To a stirred solution of ethoxy acetylene (250 mg, 1.8 mmol, 2.5 eq.) and anhydrous THF (20 mL) was 
cooled to -78 ᵒC and n-butyl lithium (720 µL, 1.79 mmol, 2.5 eq.) was added dropwise. The reaction 
mixture was stirred for 1 hour at -78 ᵒC and warmed to -40 ᵒC prior to the addition of neryl acetone 
(166)(160 mg, 0.7 mmol, 1 eq.) and was stirred for 1 hour. The reaction mixture was allowed to 
warm to room temperature and was stirred for 16 hours. The reaction was quenched with water (10 
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mL) and the products extracted with diethyl ether (3 x 10 mL). Organic extracts were washed with 
water (3 x 10 mL), brine (20 mL), dried over sodium sulphate and concentrated under vaccuo. 
Purification via flash chromatography (2% ethyl acetate in hexane) provided ester 193 as a clear oil 
(49 mg, 26%). 
 
 
A stirred solution of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate 204 (4.37 g, 13.2 mmol, 
1.5 eq.) in anhydrous tetrahydrofuran (30 mL) was cooled to 0 ᵒC and n-butyl lithium (5.3 mL, 13.2 
mmol, 1.5 eq., 2.5M in hexanes) was added dropwise. The resulting solution was stirred at room 
temperature for 1 hour, cooled to 0 ᵒC and neryl acetone 166 (1.71 g, 8.8 mmol, 1 eq.) added 
dropwise.  The reaction mixture was stirred for 16 hours at room temperature. The reaction was 
quenched with water (10 mL) and the product was extracted with diethyl ether (3 x 20 mL). The 
combined organic phases were washed with water (3 x 10 mL) and brine (2 x 10 mL), then dried over 
sodium sulphate, filtered and the solvent removed under reduced pressure. Purification via flash 
chromatography on silica gel (2% ethyl acetate in hexane) provided ester 193 as a clear oil (763 mg, 
33%). 
 
 
A stirred suspension of sodium hydride (161 mg, 6.70 mmol, 1.3 eq.) in anhydrous toluene (40 mL) 
was cooled to 0 ᵒC and 204 (2.05 g, 6.17 mmol, 1.2 eq.) was added dropwise. The reaction mixture 
was stirred at room temperature for 1 hour and cooled to -78ᵒC. 166 (1 g, 5.14 mmol, 1 eq.) was 
added dropwise and the reaction mixture stirred at room temperature for 16 hours. The reaction 
was quenched with water (20 mL) and products extracted with diethyl ether (3 x 20 mL). Organic 
extracts were washed with water (3 x 20 mL) and brine (3 x 20 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. Purification via flash chromatography (2% ethyl 
acetate in hexane) gave 193 as a clear oil (517 mg, 38%).  
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A stirred suspension of sodium hydride (185 mg, 7.72 mmol, 3 eq.) in anhydrous tetrahydrofuran (20 
mL) was cooled to 0 ᵒC and 204 (930 mg, 2.80 mmol, 1.1 eq.) was added dropwise. The reaction 
mixture was stirred at room temperature for 1 hour and cooled to 0 ᵒC. 166 (500 mg, 2.57 mmol, 1 
eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 hours. The 
reaction was quenched with water (10 mL) and products extracted with diethyl ether (3 x 10 mL). 
Organic extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over sodium 
sulphate, filtered and concentrated under reduced pressure. Purification via flash chromatography 
(10% ethyl acetate in hexane) gave 193 as a clear oil (260 mg, 38%).  
 
 
A stirred suspension of 204 (930 mg, 2.80 mmol, 1.1 eq.) in anhydrous toluene (20 mL) was cooled to 
0 ᵒC and n-BuLi (1.1 mL, 2.80 mmol, 1.1 eq, 2.5 M in hexane.) was added dropwise. The reaction 
mixture was stirred at room temperature for 1 hour and cooled to -78 ᵒC. 166 (500 mg, 2.57 mmol, 1 
eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 hours. The 
reaction was quenched with water (10 mL) and products extracted with diethyl ether (3 x 10 mL). 
Organic extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over sodium 
sulphate, filtered and concentrated under reduced pressure. Purification via flash chromatography 
(10% ethyl acetate in hexane) gave 193 as a clear oil (227 mg, 31%).  
 
 
A stirred solution of ethyl 2-(diethoxyphosphoryl)acetate 202 (865 mg, 3.9 mmol, 1.5 eq.) in 
anhydrous tetrahydrofuran (20 mL) was cooled to 0 ᵒC and n-butyl lithium (1.54 mL, 3.9 mmol, 1.5 
eq., 2.5M in hexanes) was added dropwise. The resulting solution was stirred at room temperature 
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for 1 hour, cooled to -78 ᵒC and 166 (500 mg, 2.6 mmol, 1 eq.) added dropwise.  The reaction 
mixture was stirred for 16 hours at room temperature. The reaction was quenched with water (10 
mL) and the product was extracted with diethyl ether (3 x 20 mL). The combined organic phases 
were washed with water (3 x 10 mL) and brine (2 x 10 mL), then dried over sodium sulphate, filtered 
and the solvent removed under reduced pressure. Purification via flash chromatography on silica gel 
(2% ethyl acetate in hexane) provided ester 193 as a clear oil (82 mg, 12 %). 
 
 
A stirred solution of ethyl 2-(diphenoxyphosphoryl)acetate 203 (1.85 g, 5.77 mmol, 1.5 eq.) in 
anhydrous tetrahydrofuran (40 mL) was cooled to 0 ᵒC and n-butyl lithium (2.3 mL, 5.77 mmol, 1.5 
eq., 2.5M in hexanes) was added dropwise. The resulting solution was stirred at room temperature 
for 1 hour, cooled to 0 ᵒC and 166 (750 mg, 38.5 mmol, 1 eq.) added dropwise. The reaction mixture 
was stirred for 16 hours at room temperature. The reaction was quenched with water (10 mL) and 
the product was extracted with diethyl ether (3 x 20 mL). The combined organic phases were 
washed with water (3 x 20 mL) and brine (3 x 20 mL), then dried over sodium sulphate, filtered and 
the solvent removed under reduced pressure. Purification via flash chromatography on silica gel (2% 
ethyl acetate in hexane) provided ester 193 as a clear oil (214 mg, 21 %). 
 
 
A stirred solution of 203 (1.85 g, 5.8 mmol, 1.5 eq.) in anhydrous tetrahydrofuran (50 mL) was cooled 
to 0 ᵒC and n-butyl lithium (2.3 mL, 5.8 mmol, 1.5 eq., 2.5M in hexanes) was added dropwise. The 
resulting solution was stirred at room temperature for 1 hour, cooled to -78 ᵒC and 166 (750 mg, 
3.85 mmol, 1 eq.) added dropwise.  The reaction mixture was stirred for 16 hours at room 
temperature. The reaction was quenched with water (20 mL) and the product was extracted with 
diethyl ether (40 mL). The combined organic phases were washed with water (3 x 10 mL) and brine 
(3 x 10 mL), then dried over sodium sulphate, filtered and the solvent removed under reduced 
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pressure. Purification via flash chromatography on silica gel (2% ethyl acetate in hexane) provided 
ester 193 as a clear oil (217 mg, 21%). 
 
 
A stirred suspension of sodium hydride (990 mg, 24.8 mmol, 1.7 eq.) in anhydrous toluene (30 mL) 
was cooled to 0 ᵒC and 203 (7.0 g, 21.9 mmol, 1.5 eq.) was added dropwise. The reaction mixture 
was stirred at room temperature for 1 hour and cooled to 0 ᵒC. 166 (2.83 g, 14.6 mmol, 1 eq.) was 
added dropwise and the reaction mixture stirred at room temperature for 16 hours. The reaction 
was quenched with water (20 mL) and products extracted with diethyl ether (3 x 20 mL). Organic 
extracts were washed with water (3 x 20 mL) and brine (20 mL), dried over sodium sulphate, filtered 
and concentrated under reduced pressure. Purification via flash chromatography (2% ethyl acetate 
in hexane) gave 193 as a clear oil (386 mg, 29%).  
 
 
A stirred suspension of sodium hydride (990 mg, 24.8 mmol, 1.7 eq.) in anhydrous toluene (30 mL) 
was cooled to 0 ᵒC and 203 (7.0 g, 21.9 mmol, 1.5 eq.) was added dropwise. The reaction mixture 
was stirred at room temperature for 1 hour and cooled to -78 ᵒC. 166 (2.83 g, 14.6 mmol, 1 eq.) was 
added dropwise and the reaction mixture stirred at room temperature for 16 hours. The reaction 
was quenched with water (20 mL) and products extracted with diethyl ether (3 x 20 mL). Organic 
extracts were washed with water (3 x 20 mL) and brine (20 mL), dried over sodium sulphate, filtered 
and concentrated under reduced pressure. Purification via flash chromatography (2% ethyl acetate 
in hexane) gave 193 as a clear oil (309 mg, 23%).  
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A stirred solution of 202 (630 mg, 2.57 mmol, 1 eq.) in anhydrous tetrahydrofuran (20 mL) was 
cooled to 0 ᵒC and n-butyl lithium (1.1 mL, 2.83 mmol, 1.1 eq., 2.5M in hexanes) was added 
dropwise. The resulting solution was stirred at room temperature for 1 hour, cooled to 0 ᵒC and 166 
(500 mg, 2.57 mmol, 1 eq.) added dropwise.  The reaction mixture was stirred for 16 hours at room 
temperature. The reaction was quenched with water (5 mL) and the product was extracted with 
diethyl ether (3 x 10 mL). The combined organic phases were washed with water (3 x 10 mL) and 
brine (10 mL), then dried over sodium sulphate, filtered and the solvent removed under reduced 
pressure. Purification via flash chromatography on silica gel (2% ethyl acetate in hexane) provided 
ester 193 as a clear oil (93 mg, 14%). 
 
 
A stirred suspension of sodium hydride (185 mg, 7.72 mmol, 3 eq.) in anhydrous tetrahydrofuran (20 
mL) was cooled to 0 ᵒC and 202 (630 mg, 2.80 mmol, 1.1 eq.) was added dropwise. The reaction 
mixture was stirred at room temperature for 1 hour and cooled to 0 ᵒC. 166 (500 mg, 2.57 mmol, 1 
eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 hours. The 
reaction was quenched with water (10 mL) and products extracted with diethyl ether (3 x 10 mL). 
Organic extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over sodium 
sulphate, filtered and concentrated under reduced pressure. Purification via flash chromatography 
(10% ethyl acetate in hexane) gave 193 as a clear oil (116 mg, 17%).  
 
 
A stirred solution of 202 (630 mg, 2.80 mmol, 1.1 eq.) in anhydrous tetrahydrofuran (20 mL) was 
cooled to 0 ᵒC and lithium diisopropylamide (827 mg, 7.72 mmol, 3 eq.) was added dropwise. The 
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resulting solution was stirred at room temperature for 1 hour, cooled to 0 ᵒC and 166 (500 mg, 2.57 
mmol, 1 eq.) added dropwise.  The reaction mixture was stirred for 16 hours at room temperature. 
The reaction was quenched with water (10 mL) and the product was extracted with diethyl ether (3 x 
10 mL). The combined organic phases were washed with water (3 x 10 mL) and brine (3 x 10 mL), 
then dried over sodium sulphate, filtered and the solvent removed under reduced pressure. 
Purification via flash chromatography on silica gel (2% ethyl acetate in hexane) provided ester 193 as 
a clear oil (56 mg, 8%). 
 
 
A stirred suspension of Potassium bis(trimethylsilyl)amide (7.7 mL mg, 7.72 mmol, 3 eq.) and 
18-crown-6 (2.04 g, 7.72 mmol, 3 eq.) in toluene (20 mL) was cooled to 0 ᵒC and 202 (630 mg, 2.83 
mmol, 1.1 eq.) was added dropwise. The reaction mixture was stirred at room temperature for 1 
hour and cooled to 0 ᵒC. 166 (500 mg, 2.57 mmol, 1 eq.) was added dropwise and the reaction 
mixture stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) 
and products extracted with diethyl ether (3 x 10 mL). Organic extracts were washed with water (3 x 
10 mL) and brine (3 x 10 mL), dried over sodium sulphate, filtered and concentrated under reduced 
pressure. Purification via flash chromatography (2% ethyl acetate in hexane) gave 193 as a clear oil 
(75 mg, 11%).  
 
 
A stirred solution of ethyl 2-(diethoxyphosphoryl)acetate 202 (865 mg, 3.9 mmol, 1.5 eq.) in 
anhydrous toluene (20 mL) was cooled to 0 ᵒC and n-butyl lithium (1.54 mL, 3.9 mmol, 1.5 eq., 2.5M 
in hexanes) was added dropwise. The resulting solution was stirred at room temperature for 1 hour, 
cooled to 0 ᵒC and 166 (500 mg, 2.6 mmol, 1 eq.) added dropwise.  The reaction mixture was stirred 
for 16 hours at room temperature. The reaction was quenched with water (10 mL) and the product 
was extracted with diethyl ether (3 x 20 mL). The combined organic phases were washed with water 
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(3 x 10 mL) and brine (2 x 10 mL), then dried over sodium sulphate, filtered and the solvent removed 
under reduced pressure. Purification via flash chromatography on silica gel (2% ethyl acetate in 
hexane) provided ester 193 as a clear oil (84 mg, 14%). 
 
 
A stirred suspension of sodium hydride (185 mg, 7.72 mmol, 3 eq.) in anhydrous toluene (20 mL) was 
cooled to 0 ᵒC and 202 (630 mg, 2.80 mmol, 1.1 eq.) was added dropwise. The reaction mixture was 
stirred at room temperature for 1 hour and cooled to 0 ᵒC. 166 (500 mg, 2.57 mmol, 1 eq.) was 
added dropwise and the reaction mixture stirred at room temperature for 16 hours. The reaction 
was quenched with water (10 mL) and products extracted with diethyl ether (3 x 10 mL). Organic 
extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. Purification via flash chromatography (10% ethyl 
acetate in hexane) gave 193 as a clear oil (130 mg, 19%).  
 
 
A stirred suspension of sodium hydride (185 mg, 7.72 mmol, 3 eq.) in anhydrous toluene (20 mL) was 
cooled to 0 ᵒC and 202 (630 mg, 2.80 mmol, 1.1 eq.) was added dropwise. The reaction mixture was 
stirred at room temperature for 1 hour and cooled to -78 ᵒC. 166 (500 mg, 2.57 mmol, 1 eq.) was 
added dropwise and the reaction mixture stirred at room temperature for 16 hours. The reaction 
was quenched with water (10 mL) and products extracted with diethyl ether (3 x 10 mL). Organic 
extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. Purification via flash chromatography (10% ethyl 
acetate in hexane) gave 193 as a clear oil (123 mg, 18%).  
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Preparation of (2Z, 6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (167): 
 
 
Diisobutylaluminimiun hydride (6.9 mL, 6.93 mmol, 3 eq.) was added to a stirred solution of 193 (604 
mg, 2.28 mmol, 1 eq.) in anhydrous toluene (20 mL) at -78 ᵒC. The reaction was stirred for 3 hours at 
-78 ᵒC and quenched with saturated potassium sodium tartrate solution (20 mL). Reaction products 
were extracted with dichloromethane (3 x 30 mL). Combined organic extracts were washed with 
water (3 x 20 mL), brine (2 x 20 mL), dried over sodium sulphate and concentrated under reduced 
pressure. Purification via flash chromatography on silica gel (5% ethyl acetate in hexane) to yield 167 
as a clear oil (0.487 g, 96%). 
1H NMR (300 MHz, CDCl3) δ 5.38 (1H, t, J = 7.2 Hz CCHCH2O), 5.07 – 5.01 (2H, m, 2 x (CH3)CCH), 4.02 
(2H, d, J = 7.2 Hz, CHCH2OH), 2.07 – 2.00 (4H, m, 2 x allylic CH2), 1.99 – 1.90 (4H, m, 2 x allylic CH2), 
1.68 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3)
 δ 140.0 
((CH3)CCHCH2O), 136.2 & 131.7 (2 x (CH3)CCH), 124.5 (CCHCH2O), 124.4 & 124.2 (2 x (CH3)CCH), 59.0 
(CHCH2O), 32.2 & 31.9 & 26.6 & 26.3 (4 x allylic CH2), 25.7 (CH3), 23.5 & 23.3 ((2 x (CH3)CCH), 17.7 
(CH3). LRMS (EI
+): 204.19 (75% [M – H2O]), 189.17 (40%), 161.13 (90%), 133.10 (35%), 119.08 (100%), 
105.07 (55%), 93.07 (80%), 69.07 (17%). HRMS (EI+): calculated for [C15H24][M –H2O]; 204.1878, 
found 204.1879. 
Table 9. 2D proton NMR correlations revealing spatial arrangement in 167 
167: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.38 4.02 
5.38 1.68 
5.05 2.04 
5.05 1.93 
5.05 1.58 
4.02 2.04 
 
  
214 
 
Preparation of (2Z,6Z)-1-bromo-3,7,11-trimethyldodeca-2,6,10-triene (169): 
 
 
Phosphorus tribromide (15 µL, 0.158 mmol, 1 eq.) was added dropwise to a stirred solution of 
(2Z,6Z) farnesol (167)(70 mg, 0.315 mmol, 2 eq.) in anhydrous tetrahydrofuran (3 mL) at -10 ᵒC. The 
solution was stirred for 15 minutes and concentrated under vaccuo. The residue was dissolved in 
diethyl ether (5 mL) and washed with sodium hydrogen carbonate (3 x 10 mL), water (3 x 10 mL) and 
brine (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The 
product was dried under vacuum for a further 2 hours to yield bromide as a pale yellow oil (90 mg, 
100%) which was used without further purification.  
1H NMR (300 MHz, CDCl3) δ 5.47 (1H, t, J = 8.6 Hz, CHCH2Br), 5.08 – 4.97 (2H, m, 2 x CCHCH2), 3.94 
(2H, d, J = 8.6 Hz, CH2Br), 2.11 – 2.03 (4H, m, 2 x allylic CH2), 2.01 – 1.96 (4H, m, 2 x allylic CH2) 1.71 
(3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.55 (3H, s, CH3). 
Preparation of (2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (38): 
 
 
A stirred solution of (2Z,6Z) farnesyl bromide (169)(90 mg, 0.315 mmol, 1 eq.) in anhydrous 
acetonitrile (5 mL) was added tris tetrabutyl ammonium pyrophosphate (569 g,0.473 mmol, 1.5 eq.) 
and stirred at room temperature overnight. The reaction mixture was concentrated under reduced 
pressure and the resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) 
and the tris tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange 
column containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with 
ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected 
and lyophilized to yield (2Z,6Z) farnesyl diphosphate (38) as a white powder. The powder was 
dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent A: 
acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give 
(2Z, 6Z) farnesyl diphosphate (38) as a white powder (107 mg, 30%). 
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1H NMR (400 MHz, D2O) δ 5.32 (1H, t, J = 7.2 Hz, CHCH2O), 5.12 – 5.01 (2H, m, 2 x CCHCH2), 4.30 (2H, 
t, J = 6.9 Hz, CH2O), 2.03 – 1.99 (4H, m, 2 x allylic CH2), 1.97 – 1.92 (4H, m, 2 x allylic CH2) 1.61 (3H, s, 
(CH3)CCHCH2O), 1.54 (6H, s, (CH3)2CCH), 1.48 (3H, s, CH2CH2(CH3)CCH).
13C NMR (150 MHz, CDCl3)
 δ 
142.4 ((CH3)CCHCH2O), 137.2 & 133.7 ((CH3)CCHCH2), 124.9 (CCHCH2O), 121.01 & 120.95 (CCHCH2), 
62.2 (CHCH2O), 31.5 (CH2CH2C(CH3)), 31.1 (CH2CH2C(CH3)), 25.9 ((CH3)2CH2CH2C), 25.8 
((CH3)2CH2CH2C), 24.9 ((CH3)CCH2CHO), 22.6 & 22.4 ((CH3)2CCH), 16.9 (CH2CH2(CH3)CCH).
31P NMR 
(162 MHz, CDCl3) δ -7.11 ( d, J = 21.6 Hz, CH2OP(O)2OP(O)3), -10.46 ( d, J = 21.6 Hz, CH2OP(O)2OP(O)3). 
HRMS (ES-): calculated for [C15H27O7P2][M]; 381.1232, found 381.1229.
 
8.2.2 Synthesis of (2E,6Z) farnesyl diphosphate (342) 
Preparation of ethyl (2E,6Z)-3,7,11-trimethyldodeca-2,6,10-trienoate (192): 
 
 
A stirred solution of 202 (630 mg, 2.57 mmol, 1 eq.) in anhydrous tetrahydrofuran (20 mL) was 
cooled to 0 ᵒC and n-butyl lithium (1.1 mL, 2.83 mmol, 1.1 eq., 2.5M in hexane) was added dropwise. 
The resulting solution was stirred at room temperature for 1 hour, cooled to 0 ᵒC and 166 (500 mg, 
2.57 mmol, 1 eq.) added dropwise. The reaction mixture was stirred for 16 hours at room 
temperature. The reaction was quenched with water (5 mL) and the product was extracted with 
diethyl ether (3 x 10 mL). The combined organic phases were washed with water (3 x 10 mL) and 
brine (3 x 10 mL), then dried over sodium sulphate, filtered and the solvent removed under reduced 
pressure. Purification via flash chromatography on silica gel (2% ethyl acetate in hexane) provided 
ester 192 as a clear oil (372 mg, 56%). 
1H NMR (300 MHz, CDCl3) δ 5.60 (1H, s, CCHC(O)OEt), 5.15 – 4.97 (2H, m, 2 x (CH3)CCH), 4.08 (2H, q, J 
= 7.1 Hz, OCH2CH3), 2.09 (3H, d, J = 1.2 Hz, CH2(CH3)CCHC(O)), 2.10 – 2.06 (4H, m, 2 x allylic CH2), 2.00 
– 1.89 (4H, m, 2 x allylic CH2), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3), 1.22 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.9 (CHC(O)O), 159.8 ((CH3)CCHC(O)O), 136.2 & 131.5 (2 x (CH3)CCH), 
124.2 & 123.7 (2 x (CH3)CCH), 115.6 (CCHC(O)O), 59.5 (OCH2CH3), 41.2 (CH2(CH3)CCHC(O)), 32.0 & 
26.5 (2 x CH2), 25.9 (CH2CH2(CH3)CCHC(O)), 25.7 & 23.3 & 18.8 & 17.6 (4 x CH3), 14.3 (OCH2CH3). 
LRMS (ES+): 265.22 (87% [M + H]), 243.08 (50%), 225.03 (90%), 208.04 (70%), 193.12 (30%), 180.05 
(65%), 171.10 (40%), 147.12 (25%). HRMS (ES+): calculated for [C17H29O2] [M + H]; 265.2168, found 
265.2159. 
216 
 
Preparation of (2E, 6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (168): 
 
 
A stirred solution of 192 (372 mg,1.4 mmol, 1 eq.) in anhydrous toluene (30 mL) was cooled to -78 ᵒC 
and diisobutylaluminium hydride (4.2 mL, 4.22 mmol, 3 eq.) was added dropwise. The reaction was 
stirred at -78 ᵒC for 4 hours and warmed to 0 ᵒC. Reaction was quenched with Rochelle salts (10 mL) 
and products extracted with dichloromethane (4 x 20 mL). Organic extracts were washed with water 
(3 x 20 mL) and brine (2 x 20 mL), dried over sodium sulphate, filtered and concentrated under 
reduced pressure. Purification of 168 via flash chromatography on silica gel (10% ethyl acetate in 
hexane) to yield 168 as a clear oil (303 mg, 97%). 
1H NMR (500 MHz, CDCl3) δ 5.35 (1H, t, J = 6.9, CCHCH2O), 5.07 – 5.02 (2H, m, 2 x (CH3)CCH), 4.09 
(2H, d, J = 6.9 Hz, CHCH2OH), 2.09 – 1.89 (8H, m, 4 x allylic CH2), 1.62 (3H, s, CH3), 1.62 (3H, s, CH3), 
1.61 (3H, s, CH3), 1.54 3H, s, CH3). 
13C NMR (126 MHz, CDCl3) δ 139.8 ((CH3)CCHCH2O), 135.6 & 131.6 
((2 x CH3)CCH), 124.6 (CCHCH2O), 124.3 & 123.3 (2 x (CH3)CCH), 59.4 (CHCH2O), 39.8 & 32.0 & 26.6 & 
26.2 (4 x allylic CH2), 25.7 & 23.4 & 17.7 & 16.3 (4 x CH3). LRMS (ES
+): 205.20 (100% [M – H2O]), 
143.10 (10%), 123.96 (7%) HRMS (ES+): calculated for [C15H25] [M – H2O]; 205.1956, found 205.1964. 
 
Table 10. 2D proton NMR correlations revealing spatial arrangement in 168 
168: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.35 4.09 
5.35 2.01 
5.04 2.01 
5.04 1.62 
4.09 1.62 
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Preparation of (2E,6Z)-1-bromo-3,7,11-trimethyldodeca-2,6,10-triene (345): 
 
 
To a stirred solution of (2E,6Z) farnesol (168) (303 mg, 1.36 mmol, 2 eq.) in anhydrous 
tetrahydrofuran (20 mL) was added phosphorus tribromide (64 µL, 0.68 mmol, 1 eq.) dropwise at -10 
ᵒC. The reaction mixture was stirred at -10ᵒC for 30 minutes and concentrated under vaccuo. The 
concentrate was dissolved in diethyl ether (20 mL). The organic extracts were washed with saturated 
sodium bicarbonate solution (3 x 10 mL), water (3 x 10 mL) and brine (2 x 10 mL). Organic layers 
were dried over sodium sulphate, filtered and concentrated under reduced pressure to give bromide 
(345) as a pale yellow oil (377 mg, 97%) which was used without further purification. 
1H NMR (500 MHz, CDCl3) δ 5.39 (1H, t, J = 8.4, CCHCH2Br), 5.07 – 5.02 (2H, m, 2 x (CH3)CCH), 4.09 
(2H, d, J = 8.4 Hz, CHCH2Br), 2.11 – 1.88 (8H, m, 4 x allylic CH2), 1.62 (3H, s, CH3), 1.61 (3H, s, CH3), 
1.61 (3H, s, CH3), 1.54 (3H, s, CH3). 
 
Preparation of (2E, 6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (342): 
 
 
A mixture of (2E,6Z) farnesyl bromide (345) (377 mg, 1.32 mmol, 1 eq.) and tris tetrabutyl 
ammonium pyrophosphate (2.39 g,2.64 mmol, 2 eq.) in anhydrous acetonitrile (10 mL) was stirred at 
room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and 
the resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (10 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield (2E,6Z) farnesyl diphosphate as a white powder. The powder was dissolved in 
buffer solution (10 mL)(25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent A: 
acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give 
(2E,6Z) farnesyl diphosphate as a white powder (20 mg, 3%). 
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1H NMR (400 MHz, D2O) δ 5.34 (1H, t, J = 7.2 Hz, CHCH2O), 5.13 – 5.05 (2H, m, 2 x CCHCH2), 4.31 (2H, 
t, J = 6.8 Hz, CH2O), 2.05 – 1.99 (4H, m, 2 x allylic CH2), 1.96 – 1.91 (4H, m, 2 x allylic CH2) 1.61 (3H, s, 
(CH3)CCHCH2O), 1.54 (6H, s, (CH3)2CCH), 1.49 (3H, s, CH2CH2(CH3)CCH).
 31P NMR (162 MHz, CDCl3) δ -
7.33 ( d, J = 23.2 Hz, CH2OP(O)2OP(O)3), -10.51 ( d, J = 23.2 Hz, CH2OP(O)2OP(O)3). HRMS (ES
-): 
calculated for [C15H27O7P2][M]; 381.1232, found 381.1233. 
 
8.2.3 Synthesis of (2Z,6E) farnesyl diphosphate (341) 
Preparation of (E)-1-bromo-3,7-dimethylocta-2,6-diene (347): 
 
 
Geraniol (63) (8 g, 51.9 mmol, 2 eq.) in anhydrous tetrahydrofuran (30 mL) was cooled to -10 ᵒC and 
phosphorus tribromide (7.02 g, 25.9 mmol, 1 eq.) added dropwise. Reaction mixture was stirred 
at -10 ᵒC for 20 minutes and quenched with sat. sodium bicarbonate (20 mL). Reaction product was 
extracted with diethyl ether (3 x 15 mL). Organic extracts were washed with water (3 x 10 mL), brine 
(3 x 10 mL), dried over sodium sulphate, filtered and concentrated under reduced pressure to give 
347 (11.3 g, 100%) as a pale yellow oil which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.54 (1H, t, J = 8.5, CCHCH2Br), 5.12 – 5.04 (1H, m, (CH3)CCH), 4.04 (2H, 
d, J = 8.5 Hz, CHCH2Br), 2.17 – 2.03 (4H, m, 2 x allylic CH2), 1.74 (3H, s, CH3), 1.69 (3H, s, CH3), 1.61 
(3H, s, CH3). 
Preparation of ethyl (E)-2-acetyl-5,9-dimethyldeca-4,8-dienoate (348): 
 
 
Crude bromide 347 (11.26 g, 51.9 mmol, 1 eq.) and ethyl acetoacetate (13.49 g, 103.7 mmol, 2 eq.) 
were dissolved in anhydrous acetone (50 mL). Potassium carbonate (17.9 g, 129.7 mmol, 2.5 eq.) 
was added the suspension was refluxed for 4 hours at 60 ᵒC. The reaction mixture was concentrated 
under reduced pressure and reaction products dissolved in diethyl ether (30 mL). Ethereal layer was 
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washed with water (3 x 20 mL) and brine (20 mL), dried over sodium sulphate and concentrated 
under vaccuo. Reaction product was purified by flash chromatography on silica gel (20% ethyl 
acetate in hexane) to give 348 as a clear oil (13.8 g, 99%). 
1H NMR (300 MHz, CDCl3) δ 5.08 – 5.01 (2H, m, 2 x (CH3)CCH), 4.19 (2H, q, J= 7.1 Hz, CH3CH2O), 3.45 
(1H, t, J= 7.5 Hz, COCHCO), 2.56 (2H, t, J= 7.4 Hz, CCHCH2CH), 2.23 (3H, s, COCH3), 2.10 – 1.92 (4H, m, 
2 x allylic CH2), 1.67 (3H, s, CH3), 1.63 (3H, s, CH3), 1.59 (3H, s, CH3), 1.27 (3H, t, J= 7.1 Hz,CH3CH2O). 
13C NMR (75 MHz, CDCl3) δ 203.3 (CH3CH2OC(O)), 169.6 (CH3COCH), 138.4 & 131.6 (2 x (CH3)CCH), 
124.0 & 119.6 (2 x CH3CCH), 61.4 (CH3CH2O), 59.8 (C(O)CHC(O)), 39.7 (allylic CH2), 29.2 (CH3C(O)), 
26.9 (CCHCH2CH), 26.5 (allylic CH2), 25.7 & 17.7 & 16.1 (3 x CH3), 14.1 (OCH2CH3). LRMS (ES
-): 265.18 
(100% [M - H]), 243.12 (25%), 213.00 (55%), 203.06 (10%), 187.06 (65%), 171.07 (10%), 141.02 
(35%), 116.91 (30%). HRMS (ES+): calculated for [C16H25O3] [M – H
+]; 265.1804, found 265.1797. 
 
Preparation of (E)-6,10-dimethylundeca-5,9-dien-2-one (349): 
 
 
To a solution of 348 (13.8 g, 51.9 mmol, 1 eq.) in methanol (50 mL) was added potassium hydroxide 
(8.73 g, 155.6 mmol, 3 eq.) and the reaction mixture was refluxed at 65 ᵒC for 2 hours. The reaction 
mixture was cooled to room temperature and acidified with dilute hydrochloric acid (1 M, 10 mL). 
Organic products were extracted with diethyl ether (30 mL) and combined ethereal layers were 
washed with water (3 x 20 mL) and brine (30 mL). Organic layers were dried over anhydrous sodium 
sulphate, filtered and concentrated under reduced pressure. Purification via flash chromatography 
on silica gel (10% ethyl acetate in hexane) gave 349 as a clear oil (9.37 g, 93%). 
1H NMR (300 MHz, CDCl3) δ 5.04 – 4.96 (2H, m, 2 x (CH3)CCH), 2.39 (2H, t, J = 7.3 Hz, CH2C(O)), 2.19 
(2H, dd, J = 14.6, 7.2 Hz, CH2CH2C(O)), 2.07 (3H, s, CH2C(O)CH3), 2.02 – 1.86 (4H, m,2 x allylic CH2), 
1.60 (3H, s, (CH3)CCH), 1.54 (3H, s, (CH3)CCH), 1.52 (3H, s, (CH3)CCH). 
13C NMR (75 MHz, CDCl3) δ 
209.1 (CH3C(O)), 136.4 & 131.5 (2 x (CH3)CCH), 124.2 & 122.5 (2 x (CH3)CCH), 43.8 (CH2CH2C(O)), 39.6 
& 26.6 & 22.5 (3 x allylic CH2), 30.0 (CH3C(O)) 25.7 (CH3), 17.7 & 16.0 (2 x CH3). LRMS (ES
+): 195.17 
(60% [M + H]), 177.16 (100%), 137.13 (5%), 123.97 (4%), 121.09 (4%), 109.10 (4%). HRMS (ES+): 
calculated for [C13H23O] [M + H]; 195.1749, found 195.1745. 
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Preparation of ethyl (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trienoate (350): 
 
 
A stirred suspension of sodium hydride (161 mg, 6.74 mmol, 1.5 eq.) in anhydrous toluene (30 mL) 
was cooled to 0 ᵒC and ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (2.24, 6.74 mmol, 1.5 
eq.) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour and 
cooled to 0 ᵒC. Geranyl acetone (872 mg, 4.49 mmol, 1 eq.) was added dropwise and the reaction 
mixture stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) 
and products extracted with diethyl ether (30 mL). Organic extracts were washed with water (3 x 10 
mL) and brine (20 mL), dried over sodium sulphate, filtered and concentrated under reduced 
pressure. Purification via flash chromatography (5% ethyl acetate in hexane) gave 350 as a clear oil 
(205 mg, 22%).  
1H NMR (500 MHz, CDCl3) δ 5.66 (1H, s, CCHC(O)OEt), 5.12 – 5.05 (2H, m, 2 x (CH3)CCH), 4.14 (2H, q, J 
= 7.1 Hz, OCH2CH3), 2.67 – 2.62 (2H, m, CH2(CH3)CCHC(O)), 2.21 – 2.15 (2H, m, CH2CH2(CH3)CCHC(O)), 
2.09 – 2.02 (4H, m, 2 x allylic CH2), 1.89 (3H, d, J = 1.3 Hz, CH2(CH3)CCHC(O)), 1.68 (6H, s, 2 x CH3), 
1.60 (3H, s, CH3), 1.27 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.4 (CHC(O)O), 160.3 
((CH3)CCHC(O)O), 135.8 & 131.5 (2 x (CH3)CCH), 124.3 & 124.2 (2 x (CH3)CCH), 116.2 (CCHC(O)O), 
59.5 (OCH2CH3), 33.4 (CH2(CH3)CCHC(O)) 26.7 (allylic CH2), 25.9 (CH2CH2(CH3)CCHC(O)), 25.7 (allylic 
CH2), 25.4 & 18.8 & 17.7 & 16.0 (4 x CH3), 14.35 (OCH2CH3). LRMS (ES
+): 265.22 (100% [M + H]), 
243.08 (10%), 219.17 (5%), 215.05 (2%), 191.18 (5%), 183.13 (5%). HRMS (ES+): calculated for 
[C17H29O2] [M + H]; 265.2168, found 265.2162. 
Preparation of (2Z, 6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (352): 
 
 
350 (205 mg, 0.78 mmol, 1 eq.) in anhydrous toluene (10 mL) was cooled to -78 ᵒC and diisobutyl 
aluminium hydride added dropwise. The reaction was stirred until complete consumption of starting 
material was observed via TLC (20% ethyl acetate in hexane). Reaction was warmed to 0 ᵒC, 
quenched with Rochelle salts (5 mL) and stirred at room temperature for 16 hours. Organic products 
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were extracted with dichloromethane (3 x 10 mL) and combined organic layers washed with water (3 
x 10 mL) and brine (3 x 10 mL). Organic extracts were dried over sodium sulphate, filtered and 
concentrated under reduced pressure. Purification via flash chromatography over silica (5% ethyl 
acetate in hexane) gave 352 as a clear oil (162 mg, 94%). 
1H NMR (500 MHz, CDCl3) δ 5.37 (1H, t, J = 7.1 Hz CCHCH2O), 5.06 – 5.00 (2H, m, 2 x (CH3)CCH), 4.04 
(2H, t, J = 7.1 Hz, CHCH2OH), 2.07 – 1.96 (6H, m, 3 x allylic CH2), 1.94 – 1.88 (2H, m, allylic CH2), 1.69 
(3H, s, CH3), 1.61 (3H, s, CH3), 1.53 (6H, s, 2 x CH3). 
13C NMR (126 MHz, CDCl3) δ 140.1 
((CH3)CCHCH2O), 136.0 & 131.5 (2 x (CH3)CCH), 124.4 (CCHCH2O), 124.2 & 123.6 (2 x (CH3)CCH), 59.1 
(CHCH2O), 39.7 & 32.0 & 26.7 & 26.5 (4 x allylic CH2), 25.7 (CH3), 23.5 (CH3), 17.7 & 16.0 (2 x 
(CH3)CCH). LRMS (EI
+): 222.20 (2% [M]), 204.17 (100%), 189.16 (65%), 161.13 (70%), 133.10 (40%), 
119.08 (75%), 107.08 (40%), 93.06 (95%), 69.07 (30%) HRMS (EI+): calculated for [C15H26O] [M]; 
222.1984, found 222.1982. 
Table 11. 2D proton NMR correlations revealing spatial arrangement in 352 
352: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.37 4.04 
5.37 1.69 
5.03 2.02 
5.03 1.90 
5.03 1.69 
5.03 1.61 
5.03 1.53 
4.04 2.02 
 
Preparation of (2Z,6E)-1-bromo-3,7,11-trimethyldodeca-2,6,10-triene (354): 
 
 
Phosphorus tribromide (200 µL, 0.26, 1 eq.) was added to a stirred solution of 352 (114 mg, 0.51 
mmol, 2 eq.) in anhydrous tetrahydrofuran (10 mL) at -10 ᵒC. The reaction proceeded for 15 minutes 
at which point complete consumption of starting material was observed via TLC (20% ethyl acetate 
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in hexane). Volatile solvents were removed under reduced pressure and the residue dissolved in 
diethyl ether (10 mL). Organic extracts were washed with sat. sodium bicarbonate sol. (3 x 5 mL), 
water (3 x 5 mL) and brine (2 x 5 mL). Ethereal extracts were dried over sodium sulphate, filtered 
and concentrated under vaccuo to give 354 as a crude yellow oil (146 mg, 100%) which was used 
without further purification.  
1H NMR (500 MHz, CDCl3) δ 5.47 (1H, t, J = 8.3 Hz, CCHCH2Br), 5.09 – 5.00 (2H, m, 2 x (CH3)CCH), 3.94 
(2H, d, J = 8.3 Hz, CHCH2Br), 2.12 – 2.04 (4H, m, 2 x allylic CH2), 2.01 – 1.91 (4H, m, 2 x allylic CH2), 
1.71 (3H, s, CH3), 1.62 (3H, s, CH3), 1.55 (3H, s, CH3), 1.54 (3H, s, CH3). 
Preparation of (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (341): 
 
 
Tris tetra butyl ammonium pyrophosphate (694 mg, 0.76 mmol, 1.5 eq.) in anhydrous acetonitrile (5 
mL) was added to crude bromide 354 (146 mg, 0.51 mmol, 1 eq.) under argon. The reaction was 
stirred for 16 hours at room temperature and volatile solvents removed under reduced pressure to 
give crude diphosphate as a brown oil. Crude diphosphate was dissolved in buffer solution (25 mM 
NH4HCO3, 2% iPrOH) (3 mL) and the tris tetrabutylammonium salt counter ions were exchanged for 
ammonium by ion exchange column containing Amberlyst 131 (wet H+ form) mesh cation exchange 
resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate 
fractions were collected and lyophilized to yield (2Z,6E) farnesyl diphosphate (341) as a white 
powder. The powder was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and 
purified using HPLC (Solvent A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were 
collected and lyophilized to give (2Z,6E) farnesyl diphosphate as a white powder. (52 mg, 23%). 
1H NMR (400 MHz, D2O) δ 5.32 (1H, t, J = 7.2 Hz, CHCH2O), 5.17 – 5.07 (2H, m, 2 x (CH3)CCH),  4.30 
(2H, t, J = 6.9 Hz, CH2O), 2.16 – 2.03 (4H, m, 2 x allylic CH2), 2.03 – 1.92 (4H, m, 2 x allylic CH2), 1.54 
(6H, s, (CH3)2CCH), 1.48 (3H, s, CH2CH2(CH3)CCH).
 31P NMR (162 MHz, CDCl3) δ -7.11 (d, J = 23.6 
Hz), -10.46 (d, J = 20.2 Hz). HRMS (ES-): calculated for [C15H27O7P2][M]; 381.1232, found 381.1237. 
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8.2.4 Synthesis of (2E,6E) farnesyl diphosphate (31) 
Preparation of ethyl (6E)-3,7,11-tromethyldodeca-2,6,10-trienoate (351): 
 
 
n-Butyl lithium (5.3 mL, 13.17 mmol, 1.5 eq., 2.5 M in hexane) was added to dropwise to a stirred 
solution of triethyl phosphonoacetate (202) (4.37 g, 13.17 mmol, 1.5 eq.) in anhydrous 
tetrahydrofuran (50 mL) at 0 ᵒC. The reaction was stirred at room temperature for 1 hour and cooled 
to 0 ᵒC prior to the dropwise addition of 349 (1.71 g, 8.78 mmol, 1 eq.). Reaction was stirred for 16 
hours at room temperature and quenched with water (20 mL). Organic products were extracted with 
diethyl ether (3 x 20 mL) and washed with water (3 x 20 mL), brine (3 x 20 mL) and dried over sodium 
sulphate. Organic layers were filtered and concentrated under reduced pressure. Purification via 
flash chromatography (10% ethyl acetate in hexane) gave a mixture of esters 350 and 351 as a clear 
oil (1.54 g, 66%). Flash chromatography (5% ethyl acetate in hexanes) partially separated esters 350 
and 351 for analysis.  
1H NMR (500 MHz, CDCl3) δ 5.64 (1H, s, CCHC(O)OEt), 5.16 – 5.02 (2H, m, 2 x (CH3)CCH), 4.14 (2H, q, J 
= 7.1 Hz, OCH2CH3), 2.16 (3H, d J = 1.1 Hz, CH2(CH3)CCHC(O)), 2.21 – 2.11 (4H, m, 2 x allylic CH2), 2.07 
– 1.94 (4H, m, 2 x allylic CH2), 1.68 (3H, s, CH3), 1.60 (6H, s, 2 x CH3), 1.27 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.95 (CHC(O)O), 159.92 ((CH3)CCHC(O)O), 136.14 & 131.37 (2 x 
(CH3)CCH), 123.51 & 122.89 (2 x (CH3)CCH), 115.59 (CCHC(O)O), 59.49 (OCH2CH3), 40.98 & 39.68 & 
26.65 & 25.94 (4 x allylic CH2), 25.73 & 18.83 & 17.71 & 15.99 (4 x CH3), 14.35 (OCH2CH3). LRMS (ES
+): 
265.22 (100% [M + H]), 243.08 (20%), 219.17 (15%), 215.05 (12%), 191.18 (25%), 183.13 (15%). 
HRMS (ES+): calculated for [C17H29O2] [M + H]; 265.2168, found 265.2173. 
 
Preparation of (2E, 6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (353): 
 
Esters 350 and 351 (1.53 g, 5.79 mmol, 1 eq.) in anhydrous toluene (30 mL) was cooled to -78 ᵒC. 
DIBALH (17.4 mL, 17.38 mmol, 3 eq.) was added dropwise and the reaction stirred until complete 
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consumption of starting material was observed via TLC (20% ethyl acetate in hexanes). The reaction 
was warmed to 0 ᵒC, quenched with Rochelle salts (20 mL) and stirred for 16 hours at room 
temperature. Organic products were extracted with DCM (3 x 20 mL) and washed with water (3 x 20 
mL) and brine (3 x 20 mL). Organic layers were dried over sodium sulphate, filtered and 
concentrated under vaccuo. Purification via flash chromatography (5% ethyl acetate in hexanes) 
gave 353 as a clear oil (0.998 g, 78%).  
1H NMR (300 MHz, CDCl3) δ 5.43 (1H, t, J = 6.9 Hz CCHCH2O), 5.19 – 5.05 (2H, m, 2 x (CH3)CCH), 4.16 
(2H, t, J = 6.9 Hz, CHCH2OH), 2.19 – 1.96 (8H, m, 4 x allylic CH2), 1.69 (6H, s, 2 x CH3), 1.61 (6H, s, 2 x 
CH3). 
13C NMR (75 MHz, CDCl3) δ 139.8 ((CH3)CCHCH2O), 135.4 & 131.4 (2 x (CH3)CCH), 124.3 
(CCHCH2O), 123.8 & 123.3 (2 x (CH3)CCH), 59.4 (CHCH2O), 39.7 & 39.6 & 26.7 & 26.3 (4 x allylic CH2), 
25.7 (CH3), 17.7 (CH3), 16.30 & 16.0 (2 x (CH3)CCH). LRMS (ES
+): 222.20 (2% [M]), 204.19 (40%), 
189.17 (15%), 161.13 (30%), 133.10 (22%), 119.09 (55%), 107.09 (50%), 93.07 (100%), 79.06 (55%), 
69.07 (65%). HRMS (EI+): calculated for [C15H26O] [M]; 222.1984, found 222.1994. 
Table 12. 2D proton NMR correlations revealing spatial arrangement in 353 
353: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.43 4.16 
5.43 1.65 
5.12 2.06 
5.12 1.65 
4.16 1.65 
 
Preparation of (2E,6E)-1-bromo-3,7,11-trimethyldodeca-2,6,10-triene (355): 
 
 
Phosphorus tribromide (26 µL, 0.27 mmol, 1 eq.) was added dropwise to a stirred solution of 353 
(120 mg, 0.54 mmol, 2 eq.) in anhydrous THF (10 mL) at -10 ᵒC. Reaction was quenched with sat. 
sodium bicarbonate sol. (5 mL) upon completion observed via TLC (20% ethyl acetate in hexanes). 
Reaction products were extracted with diethyl ether (3 x 10 mL) and ethereal layers were washed 
with water (3 x 10 mL) and brine (3 x 10 mL). Products were dried over sodium sulphate, filtered and 
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concentrated under reduced pressure to give 355 as a crude yellow oil (153 mg, 100%) which was 
used without further purification.  
1H NMR (300 MHz, CDCl3) δ 5.47 (1H, t, J = 8.4 Hz, CCHCH2Br), 5.06 – 4.98 (2H, m, 2 x (CH3)CCH), 3.96 
(2H, d, J = 8.4 Hz, CHCH2Br), 2.09 – 1.87 (8H, m, 4 x allylic CH2), 1.67 (3H, s, CH3), 1.62 (3H, s, CH3), 
1.53 (3H, s, CH3). 
Preparation of (2E,6E)-1-chloro-3,7,11-trimethyldodeca-2,6,10-triene (356): 
 
 
(2E,6E) Farnesol (353) (200 mg, 0.9 mmol, 1 eq.) in anhydrous dimethylformamide (20 mL) was 
cooled to 0 ᵒC and mesyl chloride (207 mg, 1.8 mmol, 2 eq.) and sec-collidine (654 mg, 5.4 mmol, 6 
eq.) added. The mixture was stirred at 0 ᵒC for 30 min and lithium chloride (165 mg, 3.6 mmol, 4 eq.) 
in anhydrous DMF (5 mL) was added dropwise. The reaction mixture was stirred for 2 hours at 0 ᵒC 
and quenched with dH2O (10 mL). The quenched reaction mixture was diluted with hexane (10 mL) 
and the aqueous layer washed with hexane (3 x 10 mL). Combined organic layers were washed with 
sat. copper sulphate solution (3 x 10 mL), sat. sodium bicarbonate solution (3 x 10 mL) and brine (20 
mL). Organic layers were dried over anhydrous magnesium sulphate, filtered and solvent removed 
under reduced pressure to give chloride 356 as a pale yellow oil (180 mg, 83%). 
1H NMR (500 MHz, CDCl3) δ 5.36 (1H, m, CCHCH2Cl), 5.06 – 4.99 (2H, m, 2 x (CH3)CCH), 3.99 (2H, d, J 
= 7.9 Hz, CHCH2Cl), 2.07 – 2.04 (4H, m, 2 x allylic CH2), 2.03 – 1.96 (4H, m, 2 x allylic CH2), 1.70 (3H, s, 
CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
Preparation of (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate (31): 
 
 
Tris tetra butyl ammonium pyrophosphate (974 mg, 1.08 mmol, 2 eq.) in anhydrous acetonitrile was 
added to crude bromide 355 (154 mg, 0.54 mmol, 1 eq.) under argon. The reaction was stirred for 16 
hours at room temperature and volatile solvents removed under reduced pressure to give crude 
diphosphate as a brown oil. Crude diphosphate was dissolved in buffer solution (25 mM NH4HCO3, 
2% iPrOH) (10 mL) and the tris tetrabutylammonium salt counter ions were exchanged for 
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ammonium by ion exchange column containing Amberlyst 131 (wet H+ form) mesh cation exchange 
resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate 
fractions were collected and lyophilized to yield (2E,6E) farnesyl diphosphate as a white powder. The 
powder was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (10 mL) and purified using 
HPLC (Solvent A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and 
lyophilized to give (2E,6E) farnesyl diphosphate as a white powder (23 mg, 10%).  
1H NMR (500 MHz, D2O) δ 5.43 – 5.33 (1H, m, CCHCH2O), 5.17 – 5.07 (2H, m, 2 x (CH3)CCH), 4.44 – 
4.37 (2H, m, CHCH2O), 2.16 – 2.03 (4H, m, 2 x allylic CH2), 2.03 – 1.92 (4H, m, 2 x allylic CH2), 1.65 
(3H, s, CH3), 1.61 (3H, s, CH3), 1.55 (6H, s, 2 x CH3). 
31P NMR (202 MHz, D2O) δ -8.71 (d, J = 24.5 
Hz), -10.60 (d, J = 20.2 Hz). HRMS (ES-): calculated for [C15H27O7P2][M]; 381.1232, found 381.1235. 
 
8.2.5 Synthesis of neryl diphosphate (39) 
Preparation of (Z)-2-acetyl-5,9-dimethyldeca-4,8-dien-1-yl diphosphate (39): 
 
 
A mixture of neryl bromide (164) (169 mg, 0.78 mmol, 1 eq.) and tris tetrabutyl ammonium 
pyrophosphate (1.05 g, 1.17 mmol, 1.5 eq.) in anhydrous acetonitrile (4 mL) was stirred at room 
temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the 
resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield neryl diphosphate as a white powder. The powder was dissolved in buffer 
solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent A: acetonitrile, solvent 
B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give neryl diphosphate as a 
white powder (12 mg, 4%). 
1H NMR (500 MHz, D2O) δ 5.38 (1H, t, J = 6.6 Hz, CCHCH2O), 5.14 (1H, t, J = 7.0 Hz, (CH3)CCH), 4.91 – 
4.86 (2H, m, CCHCH2O), 2.13 – 1.98 (4H, m, 2 x allylic CH2), 1.67 (3H, s, CH3), 1.63 (3H, s, CH3), 1.55 
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(3H, s, CH3). 
31P NMR (202 MHz, D2O) δ -7.45 (d, J = 19.4 Hz), -11.13 (d, J = 17.2 Hz). HRMS (ES
-): 
calculated for [C10H19O7P2][M]; 313.0606, found 313.0608. 
 
8.2.6 Synthesis of geranyl diphosphate (30) 
Preparation (E)-2-acetyl-5,9-dimethyldeca-4,8-dien-1-yl diphosphate (30): 
 
 
Tris tetra butyl ammonium pyrophosphate (1.16 g, 1.29 mmol, 2 eq.) in anhydrous acetonitrile (10 
mL) was added to crude bromide 347 (140 mg, 0.65 mmol, 1 eq.) under argon. The reaction was 
stirred for 16 hours at room temperature and volatile solvents removed under reduced pressure to 
give crude diphosphate as a brown oil. Crude diphosphate was dissolved in buffer solution (25 mM 
NH4HCO3, 2% iPrOH) (10 mL) and the tris tetrabutylammonium salt counter ions were exchanged for 
ammonium by ion exchange column containing Amberlyst 131 (wet H+ form) mesh cation exchange 
resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate 
fractions were collected and lyophilized to yield geranyl diphosphate as a white powder. The powder 
was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent 
A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give 
geranyl diphosphate as a white powder (27 mg, 11%).  
1H NMR (500 MHz, D2O) δ 5.39 (1H, t, J = 6.5 Hz, CCHCH2O), 5.14 (1H, t, J = 7.0 Hz, (CH3)CCH), 4.40 
(2H, t, J = 6.5 Hz, CCHCH2O), 2.11 – 1.99 (4H, m, 2 x allylic CH2), 1.64 (3H, s, CH3), 1.61 (3H, s, CH3), 
1.55 (3H, s, CH3). 
31P NMR (202 MHz, D2O) δ -7.32 (d, J = 19.4 Hz), -10.40 (d, J = 17.2 Hz). HRMS (ES
-): 
calculated for [C10H19O7P2][M]; 313.0606, found 313.0602. 
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8.2.7 Synthesis of (2E,6Z)-2-fluorofarnesyl diphosphate (230) 
Preparation of ethyl (6Z)-2-fluoro-3,7,11-trimethyldodeca-2,6,10-trienoate (243): 
 
 
2-Fluoro triethyl phosphono acetate  (241)(2.67 g, 11.0 mmol, 1.1 eq.) in anhydrous THF (40 mL) was 
cooled to 0 ᵒC and n-butyl lithium (4.4 mL, 11.0 mmol, 1.1 eq., 2.5 M in hexane) added dropwise. The 
reaction was stirred at room temperature for 1 hour and cooled to 0 ᵒC. Neryl acetone (166) (1.95 g, 
10.0 mmol, 1 eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 
hours. Reaction was quenched with water (20 mL) and reaction products extracted with diethyl 
ether (3 x 20 mL). Combined ethereal layers were washed with water (3 x 20 mL), brine (3 x 20 mL), 
dried over sodium sulphate and filtered. Product was concentrated under reduced pressure and 
purified via flash chromatography (10% ethyl acetate in hexane) gave a mixture of fluorinated esters 
242 and 243 as a clear oil (2.31 g, 82%). Flash chromatography (5% ethyl acetate in hexanes) partially 
separated esters 242 and 243 for analysis.  
1H NMR (300 MHz, CDCl3) δ 5.11 – 4.99 (2H, m, 2 x (CH3)CCH), 4.20 (2H, q, J = 7.1 Hz, OCH2CH3), 2.47 
(2H, ddd, J = 8.1, 5.1, 1.8 Hz, CH2(CH3)CCFC(O)), 2.23 – 2.14 (2H, m, CH2CH2(CH3)CCHC(O)), 2.00 – 
1.88 (4H, m, 2 x allylic CH2), 1.79 (3H, d, J = 4.3 Hz, CH2(CH3)CCHC(O)), 1.62 (6H, s, 2 x CH3), 1.54 (3H, 
s, CH3), 1.27 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 161.3 (CHC(O)O), 153.2 (d, J = 
224.2 Hz, (CH3)CC(F)), 142.0 (d, J = 18.1 Hz, (CH3)CC(F)), 136.5 &, 131.7 (2 x (CH3)CCH), 124.2 & 123.9 
(2 x (CH3)CCH), 61.0 (OCH2CH3), 32.7 (d, J = 7.0 Hz, CH2CH2(CH3)CC(F)), 31.9 & 31.4 (2 x CH2), 26.6 (d, J 
= 2.9 Hz, CH2(CH3)CC(F)), 25.7 & 23.4 & 17.6 (3 x CH3), 16.8 (d, J = 4.6 Hz, (CH3)CC(F)), 14.2 (OCH2CH3). 
19F NMR (376 MHz, CDCl3) δ -126.95. LRMS (EI
+): 282.20 (25% [M]), 262.19 (20%), 218.99 (60%), 
173.13 (55%), 137.13 (75%), 109.10 (85%), 81.17 (100%). HRMS (EI+): calculated for [C17H27O2F][M]; 
282.1995, found 282.1994. 
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Preparation of (2E,6Z)-2-fluoro-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (245): 
 
 
Fluorinated ethyl farnesoates 242 and 243 (2.31 g, 8.2 mmol, 1 eq.) in anhydrous toluene (20 mL) 
were cooled to -78 ᵒC. DIBALH (41 mL, 40.9 mmol, 5 eq.) was added dropwise and stirred until 
reaction completion was observed via TLC (20% ethyl acetate in hexane). Reaction was quenched 
with Rochelle salts (10 mL) at 0 ᵒC and the resultant mixture stirred at room temperature for 16 
hours. Reaction products were extracted using DCM (3 x 10 mL). Combined organic layers were 
washed with water (3 x 10 mL), brine (3 x 10 mL), dried over sodium sulphate, filtered and 
concentrated under reduced pressure. Purification via flash chromatography (5% ethyl acetate in 
hexane) gave 245 as a colourless oil (727 mg, 37%). 
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.06 (2H, m, 2 x (CH3)CCH), 4.21 (2H, d, J = 23.0 Hz, CFCH2OH), 
2.16 – 1.96 (8H, m, 4 x allylic CH2), 1.71 (6H, s, 2 x CH3), 1.70 (3H, s, CH3), 1.62 (3H, s, CH3). 
13C NMR 
(126 MHz, CDCl3) δ 153.6 (d, J = 244.0 Hz, (CH3)CC(F)CH2OH), 136.8 ((CH3)CCH), 131.8 ((CH3)CCH), 
124.1 & 123.9 ((CH3)CCH), 115.8 (d, J = 14.0 Hz, (CH3)CC(F)CH2OH), 57.8 (d, J = 31.6 Hz, C(F)CH2OH), 
32.0 (d, J = 4.9 Hz, CH2(CH3)CC(F)CH2OH), 26.6 & 26.0 (2 x allylic CH2), 26.2 (d, J = 3.0 Hz, 
CH2CH2(CH3)CC(F)CH2OH), 25.7 & 23.3 & 17.7 (3 x CH3), 13.6 (d, J = 8.8 Hz, (CH3)CC(F)CH2OH). 
19F 
NMR (376 MHz, CDCl3) δ -119.40. LRMS (EI
+): 222.18 (25% [M – H2O]), 202.17 (30%), 187.15 (35%), 
137.08 (40%), 105.07 (35%), 91.05 (60%), 81.07 (40%), 69.07 (100%). HRMS (EI+): calculated for 
[C15H23F][M – H2O]; 222.1784, found 222.1787. 
Table 13. 2D proton NMR correlations revealing spatial arrangement in 245 
245: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.09 2.06 
5.09 1.70 
5.09 1.62 
4.21 2.06 
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Preparation of (2E,6Z)-1-bromo-2-fluoro-3,7,11-trimethyldodeca-2,6,10-triene (246): 
 
 
245 (360 mg, 1.5 mmol, 2 eq.) in anhydrous THF (20 mL) was cooled to -10 ᵒC and PBr3 (710 µL, 0.75 
mmol, 1 eq.) added dropwise. The reaction proceeded for 50 minutes at -10 ᵒC and was quenched 
with sat. sodium bicarbonate solution (10 mL). Reaction products were extracted with diethyl ether 
(3 x 10 mL) and combined ethereal layers washed with water (3 x 10 mL), brine (3 x 10 mL) and dried 
over sodium sulphate. Organic product was filtered and concentrated under vaccuo to give 246 as a 
pale yellow oil (343 mg, 76%) which was used without further purification.  
1H NMR (500 MHz, CDCl3) δ 5.09 – 5.02 (2H, m, 2 x (CH3)CCH), 4.00 (2H, d, J = 23.0 Hz, CFCH2Br), 2.08 
– 1.91 (8H, m, 4 x allylic CH2), 1.69 (3H, s, CH3), 1.63 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
19F NMR (376 
MHz, CDCl3) δ -121.56. 
Preparation of (2E,6Z)-2-fluoro-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate 
(230): 
 
 
A mixture of crude bromide (246) (343 mg, 1.13 mmol, 1 eq.) and tris tetrabutyl ammonium 
pyrophosphate (1.53 g, 1.70 mmol, 1.5 eq.) in anhydrous acetonitrile (10 mL) was stirred at room 
temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the 
resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (10 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield diphosphate 230 as a white powder. The powder was dissolved in buffer solution 
(25 mM NH4HCO3, 2% iPrOH) (8 mL) and purified using HPLC (Solvent A: acetonitrile, solvent B: 2% 
iPrOH). The appropriate fractions were collected and lyophilized to give diphosphate 230 as a white 
powder. (22 mg, 4%). 
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1H NMR (500 MHz, CDCl3) δ 5.09 – 5.02 (2H, m, 2 x (CH3)CCH), 4.41 (2H, m, CFCH2O), 2.08 – 1.91 (8H, 
m, 4 x allylic CH2), 1.69 (3H, s, CH3), 1.63 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
19F NMR (376 MHz, CDCl3) 
δ -121.56. 31P NMR (162 MHz, CDCl3) δ -6.85 (d, J = 21.2 Hz, CH2OP(O)2OP(O)3), -10.22 (d, J = 21.2 Hz, 
CH2OP(O)2OP(O)3). HRMS (ES
-): calculated for [C15H26FO7P2][M]; 399.1138, found 399.1143. 
 
8.2.8 Synthesis of (2Z,6E)-6-fluorofarnesyl diphosphate (231) 
Preparation of ethyl (E)-2-fluoro-3,7-dimethylocta-2,6-dienoate(253) 
 
 
2-Fluoro triethyl phosphonoacetate (25.0 g, 103.2 mmol, 1.2 eq.) was added to a stirred suspension 
of sodium hydride (4.47 g, 111.8 mmol, 1.3 eq.) in anhydrous toluene (150 mL) at 0 ᵒC. The 
suspension was stirred for 1 hour at room temperature and cooled to 0 ᵒC prior to the addition of 
251 (10.85 g, 86.0 mmol, 1 eq.). The reaction mixture was stirred at room temperature for 16 hours, 
quenched with water (30 mL) and organic products extracted with diethyl ether (3 x 30 mL). Ethereal 
layers were washed with water (3 x 30 mL) and brine (3 x 30 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. Purification via flash chromatography (10% ethyl 
acetate in hexane) gave a mixture of fluorinated esters 252 and 253 as a clear oil (7.22 g, 39%). Flash 
chromatography (5% ethyl acetate in hexanes) partially separated esters 252 and 253 for analysis.  
1H NMR (300 MHz, CDCl3) δ 5.09 – 5.00 (1H, m, (CH3)CCH), 4.20 (2H , q, J = 7.1 Hz, OCH2CH3), 2.51 – 
2.44 (2H, m, CH2(CH3)CC(CH3)C(O)), 2.24 – 2.14 (2H, s, allylic CH2), 1.79 (3H, d, J = 4.3 Hz, CH3), 1.54 
(6H, s, 2 x CH3), 1.27 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 161.1 (d, J = 31.3 Hz, 
(CH3)CC(F)C(O)), 152.9 (d, J = 241.3 Hz, (CH3)CC(F)), 142.2 (d, J = 23.4 Hz, (CH3)CC(F)), 132.8 
((CH3)CCH), 123.2 ((CH3)CCH), 60.9 (OCH2CH3), 32.5 (d, J = 6.9 Hz, CH2CH2(CH3)CC(F)), 32.0 (d, J = 4.3 
Hz, CH2(CH3)CC(F)), 25.7 (CH3), 17.6 (CH3), 16.7 (CH3), 14.2 (OCH2CH3). 
19F NMR (471 MHz, CDCl3) δ -
126.81. LRMS (EI+): 214.14 (5% [M]), 194.13 (55%), 146.07 (40%), 118.04 (55%), 105.07 (35%), 91.05 
(25%), 77.04 (18%), 69.07 (100%). HRMS (EI+): calculated for [C12H19O2F][M]; 214.1369, found 
214.1369. 
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Preparation of (E)-2-fluoro-3,7-dimethylocta-2,6-dien-1-ol (255): 
 
 
DIBALH (103 mL, 103 mmol, 5 eq., 1 M in hexane) was added to a mixture of 252 and 253 (7.22 g, 
34.3, 1 eq.) in anhydrous toluene (50 mL) at  -78 ᵒC. Reaction was quenched with Rochelle salt (20 
mL) at 0 ᵒC when complete consumption of starting material was observed via TLC (20% ethyl 
acetate in hexane). The suspension was stirred for 16 hours at room temperature and organic 
products extracted with DCM (3 x 20 mL). Combined organic extracts were washed with water (3 x 
20 mL), brine (3 x 20 mL), dried over sodium sulphate, filtered and concentrated under vaccuo. 
Fluorinated alcohol 255 was purified by flash chromatography (5% ethyl acetate in hexane) to give 
255 as a clear oil (1.53 g, 26%).  
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.02 (1H, m, (CH3)CCH), 4.20 (2H , d, J = 20.9 Hz, CC(F)CH2OH), 
2.08 (4H, m, 2 x allylic CH2), 1.70 (6H, s, 2 x CH3), 1.60 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 153.6 
(d, J = 243.7 Hz, (CH3)CC(F)CH2OH), 133.1 ((CH3)CCH), 123.3 ((CH3)CCH), 115.7 (d, J = 13.9 Hz, 
(CH3)CC(F)CH2OH), 57.8 (d, J = 31.7 Hz, C(F)CH2OH), 31.8 (d, J = 4.8 Hz, CH2(CH3)CC(F)CH2OH), 26.4 (d, 
J = 3.0 Hz, allylic CH2), 25.7 (CH3), 17.66 (CH3), 13.5 (d, J = 8.9 Hz, (CH3)CC(F)CH2OH ). 
19F NMR (471 
MHz, CDCl3) δ -119.18. LRMS (EI
+): 154.12 (40% [M – H2O]), 139.09 (35%), 111.06 (100%), 109.04 
(50%), 97.04 (20%), 91.05 (30%), 77.04 (18%), 69.07 (22%). HRMS (EI+): calculated for [C10H15F][M – 
H2O]; 154.1158, found 154.1157. 
Table 14. 2D proton NMR correlations revealing spatial arrangement in 255 
255: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.09 2.08 
5.09 1.70 
5.09 1.60 
4.20 2.08 
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Preparation of (E)-1-bromo-2-fluoro-3,7-dimethylocta-2,6-diene (256): 
 
 
255 (1.53 g, 8.85 mmol, 2 eq.) in anhydrous THF (20 mL) was cooled to -10 ᵒC and PBr3 (0.41 mL, 4.43 
mmol, 1 eq.) added dropwise. Reaction was quenched with sat. sodium bicarbonate sol. (10 mL) 
after 50 minutes. Reaction products were extracted with diethyl ether (3 x 10 mL) and combined 
organic extracts were washed with water (3 x 10 mL) and brine (2 x 10 mL). Organic extracts were 
dried over sodium sulphate, filtered and concentrated under reduced pressure to give 256 as a pale 
yellow oil (2.09 g, 100%) which was used without further purification.  
1H NMR (500 MHz, CDCl3) δ 5.06 – 5.00 (1H, m, (CH3)CCH), 4.00 (2H , d, J = 23.0 Hz, CC(F)CH2Br), 2.10 
– 1.95 (4H, m, 2 x allylic CH2), 1.64 (3H, s, CH3), 1.63 (3H, s, CH3), 1.54 (3H, s, CH3). 
19F NMR (471 MHz, 
CDCl3) δ -114.49 (s). 
Preparation of ethyl (E)-2-acetyl-4-fluoro-5,9-dimethyldeca-4,8-dienoate (257): 
 
 
Ethyl acetoacetate (2.31 g, 17.78 mmol, 2 eq.) and potassium carbonate (2.46 g, 17.8 mmol, 2 eq.) 
were added to 256 (2.09 g, 8.89 mmol, 1 eq.) in dry acetone and refluxed at 60 ᵒC. Volatile solvents 
were removed under reduced pressure and organic products take into diethyl ether. Organic 
extracts were washed with water (3 x 20 mL), brine (3 x 20 mL) dried over sodium sulphate and 
filtered. Products were concentrated under vaccuo and purified by flash chromatography (20% ethyl 
acetate in hexane) to give 257 as a colourless oil (2.06 g, 74%). 
1H NMR (300 MHz, CDCl3) δ 5.08 (1H, t, J = 6.9 Hz, (CH3)CCH), 4.20 (2H, q, J = 7.1 Hz, CH3CH2O), 3.76 
(1H, t, J= 7.1 Hz, COCHCO), 2.81 (2H, dd, J = 21.6, 7.2 Hz, CCFCH2CH), 2.27 (3H, s, COCH3), 2.11 – 1.91 
(4H, m, 2 x allylic CH2), 1.69 (3H, s, CH3), 1.62 (3H, s, CH3), 1.61 (3H, s, CH3), 1.28 (3H, t, J= 7.1 
Hz,CH3CH2O). 
13C NMR (75 MHz, CDCl3) δ 202.2 (CH3C(O)CH), 169.0 (CH3CH2OC(O)), 151.2 (d, J = 
241.5 Hz, CH3CC(F)CH2), 132.3 ((CH3)CCH), 123.5 ((CH3)CCH), 114.0 (d, J = 14.3 Hz, (CH3)CC(F)CH2), 
61.6 (CH3CH2O), 56.5 (C(O)CHC(O)), 31.8 (d, J = 5.3 Hz, CH2(CH3)CC(F)CH2), 29.6 (CH3C(O)), 27.0 (d, J = 
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28.8 Hz, (CH3)CC(F)CH2), 26.4 (d, J = 3.1 Hz, (CH3)CCHCH2), 25.7 (CH3), 17.7 (CH3), 13.4 (OCH2CH3), 
13.3 (CH3). 
19F NMR (471 MHz, CDCl3) δ -112.92.
 
LRMS (EI+): 284.18 (5% [M]), 264.17 (10%), 242.17 
(7%), 215.11 (5%), 195.10 (100%), 127.06 (35%), 109.06 (30%), 69.07 (55%). HRMS (EI+): calculated 
for [C16H25O3F][M]; 284.1788, found 284.1786. 
Preparation of (E)-5-fluoro-6,10-dimethylundeca-5,9-dien-2-one (258): 
 
 
A mixture of potassium hydroxide (1.18 g, 21.10, 3 eq.) and 257 (2.0 g, 7.03 mmol, 1 eq.) in 
methanol (40 mL) was refluxed at 65 ᵒC for 3 hours. The reaction mixture was cooled to room 
temperature and acidified with 1M HCl (10 mL). Organic products were extracted with diethyl ether 
(3 x 15 mL) and washed with water (3 x 10 mL) and brine (3 x 10 mL). Washed organic layers were 
dried over sodium sulphate, filtered and concentrated under reduced pressure. Purification via flash 
chromatography gave 258 as a pale yellow oil (1.27 g, 85%).  
1H NMR (300 MHz, CDCl3) δ 5.08 (1H, t, J = 5.3 Hz, (CH3)CCH), 2.69 – 2.60 (2H, m, CH2C(O)), 2.58 – 
2.42 (2H, m, CH2CH2C(O)), 2.17 (3H, s, CH2C(O)CH3), 2.01 (4H, dt, J = 12.9, 5.9 Hz, 2 x allylic CH2), 1.69 
(3H, s, CH3), 1.62 (3H, s, CH3), 1.61 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 207.7 (CH3C(O)), 153.5 (d, 
J = 242.1 Hz, (CH3)CCF), 132.2 ((CH3)CCH), 123.6 ((CH3)CCH), 111.9 (d, J = 14.9 Hz, (CH3)CCF), 40.5 
(CH2CH2C(O)), 31.9 (d, J = 5.7 Hz, CH2(CH3)CCF), 30.0 (CH3C(O)), 26.4 (allylic CH2), 25.7 (CH3), 22.6 (d, J 
= 29.6 Hz, ((CH3)CCFCH2), 17.7 (CH3), 13.3 (d, J = 9.6 Hz, (CH3)CCF). 
19F NMR (471 MHz, CDCl3) δ -
112.97. LRMS (EI+): 212.16 (2% [M]), 192.15 (35%), 174.14 (25%), 159.12 (70%), 143.09 (100%), 
123.08 (25%), 109.06 (50%), 95.08 (55%), 79.05 (25%), 69.07 (95%). HRMS (EI+): calculated for 
[C13H21OF][M]; 212.1576, found 212.1579. 
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Preparation of ethyl (2Z,6E)-6-fluoro-3,7,11-trimethyldodeca-2,6,10-trienoate (260): 
 
 
A suspension of sodium hydride (378 mg, 9.41 mmol, 2.2 eq.) in anhydrous toluene (30 mL) was 
cooled to 0 ᵒC. 204 (2.85 mg, 8.56 mmol, 2 eq.) was added to the stirred suspension and the reaction 
stirred at room temperature for 1 hour. The reaction mixture was cooled to 0 ᵒC and 258 (909 mg, 
4.28 mmol, 1 eq.) added and reaction stirred at room temperature for 16 hours. Reaction was 
quenched with water (10 mL) and reaction products extracted with diethyl ether (3 x 20 mL). 
Combined organic extracts were washed with water (3 x 20 mL) and brine (3 x 20 mL). Extracts were 
dried over sodium sulphate, filtered and concentrated under reduced pressure. Purification via flash 
chromatography (10% ethyl acetate in hexane) gave a mixture of fluorinated esters 259 and 260 as a 
clear oil (762 mg, 63%). Flash chromatography (5% ethyl acetate in hexanes) partially separated 
esters 259 and 260 for analysis.  
1H NMR (300 MHz, CDCl3) δ 5.61 (1H, s, CCHC(O)OEt), 5.07 – 4.95 (1H, m, (CH3)CCH), 4.07 (2H, q, J = 
7.1 Hz, OCH2CH3), 2.69 (2H, t, J = 7.6 Hz, CH2(CH3)CCHC(O)), 2.35 (2H, dt, J = 23.5, 7.5 Hz, 
(CH3)CC(F)CH2), 2.06 – 1.85 (4H, m, 2 x allylic CH2), 1.82 (3H, s, CH3), 1.61 (3H, s, CH3), 1.55 (3H, d, J = 
2.3 Hz, (CH3)CC(F)CH2),1.53 (3H, s, CH3), 1.20 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 
166.1 (CHC(O)O), 159.1 ((CH3)CCHC(O)O), 154.2 (d, J = 243.8 Hz, (CH3)CCF), 132.0 ((CH3)CCH), 123.8 
((CH3)CCH) 116.8 (CCHC(O)O), 111.9 (d, J = 15.0 Hz, (CH3)CCF), 59.6 (OCH2CH3), 31.9 (d, J = 5.6 Hz, 
CH2(CH3)CCF), 30.9 (CH2(CH3)CCHC(O)), 27.3 (d, J = 29.7 Hz, (CH3)CCFCH2), 26.7 (d, J = 3.1 Hz, allylic 
CH2), 25.73 & 25.69 & 17.6 & 14.3 (4 x CH3), 13.3 (d, J = 9.7 Hz, OCH2CH3). 
19F NMR (471 MHz, CDCl3) 
δ -111.33. LRMS (EI+): 262.19 (7% [M]), 216.15 (50%), 197.10 (55%), 159.09 (47%), 145.08 (70%), 
128.07 (85%), 119.09 (100%), 105.07 (62%), 91.06 (85%), 69.07 (70%). HRMS (EI+): calculated for 
[C17H27O2F][M]; 282.1995, found 282.1991. 
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Preparation of (2Z,6E)-6-fluoro-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (262): 
 
 
DIBALH (8.1 mL, 8.10 mmol, 3 eq.) was added dropwise to a stirred solution of 259 and 260 (762 mg, 
2.70 mmol, 1 eq.) in anhydrous toluene (20 mL) at -78 ᵒC. Reaction was quenched with Rochelle salts 
(10 mL) at 0ᵒC after complete consumption of starting material was observed via TLC (20% ethyl 
acetate in hexane). The resulting mixture was stirred at room temperature for 16 hours. Reaction 
products were extracted with DCM (3 x 10 mL) and combined organic layers were washed with 
water (3 x 10 mL) and brine (3 x 10 mL). Organic layers were dried over sodium sulphate, filtered and 
concentrated under reduced pressure. Purification via flash chromatography (5% ethyl acetate in 
hexane) gave 262 as a colourless oil (266 mg, 41%). 
1H NMR (500 MHz, CDCl3) δ 5.40 (1H, t, J = 7.2 Hz CCHCH2O), 5.03 – 4.98 (1H, m, (CH3)CCH), 4.03 (2H, 
d, J = 7.2, CHCH2OH), 2.29 – 2.16 (4H, m, 2 x allylic CH2), 1.98 (2H, dd, J = 15.0, 7.4 Hz, (CH3)CCFCH2), 
1.87 – 1.82 (2H, m, allylic CH2), 1.68 (3H, s, CH3), 1.62 (3H, s, CH3), 1.55 (3H, d, J = 3.3 Hz, (CH3)CCF), 
1.53 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 154.2 (d, J = 243.0 Hz, (CH3)CCF), 138.6 & 132.2 ((2 x 
(CH3)CCH), 125.3 (CCHCH2O), 123.6 ((CH3)CCH), 112.0 (d, J = 15.3 Hz, (CH3)CCF), 59.0 (CHCH2O), 32.0 
(d, J = 5.8 Hz, CH2(CH3)CCF), 29.2 (allylic CH2), 27.2 (d, J = 29.7 Hz, (CH3)CCFCH2), 26.7 (d, J = 2.9 Hz, 
allylic CH2), 25.7 & 23.4 & 17.6 (3 x CH3), 13.2 (d, J = 9.8 Hz, (CH3)CCF). 
19F NMR (471 MHz, CDCl3) δ -
111.63. LRMS (EI+): 212.16 (3% [M – H2O]), 203.18 (8%), 202.17 (100%), 200.16 (60%), 198.14 (35%), 
187.15 (70%), 185.13 (55%), 183.12 (65%), 181.10 (22%), 179.10 (7%), 173.13 (8%). HRMS (EI+): 
calculated for [C15H23F][M – H2O]; 222.1784, found 222.1784. 
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Table 15. 2D proton NMR correlations revealing spatial arrangement in 262 
262: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.40 4.03 
5.40 1.68 
5.00 2.23 
5.00 1.62 
4.02 1.84 
 
Preparation of (2Z,6E)-1-bromo-6-fluoro-3,7,11-trimethyldodeca-2,6,10-triene (263): 
 
 
PBr3 (55 µL, 0.58 mmol, 1 eq.) was added to a stirred solution of 262 (280 mg, 1.16 mmol, 2 eq.) in 
anhydrous tetrahydrofuran (30 mL) at -10 ᵒC. Complete consumption of the reaction was observed 
via TLC (20% ethyl acetate in hexane) and was quenched with sat. sodium bicarbonate sol. (20 mL) at 
0 ᵒC. Reaction products were extracted with diethyl ether (3 x 20 mL) and combined organic layers 
washed with water (3 x 10 mL) and brine (3 x 10 mL). Organic layers were dried over sodium 
sulphate, filtered and concentrated under reduced pressure to give 263 as a pale yellow oil (353 mg, 
100%) which was used without further purification. 
1H NMR (400 MHz, CDCl3) δ 5.50 (1H, t, J = 8.5 Hz CCHCH2O), 5.07 – 4.96 (1H, m, (CH3)CCH), 3.92 (2H, 
d, J = 8.5, CHCH2Br), 2.31 – 2.16 (4H, m, 2 x allylic CH2), 2.02 – 1.80 (4H, m, 2 x allylic CH2), 1.71 (3H, s, 
CH3), 1.62 (3H, s, CH3), 1.54 (6H, s, 2 x CH3). 
19F NMR (376 MHz, CDCl3) δ -111.80. 
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Preparation of (2Z,6E)-6 fluoro-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate 
(231): 
 
 
Tris tetra butyl ammonium pyrophosphate (2.1 g, 2.33 mmol, 2 mmol) in anhydrous acetonitrile (10 
mL) was added to crude bromide 263 (353 mg, 1.16 mmol, 1 eq.) under argon. The reaction was 
stirred for 16 hours at room temperature and volatile solvents removed under reduced pressure to 
give crude diphosphate as a brown oil. Crude diphosphate was dissolved in buffer solution (25 mM 
NH4HCO3, 2% iPrOH) (10 mL) and the tris tetrabutylammonium salt counter ions were exchanged for 
ammonium by ion exchange column containing Amberlyst 131 (wet H+ form) mesh cation exchange 
resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate 
fractions were collected and lyophilized to yield diphosphate as a white powder. The powder was 
dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (10 mL) and purified using HPLC (Solvent A: 
acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give 
231 as a white powder. (5 mg, 1%). 
1H NMR (500 MHz, D2O) δ 5.46 – 5.35 (1H, m, CCHCH2O), 5.16 – 5.05 (1H, m, (CH3)CCH), 4.39 – 4.23 
(2H, m, CHCH2O), 2.38 – 2.12 (4H, m, 2 x allylic CH2), 2.09 – 1.95 (2H, m, (CH3)CCFCH2), 1.70 (3H, s, 
CH3), 1.62 (3H, s, CH3), 1.55 (6H, s, 2 x CH3). 
31P NMR (202 MHz, D2O) δ -9.01 (d, J = 13.4 Hz), -10.33 
(d, J = 16.9 Hz). 19F NMR (471 MHz, D2O) δ -111.91 (s). HRMS (ES
-): calculated for [C15H26FO7P2][M]; 
399.1138, found 399.1137. 
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8.2.9 Synthesis of (2Z,6Z)-2-methylfarnesyl diphosphate (359) 
Preparation of ethyl (2Z,6Z)-2,3,7,11-tetramethyldodeca-2,6,10-trienoate (373): 
 
 
A stirred suspension of sodium hydride (296 mg, 12.35 mmol, 1.6 eq.) in anhydrous toluene (40 mL) 
was cooled to 0 ᵒC and 371 (4 g, 11.58 mmol, 1.5 eq.) was added dropwise. The reaction mixture was 
stirred at room temperature for 1 hour and cooled to 0 ᵒC. Neryl acetone (166) (1.5 g, 7.7 mmol, 1 
eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 hours. The 
reaction was quenched with water (20 mL) and products extracted with diethyl ether (3 x 20 mL). 
Organic extracts were washed with water (20 mL) and brine (20 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. Purification via flash chromatography (10% ethyl 
acetate in hexane) gave a mixture of 372 and 373 as a clear oil (612 mg, 60%). Flash chromatography 
(5% ethyl acetate in hexanes) partially separated esters 372 and 373 for analysis. 
1H NMR (300 MHz, CDCl3) δ 5.19 – 5.11 (2H, m, 2 x (CH3)CCH), 4.19 (2H, q, J = 7.1 Hz, OCH2CH3), 2.41 
– 2.30 (2H, m, CH2(CH3)CC(CH3)C(O)), 2.21 – 2.09 (2H, m, CH2CH2(CH3)CC(CH3)C(O)), 2.02 – 1.96 (4H, 
m, 2 x allylic CH2), 1.88 (3H, d, J = 1.2 Hz, CH2(CH3)CC(CH3)C(O)), 1.85 (1H, s, (CH3)CC(CH3)C(O)), 1.79 
(3H, s, CH3), 1.62 (3H, s, CH3), 1.30 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 170.0 
(C(CH3)C(O)O), 169.8 ((CH3)CC(CH3)C(O)O), 146.1 ((CH3)CC(CH3)C(O)), 145.6 ((CH3)CC(CH3)C(O)), 136.0 
& 131.7 (2 x (CH3)CCH), 124.7 &, 124.2 (2 x (CH3)CCH), 60.0 (OCH2CH3), 36.7 (CH2(CH3)CC(CH3)C(O)), 
36.5 (CH2CH2(CH3)CC(CH3)C(O)), 31.9 & 26.9 (2 x CH2), 20.3 (CH2), 17.7 (CH2), 15.9 (CH2), 15.3 (CH2), 
14.3 (OCH2CH3). LRMS (EI
+): 278.23 (15% [M]), 232.17 (100%), 217.16 (30%), 173.10 (30%), 142.09 
(30%), 109.09 (35%), 96.06 (70%), 81.07 (25%). HRMS (EI+): calculated for [C18H30O2]; 278.2246, 
found 278.2253. 
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Preparation of (2Z,6Z)-2,3,7,11-tetramethyldodeca-2,6,10-trien-1-ol (375): 
 
 
372 and 373 (596 mg, 2.14 mmol, 1 eq.) in anhydrous toluene (20 mL) was cooled to -78 ᵒC and 
DIBALH (8.56 mL, 8.56 mmol, 4 eq., 1 M in hexane) added dropwise. The reaction was monitored by 
TLC (20% ethyl acetate in hexane) and was quenched with Rochelle salts (20 mL) at 0 ᵒC. The 
resulting mixture was stirred for 16 hours at room temperature and extracted with DCM (3 x 10 mL). 
Combined organic extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over 
sodium sulphate, filtered and concentrated under reduced pressure. Purification via flash 
chromatography (5% ethyl acetate in hexane) gave 375 as a colourless oil (207 mg, 41%).  
1H NMR (500 MHz, CDCl3) δ 5.07 – 5.02 (2H, m, 2 x (CH3)CCH), 4.01 (2H, d, J = 0.5 Hz, 
(CC(CH3)CH2OH), , 2.09 – 2.04 (2H, m, allylic CH2), 2.02 – 1.89 (6H, m, 3 x allylic CH2), 1.68 (3H, s, CH3), 
1.62 (9H, s, 3 x CH3), 1.54 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 136.2 (CC(CH3)CH2O), 132.9 
((CH3)CC(CH3)CH2O), 131.7 & 128.5 (2 x (CH3)CCH), 124.8 & 124.2 (2 x (CH3)CCH), 63.6 (CHCH2O), 34.3 
& 31.9 & 26.9 & 26.7 (4 x allylic CH2), 25.8 & 23.4 & 18.8 (3 x CH3), 17.7 (CH3), 16.9 (CH3). LRMS (ES
+): 
219.21 (100% [M – H2O]), 215.05 (18%), 163.15 (15%), 149.13 (12%), 123.96 (15%). HRMS (ES
+): 
calculated for [C16H27]
+ [M – H2O]; 219.2113, found 219.2120. 
Table 16. 2D proton NMR correlations revealing spatial arrangement in 375 
375: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.03 1.94 
5.03 1.62 
4.01 2.07 
1.68 1.62 
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Preparation of (2Z,6Z)-1-bromo-2,3,7,11-tetramethyldodeca-2,6,10-triene (376): 
 
 
A solution of 375 (206 mg, 0.87 mmol, 2 eq.) in anhydrous THF (20 mL) was cooled to -10 ᵒC and 
phosphorus tribromide (41 µL, 0.44, 1 eq.) added dropwise. Reaction was quenched with sat. 
sodium bicarbonate sol. (10 mL) at 0 ᵒC when complete consumption of starting material was 
observed via TLC (20% ethyl acetate in hexane). Reaction product was extracted with diethyl ether (3 
X 10 mL) and washed with water (3 x 10 mL) and brine (3 x 10 mL). Washed organic layers were dried 
over sodium sulphate, filtered and concentrated under reduced pressure to give 376 as a pale yellow 
oil (260 mg, 100%) which was taken forward without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.10 – 4.98 (2H, m, 2 x (CH3)CCH), 4.00 (2H, s, (CC(CH3)CH2Br), 2.09 – 
1.91 (8H, m, 4 x allylic CH2), 1.62 (6H, s, 2 x CH3), 1.54 (9H, s, 3 x CH3). 
Preparation of (2Z, 6Z)-2,3,7,11-tetramethyldodeca-2,6,10-trien-1-yl diphosphate (359): 
 
 
A mixture of crude bromide 376 (260 g, 0.87 mmol, 1 eq.) and tris tetrabutyl ammonium 
pyrophosphate (1.57 g, 1.74 mmol, 2 eq.) in anhydrous acetonitrile (10 mL) was stirred at room 
temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the 
resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (15 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield diphosphate 359 as a white powder. The powder was dissolved in buffer solution 
(25 mM NH4HCO3, 2% iPrOH) (10 mL) and purified using HPLC (Solvent A: acetonitrile, solvent B: 2% 
iPrOH). The appropriate fractions were collected and lyophilized to give diphosphate 359 as a white 
powder (7 mg, 2%). 
1H NMR (500 MHz, D2O) δ 5.17 – 5.13 (2H, m, 2 x (CH3)CCH), 4.38 (2H, d, J = 4.8 Hz, (CC(CH3)CH2O), 
2.09 – 2.04 (2H, m, allylic CH2), 2.02 – 1.89 (6H, m, 3 x allylic CH2), 1.65 (3H, s, CH3), 1.64 (3H, s, CH3), 
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1.61 (6H, s, 2 x CH3), 1.56 (3H, s, CH3). 
31P NMR (202 MHz, D2O) δ -9.41 (d, J = 13.8 Hz), -10.62 (d, J = 
17.2 Hz). HRMS (ES-): calculated for [C16H29O7P2][M]; 395.1389, found 395.1385. 
 
8.2.10 Synthesis of (2Z,6Z)-6-methylfarnesyl diphosphate (360) 
Preparation of ethyl (Z)-2,3,7-trimethylocta-2,6-dienoate (383): 
 
 
368 (24.1 g, 101.1 mmol, 1.5 eq.) was added to a stirred solution of sodium hydride (2.43 g, 101.1 
mmol, 1.5 eq.) in anhydrous toluene (100 mL) at 0 ᵒC. The reaction was stirred for 1 hour at room 
temperature, cooled to 0 ᵒC and 251 (8.55 g, 64.1 mmol, 1 eq.) was added. The reaction was stirred 
at room temperature for 16 hours and quenched with water (30 mL). Organic products were 
extracted with diethyl ether (3 x 20 mL), washed with water (30 mL), brine (30 mL), dried over 
sodium sulphate, filtered and concentrated under vaccuo. Purification via flash chromatography 
(10% ethyl acetate in hexane) gave a mixture of 382 and 383 as a clear oil (10.4 g, 73%). Flash 
chromatography (5% ethyl acetate in hexanes) partially separated esters 382 and 383 for analysis. 
1H NMR (300 MHz, CDCl3) δ 5.19 – 5.07 (1H, m, (CH3)CCH), 4.19 (2H , q, J = 7.1 Hz, OCH2CH3), 2.42 – 
2.30 (2H, m, CH2(CH3)CC(CH3)C(O)), 2.19 – 2.14 (2H, m, allylic CH2), 1.87 (3H, s, CH3), 1.85 (3H, s, CH3), 
1.80 (3H, s, CH3), 1.62 (3H, s, CH3), 1.31 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 169.9 
((CH3)CC(CH3)C(O)), 146.1 ((CH3)CC(CH3)C(O)), 145.6 ((CH3)CC(CH3)C(O)), 131.8 ((CH3)CCH), 124.0 
((CH3)CCH), 60.0 (OCH2CH3), 36.5 (CH2(CH3)CC(CH3)C(O)), 29.7 (CH2CH2(CH3)CC(CH3)C(O)), 20.9 (CH3), 
17.6 (CH3), 15.9 (CH3), 15.3 (CH3), 14.3 (OCH2CH3). LRMS (ES
+): 211.17 (97% [M]), 209.15 (100%), 
195.10 (55%), 181.12 (72%), 165.12 (50%), 153.12 (50%), 137.12 (48%), 125.96 (55%), 113.06 (25%) 
HRMS (ES+): calculated for [C13H23O2] [M]; 211.1698, found 211.1698. 
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Preparation of (Z)-2,3,7-trimethylocta-2,6-dien-1-ol (385): 
 
 
DIBALH (143 mL, 142.8 mmol, 3 eq., 1 M in hexane) was added to a mixture of 382 and 383 (10 g, 
47.6, 3 eq.) in anhydrous toluene (50 mL) at  -78 ᵒC. Reaction was quenched with Rochelle salt (30 
mL) at 0 ᵒC when complete consumption of starting material was observed via TLC (20% ethyl 
acetate in hexane). The suspension was stirred for 16 hours at room temperature and organic 
products extracted with DCM (3 x 20 mL). Combined organic extracts were washed with water (3 x 
20mL), brine (3 x 20 mL), dried over sodium sulphate, filtered and concentrated under vaccuo. 
methylated alcohols 384 and 385 was purified by flash chromatography (5% ethyl acetate in hexane) 
to give 385 as a clear oil (2.06 g, 26%).  
1H NMR (300 MHz, CDCl3) δ 5.04 (1H, t, J = 7.1 Hz, (CH3)CCH), 4.00 (2H , d, J = 0.6 Hz, CC(CH3) CH2OH), 
2.11 – 1.92 (4H, m, 2 x allylic CH2), 1.68 (3H, d, J = 0.6 Hz, CC(CH3) CH2OH), 1.62 (6H, s, 2 x CH3), 1.52 
(6H, s, 2 x CH3). 
13C NMR (75 MHz, CDCl3) δ 132.9 ((CH3)CC), 132.5 ((CH3)CC), 128.5 ((CH3)CC(CH3) 
CH2OH), 124.1 ((CH3)CCH), 63.5 (C(CH3) CH2OH), 34.1 & 27.1 (2 x allylic CH2), 25.7 & 18.8 (2 x 
(CH3)CCH), 17.6 (CH3), 16.8 (C(CH3) CH2OH). LRMS (EI
+): 150.14 (65% [M – H2O]), 135.12 (70%), 
133.10 (80%), 107.08 (100%), 91.05 (55%), 79.06 (20%). HRMS (EI+): calculated for [C11H18]
+ [M – 
H2O]; 150.1409, found 150.1403.  
Table 17. 2D proton NMR correlations revealing spatial arrangement in 385 
385: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.04 2.02 
5.04 1.5 
4.00 2.02 
1.68 1.52 
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Preparation of (Z)-1-bromo-2,3,7-trimethylocta-2,6-diene (386): 
 
 
Phosphorus tribromide (0.57 mL, 6.03 mmol, 1 eq.) was added dropwise to a stirred solution of 385 
(2.03 g, 12.06 mmol, 2 eq.) in anhydrous tetrahydrofuran (20 mL) at -10 ᵒC. The solution was stirred 
for 15 minutes and concentrated under vaccuo. The residue was dissolved in diethyl ether (20 mL) 
and washed with sodium hydrogen carbonate (3 x 10 mL), water (3 x 10 mL) and brine (10 mL), dried 
over sodium sulfate, filtered and concentrated under reduced pressure to yield bromide as a pale 
yellow oil (2.78 g, 100%) which was used without further purification.  
1H NMR (300 MHz, CDCl3) δ 5.22 – 5.10 (1H, m, (CH3)CCH), 4.09 (2H, s, CC(CH3) CH2Br), 2.21 – 2.02 
(4H, m, 2 x allylic CH2), 1.79 (3H, s, CH3), 1.78 (3H, s, CH3), 1.72 (3H, s, CH3), 1.71 (3H, s, CH3), 1.63 
(3H, s, CH3). 
Preparation of ethyl (Z)-2-acetyl-4,5,9-trimethyldeca-4,8-dienoate (387): 
 
 
Crude bromide 386 (2.78 g, 12.03 mmol, 1 eq.) and ethyl acetoacetate (3.13 g, 24.05 mmol, 2 eq.) 
were dissolved in anhydrous acetone (30 mL). Potassium carbonate (3.32 g, 24.05 mmol, 2 eq.) was 
added the suspension was refluxed for 4 hours at 60 ᵒC. The reaction mixture was concentrated 
under reduced pressure and reaction products dissolved in diethyl ether (30 mL). Ethereal layer was 
washed with water (3 x 20 mL) and brine (2 x 20 mL), dried over sodium sulphate and concentrated 
under vaccuo. Reaction product was purified by flash chromatography on silica gel (20% ethyl 
acetate in hexane) to give 387 as a clear oil (1.52 g, 45%). 
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.08 (1H, m, (CH3)CCH), 4.17 (1H, q, J= 7.1 Hz, CH3CH2O), 4.16 (1H, 
q, J= 7.1 Hz, CH3CH2O), 3.62 – 3.55 (1H, m, COCHCO)., 2.64 (1H, qd, J = 14.1 Hz, 0.7 Hz, 
CC(CH3)CH2CH), 2.61 (1H, qd, J = 14.1 Hz, 0.7 Hz, CC(CH3)CH2CH), 2.22 (3H, s, COCH3), 2.13 – 1.95 (4H, 
m, 2 x allylic CH2), 1.69 (s, 3H), 1.63 (3H, d, J = 0.7 Hz, CH3), 1.61 (3H, s, CH3), 1.27 (1H, t, J = 7.1 Hz, 
CH3CH2O). 1.26 (1H, t, J = 7.1 Hz, CH3CH2O). 1.26 (1H, t, J = 7.1 Hz, CH3CH2O). 
13C NMR (75 MHz, 
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CDCl3) δ 203.4 (CH3C(O)CH), 170.0 (CH3CH2OC(O)), 131.8 ((CH3)CCH), 131.7 ((CH3)CC(CH3)), 124.2 
(CH3CCH), 123.8 ((CH3)CC(CH3)), 61.3 (CH3CH2O), 58.6 (C(O)CHC(O)), 34.4 (allylic CH2), 32.5 
(CC(CH3)CH2), 29.2 (CH3C(O)), 27.0 (allylic CH2), 25.7 (CH3), 18.6 (CH3), 18.1 (CH3), 17.6 (CH3), 14.1 
(OCH2CH3).
 
LRMS (ES-): 279.20 (50% [M]), 259.04 (15%), 213.03 (100%), 197.91 (5%), 185.00 (5%), 
162.84 (7%), 141.01 (15%), 120.90 (17%), 118.9 (30%). HRMS (ES-): calculated for [C17H27O3][M]; 
279.1960, found 279.1961. 
Preparation of (Z)-5,6,10-trimethylundeca-5,9-dien-2-one (388): 
 
 
A mixture of potassium hydroxide (830 mg, 14.77 mmol, 3 eq.) and 387 (1.38 g, 4.92 mmol, 1 eq.) in 
methanol (30 mL) was refluxed at 70 ᵒC for 3 hours. The reaction mixture was cooled to room 
temperature and acidified with 1M HCl. Organic products were extracted with diethyl ether (3 x 20 
mL) and washed with water (3 x 20 mL) and brine (3 x 10 mL). Washed organic layers were dried 
over sodium sulphate, filtered and concentrated under reduced pressure. Purification via flash 
chromatography gave 388 as a pale yellow oil (1.01 g, 99%).  
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.06 (1H, m, (CH3)CCH), 2.51 – 2.42 (2H, m, CH2C(O)), 2.34 – 2.23 
(2H, m, CH2CH2C(O)), 2.15 (3H, s, CH2C(O)CH3), 2.07 – 1.95 (4H, m, 2 x allylic CH2), 1.69 (3H, s, CH3), 
1.64 (3H, s, CH3), 1.62 (3H, s, CH3), 1.61 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 209.3 (CH3C(O)), 
131.6 ((CH3)CCH), 129.3 ((CH3)CC(CH3)), 126.6 ((CH3)CC(CH3)), 124.4 ((CH3)CCH), 42.9 (CH2CH2C(O)), 
34.3 (CH2CH2C(O)), 29.9 (CH3C(O)), 28.3 & 27.1 (2 x allylic CH2), 25.8 & 18.5 & 18.2 & 17.6 (4 x CH3). 
LRMS (ES+): 209.19 (50% [M + H]), 191.18 (100%), 151.14 (5%), 135.11 (5%). HRMS (ES+): calculated 
for [C14H25O][M + H]; 209.1905, found 209.1907. 
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Preparation of ethyl (2Z,6Z)-3,6,7,11-tetramethyldodeca-2,6,10-trienoate (390): 
 
 
A stirred suspension of sodium hydride (230 mg, 5.7 mmol, 1.6 eq.) in anhydrous toluene (30 mL) 
was cooled to 0 ᵒC and 204 (1.75 g, 5.34 mmol, 1.5 eq.) was added dropwise. The reaction mixture 
was stirred at room temperature for 1 hour and cooled to 0 ᵒC. Methyl neryl acetone(388) (743 mg, 
3.56 mmol, 1 eq.) was added dropwise and the reaction mixture stirred at room temperature for 16 
hours. The reaction was quenched with water (20 mL) and products extracted with diethyl ether (3 x 
10 mL). Organic extracts were washed with water (3 x 20 mL) and brine (20 mL), dried over sodium 
sulphate, filtered and concentrated under reduced pressure. Purification via flash chromatography 
(10% ethyl acetate in hexane) gave a mixture of 389 and 390 as a clear oil (772 mg, 42%). Flash 
chromatography (5% ethyl acetate in hexanes) partially separated esters 389 and 390 for analysis. 
1H NMR (300 MHz, CDCl3) δ 5.57 (1H, s, CCHC(O)OEt), 5.10 – 5.02 (1H, m, (CH3)CCH), 4.06 (2H, q, J = 
7.1 Hz, OCH2CH3), 2.57 (2H, dd, J = 9.5, 6.9 Hz, CH2(CH3)CCHC(O)), 2.10 (2H, dd, J = 9.3, 7.0 Hz, 
CH2CH2(CH3)CCHC(O)), 1.99 – 1.91 (4H, m, 2 x allylic CH2), 1.83 (3H, d, J = 1.3 Hz, CH2(CH3)CCHC(O)), 
1.63 (3H, s, CH3), 1.61 (3H, s, CH3), 1.57 (3H, s, CH3), 1.53 (3H, s, CH3), 1.20 (3H, t, J = 7.1 Hz, 
OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.3 (CHC(O)O), 160.4 ((CH3)CCHC(O)O), 131.6 & 128.8 & 
127.8 ((CH3)CC), 124.6 ((CH3)CCH), 115.9 (CCHC(O)O), 59.4 (OCH2CH3), 34.3 (allylic CH2), 32.9 
(CH2(CH3)CCHC(O)), 32.7 (CH2CH2(CH3)CCHC(O)), 27.2 (allylic CH2), 25.8 & 25.5 & 18.5 & 18.3 & 17.6 
(5 x CH3), 14.4 (OCH2CH3). LRMS (ES
+): 279.23 (100% [M + H]), 265.06 (45%), 243.08 (55%), 233.19 
(6%), 205.19 (7%), 200.01 (3%), 151.15 (3%). HRMS (ES+): calculated for [C18H31O2][M + H]; 279.2324, 
found 279.2323. 
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Preparation of (2Z,6Z)-3,6,7,11-tetramethyldodeca-2,6,10-trien-1-ol (392): 
 
 
Esters 389 and 390 (753 mg, 2.7 mmol, 1 eq.) in anhydrous toluene (20 mL) was cooled to -78 ᵒC. 
DIBALH (13.5 mL, 13.5 mmol, 5 eq., 1 M in hexane) was added dropwise and the reaction stirred 
until complete consumption of starting material was observed via TLC (20% ethyl acetate in 
hexanes). The reaction was warmed to 0 ᵒC, quenched with Rochelle salts (5 mL) and stirred for 16 
hours at room temperature. Organic products were extracted with DCM (3 x 10 mL) and washed 
with water (3 x 10 mL) and brine (3 x 10 mL). Organic layers were dried over sodium sulphate, 
filtered and concentrated under vaccuo. Purification via flash chromatography (5% ethyl acetate in 
hexanes) gave 192 as a clear oil (189 mg, 18%).  
1H NMR (300 MHz, CDCl3) δ 5.45 (1H, t, J = 7.2 Hz, (CH3)CCHCH2OH), 5.17 – 5.12 (1H, m, (CH3)CCH), 
4.10 (2H, d, J = 7.1 Hz, (CCHCH2OH), 2.12 (4H, s, 2 x allylic CH2), 2.03 (4H, d, J = 2.6 Hz, 2 x allylic CH2), 
1.79 (3H, s, CH3), 1.70 (3H, s, CH3), 1.67 (3H, s, CH3), 1.65 (3H, s, CH3), 1.62 (3H, s, CH3). 
13C NMR (75 
MHz, CDCl3) δ 140.5 ((CH3)CC(CH3)CH2O), 131.6 & 129.1 & 128.0 (3 x(CH3)CC), 124.4 & 124.2 (2 x 
(CH3)CCH), 59.0 (CHCH2O), 34.4 & 33.1 & 31.1 & 27.2 (4 x allylic CH2), 25.8 & 23.7 & 18.7 (3 x CH3), 
18.4 (CH3), 17.7 (CH3). LRMS (EI
+): 218.20 (70% [M – H2O]), 203.18 (50%), 175.15 (75%), 162.14 
(12%), 149.13 (35%), 135.12 (60%), 121.10 (35%), 107.09 (100%), 93.07 (37%), 79.05 (7%), 69.07 
(9%). HRMS (EI+): calculated for [C16H26][M – H2O]; 218.2035, found 218.2035. 
Table 18. 2D proton NMR correlations revealing spatial arrangement in 392 
392: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.45 4.10 
5.45 1.79 
5.15 2.03 
5.15 1.67 
4.10 2.12 
1.79 1.70 
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Preparation of (2Z,6Z)-1-bromo-3,6,7,11-tetramethyldodeca-2,6,10-triene (393): 
 
 
Phosphorus tribromide (34 µL, 0.36, 1 eq.) was added to a stirred solution of 392 (172 mg, 0.73 
mmol, 2 eq.) in anhydrous tetrahydrofuran (10 mL) at -10 ᵒC. The reaction proceeded for 15 minutes 
at which point complete consumption of starting material was observed via TLC (20% ethyl acetate 
in hexane). Volatile solvents were removed under reduced pressure and the residue dissolved in 
diethyl ether (3 x 10 mL). Organic extracts were washed with sat. sodium bicarbonate sol. (3 x 10 
mL), water (3 x 10 mL) and brine (2 x 10 mL). Ethereal extracts were dried over sodium sulphate, 
filtered and concentrated under vaccuo to give 393 as a crude yellow oil (218 mg, 100%) which was 
used without further purification.  
1H NMR (300 MHz, CDCl3) δ 5.33 (1H, t, J = 7.6 Hz, (CH3)CCHCH2Br), 5.21 – 5.05 (1H, m, (CH3)CCH), 
4.02 (2H, d, J = 7.6 Hz, (CCHCH2Cl), 2.23 – 1.99 (8H, m, 4 x allylic CH2), 1.71 (3H, s, CH3), 1.69 (3H, s, 
CH3), 1.66 (3H, s, CH3), 1.64 (6H, s, 2 x CH3). 
Preparation of (2Z, 6Z)-6 methyl-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate 
(360): 
 
 
A mixture of 393 (218 mg, 0.73 mmol, 1 eq.) and tris tetrabutyl ammonium pyrophosphate (1.31 g, 
1.46 mmol, 2 eq.) in anhydrous acetonitrile (10 mL) was stirred at room temperature for 16 hours. 
The reaction mixture was concentrated under reduced pressure and the resultant residue dissolved 
in buffer solution (25 mM NH4HCO3, 2% iPrOH) (10 mL) and the tris tetrabutylammonium salt 
counter ions were exchanged for ammonium by ion exchange column containing Amberlyst 131 
(wet H+ form) mesh cation exchange resin pre-equilibrated with ion-exchange buffer (25 mM 
NH4HCO3, 2% isopropanol). The appropriate fractions were collected and lyophilized to yield 
diphosphate 360 as a white powder. The powder was dissolved in buffer solution (25 mM NH4HCO3, 
2% iPrOH) (7 mL) and purified using HPLC (Solvent A: acetonitrile, solvent B: 2% iPrOH). The 
appropriate fractions were collected and lyophilized to give 360 as a white powder (6 mg, 2%). 
249 
 
1H NMR (500 MHz, D2O) δ 5.47 – 5.39 (1H, m, (CH3)CCHCH2O), 5.16 – 5.08 (1H, m, (CH3)CCH), 4.42 – 
4.36 (2H, m, CCHCH2O), 2.17 – 2.07 (4H, m, 2 x allylic CH2), 2.02 (4H, m, 2 x allylic CH2), 1.67 (3H, s, 
CH3), 1.61 (3H, s, CH3), 1.58 (6H, s, 2 x CH3), 1.55 (3H, s, CH3). 
31P NMR (202 MHz, D2O) δ -9.51 (d, J = 
11.0 Hz), -10.69 (d, J = 18.3 Hz). HRMS (ES-): calculated for [C16H29O7P2][M]; 395.1389, found 
395.1390. 
 
8.2.11 Synthesis of (2Z,6Z)-[6-2H]-farnesyl diphosphate (232) 
Preparation of ethyl 2-deutero-3,7-dimethylocta-2,6-dienoate (274): 
 
 
251 (1.8 g, 14.3 mmol, 1 eq.) in anhydrous THF (30 mL) was cooled to -78 ᵒC and n-butyl lithium (14.3 
mL, 2.5 M, 35.7 mmol, 2.5 eq.) added dropwise. The reaction mixture was warmed to -40 ᵒC and 
ethoxy acetylene (191)(2.5 g, 35.7 mmol, 2.5 eq.) added dropwise. The reaction mixture was slowly 
warmed to room temperature and stirred for 16 hours. The reaction was mixture was cooled to 0 ᵒC 
and quenched with D2SO4 / D2O (10 mL). Reaction products were extracted with diethyl ether (3 x 10 
mL), washed with D2O (3 x 10 mL), brine (3 x 10 mL), dried over sodium sulphate and filtered. 
Organic products were concentrated under reduced pressure and purified by silica column (10% 
ethyl acetate in hexane) gave a mixture of 273 and 274 as a clear oil (1.25 g, 44%). 
 
 
Sodium hydride (1.07 g, 26.8 mmol, 1.2 eq.) in anhydrous toluene (50 mL) was cooled to 0 ᵒC and 
272 (7.74 g, 24.6 mmol, 1.1 eq.) was added dropwise. The reaction was stirred for 1 hour at room 
temperature, cooled to 0 ᵒC and 251 (2.8 g, 22.3 mmol, 1 eq.) was added. The reaction was stirred at 
room temperature for 16 hours and quenched with D2O (20 mL). Organic products were extracted 
with diethyl ether (3 x 20 mL), washed with D2O (3 x 20 mL), brine (20 mL), dried over sodium 
sulphate, filtered and concentrated under vaccuo. Purification via flash chromatography (10% ethyl 
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acetate in hexane) gave a mixture of 273 and 274 as a clear oil (2.98 g, 68%, 30% 2H incorporation). 
Flash chromatography (5% ethyl acetate in hexanes) partially separated esters 27 and 274 for 
analysis. 
1H NMR (300 MHz, CDCl3) δ 5.53 (0.7H, s, (CH3)CCH/D), 5.08 – 4.92 (1H, m, (CH3)CCH), 4.01 (2H , q, J 
= 7.1 Hz, OCH2CH3), 2.56 – 2.45 (2H, m, CH2(CH3)CC(CH3)C(O)), 2.09 – 1.97 (2H, m, allylic CH2), 1.76 
(3H, s, CH3), 1.56 (3H, s, CH3), 1.50 (3H, s, CH3), 1.15 (3H, t, J = 7.1 Hz, OCH2CH3).
2H NMR (77 MHz) δ 
5.67 (12H, s, (CH3)CCD).
13C NMR (75 MHz, CDCl3) δ 169.7 ((CH3)CC(D)C(O)), 146.0 ((CH3)CC(D)C(O)), 
145.6 ((CH3)CC(D)C(O)), 131.8 ((CH3)CCH), 124.0 ((CH3)CCH), 60.0 (OCH2CH3), 36.5 
(CH2(CH3)CC(D)C(O)), 29.7 (CH2CH2(CH3)CC(D)C(O)), 21.0 (CH3), 17.6 (CH3), 15.9 (CH3), 15.3 (CH3), 14.3 
(OCH2CH3). 
Preparation of (Z)-2-deutero-3,7-dimethylocta-2,6-dien-1-ol (276): 
 
 
Esters 273 and 274 (1.25 g, 5.81 mmol, 1 eq.) in anhydrous toluene (20 mL) was cooled to -78 ᵒC and 
DIBALH (29 mL, 1 M, 29.01 mmol, 5 eq.) was added dropwise. Reaction mixture was stirred at room 
temperature for 16 hours and cooled to 0 ᵒC prior to being quenched by the addition of sat. Rochelle 
salts (30 mL). Reaction products were extracted with DCM (3 x 20 mL) and combined organic 
extracts washed with water (3 x 20 mL) and brine (3 x 20 mL). Washed organic extracts were dried 
over anhydrous sodium sulphate, filtered and concentrated under vaccuo. Purification via flash 
chromatography (5% ethyl acetate in hexanes) gave 276 as colourless oil (767 mg, 43%). 
1H NMR (500 MHz, CDCl3) δ 5.08 – 4.99 (1.7H, m, (CH3)CCH & (CH3)CCD), 4.02 (2H, s, 
(CH3)CH/DCH2OH), 2.06 – 1.97 (4H, m, 2 x allylic CH2), 1.68 (3H, s, CH3), 1.62 (3H, s, CH3), 1.54 (3H, s, 
CH3).
13C NMR (126 MHz, CDCl3) δ 140.0 ((CH3)CC), 132.5 ((CH3)CC), 124.3 – 123.9 ((CH3)CCDCH2OH), 
123.8 ((CH3)CC), 58.9 (C(CH3) CH2OH), 31.9 & 26.5 (2 x allylic CH2), 25.7 & 23.4 (2 x (CH3)CCH), 17.7 
(CH3).
2H NMR (61 MHz) δ 5.14 (12H, s, (CH3)CCD). 
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Table 19. 2D proton NMR correlations revealing spatial arrangement in 276 
276: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.04 4.02 
5.04 2.02 
5.04 1.68 
4.02 2.02 
 
Preparation of (Z)-1-bromo-2-deutero-3,7-dimethylocta-2,6-diene (278): 
 
 
Phosphorus tribromide (0.6 mL, 0.65 mmol, 1 eq.) was added dropwise to a stirred solution of 276 
(201 mg, 1.3 mmol, 2 eq.) in anhydrous THF (10 mL) at -10 ᵒC. The reaction mixture was stirred at -10 
ᵒC until complete consumption of starting material was observed via TLC (20% ethyl acetate in 
hexanes), warmed to 0 ᵒC and quenched with sat. sodium bicarbonate solution (5 mL). Reaction 
product was extracted with diethyl ether (3 x 5 mL), washed with water (3 x5 mL), brine (3 x5 mL) 
and dried over sodium sulphate. Dried organic extracts were filtered and concentrated under 
reduced pressure to give 278 a pale yellow oil (282 mg, 100%) which was taken forward without 
further purification. 
1H NMR (300 MHz, CDCl3) δ 5.08 – 5.01 (1H, m, (CH3)CCH), 3.94 (2H, s, CC(D) CH2Br), 2.11 – 2.00 (4H, 
m, 2 x allylic CH2), 1.71 (3H, s, CH3), 1.62 (3H, s, CH3), 1.55 (3H, s, CH3). 
2H NMR (77 MHz) δ 5.51 (12H, 
s, (CH3)CCD). 
Preparation of ethyl (Z)-2-acetyl-4-deutero-5,9-dimethyldeca-4,8-dienoate (279): 
 
 
Crude bromide 278 (282 mg, 1.3 mmol, 1 eq.), potassium carbonate (360 mg, 2.6 mmol, 2 eq.) and 
ethyl acetoacetate (337 mg, 2.6 mmol, 2 eq.) in anhydrous acetone (20 mL) was heated under reflux 
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at 60 ᵒC for 3 hours. The reaction was quenched with water (10 mL) and reaction products extracted 
with diethyl ether (3 x 10 mL). Combined organic extracts were washed with water (3 x 10 mL), brine 
(3 x 10 mL), dried over anhydrous sodium sulphate and filtered. Filtered organic extracts were 
concentrated under reduced pressure and purified via flash chromatography (20% ethyl acetate in 
hexanes) to give 279 as a clear yellow oil (282 mg, 71%). 
1H NMR (300 MHz, CDCl3) δ 5.16 – 4.98 (1.7H, m, (CH3)CCH/D), 4.19 (2H, q, J = 7.1 Hz, CH3CH2O), 3.42 
(1H, t, J = 7.6 Hz, COCHCO), 2.55 (2H, t, J = 6.9 Hz, CCH/DCH2CH), 2.23 (3H, s, COCH3), 2.11 – 2.00 (4H, 
m, 2 x allylic CH2), 1.69 (3H, s, CH3), 1.68 (3H, s, CH3), 1.61 (3H, s, CH3), 1.27 (3H, t, J = 7.1 
Hz,CH3CH2O). 
13C NMR (75 MHz, CDCl3) δ 203.18 (CH3CH2OC(O)), 169.61 (CH3COCH), 138.37 & 131.89 
((CH3)CCH & (CH3)CCD), 123.99 (CH3CCH), 120.39 – 119.49 (CH3CCD). 61.33 (CH3CH2O), 60.02 
(C(O)CHC(O)), 31.88 (allylic CH2), 29.12 (CH3C(O)), 26.54 (CCDCH2CH), 26.41 (allylic CH2), 25.73 & 
23.37 (2 x CH3), 17.67 (CH3), 14.12 (OCH2CH3). 
2H NMR (77 MHz) δ 5.02 (12H, s, (CH3)CCD). 
Preparation of (Z)-5-deutero-6,10-dimethylundeca-5,9-dien-2-one (280): 
 
 
Keto ester 279 (245 mg, 0.92 mmol, 1 eq.) was dissolved in methanol (20 mL) and potassium 
hydroxide (154 mg, 2.75 mmol, 3 eq.) added. The reaction mixture was heated under reflux at 80 ᵒC 
for 3 hours and quenched with water (10 mL). Quenched reaction mixture was acidified by the 
addition of 1 M hydrochloric acid (5 mL) and products extracted with diethyl ether (3 x 10 mL). 
Combined organic extracts were washed with water (3 x 10 mL), brine (3 x 10 mL), dried over 
anhydrous sodium sulphate and filtered. Organic extracts were concentrated under vaccuo and 
purified via flash chromatography (20% ethyl acetate in hexanes) to give 280 as a colourless oil (168 
mg, 94%). 
1H NMR (300 MHz, CDCl3) δ 5.15 – 5.03 (1.7H, m, (CH3)CCH & (CH3)CCH/D), 2.46 (2H, t, J = 7.4 Hz, 
CH2C(O)), 2.31 – 2.21 (2H, m, CH2CH2C(O)), 2.15 (3H, s, CH2C(O)CH3), 2.07 – 1.99 (4H, m, 2 x allylic 
CH2), 1.69 (6H, s, 2 x CH3), 1.62 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 209.1 (CH3C(O)), 136.4 & 
131.7 (2 x (CH3)CCH), 124.2 ((CH3)CCH), 122.5 – 120.5 (m, (CH3)CCH/D), 44.0 (CH2CH2C(O)), 31.8 & 
26.5 (2 x allylic CH2), 30.0 (CH3C(O)), 25.8 & 23.3 (2 x (CH3)CCH), 22.2 (CH2CH2CO), 17.7 (CH3). 
2H NMR 
(61 MHz) δ 5.17 (12H, s, (CH3)CCD). 
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Preparation of ethyl (2Z,6Z)-6-deutero-3,7,11-trimethyldodeca-2,6,10-trienoate (282): 
 
 
Sodium hydride (333 mg, 8.43 mmol, 2.2 eq.) in anhydrous toluene (20 mL) was cooled to 0 ᵒC. 204 
(2.52 g, 7.58 mmol, 2 eq.) was added dropwise to the stirred suspension and the reaction mixture 
stirred at room temperature for 1 hour. The reaction mixture was cooled to 0 ᵒC and 280 (740 mg, 
3.79 mmol, 1 eq.) added dropwise and stirred for 16 hours at room temperature. The reaction was 
quenched with water (10 mL) and organic products extracted with diethyl ether (3 x 10 mL) and 
combined organic extracts washed with water (3 x 10 mL) and brine (2 x 10 mL). Washed organic 
extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced 
pressure. Purification via flash chromatography (10% ethyl acetate in hexane) gave a mixture of 281 
and 282 as a clear oil (693 mg, 69%). Flash chromatography (5% ethyl acetate in hexanes) partially 
separated esters 281 and 282 for analysis. 
1H NMR (300 MHz, CDCl3) δ 5.67 (1H, s, CCHC(O)OEt), 5.23 – 5.04 (1.7H, m, (CH3)CCH & (CH3)CCH/D), 
4.15 (2H, q, J = 7.1 Hz, OCH2CH3), 2.65 (2H, t, J = 7.8 Hz, CH2(CH3)CCHC(O)), 2.19 – 2.15 (2H, m, 
CH2CH2(CH3)CCHC(O)), 2.09 – 2.04 (4H, m, 2 x allylic CH2), 1.90 (3H, s, CH3), 1.70 (3H, s, CH3), 1.62 
(3H, s, CH3), 1.29 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 166.3 (CHC(O)O), 160.1 
((CH3)CCHC(O)O), 136.2 & 131.5 (2 x (CH3)CCH), 124.5 – 124.3 (m, (CH3)CCD), 124.2 ((CH3)CCH), 116.2 
(CCHC(O)O), 59.5 (OCH2CH3), 33.7 (CH2(CH3)CCHC(O)), 31.9 & 26.6 (2 x CH2), 26.5 
(CH2CH2(CH3)CCHC(O)), 25.8 & 25.4 & 23.4 & 17.7 (4 x CH3), 14.4 (OCH2CH3). 
2H NMR (77 MHz) δ 5.69 
(12H, s, (CH3)CCD). 
Preparation of (2Z,6Z)-6-deutero-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (284): 
 
 
Esters 281 and 282 (884 mg, 3.33 mmol, 1 eq.) in anhydrous toluene (20 mL) was cooled to -78 ᵒC 
and DIBALH (16.7 mL, 16.7 mmol, 5 eq., 1 M in hexane) added dropwise. The reaction mixture was 
stirred at -78 ᵒC until complete consumption of starting material was observed via TLC (20% ethyl 
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acetate in hexanes), quenched with Rochelle salts (10 mL) and stirred for 16 hours at room 
temperature. Organic products were extracted with DCM (3 x 10 mL) and combined organic 
products washed with water (3 x 10 mL), brine (2 x 10 mL) and dried over anhydrous sodium 
sulphate. Dried organic extracts were filtered, concentrated under reduced pressure and purified via 
flash chromatography (5% ethyl acetate in hexanes) to give 284 as a colourless oil (172 mg, 23%). 
1H NMR (300 MHz, CDCl3) δ 5.38 (1H, t, J = 7.1 Hz CCHCH2O), 5.11 – 4.98 (1.7H, m, (CH3)CCH & 
(CH3)CCH/D), 4.02 (2H, t, J = 7.1 Hz, CHCH2OH), 2.10 – 1.87 (8H, m, 4 x allylic CH2), 1.68 (3H, s, CH3), 
1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 139.9 ((CH3)CCHCH2O), 136.1 & 
131.7 (2 x (CH3)CCH), 124.8 – 124.4 ((CH3)CCD), 124.5 (CCHCH2O) 124.2 ((CH3)CCH), 59.0 (CHCH2O), 
32.2 & 31.9 & 26.6 & 26.2 (4 x allylic CH2), 25.7 (CH3), 23.4 & 23.2 ((2 x (CH3)CCH), 17.6 (CH3). 
2H NMR 
(61 MHz) δ 5.13 (12H, s, (CH3)CCD). 
Table 20. 2D proton NMR correlations revealing spatial arrangement in 284 
284: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.38 4.02 
5.38 1.68 
5.05 2.04 
5.05 1.68 
5.05 1.62 
4.02 2.04 
 
Preparation of (2Z,6Z)-1-bromo-6-deutero-3,7,11-trimethyldodeca-2,6,10-triene (285): 
 
 
Alcohol 284 (172 mg, 0.77 mmol, 2 eq.) was dissolved in anhydrous tetrahydrofuran (10 mL) and 
cooled to -10 ᵒC. Phosphorus tribromide (36 µL, 0.38 mmol, 1 eq.) was added dropwise and the 
reaction mixture stirred at -10 ᵒC until complete consumption of starting material was observed via 
TLC (20% ethyl acetate in hexanes). The reaction was quenched with sat. sodium bicarbonate 
solution (5 mL) and organic products extracted with diethyl ether (3 x 10 mL). Combined organic 
extracts were washed with water (3 x 10 mL), brine (10 mL), dried over anhydrous sodium sulphate 
255 
 
and filtered. Filtered organic extracts were concentrated under reduced pressure to give 285 as a 
pale yellow oil (209 mg, 95%) which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.36 (1H, t, J = 7.1 Hz CCHCH2Br), 5.09 – 4.95 (1.7H, m, (CH3)CCH & 
(CH3)CCH/D), 3.87 (2H, t, J = 7.1 Hz, CHCH2Br), 2.10 – 1.87 (8H, m, 4 x allylic CH2), 1.68 (3H, s, CH3), 
1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3).
2H NMR (61 MHz) δ 5.15 (12H, s, (CH3)CCD). 
 
8.2.12 Synthesis of (2Z,6Z)-(S)-[1-2H]-farnesyl diphosphate (233) 
Preparation of (2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienal (217): 
 
 
(2Z,6Z) farnesol 167 (526 mg, 2.37 mmol, 1 eq.) was added to a stirred suspension of 4-acetamido-
2,2,6,6-tetramethyl-1-oxopiperidin-1-ium tetra fluoroborate salt, (TEMPO salt, 226) (781 mg, 2.60 
mmol, 1.1 eq.) and silica (20 mg, 0.33 mmol, 0.14 eq.) in dichloromethane (10 mL). The reaction was 
stirred at room temperature until complete consumption of starting material was observed via TLC 
(20% ethyl acetate in hexanes). Reaction mixture was filtered through a silica plug with 
dichloromethane. Eluent was concentrated under vaccuo to give 217 as a pale yellow oil (516 mg, 
99%) which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 9.98 (1H, d, J = 7.9 Hz, CHC(O)H), 5.87 (1H, d, J = 7.9 Hz, CHCH(O)), 5.22 
(1H, t, J = 5.7 Hz, (CH3)CCH), 5.04 (1H, t, J = 6.5 Hz, (CH3)CCH), 2.20 (2H, t, J = 7.3 Hz, allylic CH2), 2.15 
– 2.07 (2H, m, allylic CH2), 2.07 – 1.98 (4H, m, 2 x allylic CH2), 1.73 (3H, s, CH3), 1.69 (3H, s, CH3), 1.61 
(3H, s, CH3), 1.47 (3H, s, CH3). 
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Table 21. 2D proton NMR correlations revealing spatial arrangement in 217 
217: NOESY 1H - 1H interactions 
From / ppm To / ppm 
9.98 2.20 
9.98 5.22 
5.22 1.73 
5.04 2.11 
5.04 2.01 
5.04 1.69 
 
Preparation of (2Z,6Z)-1-deutero-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (287): 
 
 
Crude aldehyde 217 (521 mg, 2.36 mmol, 1 eq.) was added to a stirred solution of sodium 
borodeuteride (300 mg, 7.10 mmol, 3 eq.) in ethanol (20 mL). The reaction mixture was stirred at 
room temperature until complete consumption of starting material was observed via TLC (20% ethyl 
acetate in hexane). Reaction mixture was quenched with hydrochloric acid (1 M, 5 mL) and organic 
products extracted with diethyl ether (3 x 10 mL). Combined organic extracts were washed with 
water (3 x 10 mL) and brine (2 x 10 mL), dried over anhydrous sodium sulphate and filtered. Filtered 
organic extracts were concentrated under reduced pressure and purified via silica chromatography 
(20% ethyl acetate in hexanes) to give 287 as a colourless oil (528 mg, 100%). 
1H NMR (500 MHz, CDCl3) δ 5.37 (1H, d, J = 7.0 Hz, CCHCHDO), 5.08 – 4.99 (2H, m, 2 x (CH3)CCH), 
4.00 (1H, d, J = 7.0 Hz, CHCHDOH), 2.06 – 2.00 (4H, m, 2 x allylic CH2), 1.99 – 1.94 (4H, m, 2 x allylic 
CH2), 1.68 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.0 
((CH3)CCHCHDO), 136.2 & 131.7 (2 x (CH3)CCH), 124.5 (CCHCHDO), 124.4 & 124.2 (2 x (CH3)CCH), 
59.1 – 58.3 (CHCHDO), 32.2 & 31.9 & 26.6 & 26.3 (4 x allylic CH2), 25.8 (CH3), 23.5 & 23.4 ((2 x 
(CH3)CCH), 17.7 (CH3). 
2H NMR (77 MHz, CDCl3) δ 4.06 (1 x 
2H, s, CCHCHDO). LRMS (EI+): 205.20 (80% 
[M – H2O]), 190.17 (50%), 162.14 (95%), 143.08 (65%), 134.11 (70%), 120.09 (100%), 106.08 (80%), 
93.07 (95%), 80.06 (47%), 67.05 (30%). HRMS (EI+): calculated for [C15H25][M – H2O]; 205.1955, found 
205.1956. 
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Table 22. 2D proton NMR correlations revealing spatial arrangement in 287 
287: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.37 4.00 
5.37 1.68 
5.04 2.03 
5.04 1.97 
5.04 1.62 
4.00 2.03 
 
Preparation of (2Z,6Z)-1-deutero-3,7,11-trimethyldodeca-2,6,10-trienal (288): 
 
 
TEMPO salt 226 (781 mg, 2.60 mmol, 1.1 eq.) and silica (20 mg, 0.33 mmol, 0.14 eq.) was suspended 
in dichloromethane (20 mL). Alcohol 287 was added dropwise to the stirred suspension and the 
reaction monitored by TLC (20% ethyl acetate in hexanes) until complete consumption of starting 
material was observed. Reaction mixture was filtered through a silica plug with DCM and the eluent 
concentrated under reduced pressure to give 288 as a pale yellow oil (507 g, 97%, 80% 2H 
incorporation) which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 9.91 (0.2H, d, J = 7.9 Hz, CHC(O)H/D), 5.55 (1H,s, CHC(O)H), 5.19 – 5.04 
(1H,m, (CH3)CCH), 4.99 – 4.81 (1H, m, (CH3)CCH), 2.20 (2H, t, J = 7.3 Hz, allylic CH2), 2.15 – 2.07 (2H, 
m, allylic CH2), 2.07 – 1.98 (4H, m, 2 x allylic CH2), 1.73 (3H, s, CH3), 1.69 (3H, s, CH3), 1.61 (3H, s, CH3), 
1.47 (3H, s, CH3). 
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Preparation of (2Z,6Z)-1,1-di deutero-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (289): 
 
 
A mixture of ethyl farnesoates 182 and 183 (150 mg, 0.57 mmol, 1 eq.) was added to a stirred 
suspension of lithium aluminium deuteride (72 mg, 1.7 mmol, 3 eq.) in anhydrous tetrahydrofuran 
(20 mL). Reaction was stirred for 1 hour at -78 ᵒC and 16 hours at temperature and quenched with 
hydrochloric acid (1 M). Reaction products were extracted with diethyl ether (3 x 10 mL) and 
combined organic extracts washed with water (3 x 10 mL), brine (2 x 10 mL), dried over anhydrous 
sodium sulphate and filtered. Purification by flash chromatography (5% ethyl acetate in hexane) 
gave 289 as a colourless oil (33 mg, 26%). 
 
 
To a suspension of sodium borodeuteride (287 mg, 6.87 mmol, 3 eq.) in ethanol (10 mL) was added 
crude aldehyde 288 (507 mg, 2.29 mmol, 1 eq.) and the reaction stirred at room temperature. The 
reaction was quenched with 1 M hydrochloric acid (5 mL) upon complete consumption starting 
material by TLC (20% ethyl acetate in hexanes). Organic products were extracted with diethyl ether 
(3 x 10 mL) and washed with water (3 x 10 mL), brine (3 x 10 mL), dried over anhydrous sodium 
sulphate and filtered. Dried organic extracts were concentrated under reduced pressure and purified 
via flash chromatography (20% ethyl acetate in hexanes) to give 289 as a colourless oil (506 mg, 
99%, 91% 2H incorporation). 
1H NMR (300 MHz, CDCl3) δ 5.37 (1H, s, CCHCD2O), 5.04 (2H, t, J = 6.6 Hz, 2 x (CH3)CCH), 2.04 – 1.89 
(8H, m, 4 x allylic CH2), 1.68 (3H, d, J = 1.4 Hz, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
13C NMR 
(75 MHz, CDCl3) δ 140.1 ((CH3)CCHCD2O), 136.2 & 131.7 (2 x (CH3)CCH), 124.5 (CCHCD2O), 124.3 & 
124.8 (2 x (CH3)CCH), 32.2 & 31.9 & 26.6 & 26.3 (4 x allylic CH2), 25.8 (CH3), 23.5 & 23.7 ((2 x 
CH3)CCH), 17.7 (CH3). 
2H NMR (77 MHz,) δ 4.05 (2 x 2H, d, J = 0.6 Hz, CCHCD2O). LRMS (EI
+): 206.20 
(75% [M – H2O]), 191.18 (40%), 163.14 (90%), 135.11 (32%), 121.09 (100%), 107.08 (53%), 95.08 
(80%), 71.0 (20%). HRMS (EI+): calculated for [C15H24][M –HDO]; 206.2019, found 206.2024. 
259 
 
Preparation of (2Z,6Z)-1-deutero-3,7,11-trimethyldodeca-2,6,10-trienal (290): 
 
 
Alcohol 289 (100 mg, 0.45 mmol, 1 eq.) was added to a stirred suspension of TEMPO salt (226) (147 
mg, 0.49 mmol, 1.1 eq.) and silica (3 mg, 0.044 mmol, 0.14 eq.) in dichloromethane. The reaction 
mixture was stirred at room temperature until complete consumption of starting material was 
observed via TLC (20% ethyl acetate in hexanes).Reaction mixture was filtered through a silica plug 
with dichloromethane and the eluent concentrated under reduced pressure to give aldehyde 290 as 
a crude yellow oil (97 mg, 100%, 100% 2H incorporation). Crude aldehyde 290 was used without 
further purification. 
1H NMR (300 MHz, CDCl3) δ  5.85 (1H, s, , CHC(O)H), 5.18 (1H, t, J = 5.8 Hz, (CH3)CCH), 5.05 (1H, t, J = 
6.5 Hz, (CH3)CCH), 2.21 (2H, t, J = 7.3 Hz, allylic CH2), 2.17 – 2.10 (2H, m, allylic CH2), 2.07 – 1.99 (4H, 
m, 2 x allylic CH2), 1.74 (3H, s, CH3), 1.67 (3H, s, CH3), 1.61 (3H, s, CH3), 1.48 (3H, s, CH3). 
Preparation of (S,2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-d-1-ol (291): 
 
 
(R)-Alpine borane (975 µL, 0.49 mmol, 1.24 eq., 0.5 M in THF) was added to aldehyde 290 (87 mg, 
0.39 mmol, 1 eq.) in anhydrous tetrahydrofuran (10 mL). The reaction was quenched with 
acetaldehyde (11 µL, 0.197 mmol, 0.5 eq.) after stirring at room temperature for 4 hours. Reaction 
solvent was removed under reduced pressure and subjected to high vacuum for 1 hour to remove 
pinene. Organic products were dissolved in diethyl ether (5 mL) and cooled to 0 ᵒC. 2-Aminoethanol 
(26 µL, 0.43 mmol, 1.1 eq.) was added at 0 ᵒC; the resultant precipitate was filtered, washed with 
cold diethyl ether and the filtrate washed with water (3 x 5 mL). Organic layers were dried over 
anhydrous magnesium sulphate, filtered and concentrated under vaccuo. The crude product was 
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purified via flash chromatography (10:1 toluene / ethyl acetate) to give the desired alcohol 291 as a 
colourless oil (42 mg, 47%). Enantiomeric analysis was determined by the synthesis of Mosher esters 
and analysis of the 1H NMR spectrum. 
1H NMR (300 MHz, CDCl3) δ 5.38 (1H, d, J = 7.2 Hz CCHCHDO), 5.07 – 5.01 (2H, m, 2 x (CH3)CCH), 4.00 
(1H, d, J = 7.2 Hz, CHCHDOH), 2.06 – 2.00 (4H, m, 2 x allylic CH2), 1.99 – 1.91 (4H, m, 2 x allylic CH2), 
1.68 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.0 
((CH3)CCHCHDO), 136.2 & 131.7 (2 x (CH3)CCH), 124.5 (CCHCHDO), 124.4 & 124.2 (2 x (CH3)CCH), 
59.4 – 58.2 (CHCHDO), 32.2 & 31.9 & 26.6 & 26.3 (4 x allylic CH2), 25.8 (CH3), 23.5 & 23.4 ((2 x 
(CH3)CCH), 17.7 (CH3). 
2H NMR (77 MHz) δ 3.98 (1 x 2H, s, CCHCHDO). ). LRMS (EI+): 206.20 (72% [M – 
H2O]), 191.18 (40%), 163.14 (90%), 135.11 (32%), 121.09 (100%), 107.08 (53%), 95.08 (77%), 71.0 
(18%). HRMS (EI+): calculated for [C15H24][M –HDO]; 206.2019, found 206.2018. 
Table 23. 2D proton NMR correlations revealing spatial arrangement in 291 
291: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.38 4.00 
5.38 1.68 
5.04 2.03 
5.04 1.95 
5.04 1.62 
4.00 2.03 
 
Preparation of (S)-[1-2H]-(2Z,6Z) farnesol Mosher esters (297 and 298) 
 
 
To a stirred solution of (S)-[1-2H]-(2Z,6Z)-farnesol 291 (1 mg, 0.0045 mmol, 1 eq.) and pyridine (1.1 
mg, 0.0139, 3.1 eq.) in anhydrous dichloromethane (1 mL) was added (S)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride (2.4 mg, 0.0094 mmol, 2.1 eq.) and stirred for 6 hours at room 
temperature. Reaction was quenched with water (500 µL) and the crude product dissolved in diethyl 
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ether (2 mL). The solution was washed with 0.1 M hydrochloric acid (1 mL), sat. sodium bicarbonate 
solution (1 mL), water (1 mL) and dried over anhydrous magnesium sulphate. Dried organic fraction 
were purified by preparative TLC (20% ethyl acetate in hexane) and extracted directly into 
deuterated chloroform for 1H NMR analysis. 
1H NMR (600 MHz, CDCl3) δ 7.56 – 7.53 (3H, m, 3 x aromatic H), 7.42 – 7.40 (2H, m, 2 x aromatic H), 
5.40 (1H, d, J = 7.1 Hz, CCHCHDO), 5.14 – 5.06 (2H, m, 2 x ((CH3)CCH), 4.78 (1H, d, J = 7.1 Hz, CHDO), 
3.58 (3H, s, OCH3), 2.20 – 1.97 (8H, m, 4 x allylic CH2), 1.78 (3H, s, CH3), 1.70 (6H, s, 2 x CH3), 1.62 (3H, 
s, CH3). 
 
 
(S)-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (2.4 mg, 0.0094 mmol, 2.1 eq.) was added to 
a stirred solution of (S)-[1-2H]-(2Z,6Z) farnesol 291 (1 mg, 0.0045 mmol, 1 eq.) and pyridine (1.1 mg, 
0.0139, 3.1 eq.) in anhydrous dichloromethane (1 mL) and stirred for 6 hours at room temperature. 
Reaction was quenched with water (500 µL) and the crude product dissolved in diethyl ether (2 mL). 
The solution was washed with 0.1 M hydrochloric acid (1 mL), sat. sodium bicarbonate solution (1 
mL), water (1 mL) and dried over anhydrous magnesium sulphate. Dried organic fraction were 
purified by preparative TLC (20% ethyl acetate in hexane) and extracted directly into deuterated 
chloroform for 1H NMR analysis. 
1H NMR (600 MHz, CDCl3) δ 7.56 – 7.53 (3H, m, 3 x aromatic H), 7.42 – 7.40 (2H, m, 2 x aromatic H), 
5.40 (1H, d, J = 7.0 Hz, CCHCHDO), 5.14 – 5.06 (2H, m, 2 x ((CH3)CCH), 4.82 (1H, d, J = 7.0 Hz, CHDO), 
3.58 (3H, s, OCH3), 2.21 – 1.97 (8H, m, 4 x allylic CH2), 1.79 (3H, s, CH3), 1.72 (6H, s, 2 x CH3), 1.62 (3H, 
s, CH3). 
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(R,2Z,6Z)-1-chloro-3,7,11-trimethyldodeca-2,6,10-triene-1-d (292): 
 
 
N-Chlorosuccinamide (55 mg, 0.414 mmol, 2.2 eq.) in anhydrous dichloromethane (3 mL) was cooled 
to -40 ᵒC and dimethyl sulphide (33 µL, 0.451 mmol, 2.4 eq.) added dropwise. The mixture was 
warmed to 0 ᵒC, cooled to -40 ᵒC and (S)-[1-2H]-farnesol 291 (42 mg, 0.188 mmol, 1 eq.) in anhydrous 
dichloromethane (1 mL) was added to the suspension dropwise. The reaction was allowed to warm 
to 0 ᵒC over 1 hour, stirred at 0 ᵒC for 1 hour and at room temperature for 15 minutes. The reaction 
mixture was diluted with dichloromethane (2 mL), washed with cold brine (2 mL) and the aqueous 
layer washed with cold hexane (3 x 3 mL). Combined organic layers were washed with water (3 x 2 
mL), brine (3 x 2 mL), dried over anhydrous sodium sulphate and filtered. Solvent was removed 
under reduced pressure to give chloride 292 as a pale yellow oil (41 mg, 91%). 
1H NMR (500 MHz, CDCl3) δ 5.37 (1H, d, J = 7.9 Hz CCHCHDCl), 5.08 – 5.00 (2H, m, 2 x (CH3)CCH), 3.99 
(1H, d, J = 7.9 Hz, CHCHDCl), 2.07 – 2.03 (4H, m, 2 x allylic CH2), 2.01 – 1.95 (4H, m, 2 x allylic CH2), 
1.70 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
2H NMR (77 MHz) δ 4.05 (1 x 2H, s, 
CCHCHDCl). 
(S,2Z,6Z) -3,7,11-trimethyldodeca-2,6,10-trien-1-d – yl diphosphate (233): 
 
 
A mixture of crude chloride 292 (41 mg, 0.170 mmol, 1 eq.) and tris tetrabutyl ammonium 
pyrophosphate (306 mg, 0.339 mmol, 2 eq.) in anhydrous acetonitrile (2 mL) was stirred at room 
temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the 
resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield diphosphate 233 as a white powder. The powder was dissolved in buffer solution 
(25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent A: acetonitrile, solvent B: 2% 
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iPrOH). The appropriate fractions were collected and lyophilized to give diphosphate 233 as a white 
powder (1 mg, 1%). 
1H NMR (300 MHz, CDCl3) δ 2.01 – 1.76 (4H, m, 2 x allylic CH2), 1.62 – 1.39 (4H, m, 2 x allylic CH2), 
1.25 (3H, s, CH3), 1.19 (6H, s, 2 x CH3), 1.14 (3H, s, CH3). HRMS (ES
-): calculated for [C15H26DO7P2][M]; 
382.1295, found 382.1294. 
8.2.13 Synthesis of (2Z,6Z)-(R)-[1-2H]-farnesyl diphosphate (234) 
Preparation of (R,2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-d-1-ol (300): 
 
 
Aldehyde 290 (73 mg, 0.33 mmol, 1 eq.) was dissolved in anhydrous tetrahydrofuran (5 mL). 
(S)-Alpine borane (817 µL, 0.41 mmol, 1.24 eq., 0.5 M in THF) was added and the reaction stirred at 
room temperature for 4 hours. Acetaldehyde (9.3 µL) was added to the reaction mixture, solvent 
removed under reduced pressure and the crude product subjected to high vacuum for 1 hour to 
remove pinene. Concentrated product was dissolved in diethyl ether (5 mL), cooled to 0 ᵒC and 
2-aminoethanol (22 µL) added dropwise. The resultant precipitate was washed with diethyl ether (5 
mL) and the filtrate washed with water (3 x 5 mL). Organic filtrate was washed with water (3 x 5 mL), 
dried over anhydrous magnesium sulphate and concentrated under reduced pressure. Crude 
product was purified via flash chromatography (10:1 toluene / ethyl acetate) to afford alcohol 300 
and a colourless oil (32 mg, 43%). Enantiomeric analysis was determined by the synthesis of Mosher 
esters and analysis of the 1H NMR spectrum. 
1H NMR (300 MHz, CDCl3) δ 5.37 (1H, d, J = 6.9 Hz CCHCHDO), 5.08 – 4.98 (2H, m, 2 x (CH3)CCH), 4.00 
(1H, d, J = 6.9 Hz, CHCHDOH), 2.06 – 2.00 (4H, m, 2 x allylic CH2), 1.99 – 1.91 (4H, m, 2 x allylic CH2), 
1.68 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3).
13C NMR (75 MHz, CDCl3) δ 140.0 
((CH3)CCHCHDO), 136.2 & 131.7 (2 x (CH3)CCH), 124.5 (CCHCHDO), 124.4 & 124.2 (2 x (CH3)CCH), 
59.1 – 58.3 (CHCHDO), 32.2 & 31.9 & 26.6 & 26.3 (4 x allylic CH2), 25.7 (CH3), 23.5 & 23.4 ((2 x 
(CH3)CCH), 17.7 (CH3).
2H NMR (77 MHz) δ 3.96 (1 x 2H, s, CCHCHDO). LRMS (EI+): 206.20 (78% [M – 
H2O]), 191.18 (40%), 163.14 (87%), 135.11 (35%), 121.09 (100%), 107.08 (57%), 95.08 (75%), 71.0 
(20%). HRMS (EI+): calculated for [C15H24][M –HDO]; 206.2019, found 206.2015.  
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Table 24. 2D proton NMR correlations revealing spatial arrangement in 300 
300: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.37 4.00 
5.37 1.68 
5.03 2.03 
5.03 1.95 
5.03 1.62 
4.00 2.03 
 
Preparation of (R)-[1-2H]-(2Z,6Z) farnesol Mosher esters (303 and 304) 
 
 
To a stirred solution of (R)-[1-2H]-(2Z,6Z) farnesol 300 (1 mg, 0.0045 mmol, 1 eq.) and pyridine (1.1 
mg, 0.0139, 3.1 eq.) in anhydrous dichloromethane (1 mL) was added (S)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride (2.4 mg, 0.0094 mmol, 2.1 eq.) and stirred for 6 hours at room 
temperature. Reaction was quenched with water (500 µL) and the crude product dissolved in diethyl 
ether (2 mL). The solution was washed with 0.1 M hydrochloric acid (1 mL), sat. sodium bicarbonate 
solution (1 mL), water (1 mL) and dried over anhydrous magnesium sulphate. Dried organic fraction 
were purified by preparative TLC (20% ethyl acetate in hexane) and extracted directly into 
deuterated chloroform for 1H NMR analysis. 
1H NMR (600 MHz, CDCl3) δ 7.56 – 7.52 (3H, m, 3 x aromatic H), 7.43 – 7.40 (2H, m, 2 x aromatic H), 
5.40 (1H, d, J = 6.7 Hz, CCHCHDO), 5.14 – 5.08 (2H, m, 2 x ((CH3)CCH), 4.83 (1H, d, J = 6.8 Hz, CHDO), 
3.57 (3H, s, OCH3), 2.16 – 2.00 (8H, m, 4 x allylic CH2), 1.78 (3H, s, CH3), 1.70 (3H, s, CH3), 1.69 (3H, s, 
CH3), 1.62 (3H, s, CH3). 
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(S)-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (2.4 mg, 0.0094 mmol, 2.1 eq.) was added to 
a stirred solution of (R)-[1-2H]-(2Z,6Z) farnesol 300 (1 mg, 0.0045 mmol, 1 eq.) and pyridine (1.1 mg, 
0.0139, 3.1 eq.) in anhydrous dichloromethane (1 mL) and stirred for 6 hours at room temperature. 
Reaction was quenched with water (500 µL) and the crude product dissolved in diethyl ether (2 mL). 
The solution was washed with 0.1 M hydrochloric acid (1 mL), sat. sodium bicarbonate solution (1 
mL), water (1 mL) and dried over anhydrous magnesium sulphate. Dried organic fraction were 
purified by preparative TLC (20% ethyl acetate in hexane) and extracted directly into deuterated 
chloroform for 1H NMR analysis. 
1H NMR (600 MHz, CDCl3) δ 7.56 – 7.51 (3H, m, 3 x aromatic H), 7.43 – 7.39 (2H, m, 2 x aromatic H), 
5.40 (1H, d, J = 6.7 Hz, CCHCHDO), 5.14 – 5.07 (2H, m, 2 x ((CH3)CCH), 4.78 (1H, d, J = 6.7 Hz, CHDO), 
3.58 (3H, s, OCH3), 2.17 – 1.99 (8H, m, 4 x allylic CH2), 1.78 (3H, s, CH3), 1.70 (3H, s, CH3), 1.69 (3H, s, 
CH3), 1.62 (3H, s, CH3). 
(S,2Z,6Z)-1-chloro-3,7,11-trimethyldodeca-2,6,10-triene-1-d (301): 
 
 
Dimethyl sulphide (57 µL, 0.784 mmol, 2.4 eq.) added dropwise to a suspension of 
N-chlorosuccinamide (96 mg, 0.719 mmol, 2.2 eq.) in anhydrous dichloromethane (4 mL) at -40 ᵒC. 
The mixture was briefly warmed to 0 ᵒC prior to the suspension being cooled to -40 ᵒC and (R)-[1-2H]-
farnesol 300 (73 mg, 0.327 mmol, 1 eq.) in anhydrous dichloromethane (1 mL) added dropwise. The 
reaction was warmed to 0 ᵒC over 1 hour, stirred at 0 ᵒC for 1 hour and then room temperature for 
15 minutes. The reaction mixture was diluted with dichloromethane (2 mL), washed with cold brine 
(2 mL) and the aqueous layer washed with cold hexane (3 x 3 mL). Combined organic layers were 
washed with water (3 x 3 mL), brine (3 x 3 mL), dried over anhydrous sodium sulphate and filtered. 
Solvent was removed under reduced pressure to give chloride 301 as a pale yellow oil (70 mg, 89%). 
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1H NMR (500 MHz, CDCl3) δ 5.37 (1H, d, J = 7.9 Hz CCHCHDCl), 5.07 – 5.02 (2H, m, 2 x (CH3)CCH), 3.99 
(1H, d, J = 7.9 Hz, CHCHDCl), 2.07 – 2.03 (4H, m, 2 x allylic CH2), 2.00 – 1.95 (4H, m, 2 x allylic CH2), 
1.70 (3H, s, CH3), 1.62 (6H, s, 2 x CH3), 1.54 (3H, s, CH3). 
2H NMR (77 MHz) δ 4.05 (1 x 2H, s, 
CCHCHDCl). 
 
(R,2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-d – yl diphosphate (234): 
 
 
A mixture of 301 (70 mg, 0.289 mmol, 1 eq.) and tris tetrabutyl ammonium pyrophosphate (522 mg, 
0.579 mmol, 2 eq.) in anhydrous acetonitrile (4 mL) was stirred at room temperature for 16 hours. 
The reaction mixture was concentrated under reduced pressure and the resultant residue dissolved 
in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and the tris tetrabutylammonium salt counter 
ions were exchanged for ammonium by ion exchange column containing Amberlyst 131 (wet H+ 
form) mesh cation exchange resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% 
isopropanol). The appropriate fractions were collected and lyophilized to yield diphosphate as a 
white powder. The powder was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and 
purified using HPLC (Solvent A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were 
collected and lyophilized to give 234 as a white powder (2 mg, 2%). 
1H NMR (300 MHz, CDCl3) δ 2.02 – 1.73 (4H, m, 2 x allylic CH2), 1.61 – 1.40 (4H, m, 2 x allylic CH2), 
1.22 (3H, s, CH3), 1.18 (6H, s, 2 x CH3), 1.14 (3H, s, CH3). HRMS (ES
-): calculated for [C15H26DO7P2][M]; 
382.1295, found 382.1299. 
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8.2.14 Synthesis of (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) 
Preparation of (2Z,6Z)-1- tritio-3,7,11-trimethyldodeca-2,6,10-trien-1-yl diphosphate 
(229): 
 
 
Sodium [3H] borohydride 5 mCi (15 mCi/mmol) in anhydrous tetrahydrofuran (0.5 mL) was cooled to 
0 ᵒC. (2Z,6Z) farnesal (217) (20 mg, 0.091 mmol, 1 eq.) in anhydrous tetrahydrofuran (0.3 mL) was 
added to the reaction mixture and stirred at 0 ᵒC for 4 hours. Sodium borohydride (10 mg, 0.272 
mmol, 3 eq.) in anhydrous tetrahydrofuran (0.3 mL) was added to the reaction mixture and stirred at 
0 ᵒC for 16 hours. The reaction was quenched with brine (0.5 mL) and the reaction product extracted 
with diethyl ether (3 x 0.5 mL). Combined organic extracts were washed with water (3 x 1 mL), brine 
(3 x 0.5 mL), dried by passage through a pipette of sodium sulfate and concentrated under a stream 
of nitrogen to give (2Z,6Z)-[1-3H]-farnesol (227) as a colourless oil (20 mg, 100%). Analysis via TLC 
(20% ethyl acetate in hexane) showed a single reaction product. A sample from the TLC plate was 
suspended in Ecoscint A scintillation cocktail (15 mL) and analysed using a liquid scintillation counter 
confirming tritium incorporation. The reaction product 227 was taken forward without further 
purification.  
Alcohol 227 (20 mg, 0.091 mmol, 1 eq.) was dissolved in anhydrous tetrahydrofuran (2 mL) and 
cooled to -10 ᵒC. Phosphorus tribromide (5 µL, 0.045 mmol, 0.5 eq.) was added to the reaction 
mixture an stirred at -10 ᵒC until complete consumption of starting material was observed via TLC 
(20% ethyl acetate in hexane). Saturated sodium bicarbonate solution (1 mL) was added and 
reaction mixture stirred until effervescence had ceased. The organic layer was removed and the 
aqueous layers extracted with diethyl ether (3 x 1 mL). Combined organic layers were washed with 
sat. sodium bicarbonate solution (3 x 1 mL), water (3 x 1 mL) and brine (3 x 1 mL). Washed organic 
layers were dried by passage through a pipette of sodium sulfate and concentrated under a stream 
of nitrogen to give crude bromide 228 as a pale yellow oil (22 mg, 85%). Crude bromide 228 was 
analysed via TLC (20% ethyl acetate in hexane) and showed a single product. A sample from the 
product spot was removed from the TLC plate, suspended in Ecoscint A scintillation cocktail (15 mL) 
and analysed using a liquid scintillation counter confirming tritium incorporation. Crude bromide 228 
was taken forward without further purification. 
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A solution of tris-tetra-n-butyl ammonium hydrogen pyrophosphate (104 mg, 0.115 mmol, 1.5 eq.) in 
anhydrous acetonitrile (1 mL) was added to a stirred solution of bromide 228 (22 mg, 0.0766, 1 eq.) 
in anhydrous acetonitrile (0.5 mL) and stirred at room temperature for 16 hours. Solvent was 
removed under a stream of nitrogen to give crude diphosphate as a pale brown oil. Crude 
diphosphate was dissolved in 25 mM ammonium bicarbonate, 2% isopropanol buffer (2 mL), applied 
to a 1 x 6 cm column of Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated 
with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol) and slowly eluted with the same buffer. 
Eluent fractions were tested for radioactivity by sample dilution into Ecoscint A scintillation cocktail 
(15 mL) and radioactive fractions lyophilised to give a white powder. Lyophilised product was 
dissolved in 25 mM ammonium bicarbonate, 2% isopropanol buffer (2 mL) and applied to a SNAP 
Ultra C18 Biotage column. Product was eluted with H2O (2 x column volume), H2O:MeCN (2:1)(1 x 
column volume), H2O:MeCN (1:1)(2 x column volume), H2O:MeCN (1:2)(1 x column volume) and 
MeCN (2 x column volume). Fractions eluted by H2O:MeCN (1:1) exhibited radioactivity when diluted 
in Ecoscint A scintillation cocktail (15 mL)and analysed via liquid scintillation counter. Appropriate 
fractions were combined and lyophilised to give (2Z,6Z)–[1-3H]–farnesyl diphosphate (229) as a 
white powder 1.55 mCi (specific activity = 0.028 Ci mmol-1, 18 mg, 46% over 3 steps). 
8.2.15 Synthesis of (2Z,6Z)-10,11-epoxyfarnesyl diphosphate (361) 
Preparation of 2-(((2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)tetrahydro-2H-
pyran (395): 
 
 
Pyridinium p-toluenesulfonate (154 mg, 0.61 mmol, 0.1 eq.) was added to stirred solution of (2Z,6Z) 
farnesol 167 (1.35 g, 6.1 mmol, 1 eq.) and 3,4-dihydropyran DHP (1.41 g, 15.3 mmol, 2.5 eq.) in 
dichloromethane(40 mL). The reaction was stirred at room temperature for 2 hours and water 
added to the reaction mixture. The aqueous layer was washed with dichloromethane (3 x 20 mL) and 
combined organic layers washed with brine (30 mL). Washed organic layers were dried over 
anhydrous sodium sulphate, filtered and solvent removed under reduced pressure. Purification via 
flash chromatography (10% ethyl acetate in hexanes) afforded 395 as a colourless oil (1.86 g, 100%). 
1H NMR (300 MHz, CDCl3) δ 5.39 (1H, t, J = 6.3 Hz, CHCH2O), 5.18 – 5.05 (2H, m, 2 x(CH3)CCH), 4.68 – 
4.61 (1H, m, OCHO), 4.11 (2H, ddd, J = 19.3, 11.8, 6.3 Hz, CHCH2O), 3.94 – 3.47 (2H, m, CHOCH2), 2.07 
(8H, m,4 x CH2), 1.92 – 1.44 (6H, m, CH(CH2)3CH2O), 1.76 (3H, s, CH3), 1.69 (6H, s, 2 x CH3), 1.62 (3H, s, 
269 
 
CH3). 
13C NMR (125 MHz, CDCl3)
 δ 140.5 & 135.6 & 131.6 (3 x (CH3)CCH), 124.6 & 124.3 (2 x 
(CH3)CCH), 121.6 ((CH3)CCHCH2O), 97.9 (OCHO), 63.45 (CHCH2O), 62.2 (OCH2(CH2)3), 32.3 & 31.8 & 
26.6 & 26.4 (4 x allylic CH2), 30.5 (OCH2CH2), 25.6 (CH3), 25.3 (CH2), 23.4 & 23.2 (2 x CH3), 19.6 (CH2), 
17.5 (CH3). LRMS (ES
+): 329.25 (100% [M + Na]). HRMS (ES+): calculated for [C20H34O3Na]; 329.2457, 
found 329.2462. 
Preparation of (6Z,10Z)-2-bromo-2,6,10-trimethyl-12-((tetrahydro-2H-
pyran-2yl)oxy)dodeca-6,10-dien-3-ol (396): 
 
 
395 (1.83 g, 5.96 mmol, 1 eq.) was dissolved in THF:H2O (50 mL, 2:1) and cooled to 0 ᵒC. 
N-bromosuccinimide (1.17 g, 6.56 mmol, 1.1 eq.) was added in portions over 30 minutes at 0 ᵒC and 
stirred for 2 hours, warmed to room temperature and stirred for a further 2 hours. The reaction was 
diluted with hexane (30 mL), separated with brine (20 mL) and the aqueous layer extracted washed 
with hexane (3 x 10 mL). The combined organic extracts were dried over anhydrous sodium sulphate 
and concentrated under reduced pressure. Purification via flash chromatography (20% ethyl acetate 
in hexane) gave 396 as a pale yellow oil (983 mg, 40%). 
1H NMR (300 MHz, CDCl3) δ 5.39 (1H, t, J = 6.3 Hz, CHCH2O), 5.25 – 5.16 (1H, m, (CH3)CCH), 4.65 (1H, 
t, J = 3.4 Hz, OCHO), 4.29 – 3.98 (2H, m, CHCH2O), 3.96 (1H, dd, J = 11.3, 1.8 Hz, CBrC(OH)H), 3.90 – 
3.49 (2H, m, CHOCH2), 2.33 – 1.97 (8H, m, 4 x CH2), 1.90 – 1.46 (6H, m, CH(CH2)3CH2O) 1.78 (3H, s, 
CH3), 1.69 (3H, s, CH3), 1.36 (3H, s, CH3), 1.35 (3H, s, CH3). 
13C NMR (125 MHz, CDCl3)
 δ 140.2 & 133.9 
(2 x (CH3)CCH), 126.3 & 121.7 (2 x (CH3)CCH), 97.9 (OCHO), 72.4 (CBrC(OH)), 70.8 (CBrC(OH)), 63.6 
(CHCH2O), 62.1 (OCH2(CH2)3), 32.5 & 32.3 & 26.4 (3 x allylic CH2), 30.7 & 30.5 (2 x CH2), 26.64 & 26.61 
(2 x CH3CBr), 25.5 (CH2), 23.7 & 23.3 (2 x CH3), 19.5 (CH2). LRMS (AP
+): 425.17 (100% [M + Na]), 
387.25 (20%), 345.24 (30%), 306.09 (15%), 243.08 (10%), 203.18 (12%). HRMS (AP+): calculated for 
[C20H35O3BrNa]; 425.1667, found 425.1657. 
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Preparation of 2-(((2Z,6Z)-9-(3,3-dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-
yl)oxy)tetrahydro-2H-pyran (397): 
 
 
396 (901 mg, 2.25 mmol, 1 eq.) in methanol (50 mL) was stirred at room temperature and potassium 
carbonate (623 mg, 4.5 mmol, 2 eq.) added. The resultant suspension was stirred for 1 hour and 
concentrated under reduced pressure prior to dilution with water (50 mL) and brine (20 mL). The 
aqueous layer was separated, washed with hexane (3 x 30 mL) and combined organic fractions with 
1 M hydrochloric acid (20 mL), brine (30 mL) and dried of anhydrous sodium sulphate. Dried organic 
extracts were filtered, concentrated under vaccuo and purified by column chromatography (20% 
ethyl acetate in hexane) to give 397 as a colourless oil (710 mg, 99%). 
1H NMR (300 MHz, CDCl3) δ 5.39 (1H, t, J = 6.4 Hz, CHCH2O), 5.22 – 5.10 (1H, m, (CH3)CCH), 4.67 – 
4.59 (1H, m, OCHO), 4.10 (2H, ddd, J = 19.1, 11.3, 7.4 Hz, CHCH2O), 3.93 – 3.44 (2H, m, CHOCH2), 2.72 
(1H, t, J = 6.3 Hz, C(O)CH), 2.24 – 2.02 (6H, m, 3 x CH2), 1.90 – 1.45 (8H, m, 3 x CH(CH2)3CH2O & 
C(O)CHCH2), 1.76 (3H, s, CH3), 1.70 (3H, s, CH3), 1.31 & 1.28 (6H, s, 2 x (CH3)2C(O)C). 
13C NMR (75 
MHz, CDCl3) δ 140.3 & 134.6 (2 x (CH3)CCH), 125.2 & 121.7 (2 x (CH3)CCH), 97.9 (OCHO), 64.1 
(C(O)CH), 63.4 (CHCH2O), 62.2 (OCH2(CH2)3), 58.4 (C(O)CH), 32.3 & 28.5 &26.5 (3 x allylic CH2), 30.7 
(OCH2CH2), 27.4 (CH2), 25.5 (CH2), 24.9 (CH3), 23.6 & 23.3 (2 x CH3C(O)C), 19.6 (CH2), 18.7 (CH3). LRMS 
(ES+): 345.24 (100% [M + Na]), 221.19 (40%), 203 (20%]). HRMS (ES+): calculated for [C20H34O3Na]; 
345.2406, found 345.2404. 
Preparation of (2Z,6Z)-9-(3,3-dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-ol (398): 
 
 
p-Toluenesulfonic acid (5.9 mg, cat.) was added to a stirred solution of 397 (100 mg, 0.31 mmol, 1 
eq.) in methanol (10 mL) and stirred at room temperature for 2 hours. The reaction volume was 
reduced by 80% under vaccuo and diluted with sat. sodium bicarbonate solution (10 mL) and 
separated with hexane (10 mL). The aqueous layer was washed with hexane (3 x 10 mL) and 
combined organic fraction washed with brine (10 mL), dried over anhydrous sodium sulphate and 
271 
 
filtered. Solvent was removed under reduced pressure and purified by flash chromatography (20% 
ethyl acetate in hexane) to give 398 as a colourless oil (68 mg, 92%). 
1H NMR (300 MHz, CDCl3) δ 5.37 (1H, t, J = 7.2 Hz, CHCH2OH), 5.09 (1H, t, J = 6.5 Hz, (CH3)CCH), 4.02 
(2H, d, J = 7.2 Hz, CHCH2O), 3.32 (1H, dd, J = 10.4, 1.8 Hz, C(O)CH) 2.44 – 2.28 (2H, m, C(O)CCH2), 2.12 
– 1.93 (6H, m, 3 x allylic CH2), 1.68 (3H, s, CH3), 1.62 (3H, s, CH3), 1.05 & 1.02 (2 x 3H, s, (CH3)2C(O)C). 
13C NMR (75 MHz, CDCl3) δ 140.1 & 135.9 (2 x (CH3)CCH), 125.2 & 124.4 (2 x (CH3)CCH), 76.3 
(C(O)CH), 58.8 (CHCH2O), 49.1 (C(O)CH), 32.3 & 28.9 & 26.8 (3 x allylic CH2), 29.6 (C(O)CHCH2), 23.8 & 
23.3 (2 x CH3C(O)C), 20.7 (CH3), 18.9 (CH3). LRMS (ES
+): 221.19 (100% [M – H2O]), 203.18 (15%). 
HRMS (ES+): calculated for [C15H25O]
+ [M – H2O]; 221.1905, found 221.1906. 
Preparation of 3-((3Z,7Z)-9-bromo-3,7-dimethylnona-3,7-dien-1-yl)-2,2-dimethyloxirane 
(399): 
 
 
Alcohol 398 (44 mg, 0.18 mmol, 2 eq.) in anhydrous tetrahydrofuran (5 mL) was cooled to -10 ᵒC and 
phosphorus tribromide (9 µL, 0.09 mmol, 1 eq.) added dropwise. The reaction mixture was stirred at 
-10 ᵒC until complete consumption of starting material was observed via TLC (20% ethyl acetate in 
hexane) and quenched with sat. sodium bicarbonate solution (3 mL). Organic product was extracted 
with diethyl ether (3 x 5 mL) and combined organic extracts washed with water (3 x 5 mL), brine (3 x 
5 mL), dried over anhydrous sodium sulphate and filtered. Solvent was removed under vaccuo to 
give bromide 399 as a pale yellow oil (55 mg, 97%) which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.35 (1H, t, J = 7.2 Hz, CHCH2Br), 5.09 (1H, t, J = 6.5 Hz, (CH3)CCH), 3.97 
(2H, d, J = 7.2 Hz, CHCH2Br), 3.32 (1H, dd, J = 10.4, 1.8 Hz, C(O)CH) 2.44 – 2.28 (2H, m, C(O)CCH2), 
2.12 – 1.93 (6H, m, 3 x allylic CH2), 1.68 (3H, s, CH3), 1.62 (3H, s, CH3), 1.05 & 1.02 (2 x 3H, s, 
(CH3)2C(O)C). 
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Preparation of 3-((3Z,7Z)-9-bromo-3,7-dimethylnona-3,7-dien-1-yl)-2,2-dimethyloxirane 
diphosphate (361): 
 
 
A mixture of 399 (55 mg, 0.18 mmol, 1 eq.) and tris tetrabutyl ammonium pyrophosphate (333 mg, 
0.37 mmol, 2 eq.) in anhydrous acetonitrile (3 mL) was stirred at room temperature for 16 hours. 
The reaction mixture was concentrated under reduced pressure and the resultant residue dissolved 
in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and the tris tetrabutylammonium salt counter 
ions were exchanged for ammonium by ion exchange column containing Amberlyst 131 (wet H+ 
form) mesh cation exchange resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% 
isopropanol). The appropriate fractions were collected and lyophilized to yield diphosphate as a 
white powder. The powder was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and 
purified using HPLC (Solvent A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were 
collected and lyophilized to give 361 as a white powder (0.7 mg, 1%). 
1H NMR (500 MHz, D2O) δ 5.42 – 5.36 (1H, m, (CH3)CCHCH2O), 5.15 – 5.09 (1H, m, (CH3)CCH), 4.41 – 
4.36 (2H, m, CCHCH2O), 3.57 (1H, dd, J = 10.4, 1.8 Hz, C(O)CH), 2.18 – 2.04 (4H, m, 2 x allylic CH2), 
2.02 – 1.88 (4H, m, 2 x allylic CH2), 1.70 (3H, s, CH3), 1.64 (3H, s, CH3), 1.58 (6H, s, 2 x CH3). 
31P NMR 
(202 MHz, D2O) δ -8.71 (d, J = 12.0 Hz), -9.95 (d, J = 16.3 Hz). HRMS (ES
-): calculated for 
[C15H27O8P2][M]; 397.1181, found 397.1177. 
8.2.16 Synthesis of (2Z,6Z,10Z)-12-methoxyfarnesyl diphosphate(362) 
Preparation of (4Z,8Z)-4,8-dimethyl-10-((tetrahydro-2H-pyran-2-yl)oxy)deca-4,8-dienal 
(401): 
 
 
A solution of periodic acid (462 mg, 2.03 mmol, 1.1 eq.) and sodium periodate (197 mg, 0.92 mmol , 
0.5 eq.) in dH2O was added dropwise over 15 minutes to a stirred solution of 397 (594 mg, 1.84 
mmol, 1 eq.) in THF:H2O (16.5 mL, 10:1) at 0 ᵒC. The reaction was stirred for 30 minutes at 0 ᵒC and 
warmed to room temperature and stirred for a further 2 hours. The reaction was quenched with sat. 
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sodium bicarbonate sol. (10 mL) and separated with hexane (20 mL). The aqueous layer was washed 
with hexane (3 x 10 mL) and the combined organic extracts washed with 1M hydrochloric acid (10 
mL), brine (2 x 10 mL), dried over anhydrous sodium sulphate and filtered. Solvent was removed 
under reduced pressure and purified by column chromatography (10% ethyl acetate in hexane) to 
give 401 as a colourless oil (452 mg, 71%). 
1H NMR (300 MHz, CDCl3) δ 9.79 (1H, s, (O)CHCH2), 5.40 (1H, t, J = 5.6 Hz, CHCH2O), 5.23 – 5.11 (1H, 
m, CHCH2CH2), 4.63 (1H, s, OCHO), 4.10 (2H, ddd, J = 19.3, 11.8, 6.3 Hz, CHCH2O ), 3.92 – 3.46 (2H, m, 
CHOCH2), 2.57 – 2.47 (2H, m, (O)CHCH2), 2.39 – 2.31 (2H, m, (O)CHCH2CH2 ), 2.11 (4H, s, 2 x allylic 
CH2), 1.90 – 1.45 (6H, m, 3 x CH2), 1.76 (3H, s, CH3), 1.69 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 
202.3 ((O)CHCH2), 140.2 & 133.4 (2 x (CH3)CCH), 126.0 & 121.8 (2 x (CH3)CCH), 97.9 (OCHO), 63.4 
(CHCH2O), 62.2 (OCH2(CH2)3), 42.4 ((O)CHCH2), 32.2 & 26.5 (2 x CH2CH2), 30.7 (OCH2CH2), 25.5 (CH2), 
24.2 (CH2), 23.6 & 23.1 (2 x CH3), 19.6 (CH2). LRMS (ES+): 303.19 (100% [M + Na]), 243.08 (50%), 
179.14 (20%), 161.12 (20%). HRMS (ES+): calculated for [C17H28O3Na]; 303.1936, found 303.1933. 
Preparation of ethyl (2Z,6Z,10Z)-2,6,10-trimethyl-12-((tetrahydro-2H-pyran-2-
yl)oxy)dodeca-2,6,10-trienoate (402): 
 
 
371 (187 mg, 0.54 mmol, 2 eq.) was added to a stirred suspension of sodium hydride (24 mg, 0.6 
mmol, 2.2 eq.) in anhydrous toluene (20 mL) at 0 ᵒC. The reaction mixture was warmed to room 
temperature and stirred for 1 hour. The reaction mixture was cooled to 0 ᵒC and 401 (76 mg, 
0.27mmol, 1 eq.) was added dropwise and stirred for 16 hours at room temperature. The reaction 
was quenched with water (5 mL) and organic products extracted with diethyl ether (3 x 10 mL). 
Combined organic extracts were washed with water (3 x 10 mL), brine (3 x 10 mL), dried over 
anhydrous sodium sulphate and filtered. Solvent was removed under reduced pressure and crude 
product purified via flash chromatography (10% ethyl acetate in hexane) to give ester 402 as a 
colourless oil (94 mg, 95%). 
1H NMR (300 MHz, CDCl3) δ 5.91 (1H, td, J = 7.4, 1.4 Hz, (EtO(O)CCCH)), 5.39 (1H, t, J = 7.6 Hz, 
CHCH2O), 5.19 – 5.11 (1H, m, (CH3)CCH), 4.64 (1H, t, J = 3.4 Hz, OCHO), 4.21 (3H, q, J = 7.1 Hz, 
CH3CH2O), 4.29 – 3.94 (2H, m, CHCH2O), 3.93 – 3.47 (2H, m, CHOCH2), 2.55 (2H, q, J = 7.4 Hz, 
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(EtO(O)CCCHCH2), 2.18 – 2.03 (6H, m, 3 x allylic CH2), 1.90 (3H, s, CH3), 1.76 (3H, s, CH3), 1.69 (3H, s, 
CH3), 1.67 – 1.47 (6H, m, 3 x CH2), 1.31 (3H, t, J = 7.1 Hz,CH3CH2O). 
13C NMR (75 MHz, CDCl3) δ 168.1 
(EtOC(O)CCH), 142.2 (EtOC(O)CCH), 140.4 & 134.9 & 127.4 (3 x (CH3)CCH), 125.2 & 121.7 (2 x 
(CH3)CCH), 97.9 (OCHO), 63.4 (CHCH2O) 62.2 (OCH2(CH2)3), 60.1 (CH3CH2O), 32.4 & 31.3 & 26.5 (3 x 
allylic CH2), 30.7 (OCH2CH2) 27.9 (EtOC(O)CCHCH2), 25.5 (CH2), 23.61 (CH2), 23.2 (CH3), 22.7 (CH3), 
20.7 (CH3), 14.3 (CH3CH2O). LRMS (AP+): 387.25 (100% [M + Na]), 306.09 (10%), 263.20 (35%), 217.16 
(10%), 161.12 (20%). HRMS (AP+): calculated for [C22H36O4Na]; 387.2511, found 387.2503. 
Preparation of (2Z,6Z,10Z)-2,6,10-trimethyl-12-((tetrahydro-2H-pyran-2-yl)oxy)dodeca-
2,6,10-trien-1-ol (403): 
 
 
Ester 402 (94 mg, 0.26 mmol, 1 eq.) in anhydrous toluene (10 mL) was cooled to -78 ᵒC and DIBALH 
(770 µL, 0.77 mmol, 3 eq.) added dropwise. Reaction was stirred at -78 ᵒC until complete 
consumption of starting material was observed via TLC (20% ethyl acetate in hexane), warmed to 
room temperature and quenched with Rochelle salts (2 mL). Quenched reaction mixture was stirred 
at room temperature for 16 hours and reaction products extracted with DCM (3 x 5 mL). Combined 
organic extracts were washed with water (3 x 5 mL), brine (3 x 5 mL), dried over anhydrous sodium 
sulphate and filtered. Solvent was removed under reduced pressure and crude products purified by 
column chromatography (10% ethyl acetate in hexane) to give alcohol 403 as a colourless oil (89 mg, 
100%). 
1H NMR (300 MHz, CDCl3) δ 5.31 (1H, t, J = 6.9 Hz, (HOCH2(CH3)CCH), 5.21 (1 H, t, J = 7.1 Hz, 
CHCH2O), 5.07 (1H, t, J = 7.9 Hz, (CH3)CCH), 4.56 (1H, t, J = 3.6 Hz, OCHO), 4.03 (2H, dd, J = 11.8, 7.0 
Hz, CHCH2O), 4.02 (2H, s, CH2OH), 3.85 – 3.40 (2H, m, CHOCH2), 2.11 – 1.92 (8H, m, 4 x allylic CH2), 
1.73 (3H, s, CH3), 1.68 (3H, s, CH3), 1.61 (3H, s, CH3), 1.58 – 1.37 (6H, m, 3 x CH2). 
13C NMR (75 MHz, 
CDCl3) δ 140.4 & 135.3 & 134.9 (3 x (CH3)CCH), 127.9 (CHCH2O), 125.2 ((CH3)CCH), 121.6 
(HOCH2(CH3)CCH), 97.9 (OCHO), 63.5 (CHCH2O), 62.1 (OCH2(CH2)3), 61.4 (CH2OH), 32.5 & 32.0 & 26.7 
& 26.2 (4 x allylic CH2) 30.7 (OCH2CH2), 25.5 (CH2), 23.7 & 23.5 & 21.4 (3 x CH3), 19.5 (CH2). LRMS 
(ES+): 345.24 (100% [M + Na]), 305.25 (10%), 287.24 (7%), 265.06 (7%), 243.08 (6%), 221.19 (12%), 
203.18 (30%), 163.15 (3%). HRMS (ES+): calculated for [C20H34O3Na]; 345.2406, found 345.2421.  
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Table 25. 2D proton NMR correlations revealing spatial arrangement in 403 
403: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.31 3.62 / 1.68 
5.21 2.01 / 1.61 
5.07 1.68 / 2.01 
4.02 2.01 / 1.68  
 
Preparation of 2-(((2Z,6Z,10Z)-12-methoxy-3,7,11-trimethyldodeca-2,6,10-trien-1-
yl)oxy)tetrahydro-2H-pyran (404): 
 
 
A solution of 403 (168 mg, 0.52 mmol, 1 eq.) in anhydrous tetrahydrofuran (5 mL) was added 
dropwise to a stirred suspension of sodium hydride (125 mg, 3.13 mmol, 6 eq.) in anhydrous 
tetrahydrofuran (20 mL) and stirred for 15 minutes. Methyl iodide (2.81 g, 19.83 mmol, 38 eq.) was 
added dropwise and stirred for 48 hours at room temperature at which complete consumption of 
starting material was observed via TLC (20% ethyl acetate in hexane). The reaction was quenched 
with 1 M hydrochloric acid (10 mL) and the aqueous layer extracted with diethyl ether (3 x 10 mL). 
Combined organic layers were washed with sat. sodium bicarbonate (3 x 10 mL), water (3 x 10 mL), 
brine (3 x 10 mL),dried over anhydrous sodium sulphate and filtered. Solvent was removed under 
reduced pressure and crude product was purified by column chromatography (20% ethyl acetate in 
hexane) to give 404 as a colourless oil (88 mg, 52%). 
1H NMR (300 MHz, CDCl3) δ 5.44 – 5.32 (1H, m, (CH3OCH2(CH3)CCH), 5.20 – 5.07 (1 H, m, CHCH2O), 
4.64 (1H, s, OCHO)), 4.11 (2H, dd, J = 11.6, 7.1 Hz, CHCH2O), 3.93 (2H, s, CH2OCH3), 3.87 – 3.45 (2H, 
m, CHCH2O), 3.30 (3H, s, CH2OCH3), 2.19 – 2.00 (8H, m, 4 x allylic CH2), 1.75 (3H, s, CH3), 1.69 (3H, s, 
CH3), 1.91 – 1.49 (6H, m, 3 x CH2), 1.27 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.4 & 135.1 & 
132.1 (3 x (CH3)CCH), 129.2 (CHCH2O), 125.0 ((CH3)CCH), 121.6 (CH3OCH2(CH3)CCH), 97.9 (OCHO), 
70.7 (CH3OCH2), 63.4 (CHCH2O), 62.2 (OCH2(CH2)3), 57.6 (CH3OCH2), 32.4 & 32.1 & 26.6 & 26.2 (4 x 
allylic CH2), 30.7 (CH2),  25.5 (CH2), 23.6 & 23.4 & 21.5 (3 x CH3), 19.6 (CH2). LRMS (ES
+): 359.26 (100% 
[M + Na]), 287.24 (7%), 235.21 (5%), 203.18 (32%), 163.14 (2%). HRMS (ES+): calculated for 
[C21H36O3Na]; 359.2562, found 359.2567. 
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Preparation of (2Z,6Z,10Z)-12-methoxy-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (405): 
 
 
To a stirred solution of 404 (59 mg, 0.17 mmol, 1 eq.) in methanol (5 mL) was added 
p-toluenesulfonic acid (3 mg, cat.) and stirred at room temperature for 2 hours. The reaction volume 
was reduced by 80% under vaccuo and diluted with sat. sodium bicarbonate solution (5 mL) and 
separated with hexane (5 mL). The aqueous layer was washed with hexane (3 x 5 mL) and combined 
organic fraction washed with brine (10 mL), dried over anhydrous sodium sulphate and filtered. 
Solvent was removed under reduced pressure and purified by flash chromatography (20% ethyl 
acetate in hexane) to give 405 as a colourless oil (22 mg, 54%). 
1H NMR (300 MHz, CDCl3) δ 5.38 (1H, t, J = 6.8 Hz, (CH3OCH2(CH3)CCH), 5.30 (1H, t, J = 7.0 Hz, 
CHCH2O), 5.12 – 5.00 (1H, m, CH2(CH3)CCH), 4.02 (2H, d, J = 7.0 Hz, CHCH2O), 3.85 (2H, s, 
CH3OCH2(CH3)CCH), 3.22 (3H, s, CH3OCH2(CH3)), 2.13 – 1.92 (8H, m, 4 x CH2), 1.68 (6H, s, 3 x CH3), 
1.62 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 139.8 & 135.6 & 132.2 (3 x (CH3)CCH), 129.1 (CHCH2O), 
124.9 & 124.5 (2 x (CH3)CCH), 70.9 (CH3OCH2), 59.0 (CHCH2O), 57.7 (CH3OCH2), 32.2 & 32.1 & 26.4 & 
26.2 (4 x allylic CH2), 23.5 & 23.3 & 21.6 (3 x CH3). LRMS (ES
+): 252.22 (2% [M]), 235.21 (45%), 203.18 
(7%), 189.17 (14%), 163.14 (3%), 147.11 (2%). HRMS (EI+): calculated for [C16H28O2] [M]; 252.2089, 
found 252.2088. 
Preparation of (2Z,6Z,10Z)-12-methoxy-1-bromo-2,6,10-trimethyldodeca-2,6,10-triene 
(406): 
 
 
Phosphorus tribromide (9 µL, 0.09 mmol, 1 eq.) was added dropwise to a stirred solution of 405 (45 
mg, 0.18 mmol, 2 eq.) in anhydrous THF (10 mL) at -10 ᵒC. the reaction mixture was stirred at -10 ᵒC 
until complete consumption of starting material was observed via TLC (20% ethyl acetate in hexane). 
Reaction was quenched with sat. sodium bicarbonate sol (5 mL) and product extracted with diethyl 
ether (3 x 5 mL). Combined organic extracts were washed with water (3 x 5 mL), brine (3 x 5 mL), 
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dried over anhydrous sodium sulphate and filtered. Solvents were removed under reduced pressure 
to give bromide 406 as a pale yellow oil (56 mg. 100%) that was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 5.51 – 5.45 (1H, m, (CH3OCH2(CH3)CCH), 5.35 – 5.26 (1H, t, J = 7.0 Hz, 
CHCH2Br), 5.09 – 5.01 (1H, m, CH2(CH3)CCH), 3.93 (2H, d, J = 8.4 Hz, CHCH2Br), 3.85 (2H, s, 
CH3OCH2(CH3)CCH), 3.22 (3H, s, CH3OCH2(CH3)), 2.28 – 1.97 (8H, m, 4 x CH2), 1.67 (3H, s, CH3), 1.61 
(3H, s, CH3), 1.55 (3H, s, CH3). 
Preparation of (2Z,6Z,10Z)-12-methoxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl 
diphosphate (362): 
 
 
Tris tetra butyl ammonium pyrophosphate (240 mg, 0.266 mmol, 1.5 eq.) in anhydrous acetonitrile 
(3 mL) was added to crude bromide 406 (56 mg, 0.178 mmol, 1 eq.) under argon. The reaction was 
stirred for 16 hours at room temperature and volatile solvents removed under reduced pressure to 
give crude diphosphate as a brown oil. Crude diphosphate was dissolved in buffer solution (25 mM 
NH4HCO3, 2% iPrOH) (5 mL) and the tris tetrabutylammonium salt counter ions were exchanged for 
ammonium by ion exchange column containing Amberlyst 131 (wet H+ form) mesh cation exchange 
resin pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate 
fractions were collected and lyophilized to yield diphosphate 362 as a white powder. The powder 
was dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (5 mL) and purified using HPLC (Solvent 
A: acetonitrile, solvent B: 2% iPrOH). The appropriate fractions were collected and lyophilized to give 
362 as a white powder (2 mg, 2%).  
1H NMR (500 MHz, D2O) δ 5.41 – 5.30 (2H, m, 2 x (CH3)CCH)), 5.14 – 5.06 (1H, m, (CH3)CCH), 4.36 – 
4.30 (2H, m, CHCH2O), 3.88 (2H, s, CH3OCH2(CH3)CCH), 3.18 (3H, s, CH3OCH2(CH3)), 2.10 – 1.94 (8H, 
m, 4 x CH2), 1.64 (3H, s, CH3), 1.59 (3H, s, CH3), 1.56 (3H, s, CH3).
 31P NMR (202 MHz, D2O) δ -5.87 (d, J 
= 19.0 Hz), -9.43 (d, J = 17.7 Hz). HRMS (ES-) [C16H29O8P2][M]; 411.1338, found 411.1338. 
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8.2.17 Synthesis of (2Z,6Z,10E)-13-methoxyfarnesyl diphosphate(363) 
Preparation of ethyl (2E,6Z,10Z)-2,6,10-trimethyl-12-((tetrahydro-2H-pyran-2-
yl)oxy)dodeca-2,6,10-trienoate (417): 
 
 
A stirred solution of 368 (440 mg, 1.27 mmol, 2 eq.) in anhydrous tetrahydrofuran (20 mL) was 
cooled to 0 ᵒC and n-butyl lithium (51 µL, 1.27 mmol, 2 eq., 2.5M in hexanes) was added dropwise. 
The resulting solution was stirred at room temperature for 1 hour, cooled to 0 ᵒC and 401 (178 mg, 
0.64 mmol, 1 eq.) added dropwise. The reaction mixture was stirred for 16 hours at room 
temperature. The reaction was quenched with water (5 mL) and the product was extracted with 
diethyl ether (3 x 5 mL). The combined organic phases were washed with water (3 x 10 mL) and brine 
(2 x 10 mL), then dried over sodium sulphate, filtered and the solvent removed under reduced 
pressure. Purification via flash chromatography on silica gel (5% ethyl acetate in hexane) provided 
ester 417 as a clear oil (210 mg, 91%). 
1H NMR (300 MHz, CDCl3) δ 6.75 (1H, td, J = 7.3, 1.4 Hz, (EtO(O)CCCH)), 5.43 – 5.36 (1H, m, CHCH2O), 
5.17 (1H, dt, J = 9.2, 2.8 Hz, (CH3)CCH), 4.63 (1H, t, J = 3.4 Hz, OCHO), 4.19 (3H, q, J = 7.1 Hz, 
CH3CH2O), 4.27 – 3.94 (2H, m, CHCH2O), 3.93 – 3.47 (2H, m, CHOCH2), 2.32 – 2.05 (8H, m, 4 x allylic 
CH2), 1.85 (3H, s, CH3), 1.76 (3H, d, J = 1.0 Hz, CH3), 1.71 (3H, s, CH3), 1.65 – 1.47 (6H, m, 3 x CH2), 
1.30 (3H, t, J = 7.1 Hz,CH3CH2O). 
13C NMR (75 MHz, CDCl3) δ 168.2 (EtOC(O)CCH), 141.6 
(EtOC(O)CCH), 140.3 & 134.4 & 127.9 (3 x (CH3)CCH), 125.5 & 121.7 (2 x (CH3)CCH), 97.9 (OCHO), 
63.4 (CHCH2O), 62.2 (OCH2(CH2)3), 60.4 (CH3CH2O), 32.3 & 30.6 & 27.3 & 26.9 (4 x allylic CH2), 30.7 
(OCH2CH2), 25.5 (CH2), 25.3 (CH2), 23.6 (CH3), 23.3 (CH3), 14.3 (CH3CH2O), 12.4 (CH3). LRMS (ES
+): 
387.25 (70% [M + Na]), 382.30 (35%), 263.20 (100%), 217.16 (5%), 189.16 (10%). HRMS (ES+): 
calculated for [C22H36O4Na]; 387.2511, found 387.2517. 
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Preparation of ethyl (2E,6Z,10Z)-2,6,10-trimethyl-12-((tetrahydro-2H-pyran-2-
yl)oxy)dodeca-2,6,10-trien-1-ol (418): 
 
 
Diisobutylaluminimiun hydride (922 µL, 0.922 mmol, 3 eq.) was added to a stirred solution of 417 
(112 mg, 0.307 mmol, 1 eq.) in anhydrous toluene (5 mL) at -78 ᵒC. The reaction was stirred for 3 
hours at -78 ᵒC and quenched with saturated potassium sodium tartrate solution (5 mL). Reaction 
products were extracted with dichloromethane (3 x 5 mL). Combined organic extracts were washed 
with water (3 x 5 mL), brine (3 x 5 mL), dried over sodium sulphate and concentrated under reduced 
pressure. Purification via flash chromatography on silica gel (20% ethyl acetate in hexane) to yield 
418 as a clear oil (97 mg, 98%). 
1H NMR (300 MHz, CDCl3) δ 5.37 – 5.27 (2H, m, 2 x (CH3)CCH), 5.12 – 5.00 (1H, m, (CH3)CCH), 4.57 (1H, 
t, OCHO), 4.20 – 3.86 (2H, m, CHCH2O), 3.92 (2H, s, CH2OH), 3.85 – 3.38 (2H, m, CHOCH2), 2.13 – 1.90 
(8H, m, 4 x allylic CH2), 1.69 (3H, s, CH3), 1.61 (3H, s, CH3), 1.60 (3H, s, CH3), 1.56 – 1.40 (6H, m, 3 x 
CH2), 1.18 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.4 & 135.3 & 135.0 (3 x (CH3)CCH), 125.5 
(CHCH2O), 124.9 ((CH3)CCH), 121.6 (HOCH2(CH3)CCH), 97.8 (OCHO), 68.8 (CH2OH), 63.5 (CHCH2O), 
62.1 (OCH2(CH2)3), 32.5 & 31.5 & 26.6 & 26.1 (4 x allylic CH2), 30.7 (OCH2CH2) 25.5 (CH2), 23.6 & 23.3 
& 21.3 (3 x CH3), 19.4 (CH2). LRMS (ES
+): 345.24 (100% [M + Na]), 323.15 (2%), 203.18 (6%). HRMS 
(ES+): calculated for [C22H36O3Na]; 345.2406, found 345.2409.  
Table 26. 2D proton NMR correlations revealing spatial arrangement in 418 
418: NOESY 1H - 1H interactions 
From / ppm To / ppm 
5.32 1.61 / 1.48 
5.06 1.61 
3.92 5.06 / 1.69 
2.02 1.69 
 
280 
 
Preparation of 2-(((2Z,6Z,10Z)-13-methoxy-3,7,11-trimethyldodeca-2,6,10-trien-1-
yl)oxy)tetrahydro-2H-pyran (419): 
 
 
To a stirred suspension of sodium hydride (121 mg, 3.03 mmol, 6 eq.) in anhydrous tetrahydrofuran 
(20 mL) a solution of 418 (163 mg, 0.51 mmol, 1 eq.) in anhydrous tetrahydrofuran (5 mL) was added 
dropwise and stirred for 15 minutes. Methyl iodide (2.73 g, 19.2 mmol, 38 eq) was added dropwise 
and stirred for 48 hours at room temperature at which complete consumption of starting material 
was observed via TLC (20% ethyl acetate in hexane). The reaction was quenched with 1 M 
hydrochloric acid (5 mL) and the aqueous layer extracted with diethyl ether (3 x 10 mL). Combined 
organic layers were washed with sat. sodium bicarbonate (3 x 10 mL), water (3 x 10 mL), brine (3 x 
10 mL),dried over anhydrous sodium sulphate and filtered. Solvent was removed under reduced 
pressure and crude product was purified by column chromatography (20% ethyl acetate in hexane) 
to give 419 as a colourless oil (95 mg, 56%). 
1H NMR (300 MHz, CDCl3) δ 5.49 – 5.34 (1H, m, (CH3OCH2(CH3)CCH), 5.20 – 5.06 (1 H, m, CHCH2O), 
4.64 (1H, s, OCHO), 3.94 – 3.48 (2H, m, CHCH2O), 3.80 (2H, s, CH2OCH3), 3.94 – 3.48 (2H, m, CHCH2O), 
3.28 (3H, s, CH2OCH3), 2.28 – 1.99 (8H, m, 4 x allylic CH2), 1.76 (3H, s, CH3), 1.70 (3H, s, CH3), 1.90 – 
1.47 (6H, m, 3 x CH2), 1.66 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 140.5 & 135.3 & 132.2 (3 x 
(CH3)CCH), 128.0 (CHCH2O), 124.8 ((CH3)CCH), 121.6 (CH3OCH2(CH3)CCH), 97.9 (OCHO), 72.3 
(CH3OCH2), 63.4 (CHCH2O), 62.2 (OCH2(CH2)3), 57.4 (CH3OCH2), 32.4 & 31.6 & 26.5 & 26.3 (4 x allylic 
CH2), 30.7 (CH2), 25.5 (CH2), 23.6 & 23.4 & 22.7 (3 x CH3), 19.6 (CH2). LRMS (ES
+): 359.26 (100% [M + 
Na]), 319.27 (2%), 287.24 (7%), 235.21 (5%), 203.18 (32%), 163.14 (2%), 147.11 (2%). HRMS (ES+): 
calculated for [C21H36O3Na]; 359.2562, found 359.2565. 
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Preparation of (2Z,6Z,10E)-12-methoxy-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (420): 
 
 
p-Toluenesulfonic acid (5 mg, cat.) was added to a stirred solution of 419 (99 mg, 0.29 mmol, 1 eq.) 
in methanol (5 mL) and stirred at room temperature for 2 hours. The reaction volume was reduced 
by 80% under vaccuo and diluted with sat. sodium bicarbonate solution (5 mL) and separated with 
hexane (5 mL). The aqueous layer was washed with hexane (3 x 5 mL) and combined organic fraction 
washed with brine (5 mL), dried over anhydrous sodium sulphate and filtered. Solvent was removed 
under reduced pressure and purified by flash chromatography (20% ethyl acetate in hexane) to give 
420 as a colourless oil (73 mg, 98%). 
1H NMR (300 MHz, CDCl3) δ 5.53 – 5.35 (2H, m, 2 x (CH3)CCH), 5.21 – 5.08 (1H, m, (CH3)CCH), 4.10 
(2H, d, J = 7.0 Hz, CHCH2O), 3.80 (2H, s, CH3OCH2(CH3)CCH), 3.29 (3H, s, CH3OCH2(CH3)), 2.31 – 2.01 
(8H, m, 4 x CH2), 1.76 (3H, s, CH3), 1.71 (3H, s, CH3), 1.66 (3H, s, CH3). 
13C NMR (75 MHz, CDCl3) δ 
139.9 & 135.9 & 132.3 (3 x (CH3)CCH), 127.8 (CHCH2O), 124.8 & 124.5 (2 x (CH3)CCH), 78.7 
(CH3OCH2), 59.0 (CHCH2O), 57.5 (CH3OCH2), 32.2 & 31.5 & 26.4 & 26.3 (4 x allylic CH2), 23.5 & 23.3 & 
13.8 (3 x CH3). LRMS (ES
+): 252.22 (2% [M]), 235.21 (45%), 203.18 (10%), 189.17 (14%), 163.14 (5%), 
147.11 (2%). HRMS (EI+): calculated for [C16H28O2] [M]; 252.2089, found 252.2093. 
Preparation of (2E,6Z,10Z)-12-bromo-1-methoxy-2,6,10-trimethyldodeca-2,6,10-triene 
(421): 
 
 
Phosphorus tribromide (11 µL, 0.12 mmol, 1 eq.) was added dropwise to a stirred solution of 420 (60 
mg, 0.24 mmol, 2 eq.) in anhydrous THF (10 mL) at -10 ᵒC. Reaction was quenched with sat. sodium 
bicarbonate sol. (5 mL) upon completion observed via TLC (20% ethyl acetate in hexanes). Reaction 
products were extracted with diethyl ether (3 x 5 mL) and ethereal layers were washed with water (3 
x 5 mL) and brine (3 x 5 mL). Products were dried over sodium sulphate, filtered and concentrated 
under reduced pressure to give 421 as a crude yellow oil (75 mg, 100%) which was used without 
further purification.  
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1H NMR (300 MHz, CDCl3) δ 5.39 – 5.27 (2H, m, 2 x (CH3)CCH), 5.09 – 5.01 (1H, m, (CH3)CCH), 4.06 
(2H, d, J = 8.4 Hz, CHCH2Br), 4.00 (2H, s, CH3OCH2(CH3)CCH), 3.29 (3H, s, CH3OCH2(CH3)), 2.23 – 1.93 
(8H, m, 4 x CH2), 1.68 (3H, s, CH3), 1.62 (3H, s, CH3), 1.58 (3H, s, CH3). 
Preparation of (2E,6Z,10Z)- 1-methoxy-2,6,10-trimethyldodeca-2,6,10-trien-12-yl 
diphosphate (363): 
 
 
A mixture of crude bromide 421 (75 mg, 0.238 mmol, 1 eq.) and tris tetrabutyl ammonium 
pyrophosphate (322 mg, 0.357 mmol, 1.5 eq.) in anhydrous acetonitrile (5 mL) was stirred at room 
temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the 
resultant residue dissolved in buffer solution (25 mM NH4HCO3, 2% iPrOH) (7 mL) and the tris 
tetrabutylammonium salt counter ions were exchanged for ammonium by ion exchange column 
containing Amberlyst 131 (wet H+ form) mesh cation exchange resin pre-equilibrated with ion-
exchange buffer (25 mM NH4HCO3, 2% isopropanol). The appropriate fractions were collected and 
lyophilized to yield diphosphate 363 as a white powder. The powder was dissolved in buffer solution 
(25 mM NH4HCO3, 2% iPrOH) (10 mL) and purified using HPLC (Solvent A: acetonitrile, solvent B: 2% 
iPrOH). The appropriate fractions were collected and lyophilized to give diphosphate 363 as a white 
powder (2 mg, 2%). 
1H NMR (500 MHz, D2O) δ 5.47 – 5.35 (2H, m, 2 x (CH3)CCH), 5.19 – 5.08 (1H, m, (CH3)CCH), 4.48 – 
4.33 (2H, m, CHCH2O) 3.81 (2H, s, CH3OCH2(CH3)CCH), 3.21 (3H, s, CH3OCH2(CH3)), 2.17 – 1.96 (8H, m, 
4 x CH2), 1.83 (3H, s, CH3), 1.62 (3H, s, CH3), 1.57 (3H, s, CH3).
 31P NMR (202 MHz, D2O) δ -5.92 (d, J = 
19.1 Hz), -9.48 (d, J = 17.9 Hz). [C16H29O8P2][M]; 411.1338, found 411.1333. 
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8.2.18 Synthesis of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (204) 
Preparation of ethyl 2-(bis((trimethylsilyl)oxy)phosphoryl)acetate (205): 
 
 
Triethyl phosphono acetate (202) (2.26 g, 10.0 mmol, 1 eq.) and trimethyl silyl chloride (5.47 g, 50 
mmol, 5 eq.) were placed in a sealed pressurised tube under argon and stirred at 60 ᵒC for 7 days. 
The mixture was concentrated under a steam of nitrogen and dried under vacuum for 1 hour to give 
205 as a light yellow oil (2.64 g, 84%) which was taken forward without further purification.  
 
 
Triethyl phosphono acetate (202) (15 g, 59.3 mmol, 1 eq.) was added to trimethyl silyl bromide (39 
mL, 296.1 mmol, 5 eq.) and refluxed at 80 ᵒC for 5 hours. The mixture was concentrated under a 
steam of nitrogen and dried under vacuum for 1 hour to give 205 as an orange oil (20 g, 100%) which 
was taken forward without further purification. 
1H NMR (300 MHz, CDCl3) δ 4.13 (2H, q, J = 7.1 Hz, OCH2CH3), 2.92 (2H, d, J= 22.2 Hz, PCH2CO), 1.22 
(3H, t, J = 7.1 Hz, OCH2CH3), 0.26 (18H, s, 2 x (CH3)3Si). 
31P NMR (162 MHz, CDCl3) δ 13.93. LRMS (ES
+): 
312.10 (10% [M]), 297.08 (40%), 269.04 (70%), 211.00 (100%). HRMS (ES+): calculated for 
[C10H25O5Si2P]
+; 312.0974, found 312.0978. 
Preparation of ethyl 2-(dichlorophosphoryl)acetate (206): 
 
 
A stirred solution of ethyl 2-(bis((trimethylsilyl)oxy)phosphoryl)acetate (205) (20 g, 59.25 mmol, 1 
eq.) in dichloromethane (50 mL) was added dropwise oxalyl chloride (21.3 g, 279.25 mmol, 2.5 eq.), 
dimethyl formamide (0.1 mL, cat.) and stirred for 2 hours. The mixture was concentrated under a 
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steam of nitrogen and dried under vacuum for 1 hour to give 206 as a light orange oil (13.7 g, 100%) 
which was taken forward without further purification. 
1H NMR (300 MHz, CDCl3) δ 4.31 (2H, q, J = 7.1 Hz, OCH2CH3), 3.75 (2H, d, J= 19.1 Hz, PCH2CO), 1.34 
(3H, t, J = 7.1 Hz, OCH2CH3). 
31P NMR (162 MHz, CDCl3) δ 33.42. 
Preparation of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (204): 
 
 
A stirred solution of ethyl 2-(dichlorophosphoryl)acetate (206) (13.7 g, 59.25 mmol, 1 eq.) in 
dichloromethane (50 mL) was cooled to 0 ᵒC. A solution of 2,2,2-tri fluoro ethanol (26.8 g, 268.1 
mmol, 4 eq.) and triethylamine (40.7 g, 402.15 mmol, 6 eq.) was cooled to 0 ᵒC and added to the 
reaction mixture dropwise. 4-dimethylaminopyridine (164 mg, 1.34 mmol, 0.02 eq.) was added and 
the reaction mixture was stirred for 2 hours at room temperature, diluted with dichloromethane 
(100 mL) and stirred for 1 hour. Mixture was washed with water (3 x 50 mL) and brine (3 x 50 mL), 
dried over magnesium sulfate and concentrated under reduced pressure. Purification via flash 
chromatography on silica gel (40% ethyl acetate in hexane) provided phosphono acetate 204 as a 
brown oil (10.48 g, 47%). 
1H NMR (300 MHz, CDCl3) δ 4.40 (2H, quin, J = 8.1 Hz, OCH2CF3), 4.16 (2H, q, J = 7.2 Hz, OCH2CH3), 
3.10 (2H, d, J= 21.1 Hz, PCH2CO), 1.23 (3H, t, J = 7.2 Hz, OCH2CH3). 
13C NMR (125 MHz, CDCl3)
 δ 164.7 
(CH2C(O)OCH2), 124.3 (d, JCF = 8.2 Hz, OCH2CF3), 120.6 (d, JCF = 8.6 Hz, OCH2CF3), 62.8 (d, 
3JCF = 5.5 Hz, 
2 x CF3CH2O), 62.3 (2 x CH3CH2O), 34.0 (d, JCP = 144.5 Hz, P(O)CH2CO), 13.9 (OCH2CH3). 
31P NMR (202 
MHz, CDCl3)
 δ 23.55. 19F NMR (471 MHz, CDCl3)
 δ -77.11. LRMS (ES+): 333.03 (100% [M + H]), 305.00 
(15%), 286.99 (10%). HRMS (ES+): calculated for [C8H12O5F6P]
+; 333.0327, found 333.0327. 
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8.2.19 Synthesis of ethyl 2-(diphenoxyphosphoryl)acetate (203) 
Preparation of ethyl 2-(diphenoxyphosphoryl)acetate (203): 
 
 
205 (3.51 g,15 mmol, 1 eq.) was added dropwise over 30 minutes to a stirred suspension of sodium 
hydride (360 mg, 15 mmol, 1 eq.) in anhydrous THF (40 mL) and stirred at room temperature for 1 
hour. Ethyl bromoacetate (2.5 g, 15 mmol, 1 eq.) was added to the reaction mixture dropwise over 
30 minutes and the reaction mixture stirred at room temperature for 16 hours. The reaction was 
quenched with water (20 mL) and organic products extracted with DCM (3 x 20 mL). Combined 
organic layers were washed with brine (3 x 20 mL), dried over anhydrous magnesium sulphate and 
filtered. Solvent was removed under vaccuo and the crude product purified by flash chromatography 
on silica (50% ethyl acetate in hexane) to give 203 as a colourless oil (3.27 g, 68%). 
1H NMR (300 MHz, CDCl3) δ 7.40 – 7.17 (10H, m, 10 x aromatic CH), 4.25 (2H, q, J = 7.1 Hz, OCH2CH3), 
3.29 (2H, d, J = 21.6 Hz, PCH2CO), 1.29 (3H, t, J = 7.1 Hz, OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 164.82 
(CH2C(O)OCH2), 150.02 and 149.91 (2 x OC(CH)5), 129.89, 125.61, 125.59, 120.70 and 120.64 
(aromatic C), 62.08 (OCH2CH3), 34.09 (d, JCP = 137.2 Hz, P(O)CH2CO), 14.10 (OCH2CH3). LRMS (ES
+): 
321.09 (100% [M + H]), 275.05 (25%). HRMS (ES+): calculated for [C16H18O5P]; 321.0892, found 
321.0878. 
 
8.2.20 Synthesis of ethyl 2-(diethoxyphosphoryl)propanoate (368) 
Preparation of ethyl 2-(diethoxyphosphoryl)propanoate (368): 
 
 
A mixture of ethyl 2-bromopropionate 367 (15.0 g, 82.8 mmol, 1 eq.) and triethyl phosphite (13.75 g, 
82.8 mmol, 1 eq.) were heated under reflux at 150 ᵒC for 16 hours. Product was purified via vacuum 
distillation giving 368 as a light brown oil (11.3 g, 57%). 
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1H NMR (300 MHz, CDCl3) δ 4.31 – 4.01 (6H, m, 3 x OCH2CH3), 3.01 (1H, dq, J = 23.4, 7.3 Hz, 
PCH(CH3)), 1.43 (3H, dd, J = 18.0, 7.3 Hz), 1.35 (3H, t, J = 2.2 Hz, OCH2CH3), 1.32 (3H, t, J = 2.2 Hz, 
OCH2CH3), 1.29 (3H, t, J = 2.2 Hz, OCH2CH3). 
13C NMR (125 MHz, CDCl3)
 δ 169.8 (d, 3JCP = 4.58, 
CHC(O)OCH2),  62.7 & 62.6 (2 x CH3CH2OP), 61.4 (CH3CH2O), 30.3 (d, 
2JCP = 133.46, 
 PCH(CH3)C(O)), 
16.43 & 16.40 (2 x P(O)CH2CH3), 11.6 (C(O)OCH2CH3). 
31P NMR (202 MHz, CDCl3) δ 23.8. LRMS (ES
+): 
239.10 (100% [M + H]), 211.07 (25%). HRMS (ES+): calculated for [C9H20O5P]
+; 239.1042, found 
239.1048. 
 
8.2.21 Synthesis of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)propanoate (371) 
Preparation of ethyl 2-(bis((trimethylsilyl)oxy)phosphoryl)proponate (369): 
 
 
A mixture of trimethyl silyl bromide (32.1 g, 20.9 mmol, 5 eq.) and ethyl 
2-(diethoxyphosphoryl)propanoate (368) (10 g, 4.19 mmol, 1 eq.) was refluxed at 80 ᵒC for 16 hours. 
The mixture was concentrated under a steam of nitrogen and dried under vacuum to give 369 as an 
orange oil (13.1 g, 100%) which was taken forward without further purification. 
1H NMR (500 MHz, CDCl3) δ 4.16 – 4.08 (2H, m, CH2CH3), 2.87 (1H, dd, J = 23.4, 6.6 Hz, PCH(CH3)CO), 
1.35 (3H, dd, J = 18.7, 7.1 Hz, PCH(CH3)), 1.22 (3H, t, J = 7.1 Hz, CH2CH3), 0.24 (18H, s, 6 x CH3Si). 
31P 
NMR (202 MHz, CDCl3) δ 4.71. LRMS (AP
+): 327.12 (100% [M + H]), 242.28 (5%). HRMS (AP+): 
calculated for [C10H28O5Si2P]
+; 327.1213, found 327.1205 
Preparation of ethyl 2-(dichlorophosphoryl)propanoate (370): 
 
 
Oxalyl chloride (13.3 g, 10.49 mmol, 2.5 eq.) was added dropwise to a stirred solution of 369 (13.1 g, 
4.19 mmol, 1 eq.) in dichloromethane (50 mL), dimethyl formamide (100 µL, cat.) was added and the 
mixture was stirred for 3 hours. The mixture was concentrated under a steam of nitrogen and 
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solvent removed under vacuum to give 370 as a light orange oil (9.19 g, 100%) which was taken 
forward without further purification. 
1H NMR (500 MHz, CDCl3) δ 4.27 – 4.12 (2H, m, OCH3CH2), 3.58 (1H, dq, J = 18.5, 7.2 Hz, 
PCH(CH3)CO), 1.59 (3H, dd, J = 27.3, 7.2 Hz, PCH(CH3)CO), 1.23 (3H, t, J = 7.1 Hz, OCH2CH3). 
31P NMR 
(202 MHz, CDCl3) δ 44.24. LRMS (ES+): 218.89 (2% [M]), 190.94 (67%), 172.93 (100%), 145.95 (62%), 
117.91 (77%), 82.95 (20%). 
Preparation of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)propanoate (371): 
 
 
A solution of 2,2,2-tri fluoro ethanol (12 mL, 16.8 mmol, 4 eq.) and triethylamine (35 mL, 251 mmol, 
6 eq.) was added dropwise to a stirred solution of 370 (9.19 g, 4.19 mmol, 1 eq.) in dichloromethane 
(50 mL) at 0 ᵒC. 4-Dimethylaminopyridine (10 mg, 0.094 mmol, 0.02 eq.) was added and the reaction 
mixture was stirred for 4 hours at room temperature, diluted with dichloromethane (100 mL) and 
stirred for 16 hours. Mixture was washed with water (3 x 50 mL) and brine (3 x 50 mL), dried over 
magnesium sulfate and concentrated under reduced pressure. Purification via flash chromatography 
on silica gel (50% ethyl acetate in hexane) provided phosphono acetate 371 as a brown oil (8.72 g, 
60%). 
1H NMR (500 MHz, CDCl3) δ 4.38 – 4.25 (4H, m, 2 x CHCF3), 4.11 (2H, q, J = 7.1, OCH2CH3), 3.11 – 3.01 
(1H, dq, J = 22.5, 7.4 Hz, PCH(CH3)), 1.39 (3H, dd, J = 19.4, 7.4 Hz, PCH(CH3)), 1.17 (3H, t, J = 7.1 Hz, 
OCH2CH3). 
13C NMR (75 MHz, CDCl3) δ 168.5 (CHC(O)OCH3), 124.3 (d, JCF = 8.0 Hz, OCH2CF3), 120.6 (d, 
J = 8.3 Hz, OCH2CF3), 62.8 (d, 
3JCF = 6.0 Hz, OCH2CF3), 62.2 (2 x OCH2CH3), 39.5 (d, JCP = 140.8 Hz, 
PCH(CH3)),.13.9 (OCH2CH3), 11.6 (d, 
2 JCP = 6.6 Hz, PCH(CH3)). 
31P NMR (202 MHz, CDCl3) δ 27.15. 
19F 
NMR (471 MHz, CDCl3) δ -75.42. LRMS (ES
+): 347.05 (100% [M + H]), 319.02 (30%), 273.02 (5%). 
HRMS (ES+): calculated for [C9H14O5F6P]; 347.0483, found 347.0485. 
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8.2.22 Synthesis of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate-d2 (272) 
Preparation of ethyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate-d2 (272): 
 
 
A mixture of 204 (2.0 g, 6.02 mmol, 1 eq.) and potassium carbonate (2.50 g, 18.06 mmol, 3 eq.) in 
deuterium oxide (40 mL) was refluxed at 100 ᵒC for 16 hours. Reaction mixture was extracted with 
dichloromethane (3 x 20 mL) to give 272 as a colourless oil (1.91 g, 95%, 100% 2H incorporation). 
1H NMR (400 MHz, CDCl3) δ 4.30 – 4.05 (6H, m, 3 x OCH2CH3), 1.43 – 1.21 (9H, m, 3 x OCH2CH3). 
31P 
NMR (162 MHz, CDCl3) δ 19.81. 
2H NMR (61 MHz, CDCl3) δ 2.90 (2 x 
2H, d, J = 3.0 H). 
 
8.2.23 Synthesis of 4-acetamido-2,2,6,6-tetramethyl-1-oxopiperidin-1-ium tetra 
fluoroborate salt (226) 
Preparation of 4-acetamido-2,2,6,6-tetramethyl-1-oxopiperidin-1-ium tetra fluoroborate 
salt (226): 
 
 
Fluoroboric acid (3.1 mL, 25.1 mmol, 1.16 eq., 50% aqueous solution) was added dropwise over 30 
minutes to a stirred suspension of 4-acetylamino-2,2,6,6-tetramethyl-1-piperidinyloxy TEMPO 226 
(5.0 g, 25.1 mmol, 1 eq.) in water(20 mL). The reaction was stirred for 30 minutes and sodium 
hypochlorite (7.23 mL, 10.9 mmol, 0.5 eq., 10-15% available Cl) added dropwise over 1 hour. The 
slurry was cooled to 0 ᵒC, stirred for 1 hour and diluted with water (20 mL). Aqueous phase was 
extracted with dichloromethane (3 x 20 mL) and the product isolated from the aqueous phase by 
lyophilisation to give 226 as a yellow powder (5.47 g, 78%). 
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LRMS (ES+): 215.18 (100% [M]), 199.14 (12%), 140.10 (6%). HRMS (ES+): calculated for 
[C11H23O2N2][M]; 215.1760, found 215.1755. 
8.2.24 Synthesis of tert-butyl 2-acetoxy-3-oxobutanoate (184) 
Preparation of tert-butyl 2-bromo-3-oxobutanoate (183): 
 
 
N-Bromosuccinimide (5.87 g, 3.7 mmol, 1.2 eq.) was added portion wise to a stirred solution of 
tert-butyl acetoacetate 182 (4.75 g, 3.0 mmol, 1 eq.) in acetone (20 mL). The suspension was stirred 
for 16 hours at room temperature, filtered through celite (ethyl acetate eluent) and filtrate 
concentrated under reduced pressure. Crude product was dissolved in hexane (20 mL) and the 
organic layer washed with water (3 x 10 mL), brine (3 x 10 mL), dried over anhydrous magnesium 
sulphate and filtered. Removal of solvent under vaccuo gave 183 as a colourless oil (6.00 g, 85%) 
which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 4.69 (1H, s, CHBr), 2.43 (3H, s, C(O)CH3), 1.50 (9H, s, OC(CH3)3). 
Preparation of tert-butyl 2-acetoxy-3-oxobutanoate (184): 
 
 
183 (7.06 g, 2.5 mmol, 1 eq.) was added to a stirred suspension of sodium acetate (3.76 g, 3.57 
mmol, 1.4 eq.) in dimethylformamide (25 mL). The reaction was stirred at room temperature for 3 
hours and water (20 mL) added to the mixture. The aqueous layer was extracted with ethyl acetate 
(3 x 10 mL) and combined organic layers washed with water (3 X 10 mL), brine (1 x 20 mL), dried 
over anhydrous sodium sulphate and filtered. Solvent was removed under reduced pressure and 
crude product purified by flash chromatography on silica (40% ethyl acetate in hexane) to give 184 
as a colourless oil (6.12 g, 95%).  
1H NMR (300 MHz, CDCl3) δ 5.41 (1H, s, CH(OAc)), 2.34 (3H, s, CH(OAc)C(O)CH3), 2.23 (3H, s, 
CH3C(O)OCH), 1.50 (9H, s, OC(CH3)3). 
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8.2.25 Synthesis of tris (tetrabutyl ammonium) hydrogendiphosphate 
 
 
Disodium dihydrogen diphosphate (3.3 g, 15 mmol) in aqueous ammonium hydroxide (15 mL 10% 
(v/v)) was passed through a cation-exchange column (resin: H+ form, amberlyst 131 wet, 10 g). Free 
acid was eluted with deionized water (120 mL) and the resulting solution titrated to pH 7.8 by the 
addition of tetrabutylammonium hydroxide (40% w/w in aqueous solution). The solution was 
lyophilised to give the hygroscopic product as white powder. Tris (tetrabutyl ammonium) 
hydrogendiphosphate was purified by recrystallization. The lyophilised product was partially dried by 
azeotropic removal of water by the addition of acetonitrile (30 mL) and concentration under 
reduced pressure to yield a tacky brown solid. The product was suspended in ethyl acetate (50 mL) 
and warmed to 40 °C before being filtered under vacuum to remove insoluble inorganic side 
products. The clear colourless filtrate was concentrated to half the volume and cooled to -20 °C to 
give tris (tetrabutyl ammonium) hydrogendiphosphate as white crystals (5.7 g, 43%). 
1H NMR (500 MHz, CDCl3): δ 3.17 - 3.13 (8H, m, 4 x NCH2CH2CH2CH3), 1.62-1.56 (8H, m, 4 x 
NCH2CH2CH2CH3), 1.36 - 1.27 (8H, m, 4 x NCH2CH2CH2CH3), 0.90 (12H, t, J = 7.5, 4 x NCH2CH2CH2CH3). 
31P NMR (121 MHz, D2O): δ -8.22 (s). HRMS (ES
-): calculated for (C16H39NO7P2 - [H])
-: 418.2124, found: 
418.2119. 
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